SOCIETY OF ACTUARIES



LONG TERM CARE EXPERIENCE COMMITTEE

INTERCOMPANY STUDY

1984 - 1999

InterCompany Subcommittee

Gary Corliss, Chair Roger Gagne Marylou Murphy Mark Newton Kim Tillmann

Reviewers

Linda Ball Ronald Wolf

September 2002

TABLE OF CONTENTS

INTRODUCTION		3
CALCULATIONS		6
LIMITATIONS		7
SECTION I	MORBIDITY - INCIDENCE	8
SECTION II	MORBIDITY – CONTINUANCE	12
SECTION III	CLAIM CHARACTERISTICS	16
SECTION IV	CAUSE OF CLAIM	19
SECTION V	MORTALITY	26
SECTION VI	VOLUNTARY LAPSE	35
SECTION VII	TOTAL TERMINATIONS	46
SECTION VIII	SUMMARY	52
ACKNOWLEDGEM	MENTS	53
APPENDICES		
${f A}$	CONTRIBUTING COMPANIES	
В	EXPOSURE CHARACTERISTICS	
C	CLAIM CHARACTERISTICS	
D	INCIDENCE	
${f E}$	CONTINUANCE	
${f F}$	VOLUNTARY LAPSE	
G	CAUSE OF CLAIM	
H	MORTALITY	
J	TOTAL TERMINATION	

INTRODUCTION

This document is the third Intercompany Study of the Society of Actuaries Long Term Care Experience Committee. Previous reports were published January 1995 and February 2000. The three reports of this committee are the only publicly written reports of experience on lives insured under private insurance plans in the United States. The first two reports of the Long Term Care Experience Committee were considered to be of a developmental nature. This third report will be part of regularly scheduled Society of Actuaries Experience studies.

This report, as well as the previous two, has data gathered that dates back to 1984. Data has been combined and analyzed from eighteen organizations (21 insurers) that provided information to further the knowledge of long term care insurance. Those organizations are listed in Appendix A.

Available data was collected on policies issued between January 1, 1984 through December 31, 1999. Claims incurred on policies in force during this time frame were followed from claim inception through the earlier of claim termination or June 30, 2000. Allowing a six-month period to report incurred claims should capture most of the incurred but not reported claims as of year-end 1999.

The insurers were asked to provide information on 100% of their insureds unless their volume of information was so enormous that it would alter the intercompany nature of the study. Under that circumstance, such an insurer was requested to submit a substantial but representative portion of their insureds, which would allow for an unbiased contribution but still allow for protection of the confidentiality of that company's experience.

Exposure records were submitted on 506 different policy forms. Almost 2.7 million exposure records with 7.5 million exposure years were gathered.

- 48% of the exposure was in the first two policy years.
- 73% of the exposure was on Individual, association and pseudo Group insureds.
- 27% of the exposure was on employees of employer Group programs.
- Average issue age of all insureds was 63 (down three years from the previous study).
- Female insureds represented 60% of the exposure.
- Average issue age of Individual insureds was 68.
- Average issue age for employer Group was 49.

General characteristics of the exposure file are found in Appendix B.

There were almost 700,000 claim payment records on slightly more than 50,000 claimants. Almost \$1.3 billion in benefits were reported as paid. Due to the types of policies primarily in force during the exposure period, the majority of claims submitted were for nursing home care.

- 91.5% of the number of claims were for nursing home care and 8.5% were due to home health care.
- Assisted Living information is not available separately within the data.
- 75% of all claims (open and closed) have a claim duration of one year or less.
- Average attained age on the date of incurral for claimants was 78.8.
- Female claimants received 66% of the benefit dollars.
- Average duration from issue to claim was 4.3 years (up from 2.4 years in the last study).

General characteristics of the claim file are found in Appendix C.

The Committee requested a significant amount of data from contributors. Much of that information was not available for electronic submission to enable this report to be as extensive as desired. However, the electronic data gathering of 18

organizations has improved significantly between the 1984—1987 time period and the 1992—1999 time period. One example of that improvement is found in the reporting of cause of claims. In the earliest time period, 74% of the claims had unknown causes; in the latest time period only 28% of the claims had unknown causes.

Each section of this study reports on one or more of several areas for which sufficient data is available. The areas that were included in the previous two studies are:

- Gender
- Issue Age
- Attained Age
- Elimination Period
- Policy Duration
- Individual vs. Employer Group
- Nursing Home vs. Home Care
- Issue Year
- Trends

For this current study, tables and data presented were expanded for Group information. Newly added to this study is information on Underwriting Type, Benefit Escalator Clause, and Distribution Source. A new section was added on Total Terminations because of increasing evidence that there is a significant number of deaths that are being incorrectly reported as lapses.

The compiled data verifies some long held expectations relative to long-term care:

- Incidence rates rise steadily by attained age and policy duration.
- Morbidity and Mortality selection is apparent in early policy durations.
- Mortality rates increase steadily with attained age and policy duration.

Other general results of interest:

Incidence Rates

- Incidence rates decrease as Issue Year increases, but are doing so at a slowing rate.
- Incidence rates for 20 and 90 day elimination periods are 40% and 75% respectively less than 0 day.
- Incidence rates vary from 47 to 117% of those reported in the 1985 NNHS varying with age.

Claim Continuance

- Claim continuance increases as age at claim increases.
- Only 8% of the closed claims are due to benefit expiry.
- 65% of closed claims are due to death; 26% due to recovery.

Cause of Claim

- Alzheimer's claims are the most expensive, most frequent, longest, and trending higher.
- Nervous System and Mental claims are similar in expense to Alzheimer's.
- Cancer and Injury claims are somewhat frequent but short and inexpensive.

Mortality

- Mortality rates decrease as exposure year increases, but at a slowing rate.
- Male mortality experience is 49% higher than female.

- Female mortality is 44% lower than 83 GAM, 29% lower than A2000 and 53% lower than 85-90 SOA.
- Male mortality is 51% lower than 83 GAM, 23% lower than A2000 and 53% lower than 85-90 SOA.
- Disabled Lives mortality, in aggregate, is 17 times higher than Active Lives mortality.
- Mortality for Guaranteed Issue is closer to mortality for Full Underwriting than to Simplified Underwriting.

Voluntary Lapse Rates

- Voluntary lapse rates generally decrease as duration increases from 1 to 10.
- Voluntary lapse rates, surprisingly, increase as duration increases above 10 for Individual but not Group.
- Employer Group voluntary lapse rates are roughly two-thirds of Individual voluntary lapse rates.
- The premium paying decision appears to be a major driver of voluntary lapse rates.

Total Termination Rates

• Total termination rates generally decrease for the first six policy durations, then increase steadily.

Antiselection

- Voluntary lapse antiselection is apparent for policies with Benefit Escalator Clause.
- Voluntary lapse antiselection appears for policies with unlimited lifetime benefits.

Home Care

• Average number of home care visits increased from 3.25 days per week to 4.29 days since the last study.

CALCULATIONS

Many tables in this report are segregated by policy duration. Duration is calculated based on exposure from either active or terminated records. From active records, duration is calculated by using only the latest record in the following formula:

```
Duration in Months = (1 + \text{Last Observation Date} - \text{Issue Date}) / \text{Days per Month} (30.42 was used as the Days per Month to account for monthly variations and leap years.)
```

From terminated policy records, duration is calculated by substituting the Termination Date for the Last Observation Date in the previous formula.

The incidence tables shown break duration down into annual periods as follows:

<u>Duration</u>	<u>Months</u>	<u>Duration</u>	<u>Months</u>
1	0 to 13	6	74 to 85
2	14 to 25	7	86 to 97
3	26 to 37	8	98 to 109
4	38 to 49	9	110 to 121
5	50 to 61	10	122 to 133

Duration 1 spans 13 months to estimate the effect of the grace period. The application of grace periods in practice varies significantly from carrier to carrier. Generally a company does not consider a policy "terminated" until at least the end of the grace period. For administrative simplicity, many carriers do not terminate (or lapse) a policy until well after the grace period has expired. The division of duration into these time periods has the effect of counting any active policy currently in its grace period in the previous duration.

Each policy is credited with a full exposure year for all integer duration years up to and including the duration year in which the observation period or termination date ends. For example, a policy whose duration is 26 months and 7 days will be included and counted as completing duration 3. This methodology will overstate duration by duration group and in total. Claim incidence and lapse rates will be understated as a result.

Incurral Date is the earliest incurred date shown on records submitted for each claimant. Issue Date is the earliest date of issue recorded for each insured.

For each claim a duration is calculated using the following formula:

```
Duration in Months = (1 + Incurral Date - Issue Date) / Days per Month (30.42 was used as the Days per Month to account for monthly variations and leap years.)
```

An incidence rate is found by dividing the number of claims in any cell by the exposure in that cell.

Data was submitted for many specific elimination periods. Since the data was very small for some elimination periods, data was aggregated into elimination period groups. The elimination period category labeled "0 Days" includes only zero day elimination period coverage. The elimination period category labeled "7-19 days" includes 5, 7, and 15 days, "30-50 days" includes 30 and 45 day but is essentially comprised of 30 day elimination period experience. The elimination period category labeled "101-730 Days" includes 150 day, 180 day and 365 day elimination period experience. Appendix B-6 details this study's exposure by elimination period. A trivial portion of all records provided contained no information on the elimination period. These records have been excluded from all calculations of incidence.

LIMITATIONS

This third Intercompany report of the SOA LTC Experience Committee includes increasingly valuable but in some instances, limited information. As one considers the findings in this report, please remember four main points. First, the data has been gathered from different companies contributing over different time frames. Only two companies have contributed to all three studies. Second, most of the claim experience is based on policies that provide little in the way of home care benefits. Therefore, this is still primarily a Nursing Facility Experience Study. Thirdly, many of the contributors write either Individual or association Group coverages which are both underwritten. Thus almost 75% of this claim experience is based on Individually underwritten insureds. Less than 12% of the claim experience is on corporate sponsored employer Group plans which often has guaranteed issue. Fourth, experience is reported exactly as calculated. There has been no attempt to smooth, interpolate or extrapolate numerical data.

Please note that this analysis, all tables and charts are based on raw data which cut across broad variations in market and product. While analyzing the data, if problems with data submissions were found, they were discussed with the contributors and corrected. However, because this analysis is based on files submitted from a variety of sources there may be other issues that weren't discovered.

Underlying these results are distortions caused by aggregating over several years the results of companies with different distribution methods, types of underwriting, target markets, pricing levels, products and administrative rules. The representation of any one company varies from cell to cell, so trends shown are in part distorted by a shift in the underlying mix. Most exposure and claims data is still from early policy durations. The voluntary lapse rates on Individual policies from duration 10 and above are surprising, which may mean that there is some improper coding of deaths. This led us to add an entire new section entitled Total Terminations to assist in understanding the total decrement of all insureds. It is also important to note that incidence and lapse rates have fallen significantly over the experience period, so averages are not indicative of levels at the end of the period. Therefore, great care needs to be exercised when applying the results in this report. Consideration must be given to whether the averages shown are appropriate for use as is, or whether adjustments need to be made for application elsewhere.

Section I

MORBIDITY - Incidence

Introduction

This section presents information on the incidence of claims for long-term care insureds.

Incidence Rates Methodology

The incidence rates developed in this report are always shown by elimination period category and attained age and are calculated based on reaching the end of the elimination period. These categories were considered to be central to any unbiased determination of incidence rates. Elimination period categories were sometimes grouped to include elimination periods less commonly found with those with the bulk of the exposure (Zero days, 7-19 days, 20 days, 30-50 days, 60 days, 90 days, 100 days, 101-730 days). Within these categories, incidence rates are classified by other variables including duration of the policy, gender, issue year, benefit period, daily benefit, and level of care (added this Study). Incidence rates are also compared to those in the 1985 National Nursing Home Survey.

Some claims were reported without any paid benefits. As a claim is only included in the incidence calculation if it reaches the end of the elimination period and has at least \$1 of paid benefits of any type, all claims reported with zero dollars of paid amounts were eliminated from all calculations of incidence rates.

Incidence Rates by Attained Age and Elimination Period (Appendix D-1)

For all elimination periods combined, the incidence rates increase markedly by attained age, rising from an overall rate of 0.03 per hundred at ages "Less than 50" to 1.65 per hundred at age group "Ages 80+". However, the overall increase in incidence rates by attained age is profoundly influenced by the change in relative exposure of the elimination period data by age group. A more useful pattern of increasing incidence rates exists when viewed by attained age within elimination period category as shown by Figure 1:

Figure 1
Incidence rates by Attained Age and Elimination Period Category

Elimination Period C	Category in Day	/S
----------------------	-----------------	----

Attained Age	Zero	20	90	100	All
Less than 50	0.08%*	0.06%*	0.02%	0.01%*	0.03%
50-59	0.13%	0.08%	0.04%	0.03%	0.06%
60-69	0.52%	0.26%	0.12%	0.11%	0.20%
70-79	1.44%	0.77%	0.35%	0.42%	0.69%
80+	2.79%	1.73%	1.28%	1.12%	1.65%

^{*}Note: These cells have exposure less than 25,000 years.

Some patterns are noted when viewing data by attained age group across elimination period categories:

- "20 day" incidence rates are generally about 40% less than "zero day" rates.
- "90 day" incidence rates are generally about 75% less than "zero day" rates and about 50% less than "20 day" rates.

• "100 day" incidence rates are near or sometimes higher than "90 day" rates. This illustrates limitations in the Study data as generally different companies contribute data in different areas and the 90-day category has a generally larger share of group data.

Incidence Rates by Attained Age, Elimination Period, and Policy Duration (Appendix D-2)

For all attained age groups and elimination period categories combined, incidence rates increase by duration group. This can be seen particularly at the older issue age groups. For all attained age groups and elimination period categories combined, the rate of increase is relatively smooth through duration 10 though, in fact, this is highly influenced by the changing mix of exposure and claims over the attained age group/elimination period cells. Rising incidence rates would reflect a typical pattern of the "wearing off" of underwriting as selection factors rise to an ultimate level.

Incidence Rates by Issue Age, Elimination Period, and Policy Duration (Appendix D-2a)

Figure 2 shows the implied select factors for various issue age categories using duration 8 as the "ultimate" duration. Incidence rates by duration category were adjusted by the average increase in incidence rates by attained age (~9.7% annually) to remove distortion introduced by advancing age. For all attained age groups and elimination period categories combined, select factors for duration one start at 35% and increase gradually. At the younger issue age groups, selection is more difficult to discern. This may be due to any of several factors affecting results at these ages including, for example, less stringent individual underwriting, incidence rates being so small already, and the impact of additional group data.

Figure 2
Implied Select Factors
Duration

Issue Age	1	2	3	4	5	6	7	8
Less than 40	106%	100%	104%	127%	101%	31%	118%	100%
40-49	109%	117%	138%	129%	117%	152%	90%	100%
50-59	44%	67%	81%	76%	80%	85%	92%	100%
60-64	27%	40%	45%	46%	54%	68%	77%	100%
65-69	26%	42%	51%	54%	63%	66%	88%	100%
70-74	33%	49%	58%	64%	67%	79%	84%	100%
75-79	46%	64%	72%	76%	82%	86%	97%	100%
80-84	49%	66%	68%	77%	75%	76%	99%	100%
Ages 85+	41%	60%	69%	79%	86%	104%	120%	100%
All Ages	35%	51%	58%	63%	67%	74%	92%	100%

Incidence Rates by Attained Age, Elimination Period, and Gender (Appendix D-3)

Overall the incidence rate for females is modestly higher than that for males, except at the younger ages. At lower elimination periods, male and female incidence rates do not generally increase with advancing age. However, at longer elimination periods, female/male ratios seem to trend upward with advancing attained ages.

Figure 3
Ratio of Female/Male Incidence Rates by Elimination Period, Attained Age Category

Elimination Period Category in Days

Attained Age	Zero	20	90	100	All
Less than 50	57%*	117%*	66%	N/A*	75%
50-59	75%*	114%	100%	100%	120%
60-69	100%	89%	104%	157%	111%
70-79	94%	105%	114%	118%	111%
80+	101%	111%	132%	122%	116%

*Note: These cells have exposure less than 25,000 years.

Incidence Rates by Duration, Issue Year, and Elimination Period (Appendix D-4)

The incidence rates by issue year have continued to improve with time. Viewed by elimination period category for all attained age groups combined, incidence rates have decreased over the issue years. In general, this decrease over issue years is also apparent for the most common attained age groups for all elimination period categories combined, though the results are certainly skewed by the general movement towards longer elimination periods over time. More prominent drops occur in the shorter elimination periods. Results are consistent at most policy durations studied. Reasons for this improvement might include improved underwriting tools, better definitions of which impairments translate into long-term care risks, and increased market penetration leading to the coverage of a broader set of health risks. However, care should be used projecting data forward as incidence rate decreases moderate significantly and, in some cases, disappear entirely from the period 1992-1995 to the period 1996-1999.

Figure 4
Incidence Rates over Issue Year Groups

Duration	Issue Year Group	20 Day Elim	90 Day Elim
1	1984-87	0.51%	0.31%
	1988-91	0.44%	0.15%
	1992-95	0.30%	0.08%
	1996-99	0.28%	0.03%
3	1984-87	0.81%	0.33%
	1988-91	0.67%	0.27%
	1992-95	0.66%	0.15%
	1996-99	0.72%	0.10%
5	1984-87	1.22%	0.40%
	1988-91	0.86%	0.43%
	1992-95	0.93%	0.31%
7	1984-87	1.42%	N/A
	1988-91	1.61%	0.42%
	1992-95	1.14%	1.59%

Incidence Rates by Attained Age, Elimination Period, and Benefit Period (Appendix D-5)

Incidence rates were compared by benefit period to ascertain any effect of antiselection. For all elimination period categories combined, incidence rates for longer benefit periods (unlimited or lifetime) do not appear to be consistently higher than in benefit period categories 1-4 or 5+ (5 or more but not unlimited) and, as attained age increases, are generally lower. Antiselection may be minimal or may be masked by the use of offers of shorter benefit periods for applicants with less robust health histories.

Incidence Rates by Attained Age, Elimination Period, and Daily Benefit (Appendix D-6)

Incidence rates were compared by daily benefit to ascertain any effect of antiselection. Looking at all elimination period categories combined, antiselection does not seem apparent.

Comparison of Incidence Rates to Admission Rates in the Report from the 1985 National Nursing Home Survey Utilization Data (Appendix D-7)

Earlier reports of the Long-Term Care Experience Committee included utilization data from the 1985 National Nursing Home Survey (NHSS). Part of the statistics presented were admission rates on three bases; all stays (stay concept), all stays (benefit period concept), and insurable stays (benefit period concept). Appendix D-7 compares the incidence rates from this current study (zero day elimination period) with selected rates from Table 3 of that general population report, specifically with those under the insurable stays (benefit period concept).

Incidence rates vary from 47% to 117% of those presented in the 1985 NNHS. Ratios are generally highest at the younger ages and lower at the older ages. Caution should be used in interpreting the results because direct comparisons are difficult to make given the differences in the data available, particularly because of the early durational experience included here.

Figure 5
Ratio of Intercompany Study Incidence Rates to 1985 NNHS Rates

1 0	
Attained Age	Both Sexes
Less than 60	1.169
60-64	1.047
65-69	0.996
70-74	0.784
75-79	0.623
80-84	0.467

Section II

MORBIDITY - Continuance

Introduction

This section presents information on the continuance of claims for long-term care insureds.

Continuance by Elimination Period (Appendix E-1)

Persistency on claim is measured from the end of the elimination period. Claims of shorter duration due to recovery or death are included in the zero day elimination period continuance but are not counted in situations of longer elimination periods.

Persistency on claim seems to differ depending on the elimination period chosen. In particular, claimants with zero day elimination periods persist on claim longer, even after long persistency on claim. In order to make a meaningful comparison, persistency must be adjusted to account for differences in elimination period. Figure 1 compares the zero day elimination period category continuance with that of the other two continuance categories. Percentages indicate the relationship between the percentage of claimants reaching the nth day for the "7-50 day" category and the "60-150 day" category to the corresponding percentages for the "Zero day" category. For example, at 90 days from incurral, 72.7% of "zero day" claims persist on claim. Applying the "7-50" day continuance factors to the 89.3% of the "zero day" claims reaching 20 days, only 56.3% of the "7-50" day claims reach 90 days. Dividing 56.3% by 72.7%, the persistency ratio is 77%. Note: Persistency is measured from the end of the elimination period for each claimant, so categories represent consolidated results for several different elimination periods. For the calculations in Figure 1, the "7-50" day category is represented by assuming all claimants have an average elimination period of 90 days.

Figure 1
Persistency on Claim Relative to Zero Day Elimination Period Category

Duration	Persistency	Adjusted	Ratio	Adjusted	Ratio
from	Zero Day	Persistency	Adj 7-50 days/	Persistency	Adj 60-150 days/
Incurral	Category	7-50 Days	Zero day	60-150 Days	Zero day
20	89.3%	89.3%	100%		
25	87.0	85.3	98		
30	85.0	81.4	96		
35	83.4	78.2	94		
40	81.8	75.0	92		
50	79.0	69.5	88		
60	77.1	65.3	85		
90	72.7	56.3	77	72.7%	100%
120	69.7	50.6	73	66.2	95
180	65.8	43.1	66	56.5	86
365	56.3	30.2	54	38.7	69
730	47.0	19.1	41	23.5	50

Continuance by Gender (Appendix E-2)

Overall the percentage persisting for n days or longer is similar for males and females. The differences by gender at early claim durations are generally small. At durations over 90 days, female continuance is greater than male continuance (see Figure 2).

Figure 2
Percentage Persisting At Least N Days by Gender

Gender

Duration from	Gender	
Incurral Date	Female	Male
1	99.82%	99.66%
2	99.40	99.14
3	98.94	98.61
4	98.33	98.02
5	97.81	97.36
10	94.60	94.03
20	89.08	88.31
30	84.49	83.48
60	75.01	74.04
90	69.24	67.78
120	65.08	63.17
180	59.41	56.23
365	48.09	42.90
730	36.66	28.41

Continuance by Age (Appendix E-3)

At almost all claim durations, persistency on claim increases as the age of the claimant increases. This may be due to fewer recoveries as age increases. However, at the longest durations for the 85+ group, persistency on claim decreased. This may be due to the rising impact of mortality on terminations while on claim (see Figure 3).

Figure 3
Percentage Persisting At Least N Days by Age at Incurral

Incurral Age Group

Duration	55-64	65-74	75-84	85-89	90+
1	99.71%	99.78%	99.74%	99.82%	99.91%
2	99.32	99.31	99.27	99.46	99.39
3	99.12	98.61	98.79	99.21	98.95
4	98.83	97.81	98.20	98.77	98.77
5	98.34	96.93	97.67	98.40	98.60
10	94.04	92.74	94.49	96.20	97.11
20	88.77	86.15	88.90	91.71	93.17
30	83.79	80.32	84.33	88.07	90.27
60	74.02	69.08	75.16	79.87	82.02
90	67.34	62.48	69.38	74.30	77.25
120	62.40	58.00	65.13	70.25	72.53
180	53.58	51.79	59.22	64.18	65.29
365	38.78	40.31	47.39	51.39	51.91
730	27.30	28.84	34.73	38.08	38.75
1095	21.04	21.33	25.41	27.38	22.37
1460	15.86	16.37	19.38	20.23	12.52
1825	12.19	12.49	14.20	10.17	3.37

Comparison of Continuance to Continuance in the Report from the 1985 National Nursing Home Survey Utilization Data (Appendix E-4)

The 1985 NHSS presented persistency on claim statistics on three bases; all stays (stay concept), all stays (benefit period concept), and insurable stays (benefit period concept). Appendix E-4 compares the persistency on claim from this current study with selected rates from that general population report, specifically with those under the insurable stays (benefit period concept).

In general, as mentioned below, persistency on claim is higher and often significantly higher, especially at the older ages, than that presented in the 1985 NNHS. Ratios are generally highest at the oldest ages and at the longer durations, diverging widely from that Report. In the age 55-64 group, the ratio of % continuing on claim after 1,095 days is 21.0% in the current Study and 19.5% in the NNHS, or a ratio of about 108%. The corresponding numbers for the age 85+ group are 26.8% and 14.7%, respectively, for a ratio of 182%.

Technical Notes on Continuance on Claim

The continuance tables in this report are based on raw claim data without any adjustments for smoothing or graduation. Some adjustments were made to the data to develop the tables and data presented. This section documents the methodology to provide a framework for understanding and developing conclusions about the limitations of the data.

A value of 1 is assigned to each day a claimant is on claim, beginning with the earliest service begin date (or, if this was not available, the incurral date) plus the elimination period and ending with the latest service end date. The service begin date is the date that services began for the claim being made. The service end date is the date that services ended for the claim payment being made. Claims incurred on which no payment was ever made or which show zero benefit days are excluded from continuance calculations.

Data were tabulated separately using different characteristics; elimination period, gender, and age. The elimination period categories were set to aggregate data into "like" periods because the data available for some elimination periods was very small.

Data were initially tabulated for claims marked either open, closed, or unknown as of the end of the observation period. There appears to be wide variation in the labeling of claims by company, so some of the data were adjusted to separate data into only an open or closed status. All claims marked closed initially remained as marked. For each claim initially marked open or unknown, if the latest service end date was different that the observation date by more than 180 days, the claim was closed. Claims marked closed due to benefit expiry were removed from continuance calculations as of the date of the last payment. A small portion of claims (all from one company) were marked as closed-benefit expiry as the date submitted was apparently miscoded.

Separating open claims from closed allows an effective study of continuance behavior. Open claim data can be used to support continuance curve research, but its usefulness is limited to the time the observation period ends. The persistency-on-claim data reported here combine the experience of the open claims (from inception to the observation date) and closed claims (throughout the claim until benefit expiry).

Appendices E-1 through E-3 are in the same format. "Number of claims open" is the number of claimants marked open with a value of 1 for that particular duration. For example, 749 claims open means that there were 749 claimants which were coded open until at least that duration. "Number of claims closed" is the number of claimants marked closed with a value of 1 until at least that particular duration. In measuring persistency from one duration to the next, only the claims that are observable at the next duration can be counted. "Beginning exposure" is the number of open claims observable at the next duration plus the number of closed claims at the current duration. Specifically, the formula is:

```
Beginning Exposure t = Observable Claims t+1 + Closed Claims t - Closed EOB t
```

The number of claims terminating on day t is calculated from the "number of claims closed" column, then adjusted for any claims closed due to benefit expiry.

```
Terminating on day t = Closed_t - Closed_{t+1} - Closed EOB_{t+1}
```

Where closed is the "number of claims closed" for that duration and Closed EOB is the "number of claims closed due to End of Benefits" for that duration.

Percent Persisting t days = Percent Persisting t-1 days * [1- (terminating on day t/beginning exposure t)]

Section III

CLAIM CHARACTERISTICS

Introduction

This section presents information on the characteristics of claims incurred by long-term care insureds and reported by the participating companies.

Records were submitted on 51,369 claimants with paid claim amounts of \$1,289,859,281. There were 682,419 claim payment records that were compressed to obtain a single record for each claimant.

A status code was assigned to these claims, based on the length of time between the last service date and June 30, 2000 (the end of the claim observation period). If the number of days was less than or equal to 180, the claim was assumed to still be open. Otherwise, a closed status was assigned. The decision to close claims after 180 days of inactivity was based on the subcommittee members' knowledge of the claims experience within their own organizations.

For purposes of this study, length of stay means length of time benefits are paid. Attained age in the claim file means the claimant's actual age at time claim is incurred (i.e., date of initial admission/visit).

Discussion

The number of claims in this study is more than double the claims in the previous study. While still small in number relative to Nursing Home claims, Home Care claims are beginning to indicate valuable information.

Gender (Appendix C-1)

The distribution of female claims (68.7%) is somewhat higher than the distribution of the insureds (59.6% from Appendix B-1). Conversely, male claims (31.3%) are lower than male distribution of insureds (40.1%).

Age at Incurral (Appendix C-2)

Over 95% of the claims were at ages 65 and over; almost 75% of the claims were for ages 75 and over.

Average Age (Appendix C-3)

The average age at time of claim is 79 for females and 78 for males.

Elimination Period (Appendix C-4)

Not surprisingly, the largest number and percentage of claims (86.9%) were presented by individuals whose policies had 0, 20, 90 or 100 days of elimination period. This follows relatively closely the exposure which had 89.3% of insureds holding policies with those elimination periods.

Incurral year (Appendix C-5)

The database has 3,200 - 5,000 claims incurred each year since 1989.

Maximum Benefit Amount (Appendix C-6)

Almost 10% of the claims were from claimants who had a lifetime or unlimited maximum benefit.

Maximum Benefit Period (Appendix C-7)

Of those claimants who had a limited benefit period, 97% were of five years or less.

Maximum Benefit Amount (Appe ndix C-8)

Of those claimants who had a limited benefit amount, 95% had a maximum benefit of \$200,000 or less.

Maximum Daily Benefit Amount (Appendix C-9)

Almost 60% of claimants had maximum daily benefits between \$50 and \$100.

Type of Policy (Appendix C-10)

As in earlier studies, the vast majority (over 90%) of claims were under Individual policies. However, Group claimants have doubled to almost 10% since the last report.

Nursing Home Length of Stay (Appendix C-11)

The average nursing home length of stay has slowly lengthened from the last study to 404 days per claimant. Group claimants (536 days) were longer than Individual claimants (394 days).

Nursing Home Diagnosis (Appendix C-12)

Alzheimer's, Hypertension, Mental and Central Nervous System claims were reported as the longest both in Individual and Group claimants.

Home Care Length of Claim (Appendix C-13)

The average home care length of stay is 354 days. As with nursing home claimants, Group claimants (411 days) were longer than Individual claimants (338 days).

Home Care Diagnosis (Appendix C-14)

As with Nursing Home claims, Alzheimer's, Mental and Central Nervous System claims were also reported to be the longest for those using Home Care.

Diagnosis by Age (Appendix C-15)

Central Nervous System claims was consistently the highest for ages under 60. Stroke predominated for those who incurred claims in their 60's. No one diagnosis predominated at age 70 and above.

Diagnosis for All Claims (Appendix C-16)

Group claims were 46% longer than Individual claims.

Claim Duration (Appendix C-17)

Most claims (75%) lasted less than one year. Few claims (1.2%) lasted more than five years. The longest claim was for 12 years.

Section IV

CAUSE OF CLAIM

Introduction

This section presents information relating to the primary diagnosis for long-term care claimants in this study. Appendices G-1 through G-12 detail number of claims, days on claim and dollars of claim payment as well as average payments, average days and average payments per day by primary diagnosis groupings along with other policy and claim characteristics. Compared with the prior study through 1993, many more nursing home and home care claim records were captured with diagnosis information (for nursing home 31,416 compared with 11,639 in the last study, for home care 4,680 compared with 1,460 in the last study). Despite this increase in data, the home care and to a lesser extent the nursing home data for some of the more detailed breakdowns is still not credible. Some judgement was used to exclude these less credible cells from our analysis and comments to follow.

Definition of Terms

Average Claim Payments: Total Payments/Tally

Average Days: Days/Tally

Average per Day: Average Claim Payments/Average Days

Days: The minimum of the number of days recorded for that claim or the length of time between the service begin date and the service end date.

Tally: Number of claims with either a nursing home and/or a home care payment. If a claim had payments in both locations it is included in the tally of both Nursing Home and Home Care/Other charts.

Total Payments: The sum of the claim payments made for that claim within that claim location.

ICD-9-CM Codes by Diagnosis (Appendix G-1)

Primary ICD9 codes were used to map claims into diagnosis categories. Appendix G-1 describes the mapping logic.

Nursing Home, Home Health Care/ADC/Other Claims: Diagnosis Category Summary (Appendix G-2)

Of the 45,336 claims that have Nursing Home payments, 31,416 (69%) were coded with primary diagnosis information (this compares to 60% in the last study). Alzheimer's claims appear to have increased in prevalence in recent years as this is the leading cause of claim in this study, where it did not rank in the top 3 for the prior study.

The leading causes of Nursing Home claims over the 1984 to 1999 period (excluding the other/unknown category) are Alzheimer's at 18.4%, followed by Injury at 13.3% and Stroke at 13.0%. Looking at average claim payments for the study, Alzheimer's claims are the most costly at \$50k, followed by Nervous System (\$42K) and Mental (\$40K). On the lower side of the average claim payments are Congenital (\$9K) and Cancer (\$12K). Looking at length of claim in days for the Nursing Home claims, Mental claims have the longest average days on claim with 629 days, followed closely by Alzheimer's with 623 days. The diagnosis group with the shortest average days on claim for Nursing Home is Cancer at 170 days. The diagnosis groups with the highest average claim payments per day are Nervous System at \$87/day,

followed by Alzheimer's at (\$80/day). Among the least costly causes, measured by average claim payments/day, are Congenital at \$46/day and Pregnancy (\$52/day).

FIGURE G-2-1: Distribution of number of Nursing Home Claims by Diagnosis (excluding claims with unknown diagnosis). The other group includes claims in the ill defined/miscellaneous condition diagnosis group as well as any diagnosis group where the prevalence of claim was less than 2.5% of the total.





Figure G-2-2: Average number of days on claim and Average cost/day for Nursing Home Claims by diagnosis (excludes claims with unknown diagnosis).



While still much smaller than the block of Nursing Home claims, the current study (with data through 1999) contributed many more home care claims than the prior study (with data through 1993). Excluding the claims with unknown diagnosis, there are 4,680 claims with Home Care/Other payments in the current study. While 30% of the Nursing Home claims are coded as diagnosis unknown, there are only 19% of the Home Care/Other claims with an unknown diagnosis. This appears to be a good trend for analysis by diagnosis group. Similar to Nursing Home claims, Alzheimer's claims on Home Care/Other have moved up to the leading cause of claim from the prior study, where they did not previously rank in the top three causes.

For the 1984 through 1999 study, the leading Home Care/Other diagnosis by count is Alzheimer's at 16.4%, followed by Injury at 15.1% and Cancer at 14.9%. Looking at average claim payments for Home Care/Other claims, Nervous system claims have the highest at \$20.3K, followed by Alzheimer's at \$14.9K. On the lower side of the average claim payments are Genitourinary (\$4.4K) and Pregnancy (\$4.5K), although both of these have fairly low frequency. Average visits for

Home Care/Other claims are the longest for Nervous System and Alzheimer's claims. Looking only at diagnosis groups with at least 50 claims contributed to the study, the Mental diagnosis group was the most costly measured by average payments/visit at \$116/visit, followed by Respiratory (\$80/visit). Among the least costly causes, measured by average claim payments/visit, are Circulatory at \$57/visit and Injury (\$60/visit). Compared with the Nursing Home claims, Home Care/Other claims have a shorter average length of claim for all diagnosis groups.

FIGURE G-2-3: Distribution of number of Home Care/Other Claims by Diagnosis (excluding claims with unknown diagnosis). The other group includes claims in the ill defined/miscellaneous condition diagnosis group as well as any diagnosis group where the prevalence of claim was less than 1.2% of the total.





Figure G-2-4: Average number of visits per claim and Average cost/visit for Home Care Claims by diagnosis (excludes claims with unknown diagnosis).



Nursing Home, Home Health Care/ADC/Other Claims: Status Type and Diagnosis Summary (Appendix G-3)

Appendix G-3 is the same as G-2, except that it further breaks claims by open versus closed claim status.

Looking at average days on claim, the open claims are longer than the closed claims for all but a few diagnosis groups, as was true in the prior study. For this study, a larger percentage of the studied claims are closed, which will help mitigate the impact future experience on open claims will have on aggregate results.

Of the Nursing Home claims contributing to the study, 88% were closed (84% in the prior study). For Home Care/Other claims, 86% were closed (81% in the prior study). Diagnosis groups with the highest percentage of open Nursing Home claims are Alzheimer's (16%) and Nervous System (14%). The lowest percentages of open claims are in the Cancer and

Pregnancy diagnosis groups (both at 2%). Alzheimer's and Nervous system diagnosis groups also had the highest percentage of open claims on the Home Care/Other claims at 27% and 28% respectively.

Nursing Home, Home Health Care/ADC/Other Claims: Gender and Diagnosis Summary (Appendix G-4)

Appendix G-4 compares claims experience by diagnosis category for males compared with females.

The trend of increased prevalence of Alzheimer's claims compared with the prior study is evident in both the male and female groups. Following Alzheimer's the next most prevalent diagnosis groups for both males and females remained unchanged from the last study (Stroke for males and Injury for females). Looking at average days, both male and female groups lengthened, however the increase for females was much greater. For all but the Congenital diagnosis group, the average claim days are longer for females compared with males.

For both the male and female groups, Alzheimer's is the leading cause of the Nursing Home claims at 20% and 18%, excluding claims with an unknown diagnosis. Nursing Home Alzheimer's claims are also the most costly for both male and female, with the highest average payments. Following Alzheimer's claims in prevalence for males (excluding claims with an unknown diagnosis) are Stroke (15%) and Circulatory (14%), while for females they are Injury (17%) and Circulatory (12%).

For Home Care/Other claims (excluding claims with an unknown diagnosis), Injury claims were the most prevalent for females at 18%, followed by Alzheimer's claims at 15%. For Male Home Care/Other claims (excluding claims with an unknown diagnosis), Alzheimer's claims were the most prevalent at 20%, followed by Cancer at 17%.

Nursing Home, Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary (Appendix G-5)

Appendix G-5 compares claims experience by diagnosis category by attained age.

For Nursing Home claims, Alzheimer's, Circulatory, Stroke and Injury claims had approximately 80% of their claims attributed to attained ages over 75. This group was only approximately 65% for Cancer and Nervous system claims. Excluding claims with attained age 00-64, with relatively few claims and short durations, the diagnosis groups of Alzheimer's, Mental, Nervous System and Stroke have average claim durations that tended to decrease with age. Diagnosis groups of Cancer and Injury tend to increase with age up until the highest ages (85+), where they drop.

The Home Care claims have a similar distribution of ages by diagnosis, although overall they appear to have younger ages. The Alzheimer's, Circulatory, Stroke and Injury claims have between 60% and 70% of their claims attributed to attained ages over 75. This group was around 40% for Cancer and Nervous system claims. Although very few claims have attained ages greater than 90, there appears to be a large increase in the average days on claims across most diagnosis groups.

Nursing Home, Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary (Appendix G-6)

Appendix G-6 compares claims experience by diagnosis group by policy duration of claim incurral.

Many of the cells in this exhibit have too few claims to be considered credible. The general trend for most diagnosis groups is for average claim payments and average days paid to decrease as policy duration increases. The high cost of


these early duration claims could have underwriting significance (possible antiselection). Diagnosis groups with the highest prevalence of early duration claims are Mental, Cancer and Congenital (only 20 claims).

Nursing Home, Home Health Care/ADC/Other Claims: Diagnosis Category by Incurred Year Group (Appendix G-7)

Appendix G-7 compares claims experience by diagnosis group by claim incurral year grouping (1984-1987;1988-1991;1992-1995;1996-1999).

For Nursing Home Claims, the prevalence of the Alzheimer's diagnosis group has steadily increased over time. The Respiratory diagnosis group has replaced Cancer as the fifth leading cause of claim for the most recent incurral year grouping. The average claim payments and the average claim days both decreased from the early claim incurral years to the later claim incurral years. The later claim incurral years have a larger portion of open claims (37% open for the 1996-1999 group compared with less than 5% open for the earlier incurral year groups). This may have the potential to increase both the average payments and average days paid on these open claims until they are closed, which could be understating these measures in the most recent incurral group. Excluding claims with incurral years before 1987, where there is very little experience by diagnosis group, Alzheimer's is the leading cause of claim for all the other incurral groups. The second leading cause of claim has varied by incurral year between Circulatory (1988-1991), Stroke (1992-1995) and Injury (1996-1999). Encouraging is the increased coding of ICD9 codes as we move toward more recent incurral years, with 74% of the 1984-1987 group coded as unknown compared with 45% for the 1988-1991 group to 16% for the 1992-1995 group. There was an increase in the number of claims with unknown diagnosis from the 1992-1995 group (16%) to the 1996-1999 group (28%), although the most recent incurral group is still lower than the earlier incurral groups. This increase is possibly caused by different levels of diagnosis coding by contributing company.

Figure G.7.1: The chart below shows the trends of five leading diagnosis groups over incurral year group for Nursing Home Claims.



Nursing Home, Home Health Care/ADC/Other Claims: Closed Status and Diagnosis Summary (Appendix G-8)

Appendix G-8 compares claims experience on closed claims by diagnosis group and claim close status (benefit expiry; death; recovery).

The majority of data is coded in the unknown claim close status at this time (72% of the nursing home claims). For nursing home claims where this data is available, the percentage closed due to death is 65%, due to recovery is 26% and due to benefit expiry is 8%. As expected, the largest average payments and largest average claim days are from nursing home claims that closed due to benefit expiry, followed by claims that closed due to death, with the smallest average payments and average claim days from claims that recovered.


By diagnosis, Alzheimer's Nursing Home claims (where coding by close code was available) had the a much larger than average percentage of claims close due to death at 82%, with benefit expiries at 12% and recoveries at 6%. In contrast, Nursing Home Injury claims (where coding by close code was available) had 40% of claims close due to death, with benefit expiries at 5% and recoveries at 54%.

Nursing Home, Home Health Care/ADC/Other Claims: Issue Year and Diagnosis Summary (Appendix G-9)

Appendix G-9 compares claims experience by diagnosis group and issue year.

The latest issue year group (1996-1999) is still too new to have credible data, while the early issue year group (1984-1987) has a large percentage of the data with an unknown diagnosis group. For nursing home claims, the most prevalent diagnosis groups for issue year group 1988-1991 are Alzheimer's, Injury and Stroke. For the issue year group 1992-1995, the most prevalent diagnosis groups are Alzheimer's and Stroke.

Figure G.9.1: The chart below shows the trends of five leading diagnosis groups by issue year grouping for Nursing Home Claims.



Nursing Home, Home Health Care/ADC/Other Claims: Underwriting Type and Diagnosis Summary (Appendix G-10)

Appendix G-10 compares claims experience by diagnosis group and underwriting type.

The underwriting categories of Full Medical and Simplified have the most credible data. For nursing home claims, claims with Simplified underwriting have much higher average claim payment and average days on claim compared with claims with Full underwriting and the total studied block on average. The higher cost for Simplified underwriting on Nursing Home claims is true for all but a few diagnosis groups.

Nursing Home, Home Health Care/ADC/Other Claims: Benefit Period Type and Diagnosis Summary (Appendix G-11)

Appendix G-11 compares claims experience by diagnosis group and benefit period limitation.

For nursing home claims, 8.5% of claims have an unlimited benefit period. By diagnosis group, Alzheimer's, Arthritis, Cancer and Stroke have the highest percentage of claims with an unlimited benefit period. While the overall average duration of claim is longer for limited benefit periods, certain diagnosis groups (Alzheimer's, Endocrine and Mental) are longer for the unlimited benefit periods.

Average Number of Home Health Care Visits Per Week By Diagnosis (Appendix G-12)

Appendix G-12 shows the average number of Home health care visits per week by diagnosis group.

Compared with the prior study, the average number of visits per week increased 32%. This increase was seen across most diagnosis groups. Diagnosis groups with the highest average number of visits per week are Circulatory (6.78 visits) and Cancer (6.40 visits). Diagnosis groups with the fewest average number of visits per week are Pregnancy (1.72 visits- only 12 claims in the study) and Genitourinary System (2.64 visits). Alzheimer's, which is consistently the most prevalent diagnosis in the study, has an average number of visits per week of 4.28, very close to the average for all diagnosis groups in the study of 4.29.

Section V

MORTALITY

Introduction

This report presents the mortality experience of long-term care insurance in the United States for contracts issued during 1984-1999. The exposure period is 1984-1999. This report addresses terminations by death. Terminations that were not identified in the data are assumed to be other than death and are not included. Four of the contributing companies did not identify the cause of termination and the data from these companies is not included in this section. Unless otherwise stated, the data is for "non-claim" or active lives. Claim deaths are included in the claim termination rates. The study included 67,925 deaths of active lives and 10,662 deaths of disabled lives.

Because there is no death benefit on most of the policies, some terminations by death may not be recorded as such. In this report, they would be counted as lapse and included in Section VI, Voluntary Lapse. Thus, mortality data reported is likely understated and lapse data may be overstated. Section VII, Total Terminations, provides information on voluntary lapse and mortality combined.

Mortality rates are broken out into the following categories:

- Active and Disabled Lives
- Attained Age
- Contract Duration
- Gender
- Underwriting Class

Total (Active and Disabled Lives) Mortality Rates

Overall, the LTCI mortality rate is about 1%. It is about 0.96% for females and 1.43% for males.




Figure 1 – Overall Mortality Rates

Total and Active Lives Mortality Compared to Industry Tables (Appendix H-1)

Long-Term Care mortality is considerably lower (25% to 55% lower) than many of the industry tables commonly used in pricing. Figures 2 and 3 below show a comparison of male and female LTC insurance mortality to three industry tables - the 1983 Group Annuity Table (83GAM), the Annuity 2000 table (A2000) and the Ultimate portion of the 1985-1990 Society of Actuaries Life Insurance table (85-90 SOA). The select portion will be addressed later in this report. Figure 2 is total lives and Figure 3 is active lives only. Including the disabled lives does not affect the overall outcome significantly.

Figure 2
Ratio of LTC Mortality to Industry Tables
Active and Disabled Lives

Attained	Female			Male		
Age	83GAM	A2000	85-90 SOA	83GAM	A2000	85-90 SOA
40-49	0.98	1.06	0.61	0.74	0.93	0.65
50-59	0.86	0.91	0.50	0.57	0.77	0.50
60-69	0.66	0.76	0.45	0.44	0.69	0.40
70-79	0.53	0.71	0.47	0.47	0.75	0.46
80-89	0.53	0.66	0.48	0.55	0.87	0.56
90-99	0.41	0.45	0.31	0.44	0.64	0.45
Total	0.56	0.71	0.47	0.49	0.77	0.47

Figure 3
Ratio of LTC Mortality to Industry Tables
Active Lives

Attained	Female		Male			
Age	83GAM	A2000	85-90 SOA	83GAM	A2000	85-90 SOA
40-49	0.93	1.00	0.57	0.69	0.88	0.61
50-59	0.81	0.86	0.47	0.54	0.73	0.48
60-69	0.62	0.71	0.42	0.41	0.65	0.37
70-79	0.46	0.61	0.40	0.42	0.66	0.41
80-89	0.41	0.52	0.38	0.45	0.71	0.46
90-99	0.31	0.34	0.24	0.37	0.54	0.38
Total	0.47	0.60	0.40	0.43	0.67	0.41

Total Lives Mortality Difference by Gender Compared to Industry Tables

Figure 4 below compares male and female mortality. The 83GAM table and A2000 table are also shown for reference. As expected, male mortality is consistently higher than female (49% higher overall). In general, male and female are closer together at the younger ages and farther apart at older ages than the A2000 table.


Figure 4
Ratio of Male to Female Mortality
Active and Disabled Lives

Attained Age	LTC	83GAM	A2000
40-49	1.63	2.17	1.85
50-59	1.50	2.28	1.77
60-69	1.48	2.26	1.64
70-79	1.65	1.87	1.57
80-89	1.70	1.63	1.29
90-99	1.42	1.39	1.06
Total	1.49	1.71	1.38

Active Lives Select Mortality Compared to 85-90 SOA Table

Figure 5 below shows a comparison of male and female LTC mortality rates to the select period of the 85-90 SOA table for durations 1 through 6. In general, except for issue ages 50-59, the level of LTC mortality is similar to the 85-90 SOA select rates. For issue ages up to age 80, the slope by duration seems flatter for LTC mortality than 85-90 SOA. At issue ages 80-85, LTC mortality is somewhat lower, but seems to have a similar slope by duration.

Figure 5 – Active Lives by Duration Compared to 85-90 SOA Select



Active Lives Ultimate Mortality Compared to the Annuity 2000 Table (Appendix H-2)

For this exhibit, durations 7-15 are assumed to be ultimate. Taking out the early duration select period does have an effect on the level of mortality at the older ages. For Males, the ultimate LTC mortality comes much closer to the A2000 table, but for Females, ultimate LTC mortality remains below the A2000 (i.e., ratio remains less than 1.00).





Figure 6 – Comparison of Total and Ultimate Active Life Mortality and A2000



Disabled Lives Mortality Compared to SOA Table 95 (Appendix H-3)

The Society of Actuaries Table 95 (SOA Table 95) is a disabled life mortality table based on a disability income insurance definition of disability. It excludes deaths from mental nervous disorders, AIDS and pregnancy. It does not provide data for age groups above age 75. Since people receiving LTC may be primarily a subset of disabled lives that is generally more disabled, it is not surprising that LTCI mortality is generally higher. However it is closer for females over age 65.

Figure 7
Ratio of LTC Mortality to SOA 95 Mortality

Age at Claim	Female	Male
Under 50	0.84	0.23
50-54	1.75	1.44
55-59	1.31	1.66
60-64	1.61	1.27
65-69	1.08	1.51
70-74	1.04	1.41
Total	1.09	1.39

Disabled Lives Mortality by Gender Compared to the SOA 95 Table

Figure 8 shows that the spread between male and female mortality for LTC disabled lives is wider than the spread in the SOA 95 table except age ages 50-54. Age ages under 50, the male/female relationship is opposite for LTC and SOA 95.

Figure 8
Ratio of Male to Female Mortality

Age at Claim	LTC	SOA 95
Under 50	0.33	1.20
50-54	0.98	1.19
55-59	1.61	1.28
60-64	0.77	0.98
65-69	1.57	1.12
70-74	1.47	1.08
Total	1.37	1.07

Trend of Active Lives Mortality By Exposure Period (Appendix H-4)

The exposure period was divided into four parts to discover any trend. Note that this is NOT issue year. A contract issued in 1986 would have its first two durations in the 1984 – 1987 exposure period and duration 3 in the 1988 – 1991 exposure period. Figures 9 and 10 below show there is significant mortality improvement over the four periods, but the trend seems to be slowing in the most recent period.




Figure 9 – Mortality by Exposure Period




Figure 10
Average Annual Mortality Improvement
Exp Period 1984-87 to Exp Period 1996-99

Attained Age	Female	Male
65	24%	22%
70	20%	24%
75	14%	19%
80	16%	18%

Exp Period 1992-95 to Exp Period 1996-1999

Attained		
Age	Female	Male
65	25%	12%
70	15%	16%
75	9%	11%
80	4%	7%

Active Lives Mortality Compared to Disabled Lives Mortality (Appendix H-5)

Disabled lives represent a very small portion of total exposure. Overall, disabled lives mortality is almost <u>seventeen</u> times active lives mortality.

Active Lives Select Mortality (Appendix H-6)

The appendix (H-6) is a table of age banded mortality rates and selection factors given an assumed select periods of 4 years, 5 years and 6 years. The select factors are calculated as the ratio of a given duration to the mortality rate we may consider to be ultimate. The three assumptions for ultimate are 1) Durations 5-15, 2) Durations 6-15 and 3) Durations 7-15. It appears that a significant select period does not exist for issue ages below age 65, although the data is sparse for issue ages below 60. For issue ages 65-69, the selection period seems to be two years. For issue ages 70 and above, the data shows that the rates have not reached ultimate by the sixth duration. Figure 11 below shows one possibility for selection factors based on the data in Appendix H-6. There is quite a bit more data in this report than there was in the prior report. The male/female differences have diminished and the apparent select period at the older ages has become longer and more definite.

Combined Gender Select Factors 120.00% 100.00% Select Factor - Iss Age 50-64 80.00% Iss Age 65-69 60.00% Iss Age 70-79 40.00% - Iss Age 80-89 20.00% 0.00% 1 2 3 4 5 6 Duration

Figure 11 – Select Factors

Mortality by Underwriting Type (Appendix H-7)

This section includes both active and disabled lives mortality. There is a significant difference in the mortality experience of groups with different types of underwriting – full, simplified and guaranteed issue. Not surprisingly, the full underwriting group has the lowest mortality as shown in Figure 12 below.




Figure 12

The difference in mortality seems to lessen with duration, but continues to be significant through the 10-year period shown in the appendix. Interestingly, the guaranteed issue group has lower mortality than the simplified underwriting group and seems to be getting closer to the full underwriting group in later durations. The guaranteed issue group is mostly group business with actively-at-work requirements. This may indicate that actively-at-work requirements may be more effective than current simplified underwriting techniques.

Section VI

VOLUNTARY LAPSE

Introduction

This section presents the voluntary lapse experience of long-term care insurance in the United States for issue years 1984 - 1998. The 1999 issues were not utilized as the exposure ceased December 31, 1999. The data presented in this section includes terminations for all reasons except death. Four of the contributing companies did not identify the cause of termination. The data from these companies has been excluded from this section and the mortality section. In addition, the lapse experience of one company was significantly different than that of the other contributing companies. The data from this company has been excluded from this section, but was included in the mortality section.

In section VII are tables showing total termination rates, which includes both lapses and deaths. Except for the data from the one company with significantly different lapse experience, data from <u>all</u> contributing companies is included in these tables.

The lapse data used for this study includes more than twice the total amount of exposure that was available for the previous study. The data extends to the first fourteen durations, compared to the first nine for the previous study. The lapse rates in the first eight durations are lower in this study than they were in the previous one. This could be the result of greater awareness of the need for long-term care insurance and the resulting value of the protection.

These differences are shown in the table below.

	Exposure		Lapse Rate	
Duration	1993 Study	1999 Study	1993 Study	1999 Study
1	1,069,648	1,905,567	15.0%	10.6%
2	723,661	1,432,141	10.6%	7.9%
3	504,159	1,095,890	9.2%	6.9%
4	308,176	829,992	9.2%	6.1%
5	153,373	600,594	11.9%	5.4%
6	53,303	403,210	14.9%	5.1%
7	21,284	252,336	10.2%	5.0%
8	5,900	174,517	5.4%	4.9%
9	1,844	124,395	3.6%	4.7%
10		73,041		5.4%
11		44,109		5.8%
12		19,900		7.4%
13		8,029		8.2%
14		1,156		11.5%
15		1		0.0%
Total	2,841,348	6,964,878	12.0%	7.6%

Definition of Terms

Duration: Duration is calculated as the number of years between the termination date and issue date. The participating company provides both dates. In calculating the duration, a one-month grace period after the coverage anniversary is assumed. For example, if coverage terminates between 1 and 13 months after the issue date, the duration is 1. If coverage terminates between 14 and 25 months after the issue date, the duration is 2, and so forth.

In Force: Coverage is considered in force if the termination reason code is specified as in force at the end of the observation period. In force business includes coverage issued from 1984 to 1998. The observation periods are calendar years 1984 through 1999.

Lapse: An individual's coverage is considered lapsed if it was terminated by the individual's 1999 coverage anniversary with one of the following reason codes:

- Terminated, reason unknown
- Terminated as a result of non payment of premiums
- Terminated as a result of expiration of benefits
- Terminated as a result of termination of the group
- Terminated for other reasons
- Terminated to reduced paid-up status
- Terminated to extended term

Coverage is not considered lapsed if:

- Terminated as a result of death
- Terminated after their 1999 coverage anniversary

Lapse Rates: Lapse rates in this report are calculated as the number of terminations (lapses) divided by the total lives exposed (in force). Lives active at the start of the experience period contribute a full year of exposure. Lapses therefore contribute a full year to both the numerator and denominator of the lapse rate calculation.

Lapse rates for the industry are calculated by dividing the sum of all of the individual company's lapses by the sum of all of the individual company's exposure. The division to calculate a lapse rate is performed as a last step. Therefore, companies with larger exposure receive greater weight than companies with smaller exposure.

For this study, lapse rates are broken out by the following categories:

- Policy Duration
- Policy Type (individual versus group)
- Issue Year Group
- Issue Age Group
- Type of Underwriting
- Gender
- Elimination Period
- Benefit Period (limited versus unlimited)
- Benefit Escalator Clause
- Premium Payment Mode
- Policy Quarter
- Distribution Type

Differences from the previous study are the addition of the breakdown by benefit period and the elimination of the breakdowns by company quartile.

Discussion

Appendices F-1 through F-10 contain detailed data on total lapses and total exposures for each of the breakdowns discussed below. These discussions contain additional graphs and tables developed using the data in the appendices that attempt to highlight observed patterns and trends. Please note that judgement was used when deciding what data to include when producing these additional graphs and tables; some cells that contain only a small amount of exposure were omitted from them.

Lapse Rates by Issue Year Group, Policy Type and Duration (Appendix F-1)

Figure 1 shows lapse rates by duration for all issue years and policy types. The lapse rates drop quickly from their initial levels until duration 9, when the rate of lapse begins to rise as duration increases. Possible explanations for this observed increase in the later durations are offered in the discussions of Figures 2, 3, and 5 that follow.







Figure 2 shows the pattern of lapse rates by duration separately for individual policies and group policies. By duration, the group insurance lapse rates generally decrease toward a low ultimate rate. Surprisingly, the individual experience shows a significant increase in lapse rates in the later durations. While there is a reasonable amount of data in these later durations, the results are not what one would expect. If true, these results would have material implications on premiums and reserves. There are probably other explanations. This could be the result of conversions from older policy forms to new ones, or it could be the result of unrecorded deaths being counted as lapses (the latter possibility suggested by the data shown in Figure 5, Lapse Rates By Issue Age Group).



Figures 3 and 4 show lapse experience by issue year group for individual and group policies respectively.


Lapse rates for individual policies are lower for the more recent issue year groups (1998 and later) than those for earlier issue years. The higher lapse rates on the older individual issues could be a result of rate increases that have been made on some of these policies. The group insurance data shows no clear pattern by issue year group.





Lapse Rates by Issue Age Group and Duration (Appendix F-2)

Figure 5 shows the pattern by duration for various issue age groups. The pattern for the "under 50" issue age group mirrors the group insurance experience shown in Figure 2. The other issue ages show a distinct pattern of higher lapse rates at the later durations, particularly for the oldest issue ages. The general pattern by duration could be the result of conversions from older policy forms to new ones; the pattern of higher lapse rates at the oldest issue ages could be unrecorded deaths being counted as lapses.



Lapse Rates by Type of Underwriting, Policy Type, and Duration (Appendix F-3)

Appendix F-3 shows lapse rates by type of underwriting, policy type, and duration. For a given policy type, the data show a consistent pattern of lower lapse rates for full underwriting. Figure 6 below illustrates this trend. Total lapse rates have been shown over the first nine durations for various combinations of underwriting type and policy type. (Nine years was used for consistency between categories; not every category had data beyond nine years.) The greater persistency associated with stricter underwriting might be explained by the fact that those who endured a more rigorous underwriting process presumably did so because they felt the value of the insurance was worth it. Those receiving simplified issue or guaranteed issue for group long-term care insurance have a simpler enrollment process, and may be more inclined to reconsider their decision to purchase the coverage.

Figure 6 Nine-year Lapse Rates Type of Policy Type Underwriting Individual Group Full 7.34% 4.80% Simplified 11.26% 7.79% Guaranteed N/A 6.21%

Lapse Rates by Gender (Appendix F-4)

Exposures coded for gender are about 61% female and 39% male. Note the "all genders" totals do not match the totals of some of the other tables. This is because records with unknown genders have been excluded entirely from Appendix 4.

Lapse rates do not differ greatly by gender, although the lapse rate for males is slightly lower until duration 11, after which the male lapse rate becomes increasingly higher. This pattern is shown in Figure 7 below. It is possible that this pattern is the result of unrecorded deaths being mistakenly counted as lapses, since the higher unreported death rate for males would become increasingly significant as the insured population ages.

	Figure 7				
Duration	Male	Female	Difference		
1	10.39%	10.78%	-0.39%		
2	7.66%	8.02%	-0.36%		
3	6.62%	7.05%	-0.43%		
4	5.79%	6.27%	-0.48%		
5	4.99%	5.60%	-0.61%		
6	4.90%	5.27%	-0.37%		
7	4.60%	5.15%	-0.55%		
8	4.43%	5.10%	-0.67%		
9	4.40%	4.89%	-0.49%		
10	5.16%	5.51%	-0.35%		
11	5.85%	5.71%	0.14%		
12	7.51%	7.32%	0.19%		
13	8.42%	8.11%	0.31%		
14	12.69%	11.16%	1.53%		
Total	7.38%	7.74%	-0.36%		

Lapse Rates by Elimination Period (Appendix F-5)

The total lapse rate by elimination period is shown in Figure 8 for the four elimination periods with the largest amount of exposure. Total lapse rates for all durations combined were used for this comparison since the distribution of data by duration is similar for each of these four elimination periods. The data suggests a trend toward higher lapse rates for policies with the shortest elimination periods. Most of the other elimination period categories have small amounts of exposure, limiting their significance. The complete data may be found in Appendix F-5.


Figure 8

Elimination		
Period (days)	Lapse Rate	Exposure
0	8.92%	708,866
20	7.80%	1,962,707
90	7.02%	1,304,903
100	7.36%	1,561,458
All	7.65%	6.818.642

Lapse Rates by Benefit Period (Appendix F-6)

Figure 9 shows the lapse rates for policies with limited lifetime benefits versus those with unlimited lifetime benefits. The lapse rates for policies with unlimited benefits are lower at most durations than those for policies with limited benefit amounts. This suggests that those who buy unlimited benefit plans value the financial and psychological security that accompanies such a benefit, and they are less inclined to voluntarily give up the protection provided by the plan.


The pattern of lapse rates for unlimited policies at durations 7 and 8 appears to be an anomaly of the data, since there is no apparent reason for the higher rates at these durations.



Lapse Rates by Benefit Escalator Clause (Appendix F-7)


Lapse data for policies with various types of benefit escalator clauses is shown in Appendix F-7. The pattern of lapses for the three most common types is shown in Figure 10. While there appears to be no significant difference in lapse rates between policies with a Future Purchase Option clause and those with an automatic benefit increase clause, the lapse rates are higher at all durations for policies with no benefit escalator clause. This difference in lapse rates for plans with and without a benefit escalator clause should be noted and taken into account by pricing actuaries. When the data is split between issue ages [64 and under] vs. issue ages [65 and over], no significant differences from the pattern in Figure 10 are observed.

It is possible that the upward trend in lapse rates at the later durations for plans without a benefit escalator clause is the result of a perceived decline in the value and utility of the coverage over the years.



Lapse Rates by Premium Payment Mode (Appendix F-8)

Figure 11 shows the pattern of lapse rates for four different frequencies of premium payment. No large differences between premium payment modes are apparent, though the lapse rates for monthly payment mode are generally slightly lower. This could be because some of the monthly payers are using payroll deduction through a group plan or electronic funds transfer.



Lapse Rates by Policy Quarter (Appendix F-9)

Figure 12 below shows that 45% of all lapses occur on or near policy anniversary. Note that because of the definition of duration, the fourth quarter includes the month prior to anniversary, the month of anniversary and the month following anniversary.








Figure 13 shows the percentage of lapses that occur in the fourth policy quarter. Note the consistent pattern after the first policy year, with between 38% and 42% of all lapses occurring in the fourth policy quarter.




The observed pattern of lapse by policy quarter varies significantly with the frequency of premium payment, indicating clearly that the premium-paying decision is a major driver of lapse rates. This is illustrated in Figures 14A, B, C, and D below, which break out the data used to create Figure 12 into its annual, semi-annual, quarterly, and monthly premium mode components. These findings suggest that the pricing actuary carefully consider the distribution of lapses when developing pricing assumptions.










Lapse Rates by Distribution Type (Appendix F-10)

Lapse Rates by distribution method are shown below in Figure 15. Lapse rates for policies where a company agent was involved in the sale are lowest at the early durations, but become the highest after 10 years. The lowest ultimate lapse rates were with Agent Type Unknown.



Section VII

TOTAL TERMINATIONS

Introduction

This section presents experience on total termination rates, which includes both lapses and deaths. Insurance issued in years 1984 – 1998 is included in this study. The 1999 issues were not utilized as the exposure ceased December 31, 1999. In addition, the voluntary lapse experience of one company was significantly different than that of the other contributing companies. The data from this company has been excluded from this section. Except for the data from the one company with significantly different lapse experience, data from all contributing companies is included in these tables.

The total termination data used for this study includes more than two and a half times the total amount of exposure that was available for the previous study. The data extends to the first fourteen durations, compared to the first nine for the previous study.

Overall, the total termination rate is 9.5%. It is the same for males and females. The total termination rates are lower at each duration than they were in the previous study, though they are close at duration nine.

These differences are shown in the table below.

	Exp	osure	Total Term	ination Rate
Duration	1993 Study	1999 Study	1993 Study	1999 Study
1	1,069,648	2,065,387	15.6%	12.9%
2	723,661	1,522,749	11.5%	9.5%
3	504,159	1,148,949	10.4%	8.4%
4	308,176	859,258	10.7%	7.6%
5	153,373	616,090	13.5%	6.9%
6	53,303	414,372	16.8%	6.8%
7	21,284	262,139	12.5%	7.0%
8	5,900	182,173	9.4%	7.3%
9	1,844	129,706	7.5%	7.4%
10		76,034		8.8%
11		44,769		9.3%
12		19,566		11.0%
13		7,889		12.0%
14		1,144		14.0%
15		1		0.0%
Total	2,841,348	7,350,226	13.0%	9.5%

In the discussion of voluntary lapse experience in Section VI, it was speculated that unrecorded deaths in the data submitted might be counted as lapses. By looking at total termination rates, this section provides an upper bound on how many insureds have terminated their coverage, regardless of the reason. In addition, this section includes data from the four contributing companies who did not identify the cause of termination. These companies were excluded from the mortality and voluntary lapse sections.


Since the voluntary lapse rates might be overstated due to unreported lapses, it is possible that the use of voluntary lapse rates developed from this data combined with the use of an industry mortality table (i.e., not based on the mortality experience shown in Section V) could result in an overstatement of total termination rates Because of this, the actuary should use caution when using the voluntary lapse data with a separate mortality table. It is hoped that the data on total termination rates presented in this study will allow the actuary to judge whether the combined lapse and mortality assumptions being considered are reasonable.

Discussion

Appendices J-1 through J-4 contain detailed data on total terminations and total exposures for each of the breakdowns discussed below. These discussions contain additional graphs and tables developed using the data in the appendices that attempt to highlight observed patterns and trends. Please note that judgement was used when deciding what data to include when producing these additional graphs and tables; some cells that contain only a small amount of exposure were omitted from them.

Total Termination Rates by Issue Age Group and Issue Year Group (Appendix J-1)

Figure 1 shows both lapse rates and total termination rates by duration for all issue ages and issue years. Both follow a similar pattern, but the difference between the total termination rate and the lapse rate appears to be increasing in general as duration increases. This is consistent with mortality rates becoming a more significant contributor to the total termination rate at the older ages.




Total termination rates by issue year group are contrasted with lapse rates in Figure 2. Overall, the total termination rate is 25% higher than the rate for lapse alone. The difference between the total termination rate and the lapse-only rate becomes larger for the earlier issue year groups. Since the individuals in the earlier issue year groups are presumably older and are past their select period, this overall pattern makes sense. Interestingly, the data shows a much wider difference for issue years 1991 and prior than for issue years 1992 and later. This sharp break could be a result of merging together data from numerous contributing companies with different amounts of exposure for the various issue year groups studied.

Figure 2
Lapse and Total Termination Rates by Issue Year Group


	Exposure		Rate		
Issue Year		Total		Total	Total Term /
Group	Lapse Only	Terminations	Lapse Only	Terminations	Lapse Only
1984-87	1,066,490	1,170,492	9.08%	12.25%	1.35
1988-91	3,355,749	3,617,950	7.05%	9.38%	1.33
1992-95	1,920,751	1,941,176	7.48%	8.31%	1.11
1996-98	621,888	620,608	8.54%	9.03%	1.06
All Years	6,964,878	7,350,226	7.61%	9.52%	1.25


Figure 3 shows total termination rates by issue age groups. There is a clear pattern of higher total termination rates at the later durations for issue ages 60 and over, and some indication of the beginning of an upward trend at the later durations for issue ages 59 and under.



The corresponding data in Figure 5 of Section VI, Lapse Rates by Issue Age Group, shows an even wider divergence in the level of reported lapse rates at the later durations between issue ages over 79 and issue ages 79 and under. In the discussion of Figure 5 it was speculated that this could be a result of unrecorded deaths in the data for the Over 79 issue age group being counted as lapses. More evidence of this can be seen in Figures 4A and 4B below.

Figure 4A compares total termination rates with lapse rates for issue age group 70 - 79. As expected, the difference between the two rates widens with increasing duration, as mortality becomes a more significant contributor to the total rate. Note, however, that the pattern shown for issue age group Over 79 in Figure 4B is <u>reversed</u>. This strongly suggests that the data submitted for issue age group Over 79 contains a significant number of unreported deaths that have been mistakenly counted as lapses in this study.





Total Termination Rates by Issue Age Group and Type of Underwriting (Appendix J-2)

Figure 5 shows lapse rates and total termination rates by type of underwriting over the first nine durations (nine years was used for consistency between categories; not every category had data beyond nine years.) When compared to the lapse only rates, the increase in total termination rates is relatively less for insureds with guaranteed issue. This is likely due to the lower issue ages of these insureds, at which mortality would be a less significant part of the total termination rate.

Note that the overall ratio of the total termination rate to the lapse only rate is 1.25 in Figure 2, but in Figure 5 it is only 1.15. A review of the data in Appendices J-1 and J-2 shows that there are differences in the total exposures, terminations, and lapse rates between the two tables. This is because records coded with an underwriting type of "unknown" have been omitted from Appendix J-2. Thus, each breakout of the data has a different set of exposures.

Figure 5
Lapse and Total Termination Rates by Type of Underwriting

Nine Year Rate					
Type of	Lapse	Total	Total Term /		
Underwriting	Only	Termination	Lapse Only		
Full	7.09%	8.06%	1.14		
Simplified	10.36%	12.27%	1.18		
Guaranteed	6.21%	6.57%	1.06		
All Known Types	7.68%	8.84%	1.15		

Total Termination Rates by Issue Age Group and Gender (Appendix J-3)

Total termination rates by issue age group and gender are shown in Appendix J-3. Figure 6 summarizes the difference between male and female total termination rates. As with the lapse only rates from Figure 7 of Section VI (reproduced below), differences in the rate by gender are small for most of the durations shown. Although the male total termination rate is less than the female rate in the first two durations, it becomes higher than the female rate in years three and beyond. The gender difference in the total termination rate generally becomes wider as duration increases, which could be the result of relatively higher male mortality rates as the insured population ages with duration.

	Figure 7			
Tot	tal Terminatio	on Rates by G	ender	Lapse Only
Duration	Male	Female	Difference	Difference
1	12.70%	13.06%	-0.36%	-0.39%
2	9.48%	9.54%	-0.06%	-0.36%
3	8.46%	8.39%	0.07%	-0.43%
4	7.70%	7.52%	0.18%	-0.48%
5	6.98%	6.82%	0.16%	-0.61%
6	7.00%	6.64%	0.36%	-0.37%
7	7.35%	6.78%	0.57%	-0.55%
8	7.52%	7.20%	0.32%	-0.67%
9	7.79%	7.22%	0.57%	-0.49%
10	9.68%	8.33%	1.35%	-0.35%
11	10.51%	8.79%	1.72%	0.14%
12	12.34%	10.42%	1.92%	0.19%
13	13.37%	11.55%	1.82%	0.31%
14	15.56%	13.53%	2.03%	1.53%
Total	9.56%	9.49%	0.07%	-0.36%

Total Termination (Mortality and Lapse) Compared to Industry Mortality Tables (Appendix J-4)

In Section V Mortality, it was commented that some deaths were probably excluded from the mortality data reported and included in the lapse data. While we can't know the number of deaths that were counted as lapse, we can compare the total termination rates to the published mortality tables as an upper bound. Figure 7 and Appendix J-4 show total terminations in the same format as Figure 2 and Appendix H-1. This information gives an idea of the range of reasonable assumptions for mortality and lapse combined in relation to the published mortality tables.

Figure 7
Ratio of LTC Terminations to Industry Mortality Tables

Attained		Female			Male	
Age	83GAM	A2000	85-90 SOA	83GAM	A2000	85-90 SOA
40-49	59.10	63.90	36.51	27.64	35.07	24.55
50-59	25.34	26.80	14.80	10.14	13.80	8.91
60-69	11.59	13.34	7.93	5.04	7.99	4.60
70-79	4.65	6.22	4.06	2.54	4.04	2.49
80-89	2.05	2.58	1.87	1.50	2.37	1.52
90-99	1.48	1.65	1.15	1.36	2.00	1.40
Total	5.22	6.63	4.39	3.05	4.82	2.96

51

Section VIII

SUMMARY

The first two reports were considered to be development activity for the intercompany study. This report and future reports are expected to be more regular and up-to-date. Potential contributors for the fourth study have already been solicited and the time frame set to collect by year-end 2002 data through the 2001 exposure period. The next report will be published during 2003. It will be in two installments. The first installment will be a Persistency Study jointly prepared by LIMRA and the SOA. The second installment will be more heavily oriented to claim data.

With each new report, it is anticipated that increased volume of data will bring increased credibility to the calculations and the ability to increasingly determine results based on a variety of marketing, sales, underwriting, and claim processing practices. Just as LTC products sold over the past 20 years have evolved steadily and quickly, so will intercompany statistical knowledge expand as LTC insurance enters the new millennium.

ACKNOWLEDGEMENTS

The Intercompany Subcommittee takes responsibility for this report. However, it must publicly recognize that contributions were made by a number of persons. Although every person's effort cannot be recognized, certain names must be mentioned.

A critical review of the Report was made by Linda Ball and Ronald Wolf.

Compilation, refinement and tabulation of the submissions as well as advice on the structure of the report was extensively performed at the Center of Medico-Actuarial Statistics by Leo DiAngelo and William McDonald. Guidance in our process and liaison with the Society of Actuaries was provided by Jack Luff of the Society staff.

Administrative Support was generously supplied by Winona Mae Berdine.

Last but very important recognition must be given to Sam Gutterman whose initial vision provided the original impetus to secure data from the early contributors. Without the data, this study would not have been possible.

InterCompany Subcommittee

Gary Corliss, Chair Roger Gagne Marylou Murphy Mark Newton Kim Tillmann

Society of Actuaries Long Term Care Experience Committee Intercompany Study 1984-1999

Appendices

<u>Appendix</u>	<u>Subject</u>
A	CONTRIBUTING COMPANIES
В	EXPOSURE CHARACTERISTICS
C	CLAIM CHARACTERISTICS
D	INCIDENCE
E	CONTINUANCE
\mathbf{F}	VOLUNTARY LAPSE
G	CAUSE OF CLAIM
Н	MORTALITY
J	TOTAL TERMINATION

Society of Actuaries Long Term Care Experience Committee Intercompany Study 1984-1999

Appendix A

Contributing Companies

AEGON,	IICA	INC
ALCON,	USA,	IIIC.

AETNA LIFE INSURANCE COMPANY

ALLSTATE LIFE INSURANCE COMPANY

AMERICAN FAMILY LIFE ASSURANCE COMPANY

BANKERS LIFE & CASUALTY

COUNTRY LIFE INSURANCE COMPANY

GE CAPITAL ASSURANCE COMPANY

JOHN HANCOCK LIFE INSURANCE COMPANY

LUTHERAN BROTHERHOOD

MEDICO LIFE INSURANCE COMPANY

MUTUAL OF OMAHA INSURANCE COMPANY

MUTUAL PROTECTIVE INSURANCE COMPANY

PHYSICIANS MUTUAL INSURANCE COMPANY

PRUDENTIAL LIFE INSURANCE COMPANY

SOUTHERN FARM BUREAU LIFE

TIME FORTIS INSURANCE COMPANY

TRANSPORT LIFE INSURANCE COMPANY

UNUM LIFE INSURANCE COMPANY

			-	
	APPENDIX B-1			
Dis	stribution of Insu	ıreds		
	by			
	Gender			
	Number of	Percentage of		
Gender	Insureds	Insureds		
Female	1,597,543	59.6		
Male	1,073,735	40.1		
Unknown	8,903	0.3		
Total	2,680,181	100.0		

	APPENDIX B-2					
		Distr	ibution of Insu	reds		
			by			
		Issue A	ge and Type o	of Policy		
	Indiv	ridual	Gr	oup	All T	ypes
	Number of	Percentage of	Number of	Percentage of	Number of	Percentage of
Age	Insureds	Insureds	Insureds	Insureds	Insureds	Insureds
<30	727	0	90,022	11.5	90,749	3.4
30-34	1,138	0.1	72,620	9.3	73,758	2.8
35-39	2,371	0.1	81,198	10.4	83,569	3.1
40-44	8,641	0.5	89,415	11.4	98,056	3.7
45-49	19,797	1	89,815	11.5	109,612	4.1
50-54	56,804	3	84,426	10.8	141,230	5.3
55-59	127,279	6.7	76,176	9.7	203,455	7.6
60-64	336,465	17.7	75,171	9.6	411,636	15.4
65-69	551,585	29	66,264	8.5	617,849	23.1
70-74	426,092	22.4	34,899	4.5	460,991	17.2
75-79	268,874	14.2	17,738	2.3	286,612	10.7
80-84	94,143	5	3,239	0.4	97,382	3.6
85+	4,950	0.3	332	0	5,282	0.2
Total	1,898,866	100.0	781,315	100.0	2,680,181	100.0
	The Average Issue Age for Individual Policies is 68.4					
	The Average Issue Age for Group Policies is 48.6					
	The Average Issue for All Types of Policies is 62.6					

APPENDIX B-3			
Dist	ribution of Insu	ıreds	
	by		
	Attained Age		
	Number of	Percentage of	
Attained Age	Insureds	Insureds	
<30	68,553	2.6	
30-34	64,146	2.4	
35-39	75,568	2.8	
40-44	87,316	3.3	
45-49	100,493	3.7	
50-54	127,256	4.7	
55-59	164,304	6.1	
60-64	272,211	10.2	
65-69	506,125	18.9	
70-74	532,961	19.9	
75-79	396,696	14.8	
80-84	211,242	7.9	
85+	73,310	2.7	
Total	2,680,181	100.0	
The Ave	rage Attained A	nge is 65.5	

	APPENDIX B-4								
			Exposure I	Distribution					
			b						
	Type of Policy, Issue Age and Gender								
		Fe	male	N	lale	Split by	Gender		
Type of		Number of	Percentage of	Number of	Percentage of	Female % of	Male % of		
Policy	Issue Age	Insureds	Insureds	Insureds	Insureds	Total	Total		
1 Olloy	1330C Age	insurcus	maurcus	insurcus	maureus	Total	Total		
Individual	<30	372	0.0	355	0.0	0.0	0.0		
	30-34	593	0.1	545	0.1	0.0	0.0		
	35-39	1,289	0.1	1,082	0.2	0.1	0.1		
	40-44	5,215	0.4	3,413	0.5	0.3	0.2		
	45-49	13,148	1.1	6,606	0.9	0.7	0.3		
	50-54	38,170	3.3	18,362	2.5	2.0	1.0		
	55-59	84,846	7.2	41,724	5.8	4.5	2.2		
	60-64	211,658	18.0	123,730	17.2	11.2	6.5		
	65-69	325,214	27.7	225,257	31.2	17.2	11.9		
	70-74	256,572	21.9	168,826	23.4	13.5	8.9		
	75-79	171,148	14.6	97,418	13.5	9.0	5.1		
	80-84	61,941	5.3	32,190	4.5	3.3	1.7		
	85+	3,502	0.3	1,448	0.2	0.2	0.1		
	Total	1,173,668	100.0	720,956	100.0	61.9	38.1		
	Total	1,173,000	100.0	720,930	100.0	61.9	30.1		
		The A	verage Issue A	ge for Females	is 68.4				
			Average Issue						
		The Averaç	ge Issue Age for	Males and Fer	males is 68.4				

		Fe	male	N	1ale	Split by	Gender
Type of		Number of	Percentage of	Number of	Percentage of	Female % of	Male %
Policy	Issue Age	Insureds	Insureds	Insureds	Insureds	Total	Tota
Group	<30	50,493	11.9	39,054	11.1	6.5	
	30-34	38,055	9.0	34,063	9.7	4.9	
	35-39	43,008	10.1	37,553	10.6	5.5	
	40-44	48,483	11.4	40,277	11.4	6.2	
	45-49	48,322	11.4	40,899	11.6	6.2	
	50-54	44,708	10.5	39,182	11.1	5.8	
	55-59	40,969	9.7	34,794	9.9	5.3	
	60-64	42,012	9.9	32,753	9.3	5.4	
	65-69	36,113	8.5	29,888	8.5	4.7	
	70-74	19,066	4.5	15,722	4.5	2.5	
	75-79	10,392	2.5	7,301	2.1	1.3	
	80-84	2,043	0.5	1,184	0.3	0.3	
	85+	211	0.1	109	0.0	0.0	
	Total	423,875	100.0	352,779	100.0	54.6	
		The A	Average Issue Aç	ae for Females	is 48.7		
			Average Issue				
The Average Issue Age for Males and Females is 48.6							

		Fei	male	Male		Split by Gender	
Type of		Number of	Percentage of	Number of	Percentage of	Female % of	Male % of
Policy	Issue Age	Insureds	Insureds	Insureds	Insureds	Total	Total
All Types	<30	50,865	3.2	39,409	3.7	1.9	1.5
7,	30-34	38,648	2.4	34,608	3.2	1.4	1.3
	35-39	44,297	2.8	38,635	3.6	1.7	1.4
	40-44	53,698	3.4	43,690	4.1	2.0	1.6
	45-49	61,470	3.8	47,505	4.4	2.3	1.8
	50-54	82,878	5.2	57,544	5.4	3.1	2.2
	55-59	125,815	7.9	76,518	7.1	4.7	2.9
	60-64	253,670	15.9	156,483	14.6	9.5	5.9
	65-69	361,327	22.6	255,145	23.8	13.5	9.6
	70-74	275,638	17.3	184,548	17.2	10.3	6.9
	75-79	181,540	11.4	104,719	9.8	6.8	3.9
	80-84	63,984	4.0	33,374	3.1	2.4	1.2
	85+	3,713	0.2	1,557	0.1	0.1	0.1
	Total	1,597,543	100.0	1,073,735	100.0	59.8	40.2
		The A	verage Issue Ag	ge for Females	is 63.2		
		The	Average Issue A	age for Males is	s 61.9		

			APPENDIX B-	5		
		Exp	oosure Distribu	tion		
			by			
		Attair	ned Age and G	ender	T	T
	-			4-1-	O dia b	0
	Female Male Split by Gender					Gender
Attained Age	Number of Insureds	Percentage of Insureds	Number of Insureds	Percentage of Insureds	Female % of Total	Male % of Total
<30	38,904	2.4	29,272	2.7	1.5	1.1
30-34	33,723	2.1	29,969	2.8	1.3	1.1
35-39	39,474	2.5	35,489	3.3	1.5	1.3
40-44	46,981	2.9	39,671	3.7	1.8	1.5
45-49	56,853	3.6	43,010	4.0	2.1	1.6
50-54	73,429	4.6	53,095	4.9	2.7	2.0
55-59	98,815	6.2	64,511	6.0	3.7	2.4
60-64	167,406	10.5	103,473	9.6	6.3	3.9
65-69	298,927	18.7	205,687	19.2	11.2	7.7
70-74	315,108	19.7	216,818	20.2	11.8	8.1
75-79	242,244	15.2	154,014	14.3	9.1	5.8
80-84	134,756	8.4	76,359	7.1	5.0	2.9
85+	50,923	3.2	22,367	2.1	1.9	0.8
Total	1,597,543	100.0	1,073,735	100.0	59.8	40.2
				Females is 66.1		
		The Average /	Attained Age fo	r Males is 64.7		

APPENDIX B-6					
Exposure Distribution					
-	by				
E	limination Perio	d			
Elimination	Number of	Percentage of			
Period Days	Insureds	Insureds			
0	320,869	12.0			
7-19	81,742	3.0			
20	511,326	19.1			
30	157,444	5.9			
31-50	19,211	0.7			
60	169,195	6.3			
90	803,560	30.0			
100	541,009	20.2			
101-359	62,956	2.3			
360-365	4,328	0.2			
730	14	0.0			
Unknown	8,527	0.3			
Total	2,680,181	100.0			

APPENDIX B-7						
Exposure Distribution						
by						
	Issue	Year and Type o	f Policy			
	Indi	vidual	G	roup		
	Number of	Percentage of	Number of	Percentage of		
Issue Year	Insureds	Insureds	Insureds	Insureds		
1984	4,752	0.3				
1985	14,507	0.8				
1986	68,403	3.6	1,125	0.1		
1987	109,074	5.7	33,154	4.2		
1988	165,956	8.7	56,585	7.2		
1989	189,683	10.0	33,627	4.3		
1990	157,639	8.3	67,181	8.6		
1991	153,146	8.1	43,232	5.5		
1992	159,502	8.4	58,052	7.4		
1993	162,081	8.5	73,311	9.4		
1994	124,432	6.6	55,814	7.1		
1995	146,347	7.7	45,656	5.8		
1996	87,083	4.6	51,792	6.6		
1997	91,573	4.8	53,621	6.9		
1998	120,442	6.3	71,219	9.1		
1999	144,246	7.6	136,946	17.5		
Total	1,898,866	100.0	781,315	100.0		

APPENDIX B-8 Exposure Distribution						
	•					
by State of						
State	Number of Insureds	Percentage of Insureds				
Alabama	17,010	0.6				
Alaska	493	0.0				
Arizona Arkansas	28,949 9,668	1.1 0.4				
California	129,754	4.8				
Colorado	23,430	0.9				
Connecticut	13,072	0.5				
Delaware	2,678	0.1				
District of Columbia	3,000	0.1				
Florida	95,044	3.5				
Georgia	30,659	1.1				
Guam	2	0.0				
Hawaii	16,777	0.6				
Idaho Illinois	9,390 73,324	0.4 2.7				
Indiana	47,977	1.8				
Iowa	72,292	2.7				
Kansas	43,777	1.6				
Kentucky	17,069	0.6				
Louisiana	18,124	0.7				
Maine	28,582	1.1				
Maryland	20,654	0.8				
Massachusetts	31,186	1.2				
Michigan	53,732	2.0				
Minnesota	25,543	1.0				
Mississippi	11,330	0.4				
Missouri	58,085	2.2				
Montana Nebraska	9,066 30,958	0.3 1.2				
Nevada	5,640	0.2				
New Hampshire	13,713	0.5				
New Jersey	21,787	0.8				
New Mexico	11,945	0.4				
New York	34,168	1.3				
North Carolina	33,843	1.3				
North Dakota	15,652	0.6				
Ohio	56,531	2.1				
Oklahoma	18,566	0.7				
Oregon	38,600	1.4				
Pennsylvania Puerto Rico	55,004 61	2.1				
Rhode Island	2,432	0.0				
South Carolina	15,117	0.1				
South Dakota	9,278	0.0				
Tennessee	32,065	1.2				
Texas	104,620	3.9				
Utah	5,741	0.2				
Vermont	4,962	0.2				
Virgin Islands	4	0.0				
Virginia	24,461	0.9				
Washington	56,160	2.1				
West Virginia	7,581	0.3				
Wisconsin	26,414	1.0				
Wyoming	2,448	0.1				
Unknown	1,161,763	43.3				
Total	2,680,181	100.0				

APPENDIX B-9							
Exposure Distribution							
	by						
Ту	pe of Benefit Pe	eriod					
Benefit	Number of	Percentage of					
Period	Period Insureds						
Days	1,416,294	52.8					
Dollars	718,964	26.8					
Unlimited	529,885	19.8					
Unknown	15,038	0.6					
Total	2,680,181	100.0					

APPENDIX B-10					
Exposure Distribution					
	by				
Max	imum Benefit F	Period			
Maximum					
Benefit	Benefit Number of Perce				
Period	Insureds	Insureds			
<= 1 Year	153,954	10.9			
2	188,109	13.3			
3	413,356	29.2			
4	240,565	17.0			
5	333,488	23.5			
6	81,707	5.8			
7	575	0.0			
10	4,540	0.3			
Total	1,416,294	100.0			

APPENDIX B-11					
Exposure Distribution					
by					
	enefit Amount				
	Number of	Percentage of			
Maximum Benefit Amount	Insureds	Insureds			
<= \$25,000	144,346	20.1			
25,001 to 50,000	127,739	17.8			
50,001 to 75,000	110,391	15.4			
75,001 to 100,000	62,847	8.7			
100,001 to 125,000	93,016	12.9			
125,001 to 150,000	63,238	8.8			
150,001 to 175,000	16,103	2.2			
175,001 to 200,000	38,361	5.3			
200,001 to 225,000	26,138	3.6			
225,001 to 250,000	4,037	0.6			
250,001 to 500,000	18,611	2.6			
500,001 to 1,000,000	14,137	2.0			
Total	718,964	100.0			

APPENDIX B-12						
Exposure Distribution						
	by					
Maximu	ım Daily Benefi	t Amount				
Daily Benefit	Number of	Percentage of				
Amount	Insureds	Insureds				
\$0-19	66,004	2.5				
20-29	26,351	1.0				
30-39	190,094	7.1				
40-49	123,425	4.6				
50-59	423,239	15.8				
60-69	279,351	10.4				
70-79	220,753	8.2				
80-89	255,698	9.5				
90-99	49,362	1.8				
100-109	503,811	18.8				
110-119	59,484	2.2				
120-129	89,517	3.3				
130-139	35,154	1.3				
140-149	23,427	0.9				
150-159	66,699	2.5				
160-169	20,270	0.8				
170-179	11,083	0.4				
180-189	7,945	0.3				
190-199	833	0.0				
200+	76,834	2.9				
Unknown	150,847	5.6				
Total	2,680,181	100.0				

APPENDIX B-13						
Exposure Distrib	Exposure Distribution					
by						
Company						
	Number of	Percentage of				
Company	Insureds	Insureds				
Aegon USA, Inc.	160,808	6.0				
Aetna	94,310	3.5				
Allstate	4,348	0.2				
AFLAC	27,525	1.0				
Bankers Life and Casualty	626,154	23.4				
Country Life Insurance Company	3,043	0.1				
GE Capital Assurance	413,217	15.4				
John Hancock	478,220	17.8				
Lutheran Brotherhood	59,279	2.2				
Medico Life	19,403	0.7				
Mutual of Omaha	87,337	3.3				
Mutual Protective	37,648	1.4				
Physicians Mutual	4,161	0.2				
Prudential	101,309	3.8				
Southern Farm Bureau	6,512	0.2				
Time Insurance Company	10,225	0.4				
Transport Life Insurance	150,744	5.6				
UnumProvident	395,938	14.8				
Total	2,680,181	100.0				

APPENDIX B-14						
	Ex	posure Distributi	on			
		by				
Type of Underwriting and Type of Policy						
	Individual		Group			
Turno of	Number of	Doroontogo of	Number of	Doroontogo of		
Type of		Percentage of		Percentage of		
Underwriting	Insureds	Insureds	Insureds	Insureds		
Full	1,359,983	71.6	139,470	17.9		
Simplified	234,235	12.3	113,625	14.5		
Guaranteed			491,018	62.8		
Other	37,531	2.0	37,024	4.7		
None	3,043	0.2				
Unknown	264,074	13.9	178	0.0		
Total	1,898,866	100.0	781,315	100.0		

APPENDIX B-15							
Exposure Distribution							
by							
Policy Duration and Type of Policy							
	Individual		Group				
Policy	Number of	Percentage of	Number of	Percentage of			
Duration	Insureds	Insureds	Insureds	Insureds			
< 1 Year	410,954	21.6	238,639	30.5			
1	402,671	21.2	134,356	17.2			
2	274,738	14.5	90,629	11.6			
3	221,841	11.7	76,355	9.8			
4	171,979	9.1	69,778	8.9			
5	126,572	6.7	70,665	9.0			
6	94,175	5.0	53,121	6.8			
7	61,399	3.2	14,109	1.8			
8	35,334	1.9	9,287	1.2			
9	28,057	1.5	23,348	3.0			
10	29,631	1.6	247	0.0			
11-15	41,515	2.2	781	0.1			
Total	1,898,866	100.0	781,315	100.0			

APPENDIX B-16				
Exposure Di	stribution			
by				
Benefit Escala	ator Clause			
Benefit Escalator Clause	Number of Insureds	Percentage of Insureds		
None	1,209,072	45.1		
Future Purchase Option	647,289	24.2		
Benefits Increase Annually	823,820	30.7		
Total	2,680,181	100.0		

APPENDIX B-17				
Exposure Distribution				
by				
Distribution	п Туре			
(Individual Poli	cies Only)			
Distribution Type	Number of Insureds	Percentage of Insureds		
Unknown	74,973	3.9		
Company Agent	455,457	24.0		
Independent Agent (Broker)	549,853	29.0		
Agent, Type Unknown	802,657	42.3		
Direct Mail	2,262	0.1		
Other	13,664	0.7		
Total	1,898,866	100.0		

APPENDIX B-18				
Exposure Dis	tribution			
by				
Premium N	Лode			
(Individual Polic	cies Only)			
Premium Mode	Number of Insureds	Percentage of Insureds		
1 Territain Wode	Ilisurcus	mourcus		
Annually	764,836	40.3		
Semi-annually	157,199	8.3		
Quarterly	241,137	12.7		
Monthly, Including Monthly EFT	567,336	29.9		
Other	13,807	0.7		
Unknown	154,551	8.1		
Total	1,898,866	100.0		

		APPENDI	X C-1	
		Claims Distr	ribution	
		by		
		Gender and Cla	im Amount	
	Number of	Percentage of		Percentage of
Gender	Claimants	Claimants	Amount of Claims	Claim Amount
Female	34,051	66.3	\$885,857,135	68.7
Male	17,318	33.7	\$404,002,146	31.3
Total	51,369	100.0	\$1,289,859,281	100.0
The Average Age at Incurral for Females is 79				
	The	Average Age at Incu	urral for Males is 78	
	The Average Age	at Incurral for Males	and Females Combine	ed is 78.8

APPENDIX C-2						
	Claims Distribution					
		by				
	A	ge at Incurral and	Claim Amount			
Age at	Number of Claimants	Percentage of Claimants	Amount of Claims	Percentage of Claim Amount		
	- Ciamianto	- Ciamianto	7 HITTOURING OF GRAINING	Oranii 7 ii ii Garii		
<30	12	0.0	\$584,787	0.0		
30-34	24	0.0	\$1,700,889	0.1		
35-39	46	0.1	\$1,919,016	0.1		
40-44	77	0.1	\$3,673,761	0.3		
45-49	108	0.2	\$4,457,165	0.3		
50-54	159	0.3	\$4,947,743	0.4		
55-59	273	0.5	\$8,836,323	0.7		
60-64	810	1.6	\$21,149,859	1.6		
65-69	3,115	6.1	\$83,014,877	6.4		
70-74	8,300	16.2	\$208,613,380	16.2		
75-79	14,411	28.1	\$373,442,425	29.0		
80-84	15,040	29.3	\$389,361,160	30.2		
85+	8,994	17.5	\$188,157,896	14.6		
Total	51,369	100.0	\$1,289,859,281	100.0		

			APPEN	DIX C-3			
	Claims Distribution					-	
	by						
			Age at Incurra	al and Gender			
	Fe	emale	ı	Male	Split by	Gender	
Age at	Number of	Percentage of	Number of	Percentage of	Female % of	Male % of	
Incurral	Claimants	Claimants	Claimants	Claimants	Total	Total	
<30	5	0.0	7	0.0	0.0	0.0	
30-34	11	0.0	13	0.0	0.0	0.0	
35-39	25	0.1	21	0.1	0.0	0.0	
40-44	34	0.1	43	0.2	0.1	0.1	
45-49	53	0.2	55	0.3	0.1	0.1	
50-54	92	0.3	67	0.4	0.2	0.1	
55-59	170	0.5	103	0.6	0.3	0.2	
60-64	508	1.5	302	1.7	1.0	0.6	
65-69	1,969	5.8	1,146	6.6	3.8	2.2	
70-74	5,181	15.2	3,119	18.0	10.1	6.1	
75-79	9,215	27.1	5,196	30.0	17.9	10.1	
80-84	10,211	30.0	4,829	27.9	19.9	9.4	
85+	6,577	19.3	2,417	14.0	12.8	4.7	
Total	34,051	100.0	17,318	100.0	66.3	33.7	
			,				
		The Average Ag	e at Incurral fo	or Females is 79			
		The Average A	ge at Incurral	for Males is 78			
	The Average Age at Incurral for Males and Females Combined is 78.8						

APPENDIX C-4					
С	Claims Distribution				
	by				
E	limination Peri	od			
Elimination	Number of	Percentage of			
Period Days	Claimants	Claimants			
0	14,541	28.3			
7-19	998	1.9			
20	18,239	35.5			
30	1,980	3.9			
31-50	37	0.1			
60	1,458	2.8			
90	3,307	6.4			
100	8,388	16.3			
101-359	590	1.1			
360-365	16	0.0			
Unknown	1,815	3.5			
Total	51,369	100.0			

			APPENDIX (C-5		
		(Claims Distribu	ution		
			by			
		Incurra	Year and Typ	e of Policy		
	Ind	dividual	(Group	All	Types
	Number of	Percentage of	Number of	Percentage of	Number of	Percentage of
Incurral Year	Claimants	Claimants	Claimants	Claimants	Claimants	Claimants
1984	7	0.0			7	0.0
1985	23	0.0			23	0.0
1986	244	0.5	9	0.2	253	0.5
1987	976	2.1	35	0.9	1,011	2.0
1988	2,047	4.3	146	3.6	2,193	4.3
1989	3,208	6.8	299	7.5	3,507	6.8
1990	4,408	9.3	384	9.6	4,792	9.3
1991	5,045	10.7	534	13.3	5,579	10.9
1992	3,921	8.3	632	15.8	4,553	8.8
1993	4,450	9.4	371	9.3	4,821	9.4
1994	4,654	9.8	425	10.6	5,079	9.9
1995	4,668	9.9	388	9.7	5,056	9.8
1996	3,343	7.1	161	4.0	3,504	6.8
1997	3,358	7.1	200	5.0	3,558	6.9
1998	3,550	7.5	219	5.5	3,769	7.3
1999	3,463	7.3	201	5.0	3,664	7.
Total	47,365	100.0	4,004	100.0	51,369	100.0

	APPENDIX C-6				
C	laims Distribution	on			
	by				
Тур	e of Benefit Pe	riod			
Type of Benefit	Number of	Percentage of			
Period	Claimants	Claimants			
Days	41,412	80.6			
Dollars	4,879	9.5			
Unlimited	5,047	9.8			
Unknown	31	0.1			
Total	51,369	100.0			

APPENDIX C-7				
	Claims Distribu	ition		
	by			
Max	ximum Benefit	Period		
Maximum				
Benefit	Number of	Percentage of		
Period	Claimants	Claimants		
<= 1 Year	9,495	22.9		
2	4,383	10.6		
3	14,837	35.8		
4	4,289	10.4		
5	7,192	17.4		
6	1,182	2.9		
7	23	0.1		
10	11	0.0		
Total	41,412	100.0		

APPENDIX C-8				
Claims Distribution				
l	ру			
Maximum Be	enefit Amount			
	Number of	Percentage of		
Maximum Benefit Amount	Claimants	Claimants		
<= \$25,000	337	6.9		
25,001 to 50,000	423	8.7		
50,001 to 75,000	932	19.1		
75,001 to 100,000	839	17.2		
100,001 to 125,000	969	19.9		
125,001 to 150,000	667	13.7		
150,001 to 175,000	86	1.8		
175,001 to 200,000	396	8.1		
200,001 to 225,000	104	2.1		
225,001 to 250,000	6	0.1		
250,001 to 500,000	71	1.5		
500,001 to 1,000,000	49	1.0		
Total	4,879	100.0		

Cla		APPENDIX C-9			
	Claims Distribution				
	by				
Maximum	Daily Benefit	Amount			
Maximum Daily	Number of	Percentage of			
Benefit Amount	Claimants	Claimants			
\$0-19	229	0.4			
20-29	738	1.4			
30-39	1,910	3.7			
40-49	5,961	11.6			
50-59	15,125	29.4			
60-69	7,280	14.2			
70-79	4,544	8.8			
80-89	3,634	7.1			
90-99	485	0.9			
100-109	3,920	7.6			
110-119	208	0.4			
120-129	417	0.8			
130-139	193	0.4			
140-149	118	0.2			
150-159	369	0.7			
160-169	72	0.1			
170-179	34	0.1			
180-189	21	0.0			
190-199	3	0.0			
200+	1,127	2.2			
Unknown	4,981	9.7			
Total	51,369	100.0			

		APPENDI	X C-10			
		Claims Dist	ribution			
		by				
	Diagı	nosis Category a	nd Type of Pol	icy		
	Ind	ividual	G	roup	All	Types
Diagnosis Category	Number of Claimants	Percentage of Claimants	Number of Claimants	Percentage of Claimants	Number of Claimants	Percentage of Claimants
Alzheimers	5,395	11.4	795	19.9	6,190	12.1
Arthritis	2,168	4.6	173	4.3	, -	4.6
Cancer	2,824		502	12.5	3,326	6.5
Circulatory	3,960		390	9.7	4,350	8.5
Congentital	25	0.1			25	0.0
Diabetes	587	1.2	50	1.2	637	1.2
Digestive System	710	1.5	39	1.0	749	1.5
Endocrine, Immunity System	451	1.0	27	0.7	478	0.9
Genitourinary System	506	1.1	45	1.1	551	1.1
Hypertension	463	_	29	0.7	492	1.0
III-defined and Misc Conditions	1,511	3.2	38	0.9	1,549	3.0
Injury	4,361	9.2	265	6.6	4,626	9.0
Mental	869	1.8	62	1.5	931	1.8
Nervous System	1,235	2.6	384	9.6	1,619	3.2
Pregnancy Disorders	50	0.1	2	0.0	52	0.1
Respiratory	1,879	4.0	96		1,975	3.8
Skin and Subcutaneous Tissue	198	0.4	8	0.2	206	0.4
Stroke	4,008	8.5	392	9.8	4,400	8.6
Other/Unknown	16,165	34.1	707	17.7	16,872	32.8
Total	47,365	100.0	4,004	100.0	51,369	100.0

		•	_	•	APPENDIX	C-11			
					Claims Distri	bution			
					by				
			Age at Incurral, Average Nu	rsing Home Leng	gth of Stay and L	eading Diagnosis Category (exclu-	ding Other/Unknov	vn)	
		In	ndividual			Group			All Types
Age at Incurral	Number of Claimants	Average Days Length of Stay	Leading Diagnosis Category	Number of Claimants	Average Days Length of Stay	Leading Diagnosis Category	Number of Claimants	Average Days Length of Stay	Leading Diagnosis Category
incurrai	Ciamants	Length of Stay	Leading Diagnosis Category	Olamants	Length of Stay	Leading Diagnosis Category	Olaimants	Length of Otay	Leading Diagnosis Category
<30				7	1,497	Nervous System	7	1,497	Nervous System
30-34	1	385	Nervous System	11	1,540	Nervous System	12	1,444	Nervous System
35-39				32	825	Nervous System	32	825	Nervous System
40-44	3	136	Nervous System	42	1,072	Nervous System	45	1,009	Nervous System
45-49	3	153	Diabetes	74	1,041	Nervous System	77	1,006	Nervous System
50-54	13	334	Alzheimers	79	962	Stroke	92	874	Stroke
55-59	55		Injury	114		Nervous System	169		Nervous System
60-64	336	355	Alzheimers	193	637	Stroke	529	458	Alzheimers
65-69	2,120	392	Mental	392	537	Stroke	2,512		Mental
70-74	6,366	390	Diabetes	675	470	Stroke	7,041	397	Diabetes
75-79	12,047	406	III-defined and Misc Conditions	851	483	Alzheimers	12,898	411	III-defined and Misc Conditions
80-84	13,082	416	Injury	646	435	Nervous System	13,728	417	Injury
85+	8,273	349	III-defined and Misc Conditions	193	468	Genitourinary System	8,466	352	III-defined and Misc Conditions
Total	42,299	394	Mental	3.309	536	Nervous System	45.608	404	Mental

APPENDIX C-12						
	Claims Distribution					
	by					
Diagnosi	s Category, Type of P	olicy, and				
Average	e Nursing Home Leng	th of Stay				
	Individual	Group	All Types			
	Average Days	Average Days	Average Days			
Diagnosis Category	Length of Stay	Length of Stay	Length of Stay			
Alzheimers	650	730	661			
Arthritis	396	487	402			
Cancer	179	213	184			
Circulatory	426	498	432			
Congentital	206		206			
Diabetes	507	370	497			
Digestive System	400	281	394			
Endocrine, Immunity System	451	440	451			
Genitourinary System	356	359	356			
Hypertension	597	636	599			
III-defined and Misc Conditions	410	302	407			
Injury	369	317	366			
Mental	637	682	640			
Nervous System	564	1093	679			
Pregnancy Disorders	414	212	410			
Respiratory	334	350	334			
Skin and Subcutaneous Tissue	377	90	366			
Stroke	468	573	477			
Other/Unknown	281	316	282			
Total Average	394	536	404			

					APPENDIX	C 12				
	AFFENDIA CITS Claims Distribution									_
						bution				
					by					
			Age at Incurral, Average Hon	ne Care Lengt	h of Stay and Lea	ding Diagnosis Category (excludi	ng Other/Unknow	n)	T	
		In	dividual			Group			All Types	
		_			_			_		
Age at	Number of	Average Days		Number of	Average Days			Average Days		
Incurral	Claimants	Length of Stay	Leading Diagnosis Category	Claimants	Length of Stay	Leading Diagnosis Category	Claimants	Length of Stay	Leading Diagnosis Category	
00	2	4000	Indiana.	6	1005	Nervous System	8	4400	Indiana.	
<30 30-34	2		Injury	12			15		Injury	
	3		Nervous System			Nervous System			Nervous System	
35-39 40-44	2		Injury Arthritis	20		Nervous System	22 42		Nervous System	
45-49	5		Cancer	37 44		Nervous System Nervous System	50		Nervous System Nervous System	
50-54	20		Digestive System	64		Nervous System	84		Nervous System	
55-59	41		Alzheimers	76		Nervous System	117		Nervous System	
60-64	159		Injury	129		Stroke	288		Stroke	
65-69	390			164		Stroke	554			
70-74	760		Nervous System Arthritis	221		Stroke	981		Nervous System Arthritis	
75-79	1.004		Cancer	232		Arthritis	1,236		Cancer	
80-84	969		Injury	116		Nervous System	1,236		Injury	_
85+	641		Injury	33		Arthritis	674		Injury	
037	041	402	nijury	33	405	Atunio	674	402	injury	
Total	4,002	338	Cancer	1,154	411	Nervous System	5,156	354	Nervous System	

APPENDIX C-14						
	Claims Distribution	l				
	by					
Diagnosis	Category, Type of I	Policy, and				
Average	e Home Care Lengt	h of Stay				
	Individual	Group	All Types			
	Average Days	Average Days	Average Days			
Diagnosis Category	Length of Stay	Length of Stay	Length of Stay			
Alzheimers	451	555	471			
Arthritis	281	428	299			
Cancer	149		156			
Circulatory	356	338	352			
Congentital	428		428			
Diabetes	440	286	403			
Digestive System	228	360	237			
Endocrine, Immunity System	308	293	305			
Genitourinary System	234	339	270			
Hypertension	301	165	280			
III-defined and Misc Conditions	296	220	291			
Injury	339	260	329			
Mental	514	324	472			
Nervous System	490	1190	847			
Pregnancy Disorders	341	179	327			
Respiratory	302	211	288			
Skin and Subcutaneous Tissue	431	12	396			
Stroke	423	586	451			
Other/Unknown	315	186	278			
Total Average	338	411	354			

					APPENDIX	C-15				
	Claims Distribution									
	by									
			Ago at Incurral Average D	uration of Tata	-	ing Diagnosis Category (excluding	Othor/Linknown)			
			Age at Incurral, Average D	uration or rota	Ciaiiii and Lead	ling Diagnosis Category (excluding	Other/Onknown)			
		In	ıdividual			Group			All Types	
			arvida.			Cidap			7 iii Typeo	
Age at	Number of	Average Days		Number of	Average Days		Number of	Average Days		
Incurral	Claimants	Length of Stay	Leading Diagnosis Category	Claimants	Length of Stay	Leading Diagnosis Category	Claimants	Length of Stay	Leading Diagnosis Category	
<30	2		Injury	10		Nervous System	12		Nervous System	
30-34	3	477	Nervous System	21	1394	Nervous System	24	1279	Nervous System	
35-39	2	56	Injury	44	952	Nervous System	46	913	Nervous System	
40-44	8	223	Arthritis	69	1018	Nervous System	77	936	Nervous System	
45-49	11	146	Cancer	97	1235	Nervous System	108	1124	Nervous System	
50-54	40	191	Alzheimers	119	1056	Nervous System	159	838	Nervous System	
55-59	119	251	Injury	154	917	Nervous System	273	626	Nervous System	
60-64	528	299	Alzheimers	282	624	Stroke	810	412	Stroke	
65-69	2,621	363	Stroke	494	540	Stroke	3,115	391	Stroke	
70-74	7,489	367	Alzheimers	811	458	Stroke	8,300	376	Alzheimers	
75-79	13,423	392	Mental	988	477	Arthritis	14,411	398	Mental	
80-84	14,334	405	Injury	706	444	Nervous System	15,040	407	Nervous System	
85+	8,785	359	Injury	209	496	Arthritis	8,994	362	Arthritis	
Total	47,365	383	Mental	4,004	561	Nervous System	51,369	397	Nervous System	

APPENDIX C-16 Claims Distribution

by

Diagnosis Category, Type of Policy, and Average Total Duration of Claim

	Individual	Group	All Types
	Average Days	Average Days	Average Days
Diagnosis Category	Length of Stay	Length of Stay	Length of Stay
Alzheimers	663	781	678
Arthritis	389	524	399
Cancer	180	217	186
Circulatory	430	496	436
Congentital	250		250
Diabetes	519	405	510
Digestive System	389	296	384
Endocrine, Immunity System	452	440	452
Genitourinary System	350	408	355
Hypertension	584	538	581
Ill-defined and Misc Conditions	410	299	407
Injury	378	328	375
Mental	643	695	646
Nervous System	577	1342	758
Pregnancy Disorders	432	196	423
Respiratory	339	353	340
Skin and Subcutaneous Tissue	400	82	388
Stroke	482	636	496
Other/Unknown	251	304	253
Total Average	383	561	397

APPENDIX C-17							
	Claims Distribution						
	by						
Cla	aim Duration in	Years					
Claim	Number of	Percentage of					
Duration	Claimants	Claimants					
<= 1 Year	38,802	75.5					
2	5,073	9.9					
3	4,248	8.3					
4	1,562	3.0					
5	1,064	2.1					
6	303	0.6					
7	164	0.3					
8	85	0.2					
9	38	0.1					
10	16	0.0					
11	12	0.0					
12	2	0.0					
	51,369	100.0					

Intercompany Study Tables.XLS

Introduction

This spreadsheet holds the proposed tables of incidence and continuance for the third LTC Intercompany Study. These tables should be used in conjunction with the commentary, temporarily written into MORBIDITY.DOC

Spreadsheet Organization

This spreadsheet is made up of several worksheets shown here:

<u>Worksheet</u>	General Description
Intro	Introduction and organization
Appendix D-1	Incidence Rates by Elimination Period and Attained Age
Appendix D-2	Incidence Rates by Elimination Period, Attained Age, and Duration
Appendix D-3	Incidence Rates by Elimination Period, Attained Age, and Gender
Appendix D-4	Incidence Rates by Elimination Period, Attained Age, Duration, and Issue Year
Appendix D-5	Incidence Rates by Elimination Period, Attained Age, and Benefit Period
Appendix D-6	

The spreadsheet is color coded for easier use as follows:

Example	<u>Description</u>
567	Numbers in blue indicate a required update for each use. Generally these
	are actual numbers; updated by manual intervention.
841.6045	Numbers in black are formula driven and require no update.
Balance	Titles of worksheets are in maroon.
How to	Areas of the Worksheet are in green.
	Orange areas indicate numbers that are temporary. These are for testing
	only and must be updated before using any portion of the spreadsheet.

How to Use this Spreadsheet

This spreadsheet requires only a few steps to use:

- 1. Check for any orange areas. The spreadsheet should not be used with these.
- 2. Update all numbers in blue to current, actual values.
- 3. Update any required data in the next section.
- 4. Recalculate.
- 5. Print any range names or export as needed.

Required Data

Some data is required to make this spreadsheet perform and print correctly:

Period Ending:	3/31/2002	Quarter 1
C-1 factor	2.86%	Asset risk factor (current client requirements); applied to total statutory reserves
C-2 factor	30.00%	Claims risk factor (current client requirements); applied to earned premium
	5.00%	Claim risk factor; applied to claim reserves
C-3 factor	0.00%	Asset/liability factor, currently zero for LTC
C-4 factor	1.50%	General business factor (current client requirements); applied to earned premium
Overall factor	100%	Target surplus factor (current client requirements); applied to total RBC requirements

Macros and Range Names

There are no macros contained in or used by this spreadsheet.

Range names are used to make printing easier.

Balance_Sheet Qtty_Income_Statement Ytd_Income_Statement Key_Indicators Source_of_Earnings_Analysis

Appendix D-1 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period and Attained Age

Elimination Period	Attained Age Group	Exposure	Claims	Rate
0	Less than 40	436	(0.00%
	40-49	2,155		0.09%
	50-59	20,741		
	60-64	49,149	139	0.28%
	65-69	171,082	1,00	0.59%
	70-74	271,377	2,810	1.04%
	75-79	251,739	4,718	3 1.87%
	80-84	147,237	4,26	2.89%
	Ages 85+	62,290	1,578	3 2.53%
	Total	976,206	14,54	1 1.49%
7-19	Less than 40	35		0.00%
	40-49	130		0.00%
	50-59	2,751		0.22%
	60-64	6,542		
	65-69	34,667		
	70-74	59,786		
	75-79	53,937		
	80-84	40,107		
	Ages 85+	18,662		
	3	-,		
	Total	216,617	998	3 0.46%
20	Less than 40	386	(0.00%
	40-49	10,269	(0.06%
	50-59	72,231	60	0.08%
	60-64	132,236		0.16%
	65-69	334,585	984	4 0.29%
	70-74	529,431	2,920	0.55%
	75-79	535,655	5,304	4 0.99%
	80-84	336,509	5,53°	1.64%
	Ages 85+	168,438	3,210	1.91%
	Total	2,119,740	18,239	0.86%
30-50	Less than 40	4,908	4	4 0.08%
	40-49	8,115		0.06%
	50-59	27,095	19	0.07%
	60-64	36,703	44	4 0.12%
	65-69	98,171	136	0.14%
	70-74	122,454	30	0.25%
	75-79	83,927	444	4 0.53%
	80-84	43,558	500	1.15%
	Ages 85+	18,667	564	3.02%
	Total	443,598	2,017	7 0.45%

60	Less than 40	65,223	30	0.05%	
	40-49	90,534	51	0.06%	
	50-59	117,692	77	0.07%	
	60-64	57,382	75	0.13%	
	65-69	69,147	172	0.25%	
	70-74	60,116	279	0.46%	
	75-79	35,095	302	0.86%	
	80-84	14,865	308	2.07%	
	Ages 85+	5,013	164	3.27%	
	Total	515,067	1,458	0.28%	
90	Less than 40	302,281	34	0.01%	
	40-49	311,241	80	0.03%	
	50-59	344,896	152	0.04%	
	60-64	205,267	199	0.10%	
	65-69	268,652	353	0.13%	
	70-74	252,169	574	0.23%	
	75-79	145,000	819	0.56%	
	80-84	65,761	702	1.07%	
	Ages 85+	19,835	394	1.99%	
	· ·				
	Total	1,915,102	3,307	0.17%	
100	Less than 40	7,133	0	0.00%	
	40-49	11,094	1	0.01%	
	50-59	71,438	23	0.03%	
	60-64	125,566	80	0.06%	
	65-69	273,225	348	0.13%	
	70-74	400,762	1,085	0.27%	
	75-79	388,110	2,254	0.58%	
	80-84	263,362	2,868	1.09%	
	Ages 85+	147,869	1,729	1.17%	
	Total	1,688,559	8,388	0.50%	
101-730	Less than 40	23,722	14	0.06%	
	40-49	49,970	40	0.08%	
	50-59	88,217	66	0.07%	
	60-64	47,042	41	0.09%	
	65-69	42,002	43	0.10%	
	70-74	34,553	77	0.22%	
	75-79	24,480	111	0.45%	
	80-84	11,898	138	1.16%	
	Ages 85+	5,156	76	1.47%	
	Total	327,040	606	0.19%	
All Periods	Less than 40	404,124	82	0.02%	
	40-49	483,508	185	0.04%	
	50-59	745,061	431	0.06%	
	60-64	659,887	810	0.12%	
	65-69	1,291,531	3,105	0.24%	
	70-74	1,730,648	8,218	0.47%	
	75-79	1,517,943	14,196	0.94%	
	80-84	923,297	14,615	1.58%	
	Ages 85+	445,930	7,912	1.77%	
	Total	8,201,929	49,554	0.60%	

Appendix D-2 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
0	1	Less than 40	296	-	0.00%
		40-49	1,225	-	0.00%
		50-59	11,899	12	0.10%
		60-64	26,680	65	0.24%
		65-69	77,935	330	0.42%
		70-74	90,173	670	0.74%
		75-79	68,802	1,041	1.51%
		80-84	34,521	691	2.00%
		Ages 85+	9,338	87	0.93%
		Total	320,869	2,896	0.90%
	2	Less than 40	80	-	0.00%
		40-49	427	-	0.00%
		50-59	4,248	6	0.14%
		60-64	10,912	27	0.25%
		65-69	41,450	270	0.65%
		70-74	58,600	541	0.92%
		75-79	46,954	837	1.78%
		80-84	25,494	676	2.65%
		Ages 85+	8,482	135	1.59%
		Total	196,647	2,492	1.27%
	3	Less than 40	39	-	0.00%
		40-49	237	-	0.00%
		50-59	2,230	4	0.18%
		60-64	5,635	23	0.41%
		65-69	25,028	174	0.70%
		70-74	42,904	471	1.10%
		75-79	36,342	676	1.86%
		80-84	20,594	579	2.81%
		Ages 85+	7,575	153	2.02%
		Total	140,584	2,080	1.48%
	4	Less than 40	13	-	0.00%
		40-49	113	-	0.00%
		50-59	1,139	3	0.26%
		60-64	2,795	15	0.54%
		65-69	14,215	104	0.73%
		70-74	30,600	359	1.17%
		75-79	27,839	529	1.90%
		80-84	16,474	547	3.32%
		Ages 85+	6,577	108	1.64%
		Total	99,765	1,665	1.67%

5	Less than 40	5	-	0.00%
	40-49	58	-	0.00%
	50-59	592	1	0.17%
	60-64	1,508	3	0.20%
	65-69	7,012	67	0.96%
	70-74	20,436	269	1.32%
	75-79	20,824	385	1.85%
	80-84	12,821	407	3.17%
	Ages 85+	5,909	70	1.18%
	Total	69,165	1,202	1.74%
6	Less than 40	3	-	0.00%
	40-49	47	1	2.13%
	50-59	329	1	0.30%
	60-64	780	3	0.38%
	65-69	2,783	29	1.04%
	70-74	12,771	173	1.35%
	75-79	15,762	275	1.74%
	80-84	10,135	341	3.36%
	Ages 85+	5,582	100	1.79%
	Total	48,192	923	1.92%
7	Less than 40	-	-	0.00%
	40-49	29	-	0.00%
	50-59	170	-	0.00%
	60-64	389	-	0.00%
	65-69	1,305	11	0.84%
	70-74	7,269	117	1.61%
	75-79	11,816	269	2.28%
	80-84	8,092	270	3.34%
	Ages 85+	5,203	153	2.94%
	Total	34,273	820	2.39%
8	Less than 40	-	-	0.00%
	40-49	12	1	8.33%
	50-59	80	-	0.00%
	60-64	210	2	0.95%
	65-69	652	9	1.38%
	70-74	4,293	78	1.82%
	75-79	9,005	202	2.24%
	80-84	6,538	223	3.41%
	Ages 85+	4,566	181	3.96%
	Total	25,356	696	2.74%

9	Less than 40	-	-	0.00%
	40-49	4	-	0.00%
	50-59	24	1	4.17%
	60-64	119	1	0.84%
	65-69	361	4	1.11%
	70-74	2,368	69	2.91%
	75-79	6,511	210	3.23%
	80-84	5,078	198	3.90%
	Ages 85+	3,683	187	5.08%
	Total	18,148	670	3.69%
10	Less than 40	-	-	0.00%
	40-49	3	-	0.00%
	50-59	17	-	0.00%
	60-64	84	-	0.00%
	65-69	224	4	1.79%
	70-74	1,393	43	3.09%
	75-79	4,540	144	3.17%
	80-84	3,814	150	3.93%
	Ages 85+	2,802	180	6.42%
	Total	12,877	521	4.05%
11-15	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	13	-	0.00%
	60-64	37	-	0.00%
	65-69	117	3	2.56%
	70-74	570	20	3.51%
	75-79	3,344	150	4.49%
	80-84	3,676	179	4.87%
	Ages 85+	2,573	224	8.71%
	Total	10,330	576	5.58%

Appendix D-2 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
7-19	1	Less than 40	22	-	0.00%
		40-49	96	-	0.00%
		50-59	1,490	2	0.13%
		60-64	3,352	5	0.15%
		65-69	16,955	17	0.10%
		70-74	21,526	27	0.13%
		75-79	19,533	45	0.23%
		80-84	14,242	50	0.35%
		Ages 85+	4,526	6	0.13%
		Total	81,742	152	0.19%
	2	Less than 40	8	-	0.00%
		40-49	19	-	0.00%
		50-59	672	1	0.15%
		60-64	1,591	3	0.19%
		65-69	9,385	19	0.20%
		70-74	14,249	27	0.19%
		75-79	12,510	40	0.32%
		80-84	9,056	52	0.57%
		Ages 85+	3,866	15	0.39%
		Total	51,356	157	0.31%
	3	Less than 40	3	-	0.00%
		40-49	11	-	0.00%
		50-59	317	1	0.32%
		60-64	801	2	0.25%
		65-69	4,780	15	0.31%
		70-74	9,615	34	0.35%
		75-79	8,424	38	0.45%
		80-84	6,266	50	0.80%
		Ages 85+	3,231	31	0.96%
		Total	33,448	171	0.51%
	4	Less than 40	2	-	0.00%
		40-49	4	-	0.00%
		50-59	137	2	1.46%
		60-64	419	2	0.48%
		65-69	2,196	6	0.27%
		70-74	6,239	19	0.30%
		75-79	5,529	38	0.69%
		80-84	4,241	40	0.94%
		Ages 85+	2,507	33	1.32%
		Total	21,274	140	0.66%

5	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	69	-	0.00%
	60-64	186	-	0.00%
	65-69	810	3	0.37%
	70-74	3,808	26	0.68%
	75-79	3,374	28	0.83%
	80-84	2,737	32	1.17%
	Ages 85+	1,810	30	1.66%
	Total	12,794	119	0.93%
6	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	36	-	0.00%
	60-64	104	-	0.00%
	65-69	304	2	0.66%
	70-74	2,408	20	0.83%
	75-79	2,216	28	1.26%
	80-84	1,726	36	2.09%
	Ages 85+	1,275	20	1.57%
	Total	8,069	106	1.31%
7	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	21	-	0.00%
	60-64	54	-	0.00%
	65-69	159	2	1.26%
	70-74	1,301	10	0.77%
	75-79	1,423	10	0.70%
	80-84	1,072	21	1.96%
	Ages 85+	839	29	3.46%
	Total	4,869	72	1.48%
8	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	8	-	0.00%
	60-64	28	2	7.14%
	65-69	64	-	0.00%
	70-74	502	5	1.00%
	75-79	690	11	1.59%
	80-84	560	16	2.86%
	Ages 85+	443	22	4.97%
	Total	2,295	56	2.44%
		_,0		,0

				0.000/	
9	Less than 40	-	-	0.00%	
	40-49		-	0.00%	
	50-59	1	-	0.00%	
	60-64	7	-	0.00%	
	65-69	14	-	0.00%	
	70-74	138	3	2.17%	
	75-79	238	6	2.52%	
	80-84	207	8	3.86%	
	Ages 85+	165	3	1.82%	
	Total	770	20	2.60%	
10	Less than 40	-	-	0.00%	
	40-49	-	-	0.00%	
	50-59	-	-	0.00%	
	60-64	-	-	0.00%	
	65-69	-	-	0.00%	
	70-74	-	1	0.00%	
	75-79	-	2	0.00%	
	80-84	-	2	0.00%	
	Ages 85+	-	-	0.00%	
	Total	-	5	0.00%	
11-15	Less than 40	-	-	0.00%	
	40-49	-	-	0.00%	
	50-59	-	-	0.00%	
	60-64	-	-	0.00%	
	65-69	-	-	0.00%	
	70-74	-	-	0.00%	
	75-79	-	-	0.00%	
	80-84	-	-	0.00%	
	Ages 85+	-	-	0.00%	
	Total	-	-	0.00%	

Appendix D-2

SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
20	1	Less than 40	174	-	0.00%
		40-49	4,559	2	0.04%
		50-59	28,036	18	0.06%
		60-64	48,793	58	0.12%
		65-69	109,735	199	0.18%
		70-74	132,214	464	0.35%
		75-79	108,827	779	0.72%
		80-84	57,930	493	0.85%
		Ages 85+	21,058	54	0.26%
		Total	511,326	2,067	0.40%
	2	Less than 40	71	-	0.00%
		40-49	2,536	-	0.00%
		50-59	17,209	13	0.08%
		60-64	31,129	53	0.17%
		65-69	78,863	228	0.29%
		70-74	106,402	546	0.51%
		75-79	91,125	736	0.81%
		80-84	52,048	539	1.04%
		Ages 85+	20,604	90	0.44%
		Total	399,987	2,205	0.55%
	3	Less than 40	43	-	0.00%
		40-49	1,498	2	0.13%
		50-59	10,865	7	0.06%
		60-64	20,693	38	0.18%
		65-69	55,905	210	0.38%
		70-74	86,776	452	0.52%
		75-79	78,304	717	0.92%
		80-84	47,042	669	1.42%
		Ages 85+	19,954	138	0.69%
		Total	321,080	2,233	0.70%
	4	Less than 40	30	-	0.00%
		40-49	799	1	0.13%
		50-59	6,520	7	0.11%
		60-64	13,033	27	0.21%
		65-69	37,889	136	0.36%
		70-74	68,296	371	0.54%
		75-79	65,896	666	1.01%
		80-84	41,461	693	1.67%
		Ages 85+	19,066	197	1.03%
		Total	252,990	2,098	0.83%

5	Less than 40	22	-	0.00%	
	40-49	407	-	0.00%	
	50-59	3,925	3	0.08%	
	60-64	8,342	20	0.24%	
	65-69	23,989	86	0.36%	
	70-74	50,917	329	0.65%	
	75-79	53,747	493	0.92%	
	80-84	35,224	710	2.02%	
	Ages 85+	18,143	205	1.13%	
	Total	194,716	1,846	0.95%	
6	Less than 40	17	-	0.00%	
	40-49	236	-	0.00%	
	50-59	2,371	5	0.21%	
	60-64	4,713	7	0.15%	
	65-69	13,225	51	0.39%	
	70-74	34,597	238	0.69%	
	75-79	42,117	500	1.19%	
	80-84	28,564	568	1.99%	
	Ages 85+	16,703	302	1.81%	
	Total	142,543	1,671	1.17%	
7	Less than 40	10	-	0.00%	
	40-49	121	-	0.00%	
	50-59	1,410	2	0.14%	
	60-64	2,285	10	0.44%	
	65-69	6,495	31	0.48%	
	70-74	20,632	168	0.81%	
	75-79	30,896	389	1.26%	
	80-84	22,175	472	2.13%	
	Ages 85+	14,645	421	2.87%	
	Total	98,669	1,493	1.51%	
8	Less than 40	6	-	0.00%	
	40-49	53	-	0.00%	
	50-59	871	3	0.34%	
	60-64	1,358	2	0.15%	
	65-69	3,601	11	0.31%	
	70-74	12,387	142	1.15%	
	75-79	22,661	299	1.32%	
	80-84	17,305	401	2.32%	
	Ages 85+	12,466	450	3.61%	
	Total	70,708	1,308	1.85%	

9	Less than 40	5	-	0.00%
	40-49	34	1	2.94%
	50-59	616	2	0.32%
	60-64	958	1	0.10%
	65-69	2,359	22	0.93%
	70-74	7,995	94	1.18%
	75-79	16,825	255	1.52%
	80-84	13,447	290	2.16%
	Ages 85+	10,112	458	4.53%
	Total	52,351	1,123	2.15%
10	Less than 40	4	-	0.00%
	40-49	17	-	0.00%
	50-59	301	-	0.00%
	60-64	647	-	0.00%
	65-69	1,610	6	0.37%
	70-74	5,252	58	1.10%
	75-79	12,517	202	1.61%
	80-84	10,228	295	2.88%
	Ages 85+	7,720	346	4.48%
	Total	38,296	907	2.37%
11-15	Less than 40	4	-	0.00%
	40-49	9	-	0.00%
	50-59	107	-	0.00%
	60-64	285	2	0.70%
	65-69	914	4	0.44%
	70-74	3,963	58	1.46%
	75-79	12,740	268	2.10%
	80-84	11,085	401	3.62%
	Ages 85+	7,967	555	6.97%
	Total	37,074	1,288	3.47%

Appendix D-2
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
30-50	1	Less than 40	2,709	3	0.11%
		40-49	4,264	1	0.02%
		50-59	15,164	7	0.05%
		60-64	19,078	16	0.08%
		65-69	44,885	24	0.05%
		70-74	43,115	53	0.12%
		75-79	28,510	60	0.21%
		80-84	14,433	81	0.56%
		Ages 85+	4,497	46	1.02%
		Total	176,655	291	0.16%
	2	Less than 40	1,194	1	0.08%
		40-49	1,774	2	0.11%
		50-59	5,087	4	0.08%
		60-64	7,364	4	0.05%
		65-69	22,547	29	0.13%
		70-74	26,264	48	0.18%
		75-79	17,673	68	0.38%
		80-84	9,202	81	0.88%
		Ages 85+	3,776	65	1.72%
		Total	94,881	302	0.32%
	3	Less than 40	492	-	0.00%
		40-49	908	1	0.11%
		50-59	3,002	3	0.10%
		60-64	4,555	10	0.22%
		65-69	14,469	25	0.17%
		70-74	19,740	36	0.18%
		75-79	13,350	58	0.43%
		80-84	7,013	82	1.17%
		Ages 85+	3,277	73	2.23%
		Total	66,806	288	0.43%
	4	Less than 40	305	-	0.00%
		40-49	559	-	0.00%
		50-59	1,807	3	0.17%
		60-64	2,662	6	0.23%
		65-69	8,356	24	0.29%
		70-74	14,164	57	0.40%
		75-79	9,706	68	0.70%
		80-84	5,059	67	1.32%
		Ages 85+	2,735	87	3.18%
		Total	45,353	312	0.69%

5	Less than 40	134	-	0.00%
	40-49	305	-	0.00%
	50-59	937	-	0.00%
	60-64	1,390	6	0.43%
	65-69	4,110	17	0.41%
	70-74	9,282	35	0.38%
	75-79	6,487	69	1.06%
	80-84	3,373	68	2.02%
	Ages 85+	2,082	91	4.37%
	Total	28,100	286	1.02%
6	Less than 40	43	-	0.00%
	40-49	147	-	0.00%
	50-59	510	2	0.39%
	60-64	787	-	0.00%
	65-69	1,930	9	0.47%
	70-74	5,367	23	0.43%
	75-79	4,019	53	1.32%
	80-84	2,114	45	2.13%
	Ages 85+	1,358	91	6.70%
	Total	16,275	223	1.37%
7	Less than 40	18	-	0.00%
	40-49	75	1	1.33%
	50-59	265	-	0.00%
	60-64	413	2	0.48%
	65-69	899	4	0.44%
	70-74	2,275	33	1.45%
	75-79	1,868	33	1.77%
	80-84	1,064	36	3.38%
	Ages 85+	580	73	12.59%
	Total	7,457	182	2.44%
8	Less than 40	8	-	0.00%
	40-49	40	-	0.00%
	50-59	175	-	0.00%
	60-64	248	-	0.00%
	65-69	513	1	0.19%
	70-74	1,183	9	0.76%
	75-79	1,120	13	1.16%
	80-84	617	18	2.92%
	Ages 85+	176	11	6.25%
	Total	4,080	52	1.27%

9	Less than 40	4	-	0.00%
	40-49	30	-	0.00%
	50-59	109	-	0.00%
	60-64	143	-	0.00%
	65-69	301	1	0.33%
	70-74	673	3	0.45%
	75-79	739	11	1.49%
	80-84	423	12	2.84%
	Ages 85+	107	4	3.74%
	Total	2,529	31	1.23%
10	Less than 40	1	-	0.00%
	40-49	13	-	0.00%
	50-59	39	-	0.00%
	60-64	63	-	0.00%
	65-69	130	2	1.54%
	70-74	311	3	0.96%
	75-79	374	7	1.87%
	80-84	203	5	2.46%
	Ages 85+	57	14	24.56%
	Total	1,191	31	2.60%
11-15	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	-	-	0.00%
	60-64	-	-	0.00%
	65-69	31	-	0.00%
	70-74	80	1	1.25%
	75-79	81	4	4.94%
	80-84	57	5	8.77%
	Ages 85+	22	9	40.91%
	Total	271	19	7.01%

Appendix D-2
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
60	1	Less than 40	23,151	10	0.04%
		40-49	24,111	14	0.06%
		50-59	32,952	18	0.05%
		60-64	20,483	24	0.12%
		65-69	26,221	39	0.15%
		70-74	21,783	58	0.27%
		75-79	13,378	81	0.61%
		80-84	5,671	70	1.23%
		Ages 85+	1,445	14	0.97%
		Total	169,195	328	0.19%
	2	Less than 40	13,488	6	0.04%
		40-49	17,153	9	0.05%
		50-59	21,493	17	0.08%
		60-64	11,094	20	0.18%
		65-69	14,660	40	0.27%
		70-74	13,409	78	0.58%
		75-79	8,402	78	0.93%
		80-84	3,942	70	1.78%
		Ages 85+	1,187	32	2.70%
		Total	104,828	350	0.33%
	3	Less than 40	9,557	2	0.02%
		40-49	13,849	15	0.11%
		50-59	17,540	13	0.07%
		60-64	8,106	10	0.12%
		65-69	10,074	27	0.27%
		70-74	9,332	45	0.48%
		75-79	5,688	59	1.04%
		80-84	2,658	78	2.93%
		Ages 85+	983	31	3.15%
		Total	77,787	280	0.36%
	4	Less than 40	7,524	11	0.15%
		40-49	11,982	3	0.03%
		50-59	14,880	10	0.07%
		60-64	6,076	11	0.18%
		65-69	6,531	20	0.31%
		70-74	5,758	37	0.64%
		75-79	3,215	44	1.37%
		80-84	1,382	40	2.89%
		Ages 85+	668	31	4.64%
		Total	58,016	207	0.36%

5	Less than 40	6,059	1	0.02%
	40-49	10,443	6	0.06%
	50-59	13,186	6	0.05%
	60-64	4,911	5	0.10%
	65-69	4,716	21	0.45%
	70-74	3,887	25	0.64%
	75-79	1,875	18	0.96%
	80-84	627	21	3.35%
	Ages 85+	362	23	6.35%
	Total	46,066	126	0.27%
6	Less than 40	4,669	-	0.00%
	40-49	8,693	3	0.03%
	50-59	11,475	9	0.08%
	60-64	4,265	3	0.07%
	65-69	4,023	11	0.27%
	70-74	3,208	15	0.47%
	75-79	1,359	11	0.81%
	80-84	337	16	4.75%
	Ages 85+	236	15	6.36%
	Total	38,265	83	0.22%
7	Less than 40	604	-	0.00%
	40-49	3,283	-	0.00%
	50-59	4,728	4	0.08%
	60-64	1,846	1	0.05%
	65-69	2,179	7	0.32%
	70-74	2,006	14	0.70%
	75-79	890	8	0.90%
	80-84	194	5	2.58%
	Ages 85+	117	15	12.82%
	Total	15,847	54	0.34%
8	Less than 40	166	-	0.00%
	40-49	966	1	0.10%
	50-59	1,353	-	0.00%
	60-64	582	1	0.17%
	65-69	731	6	0.82%
	70-74	726	4	0.55%
	75-79	286	2	0.70%
	80-84	53	7	13.21%
	Ages 85+	15	3	20.00%
	Total	4,878	24	0.49%

9	Less than 40	5	-	0.00%
	40-49	48	-	0.00%
	50-59	81	_	0.00%
	60-64	17	-	0.00%
	65-69	10	1	10.00%
	70-74	7	2	28.57%
	75-79	2	1	50.00%
	80-84	1	1	100.00%
	Ages 85+	-	-	0.00%
	7.900 00 ·			0.0070
	Total	171	5	2.92%
10	Less than 40	-	-	0.00%
	40-49	3	-	0.00%
	50-59	2	-	0.00%
	60-64	1	-	0.00%
	65-69	1	-	0.00%
	70-74	-	1	0.00%
	75-79	-	-	0.00%
	80-84	-	-	0.00%
	Ages 85+	-	-	0.00%
	Total	7	1	14.29%
11-15	Less than 40	-	-	0.00%
	40-49	3	-	0.00%
	50-59	2	-	0.00%
	60-64	1	-	0.00%
	65-69	1	-	0.00%
	70-74	-	-	0.00%
	75-79	-	-	0.00%
	80-84	-	-	0.00%
	Ages 85+	-	-	0.00%
	Total	7	-	0.00%

Appendix D-2 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
90	1	Less than 40	171,367	21	0.01%
		40-49	138,448	27	0.02%
		50-59	150,365	51	0.03%
		60-64	83,559	59	0.07%
		65-69	103,805	80	0.08%
		70-74	83,689	107	0.13%
		75-79	47,602	160	0.34%
		80-84	20,018	74	0.37%
		Ages 85+	4,707	25	0.53%
		Total	803,560	604	0.08%
	2	Less than 40	61,941	6	0.01%
		40-49	66,731	19	0.03%
		50-59	72,719	35	0.05%
		60-64	44,053	46	0.10%
		65-69	59,248	75	0.13%
		70-74	54,339	118	0.22%
		75-79	30,424	150	0.49%
		80-84	13,796	111	0.80%
		Ages 85+	3,640	32	0.88%
		Total	406,891	592	0.15%
	3	Less than 40	33,988	4	0.01%
		40-49	45,086	15	0.03%
		50-59	51,752	27	0.05%
		60-64	32,613	42	0.13%
		65-69	43,995	74	0.17%
		70-74	43,242	111	0.26%
		75-79	23,993	145	0.60%
		80-84	11,208	110	0.98%
		Ages 85+	3,242	41	1.26%
		Total	289,119	569	0.20%
	4	Less than 40	19,154	1	0.01%
		40-49	30,996	5	0.02%
		50-59	35,000	19	0.05%
		60-64	23,798	25	0.11%
		65-69	32,373	50	0.15%
		70-74	34,115	81	0.24%
		75-79	18,730	115	0.61%
		80-84	8,862	131	1.48%
		Ages 85+	2,754	67	2.43%
		Total	205,782	494	0.24%

5	Less than 40	10,001	2	0.02%	
	40-49	19,095	8	0.04%	
	50-59	20,901	13	0.06%	
	60-64	13,152	15	0.11%	
	65-69	18,108	37	0.20%	
	70-74	21,197	72	0.34%	
	75-79	12,063	115	0.95%	
	80-84	5,649	109	1.93%	
	Ages 85+	2,195	70	3.19%	
	Total	122,361	441	0.36%	
6	Less than 40	4,815	-	0.00%	
	40-49	8,334	3	0.04%	
	50-59	9,083	4	0.04%	
	60-64	4,800	7	0.15%	
	65-69	6,009	22	0.37%	
	70-74	7,888	40	0.51%	
	75-79	5,394	61	1.13%	
	80-84	2,647	72	2.72%	
	Ages 85+	1,434	50	3.49%	
	Total	50,404	259	0.51%	
7	Less than 40	498	_	0.00%	
,	40-49	1,099	2	0.18%	
	50-59	2,004	1	0.05%	
	60-64	1,424	1	0.07%	
	65-69	2,297	4	0.17%	
	70-74	3,499	19	0.54%	
	75-79	2,900	26	0.90%	
	80-84	1,520	37	2.43%	
	Ages 85+	819	39	4.76%	
	· ·				
	Total	16,060	129	0.80%	
8	Less than 40	260	-	0.00%	
	40-49	702	1	0.14%	
	50-59	1,489	2	0.13%	
	60-64	983	1	0.10%	
	65-69	1,486	6	0.40%	
	70-74	2,171	16	0.74%	
	75-79	1,910	17	0.89%	
	80-84	963	23	2.39%	
	Ages 85+	472	24	5.08%	
	Ages 85+ Total	472 10,436	24	5.08%	

9	Less than 40	180	-	0.00%
	40-49	523	-	0.00%
	50-59	1,093	-	0.00%
	60-64	638	2	0.31%
	65-69	944	4	0.42%
	70-74	1,370	2	0.15%
	75-79	1,251	14	1.12%
	80-84	628	15	2.39%
	Ages 85+	326	20	6.13%
	Ü			
	Total	6,953	57	0.82%
10	Less than 40	48	-	0.00%
	40-49	143	-	0.00%
	50-59	281	-	0.00%
	60-64	144	1	0.69%
	65-69	234	-	0.00%
	70-74	403	5	1.24%
	75-79	460	8	1.74%
	80-84	279	12	4.30%
	Ages 85+	152	16	10.53%
	Total	2,144	42	1.96%
11-15	Less than 40	29	-	0.00%
	40-49	84	-	0.00%
	50-59	209	-	0.00%
	60-64	103	-	0.00%
	65-69	153	1	0.65%
	70-74	256	3	1.17%
	75-79	273	8	2.93%
	80-84	191	8	4.19%
	Ages 85+	94	10	10.64%
	Total	1,392	30	2.16%

Appendix D-2
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
100	1	Less than 40	3,617	-	0.00%
		40-49	5,602	1	0.02%
		50-59	36,092	2	0.01%
		60-64	61,171	25	0.04%
		65-69	116,669	85	0.07%
		70-74	131,404	213	0.16%
		75-79	103,164	384	0.37%
		80-84	60,043	333	0.55%
		Ages 85+	23,247	56	0.24%
		Total	541,009	1,099	0.20%
	2	Less than 40	1,901	-	0.00%
		40-49	2,640	-	0.00%
		50-59	15,297	7	0.05%
		60-64	26,904	17	0.06%
		65-69	62,426	87	0.14%
		70-74	84,624	213	0.25%
		75-79	72,659	400	0.55%
		80-84	45,415	406	0.89%
		Ages 85+	21,681	112	0.52%
		Total	333,547	1,242	0.37%
	3	Less than 40	1,012	-	0.00%
		40-49	1,535	-	0.00%
		50-59	9,081	10	0.11%
		60-64	16,276	12	0.07%
		65-69	40,171	72	0.18%
		70-74	63,389	199	0.31%
		75-79	58,340	365	0.63%
		80-84	38,241	389	1.02%
		Ages 85+	20,149	148	0.73%
		Total	248,194	1,195	0.48%
	4	Less than 40	360	-	0.00%
		40-49	697	-	0.00%
		50-59	5,006	1	0.02%
		60-64	9,638	11	0.11%
		65-69	24,952	37	0.15%
		70-74	46,368	144	0.31%
		75-79	45,924	283	0.62%
		80-84	31,362	361	1.15%
		Ages 85+	18,176	164	0.90%
		Total	182,483	1,001	0.55%

5	Less than 40	187	-	0.00%	
	40-49	347	-	0.00%	
	50-59	2,806	2	0.07%	
	60-64	5,723	9	0.16%	
	65-69	14,615	33	0.23%	
	70-74	32,379	107	0.33%	
	75-79	35,247	218	0.62%	
	80-84	25,160	338	1.34%	
	Ages 85+	15,741	163	1.04%	
	Total	132,205	870	0.66%	
6	Less than 40	37	-	0.00%	
	40-49	162	-	0.00%	
	50-59	1,569	-	0.00%	
	60-64	2,960	5	0.17%	
	65-69	7,540	13	0.17%	
	70-74	20,366	70	0.34%	
	75-79	25,745	172	0.67%	
	80-84	19,384	255	1.32%	
	Ages 85+	13,126	177	1.35%	
	Total	90,889	692	0.76%	
_		40		0.000/	
7	Less than 40	19	-	0.00%	
	40-49	78	-	0.00%	
	50-59	826	-	0.00%	
	60-64	1,412	- 12	0.00%	
	65-69 70-74	3,396	12 55	0.35%	
	75-79	10,839 17,438	55 118	0.51% 0.68%	
	80-84	13,966	215	1.54%	
	Ages 85+	10,440	158	1.51%	
	7.g00 001	10,110	100	1.0170	
	Total	58,414	558	0.96%	
		,			
8	Less than 40	-	-	0.00%	
	40-49	23	-	0.00%	
	50-59	427	-	0.00%	
	60-64	691	1	0.14%	
	65-69	1,597	5	0.31%	
	70-74	5,493	38	0.69%	
	75-79	11,452	109	0.95%	
	80-84	10,187	165	1.62%	
	Ages 85+	8,215	164	2.00%	
	Total	38,085	482	1.27%	

9	Less than 40	-	-	0.00%
	40-49	8	-	0.00%
	50-59	202	1	0.50%
	60-64	424	-	0.00%
	65-69	972	3	0.31%
	70-74	3,006	24	0.80%
	75-79	7,572	78	1.03%
	80-84	7,257	134	1.85%
	Ages 85+	6,135	172	2.80%
	Total	25,576	412	1.61%
10	Less than 40	-	-	0.00%
	40-49	2	-	0.00%
	50-59	102	-	0.00%
	60-64	261	-	0.00%
	65-69	618	1	0.16%
	70-74	1,846	15	0.81%
	75-79	5,421	54	1.00%
	80-84	5,458	110	2.02%
	Ages 85+	4,745	147	3.10%
	Total	18,453	327	1.77%
11-15	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	30	-	0.00%
	60-64	106	-	0.00%
	65-69	269	-	0.00%
	70-74	1,048	7	0.67%
	75-79	5,148	73	1.42%
	80-84	6,889	162	2.35%
	Ages 85+	6,214	268	4.31%
	Total	19,704	510	2.59%

Appendix D-2
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Duration

Elimination Period	Duration	Attained Age Group	Exposure	Claims	Rate
101-365	1	Less than 40	6,920	5	0.07%
		40-49	9,502	13	0.14%
		50-59	15,491	16	0.10%
		60-64	9,036	5	0.06%
		65-69	9,680	3	0.03%
		70-74	8,138	13	0.16%
		75-79	5,339	18	0.34%
		80-84	2,400	15	0.63%
		Ages 85+	778	4	0.51%
		Total	67,284	92	0.14%
	2	Less than 40	4,346	4	0.09%
		40-49	7,518	9	0.12%
		50-59	11,955	4	0.03%
		60-64	6,368	6	0.09%
		65-69	6,465	5	0.08%
		70-74	5,661	7	0.12%
		75-79	3,888	23	0.59%
		80-84	1,860	13	0.70%
		Ages 85+	716	7	0.98%
		Total	48,777	78	0.16%
	3	Less than 40	3,256	1	0.03%
		40-49	6,568	7	0.11%
		50-59	10,639	7	0.07%
		60-64	5,508	4	0.07%
		65-69	5,191	4	0.08%
		70-74	4,531	10	0.22%
		75-79	3,165	11	0.35%
		80-84	1,594	14	0.88%
		Ages 85+	666	10	1.50%
		Total	41,118	68	0.17%
	4	Less than 40	2,498	1	0.04%
		40-49	5,670	4	0.07%
		50-59	9,636	10	0.10%
		60-64	4,952	3	0.06%
		65-69	4,341	5	0.12%
		70-74	3,843	8	0.21%
		75-79	2,692	7	0.26%
		80-84	1,375	14	1.02%
		Ages 85+	629	4	0.64%
		Total	35,636	56	0.16%

5	Less than 40	1,767	2	0.11%	
	40-49	4,786	2	0.04%	
	50-59	8,853	7	0.08%	
	60-64	4,663	6	0.13%	
	65-69	3,909	4	0.10%	
	70-74	3,388	4	0.12%	
	75-79	2,344	6	0.26%	
	80-84	1,212	16	1.32%	
	Ages 85+	579	5	0.86%	
	Total	31,501	52	0.17%	
	Loop than 40	4.405		0.000/	
6	Less than 40	1,495	-	0.00%	
	40-49	4,438 9,405	2	0.05%	
	50-59 60-64	8,495 4,470	9 5	0.11%	
	65-69	4,470 3,515	3	0.11%	
	70-74	3,515 2,797	8	0.09% 0.29%	
	75-79	1,974	14	0.23%	
	80-84	978	11	1.12%	
	Ages 85+	480	5	1.04%	
	7.g00 001	100	Ü	1.0170	
	Total	28,642	57	0.20%	
		-,-			
7	Less than 40	1,255	-	0.00%	
	40-49	4,041	2	0.05%	
	50-59	8,053	5	0.06%	
	60-64	4,261	5	0.12%	
	65-69	3,284	7	0.21%	
	70-74	2,395	7	0.29%	
	75-79	1,747	7	0.40%	
	80-84	829	16	1.93%	
	Ages 85+	401	8	2.00%	
	Total	26,266	57	0.22%	
8	Less than 40	1,162	_	0.00%	
	40-49	3,860	1	0.03%	
	50-59	7,765	3	0.04%	
	60-64	4,069	4	0.10%	
	65-69	3,048	7	0.23%	
	70-74	2,103	10	0.48%	
	75-79	1,549	15	0.97%	
	80-84	715	13	1.82%	
	Ages 85+	353	10	2.83%	
	Total	24,624	63	0.26%	

9	Less than 40	1,022	1	0.10%
	40-49	3,586	-	0.00%
	50-59	7,314	5	0.07%
	60-64	3,692	2	0.05%
	65-69	2,517	5	0.20%
	70-74	1,478	5	0.34%
	75-79	1,147	4	0.35%
	80-84	525	20	3.81%
	Ages 85+	276	9	3.26%
	Total	21,557	51	0.24%
10	Less than 40	1	-	0.00%
	40-49	1	-	0.00%
	50-59	10	-	0.00%
	60-64	18	1	5.56%
	65-69	42	-	0.00%
	70-74	188	3	1.60%
	75-79	504	3	0.60%
	80-84	313	6	1.92%
	Ages 85+	194	9	4.64%
	Total	1,271	22	1.73%
11-15	Less than 40	-	-	0.00%
	40-49	-	-	0.00%
	50-59	-	-	0.00%
	60-64	3	-	0.00%
	65-69	7	-	0.00%
	70-74	29	2	6.90%
	75-79	130	3	2.31%
	80-84	97	-	0.00%
	Ages 85+	84	5	5.95%
	Total	350	10	2.86%

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
0	1	Less than 40	406	-	0.00%
		40-49	1,645	-	0.00%
		50-59	18,762	16	0.09%
		60-64	55,045	89	0.16%
		65-69	102,741	382	0.37%
		70-74	78,349	726	0.93%
		75-79	50,471	1,076	2.13%
		80-84	13,409	605	4.51%
		Ages 85+	41	2	4.88%
		Total	320,869	2,896	0.90%
	2	Less than 40	167	-	0.00%
		40-49	723	-	0.00%
		50-59	9,481	11	0.12%
		60-64	33,499	94	0.28%
		65-69	67,560	382	0.57%
		70-74	48,779	639	1.31%
		75-79	29,973	940	3.14%
		80-84	6,442	425	6.60%
		Ages 85+	23	1	4.35%
		Total	196,647	2,492	1.27%
	3	Less than 40	105	-	0.00%
		40-49	463	-	0.00%
		50-59	5,998	8	0.13%
		60-64	23,539	83	0.35%
		65-69	50,286	358	0.71%
		70-74	35,224	612	1.74%
		75-79	21,311	739	3.47%
		80-84	3,641	279	7.66%
		Ages 85+	17	1	5.88%
		Total	140,584	2,080	1.48%
	4	Less than 40	59	-	0.00%
		40-49	255	-	0.00%
		50-59	3,881	8	0.21%
		60-64	16,333	63	0.39%
		65-69	37,098	302	0.81%
		70-74	24,969	513	2.05%
		75-79	15,278	615	4.03%
		80-84	1,878	163	8.68%
		Ages 85+	14	1	7.14%
		Total	99,765	1,665	1.67%

5	Less than 40	34	-	0.00%
	40-49	158	-	0.00%
	50-59	2,618	4	0.15%
	60-64	11,120	49	0.44%
	65-69	26,382	260	0.99%
	70-74	17,204	383	2.23%
	75-79	10,699	421	3.93%
	80-84	939	84	8.95%
	Ages 85+	11	1	9.09%
	Total	69,165	1,202	1.74%
6	Less than 40	31	-	0.00%
	40-49	123	1	0.81%
	50-59	1,722	5	0.29%
	60-64	7,259	51	0.70%
	65-69	18,581	176	0.95%
	70-74	12,015	291	2.42%
	75-79	7,897	362	4.58%
	80-84	555	37	6.67%
	Ages 85+	9	-	0.00%
	Total	48,192	923	1.92%
7	Less than 40	19	-	0.00%
	40-49	86	-	0.00%
	50-59	1,071	1	0.09%
	60-64	4,922	31	0.63%
	65-69	13,113	194	1.48%
	70-74	8,533	259	3.04%
	75-79	6,081	308	5.06%
	80-84	440	26	5.91%
	Ages 85+	8	1	12.50%
	Total	34,273	820	2.39%
8	Less than 40	11	-	0.00%
	40-49	53	1	1.89%
	50-59	679	3	0.44%
	60-64	3,560	43	1.21%
	65-69	9,646	150	1.56%
	70-74	6,445	214	3.32%
	75-79	4,630	253	5.46%
	80-84	326	31	9.51%
	Ages 85+	6	1	16.67%
	Total	25,356	696	2.74%

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
20	1	Less than 40	328	-	0.00%
		40-49	7,813	2	0.03%
		50-59	47,898	21	0.04%
		60-64	95,471	74	0.08%
		65-69	155,065	222	0.14%
		70-74	116,590	504	0.43%
		75-79	71,356	834	1.17%
		80-84	16,466	401	2.44%
		Ages 85+	339	9	2.65%
		Total	511,326	2,067	0.40%
	2	Less than 40	201	-	0.00%
		40-49	5,499	2	0.04%
		50-59	35,794	23	0.06%
		60-64	74,628	94	0.13%
		65-69	124,729	318	0.25%
		70-74	91,706	608	0.66%
		75-79	54,853	818	1.49%
		80-84	12,357	335	2.71%
		Ages 85+	220	7	3.18%
		Total	399,987	2,205	0.55%
	3	Less than 40	160	-	0.00%
		40-49	3,994	2	0.05%
		50-59	27,296	25	0.09%
		60-64	59,484	92	0.15%
		65-69	101,398	341	0.34%
		70-74	74,459	608	0.82%
		75-79	44,354	849	1.91%
		80-84	9,755	309	3.17%
		Ages 85+	180	7	3.89%
		Total	321,080	2,233	0.70%
	4	Less than 40	127	_	0.00%
		40-49	2,768	2	0.07%
		50-59	20,249	21	0.10%
		60-64	46,253	82	0.18%
		65-69	81,135	320	0.39%
		70-74	59,341	573	0.97%
		75-79	35,330	784	2.22%
		80-84	7,647	305	3.99%
		Ages 85+	140	11	7.86%
		Total	252,990	2,098	0.83%

5	Less than 40	100	-	0.00%
	40-49	1,921	-	0.00%
	50-59	15,083	18	0.12%
	60-64	35,347	74	0.21%
	65-69	62,857	305	0.49%
	70-74	45,869	491	1.07%
	75-79	27,423	709	2.59%
	80-84	6,007	246	4.10%
	Ages 85+	109	3	2.75%
	Total	194,716	1,846	0.95%
6	Less than 40	79	-	0.00%
	40-49	1,440	-	0.00%
	50-59	10,380	15	0.14%
	60-64	25,155	72	0.29%
	65-69	46,342	275	0.59%
	70-74	34,053	506	1.49%
	75-79	20,617	589	2.86%
	80-84	4,396	201	4.57%
	Ages 85+	81	13	16.05%
	Total	142,543	1,671	1.17%
7	Less than 40	52	-	0.00%
	40-49	1,116	-	0.00%
	50-59	6,454	15	0.23%
	60-64	16,898	61	0.36%
	65-69	32,254	262	0.81%
	70-74	23,841	389	1.63%
	75-79	14,779	548	3.71%
	80-84	3,215	213	6.63%
	Ages 85+	60	5	8.33%
	Total	98,669	1,493	1.51%
0	L 4b 40	0.4		0.000/
8	Less than 40	34	-	0.00%
	40-49	785	2	0.25%
	50-59	4,563	5	0.11%
	60-64	12,274	58	0.47%
	65-69	22,987	244	1.06%
	70-74	16,934	380	2.24%
	75-79	10,688	441	4.13%
	80-84	2,398	174	7.26%
	Ages 85+	45	4	8.89%
	Total	70,708	1,308	1.85%

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
30	1	Less than 40	3,158	3	0.09%
		40-49	4,836	1	0.02%
		50-59	18,537	6	0.03%
		60-64	29,738	15	0.05%
		65-69	45,930	21	0.05%
		70-74	30,771	55	0.18%
		75-79	16,232	57	0.35%
		80-84	7,401	82	1.11%
		Ages 85+	841	36	4.28%
		Total	157,444	276	0.18%
	2	Less than 40	1,564	1	0.06%
		40-49	2,211	2	0.09%
		50-59	8,393	5	0.06%
		60-64	16,969	8	0.05%
		65-69	27,893	42	0.15%
		70-74	18,034	53	0.29%
		75-79	9,138	59	0.65%
		80-84	4,381	90	2.05%
		Ages 85+	481	36	7.48%
		Total	89,064	296	0.33%
	3	Less than 40	765	-	0.00%
		40-49	1,254	1	0.08%
		50-59	5,836	7	0.12%
		60-64	12,374	16	0.13%
		65-69	20,421	31	0.15%
		70-74	13,034	49	0.38%
		75-79	6,423	61	0.95%
		80-84	3,195	89	2.79%
		Ages 85+	363	30	8.26%
		Total	63,665	284	0.45%
	4	Less than 40	520	-	0.00%
		40-49	828	1	0.12%
		50-59	3,988	6	0.15%
		60-64	8,406	11	0.13%
		65-69	14,225	48	0.34%
		70-74	8,866	77	0.87%
		75-79	4,240	55	1.30%
		80-84	2,197	85	3.87%
		Ages 85+	294	25	8.50%
		Total	43,564	308	0.71%

5	Less than 40	273	-	0.00%
	40-49	476	-	0.00%
	50-59	2,466	5	0.20%
	60-64	5,362	14	0.26%
	65-69	9,028	33	0.37%
	70-74	5,439	67	1.23%
	75-79	2,524	69	2.73%
	80-84	1,428	62	4.34%
	Ages 85+	244	32	13.11%
	Total	27,240	282	1.04%
6	Less than 40	114	-	0.00%
	40-49	273	2	0.73%
	50-59	1,577	-	0.00%
	60-64	3,270	11	0.34%
	65-69	5,224	25	0.48%
	70-74	3,125	54	1.73%
	75-79	1,385	45	3.25%
	80-84	827	59	7.13%
	Ages 85+	181	27	14.92%
	Total	15,976	223	1.40%
7	Less than 40	52	1	1.92%
	40-49	160	-	0.00%
	50-59	925	2	0.22%
	60-64	1,664	12	0.72%
	65-69	2,299	32	1.39%
	70-74	1,307	38	2.91%
	75-79	497	29	5.84%
	80-84	283	44	15.55%
	Ages 85+	102	21	20.59%
	Total	7,289	179	2.46%
8	Less than 40	23	-	0.00%
	40-49	113	-	0.00%
	50-59	601	-	0.00%
	60-64	980	7	0.71%
	65-69	1,261	6	0.48%
	70-74	667	19	2.85%
	75-79	216	11	5.09%
	80-84	55	6	10.91%
	Ages 85+	5	3	60.00%
	Total	3,921	52	1.33%

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
60	1	Less than 40	30,627	12	0.04%
		40-49	28,343	13	0.05%
		50-59	31,467	18	0.06%
		60-64	23,217	27	0.12%
		65-69	24,495	41	0.17%
		70-74	17,515	57	0.33%
		75-79	9,880	85	0.86%
		80-84	3,294	63	1.91%
		Ages 85+	357	12	3.36%
		Total	169,195	328	0.19%
	2	Less than 40	20,575	8	0.04%
	-	40-49	21,144	7	0.03%
		50-59	19,526	21	0.11%
		60-64	12,938	24	0.19%
		65-69	13,546	55	0.41%
		70-74	9,548	75	0.79%
		75-79	5,324	88	1.65%
		80-84	2,024	61	3.01%
		Ages 85+	203	11	5.42%
		3			
		Total	104,828	350	0.33%
	3	Less than 40	16,107	6	0.04%
		40-49	17,653	12	0.07%
		50-59	15,324	16	0.10%
		60-64	9,257	15	0.16%
		65-69	9,004	39	0.43%
		70-74	5,911	53	0.90%
		75-79	3,107	73	2.35%
		80-84	1,268	52	4.10%
		Ages 85+	156	14	8.97%
		Total	77,787	280	0.36%
	4	Less than 40	13,637	12	0.09%
		40-49	15,492	7	0.05%
		50-59	12,347	10	0.08%
		60-64	6,400	17	0.27%
		65-69	5,167	32	0.62%
		70-74	2,858	40	1.40%
		75-79	1,376	43	3.13%
		80-84	613	35	5.71%
		Ages 85+	126	11	8.73%
		Total	58,016	207	0.36%

5	Less than 40	11,657	3	0.03%
	40-49	13,821	6	0.04%
	50-59	10,430	8	0.08%
	60-64	4,779	18	0.38%
	65-69	3,156	28	0.89%
	70-74	1,392	18	1.29%
	75-79	516	21	4.07%
	80-84	240	17	7.08%
	Ages 85+	75	7	9.33%
	Total	46,066	126	0.27%
6	Less than 40	9,546	1	0.01%
	40-49	11,866	8	0.07%
	50-59	9,011	8	0.09%
	60-64	4,079	10	0.25%
	65-69	2,479	15	0.61%
	70-74	875	11	1.26%
	75-79	224	18	8.04%
	80-84	124	6	4.84%
	Ages 85+	61	6	9.84%
	Total	38,265	83	0.22%
7	Less than 40	2,544	-	0.00%
	40-49	5,048	2	0.04%
	50-59	3,809	5	0.13%
	60-64	2,313	8	0.35%
	65-69	1,451	13	0.90%
	70-74	490	7	1.43%
	75-79	113	4	3.54%
	80-84	56	10	17.86%
	Ages 85+	23	5	21.74%
	Total	15,847	54	0.34%
8	Less than 40	843	1	0.12%
	40-49	1,456	-	0.00%
	50-59	1,191	5	0.42%
	60-64	807	4	0.50%
	65-69	433	4	0.92%
	70-74	126	5	3.97%
	75-79	15	4	26.67%
	80-84	4	1	25.00%
	Ages 85+	3	-	0.00%
	Total	4,878	24	0.49%

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
90	1	Less than 40	197,795	22	0.01%
		40-49	143,162	30	0.02%
		50-59	157,226	51	0.03%
		60-64	97,648	72	0.07%
		65-69	102,635	76	0.07%
		70-74	61,509	112	0.18%
		75-79	33,013	168	0.51%
		80-84	9,360	55	0.59%
		Ages 85+	1,212	18	1.49%
		Total	803,560	604	0.08%
	2	Less than 40	83,537	7	0.01%
		40-49	71,137	21	0.03%
		50-59	79,413	47	0.06%
		60-64	55,798	52	0.09%
		65-69	60,701	96	0.16%
		70-74	34,114	133	0.39%
		75-79	17,198	165	0.96%
		80-84	4,499	52	1.16%
		Ages 85+	494	19	3.85%
		Total	406,891	592	0.15%
			,		
	3	Less than 40	51,718	8	0.02%
		40-49	49,182	13	0.03%
		50-59	58,400	45	0.08%
		60-64	42,753	51	0.12%
		65-69	46,188	98	0.21%
		70-74	25,078	136	0.54%
		75-79	12,246	147	1.20%
		80-84	3,158	51	1.61%
		Ages 85+	396	20	5.05%
		Total	289,119	569	0.20%
	4	Less than 40	33,117	2	0.01%
		40-49	34,065	11	0.03%
		50-59	41,429	28	0.07%
		60-64	32,459	40	0.12%
		65-69	35,190	81	0.23%
		70-74	18,281	111	0.61%
		75-79	8,757	129	1.47%
		80-84	2,179	70	3.21%
		Ages 85+	305	22	7.21%
		Total	205,782	494	0.24%

5	Less than 40	19,605	3	0.02%	
	40-49	21,577	11	0.05%	
	50-59	23,969	21	0.09%	
	60-64	19,142	37	0.19%	
	65-69	20,817	69	0.33%	
	70-74	10,725	114	1.06%	
	75-79	4,911	107	2.18%	
	80-84	1,380	59	4.28%	
	Ages 85+	235	20	8.51%	
	Total	122,361	441	0.36%	
6	Less than 40	9,848	-	0.00%	
	40-49	9,368	6	0.06%	
	50-59	9,862	10	0.10%	
	60-64	7,090	22	0.31%	
	65-69	7,465	42	0.56%	
	70-74	4,037	66	1.63%	
	75-79	1,899	69	3.63%	
	80-84	712	35	4.92%	
	Ages 85+	123	9	7.32%	
	Total	50,404	259	0.51%	
7	Less than 40	1,380	1	0.07%	
	40-49	1,863	2	0.11%	
	50-59	3,137	2	0.06%	
	60-64	3,081	7	0.23%	
	65-69	3,438	22	0.64%	
	70-74	1,905	33	1.73%	
	75-79	904	34	3.76%	
	80-84	311	26	8.36%	
	Ages 85+	41	2	4.88%	
	Total	16,060	129	0.80%	
	Total	10,000	129	0.0076	
8	Less than 40	871	_	0.00%	
•	40-49	1,413	2	0.14%	
	50-59	2,246	3	0.13%	
	60-64	2,056	14	0.68%	
	65-69	2,138	17	0.80%	
	70-74	1,097	19	1.73%	
	75-79	480	22	4.58%	
	80-84	123	12	9.76%	
	Ages 85+	12	1	8.33%	
	Ç				
	Total	10,436	90	0.86%	

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
100	1	Less than 40	4,050	-	0.00%
		40-49	8,109	1	0.01%
		50-59	52,437	3	0.01%
		60-64	92,311	30	0.03%
		65-69	149,398	95	0.06%
		70-74	122,991	227	0.18%
		75-79	78,653	405	0.51%
		80-84	31,909	316	0.99%
		Ages 85+	1,151	22	1.91%
		Total	541,009	1,099	0.20%
	2	Less than 40	2,279	-	0.00%
		40-49	4,717	-	0.00%
		50-59	29,157	9	0.03%
		60-64	53,514	39	0.07%
		65-69	95,718	113	0.12%
		70-74	77,894	271	0.35%
		75-79	50,215	465	0.93%
		80-84	19,321	334	1.73%
		Ages 85+	732	11	1.50%
		Total	333,547	1,242	0.37%
	3	Less than 40	1,305	-	0.00%
		40-49	3,170	3	0.09%
		50-59	20,723	12	0.06%
		60-64	38,329	28	0.07%
		65-69	72,399	145	0.20%
		70-74	59,055	283	0.48%
		75-79	38,300	453	1.18%
		80-84	14,367	260	1.81%
		Ages 85+	546	11	2.01%
		Total	248,194	1,195	0.48%
	4	Less than 40	516	-	0.00%
		40-49	1,895	-	0.00%
		50-59	14,249	8	0.06%
		60-64	27,250	26	0.10%
		65-69	54,580	104	0.19%
		70-74	44,219	258	0.58%
		75-79	29,024	358	1.23%
		80-84	10,352	235	2.27%
		Ages 85+	398	12	3.02%
		Total	182,483	1,001	0.55%

5	Less than 40	290	-	0.00%	
	40-49	1,221	-	0.00%	
	50-59	9,804	7	0.07%	
	60-64	18,979	26	0.14%	
	65-69	40,335	106	0.26%	
	70-74	32,556	207	0.64%	
	75-79	21,706	339	1.56%	
	80-84	7,043	179	2.54%	
	Ages 85+	271	6	2.21%	
	Total	132,205	870	0.66%	
6	Less than 40	74	-	0.00%	
	40-49	869	-	0.00%	
	50-59	6,119	6	0.10%	
	60-64	12,223	16	0.13%	
	65-69	28,255	80	0.28%	
	70-74	23,025	188	0.82%	
	75-79	15,762	270	1.71%	
	80-84	4,410	126	2.86%	
	Ages 85+	152	6	3.95%	
	Total	00.000	600	0.700/	
	Total	90,889	692	0.76%	
7	Less than 40	36	_	0.00%	
	40-49	576	-	0.00%	
	50-59	3,543	1	0.03%	
	60-64	7,102	21	0.30%	
	65-69	18,505	72	0.39%	
	70-74	15,300	148	0.97%	
	75-79	10,747	231	2.15%	
	80-84	2,523	80	3.17%	
	Ages 85+	82	5	6.10%	
	Total	58,414	558	0.96%	
8	Less than 40	3	-	0.00%	
	40-49	346	-	0.00%	
	50-59	2,082	4	0.19%	
	60-64	4,411	9	0.20%	
	65-69	12,146	79	0.65%	
	70-74	10,185	147	1.44%	
	75-79	7,456	187	2.51%	
	80-84	1,417	54	3.81%	
	Ages 85+	39	2	5.13%	
	Total	38,085	400	1.27%	
	TUlai	30,083	482	1.21%	

TABLE D-2a
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Duration, and Issue Age

Elimination Period	Duration	Issue Age Group	Exposure	Claims	Rate
All	1	Less than 40	248,064	43	0.02%
		40-49	207,667	62	0.03%
		50-59	344,605	131	0.04%
		60-64	411,531	322	0.08%
		65-69	615,922	865	0.14%
		70-74	459,061	1,722	0.38%
		75-79	284,531	2,697	0.95%
		80-84	95,842	1,583	1.65%
		Ages 85+	4,417	104	2.35%
		Total	2,671,640	7,529	0.28%
	2	Less than 40	117,325	21	0.02%
		40-49	116,895	41	0.04%
		50-59	194,701	123	0.06%
		60-64	258,080	324	0.13%
		65-69	412,392	1,030	0.25%
		70-74	298,326	1,829	0.61%
		75-79	180,544	2,602	1.44%
		80-84	56,302	1,359	2.41%
		Ages 85+	2,349	89	3.79%
		Total	1,636,914	7,418	0.45%
	3	Less than 40	77,926	16	0.02%
		40-49	86,138	39	0.05%
		50-59	144,579	121	0.08%
		60-64	193,490	300	0.16%
		65-69	314,988	1,042	0.33%
		70-74	224,711	1,790	0.80%
		75-79	134,557	2,390	1.78%
		80-84	39,961	1,101	2.76%
		Ages 85+	1,786	85	4.76%
		Total	1,218,136	6,884	0.57%
	4	Less than 40	54,768	15	0.03%
		40-49	64,683	30	0.05%
		50-59	105,832	92	0.09%
		60-64	142,898	249	0.17%
		65-69	238,068	911	0.38%
		70-74	166,335	1,607	0.97%
		75-79	99,645	2,045	2.05%
		80-84	27,705	942	3.40%
		Ages 85+	1,365	82	6.01%
		Total	901,299	5,973	0.66%

5	Less than 40	37,678	9	0.02%
	40-49	47,616	22	0.05%
	50-59	73,214	73	0.10%
	60-64	99,288	222	0.22%
	65-69	169,975	829	0.49%
	70-74	118,130	1,316	1.11%
	75-79	71,287	1,719	2.41%
	80-84	18,715	680	3.63%
	Ages 85+	1,005	72	7.16%
	Total	636,908	4,942	0.78%
6	Less than 40	24,987	2	0.01%
	40-49	31,985	21	0.07%
	50-59	47,059	55	0.12%
	60-64	62,784	192	0.31%
	65-69	113,561	638	0.56%
	70-74	80,376	1,162	1.45%
	75-79	49,895	1,396	2.80%
	80-84	11,982	486	4.06%
	Ages 85+	650	62	9.54%
	Total	423,279	4,014	0.95%
_				
7	Less than 40	8,914	3	0.03%
	40-49	16,439	7	0.04%
	50-59	26,834	37	0.14%
	60-64	39,076	149	0.38%
	65-69	74,815	619	0.83%
	70-74	53,613	895	1.67%
	75-79	34,461	1,189	3.45%
	80-84	7,364	425	5.77%
	Ages 85+	339	41	12.09%
		004.055	0.005	4.000/
	Total	261,855	3,365	1.29%
0	Loop than 40	6 205	2	0.039/
8	Less than 40	6,395	2	0.03%
	40-49	11,510	6	0.05% 0.16%
	50-59	18,815 26,625	31	
	60-64 65-69		145	0.54%
	70-74	51,236	526	1.03%
	70-74 75-79	36,890 24,273	808 946	2.19% 3.90%
	75-79 80-84	4,600		
	80-84 Ages 85+	4,600	294 13	6.39% 11.02%
	Ages out	110	13	11.02%
	Total	180,462	2,771	1.54%
	. 0.01	100,402	۷, ۱ ۱ ۱	1.07/0

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination Period	Attained Age Group	Gender	Exposure	Claims	Rate
	·		·		
0	Less than 40	Male	190	0	0.00%
		Female	246	0	0.00%
		Total	436	-	0.00%
	40-49	Male	751	1	0.13%
		Female	1,404	1	0.07%
		Total	2,155	2	0.09%
	50-59	Male	6,141	10	0.16%
		Female	14,600	18	0.12%
		Total	20,741	28	0.13%
	60-64	Male	14,723	40	0.27%
	00 04	Female	34,424	99	0.29%
		Total	49,147	139	0.28%
	65-69	Male	60,264	363	0.60%
		Female	110,818	642	0.58%
		Total	171,082	1,005	0.59%
	70-74	Male	102,618	1,093	1.07%
		Female	168,757	1,717	1.02%
		Total	271,375	2,810	1.04%
	75-79	Male	91,613	1,749	1.91%
		Female	160,126	2,969	1.85%
		Total	251,739	4,718	1.87%
	80-84	Male	49,592	1,400	2.82%
		Female	97,645	2,861	2.93%
		Total	147,237	4,261	2.89%
	Ages 85+	Male	16,505	438	2.65%
	-	Female	45,785	1,140	2.49%
		Total	62,290	1,578	2.53%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination	Attained Age				
Period	Group	Gender	Exposure	Claims	Rate
7-19	Less than 40		20	0	0.00%
		Female	15	0	0.00%
		Total	35	-	0.00%
	40-49	Male	38	0	0.00%
		Female	92	0	0.00%
		Total	130	-	0.00%
	50-59	Male	683	1	0.15%
	00 00	Female	2,067	5	0.24%
		Total	2,750	6	0.22%
		Total	2,700	· ·	0.2270
	60-64	Male	1,561	2	0.13%
		Female	4,981	12	0.24%
		Total	6,542	14	0.21%
	65-69	Male	11,560	17	0.15%
		Female	23,107	47	0.20%
		Total	34,667	64	0.18%
	70-74	Male	20,381	35	0.17%
		Female	39,405	137	0.35%
		Total	59,786	172	0.29%
	75-79	Male	17,575	59	0.34%
		Female	36,362	185	0.51%
		Total	53,937	244	0.45%
	80-84	Male	12,802	78	0.61%
		Female	27,305	229	0.84%
		Total	40,107	307	0.77%
		. Juli	70,101	001	5.1170
	Ages 85+	Male	5,303	56	1.06%
		Female	13,359	135	1.01%
		Total	18,662	191	1.02%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination Period	Attained Age Group	Gender	Exposure	Claims	Rate
i chod	Oroup	Ochaci	LAPOSUIC	Oldii 113	Nato
20	Less than 40	Male	165	0	0.00%
		Female	221	0	0.00%
		Total	386	-	0.00%
	10.10		0.755	0	0.050/
	40-49	Male	3,755	2	0.05%
		Female	6,480	4	0.06%
		Total	10,235	6	0.06%
	50-59	Male	23,058	17	0.07%
		Female	48,684	43	0.09%
		Total	71,742	60	0.08%
	00.04	NA-1-	40.700	00	0.400/
	60-64	Male	43,796	82	0.19%
		Female	87,755	136	0.15%
		Total	131,551	218	0.17%
	65-69	Male	123,601	351	0.28%
		Female	210,114	633	0.30%
		Total	333,715	984	0.29%
	70.74	M-I-	400.750	4.074	0.540/
	70-74	Male	199,752	1,071	0.54%
		Female	329,067	1,849	0.56%
		Total	528,819	2,920	0.55%
	75-79	Male	199,951	1,912	0.96%
		Female	335,477	3,392	1.01%
		Total	535,428	5,304	0.99%
	80-84	Male	110 //0	1 776	1.50%
	00-04	Female	118,440	1,776	
			217,992	3,755	1.72%
		Total	336,432	5,531	1.64%
	Ages 85+	Male	48,994	881	1.80%
		Female	119,439	2,335	1.95%
		Total	168,433	3,216	1.91%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination Period	Attained Age Group	Gender	Exposure	Claims	Rate
30-50	Less than 40	Male	185	0	0.00%
30 30	2033 triair 40	Female	236	0	0.00%
		Total	421	-	0.00%
	40-49	Male	3,793	2	0.05%
		Female	6,572	4	0.06%
		Total	10,365	6	0.06%
	50-59	Male	23,741	18	0.08%
		Female	50,751	48	0.09%
		Total	74,492	66	0.09%
	60-64	Male	45,357	84	0.19%
		Female	92,736	148	0.16%
		Total	138,093	232	0.17%
	65-69	Male	135,161	368	0.27%
		Female	233,221	680	0.29%
		Total	368,382	1,048	0.28%
	70-74	Male	220,133	1,106	0.50%
		Female	368,472	1,986	0.54%
		Total	588,605	3,092	0.53%
	75-79	Male	217,526	1,971	0.91%
		Female	371,839	3,577	0.96%
		Total	589,365	5,548	0.94%
	80-84	Male	131,242	1,854	1.41%
		Female	245,297	3,984	1.62%
		Total	376,539	5,838	1.55%
	Ages 85+	Male	54,297	937	1.73%
		Female	132,798	2,470	1.86%
		Total	187,095	3,407	1.82%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination Period	Attained Age Group	Gender	Exposure	Claims	Rate
60	Less than 40	Mala	27.246	1.4	0.059/
60	Less man 40	Female	27,346 37,818	14 16	0.05% 0.04%
		Total	65,164	30	0.04%
		Total	03,104	30	0.0576
	40-49	Male	37,222	29	0.08%
		Female	53,267	22	0.04%
		Total	90,489	51	0.06%
	50-59	Male	52,383	40	0.08%
		Female	65,247	37	0.06%
		Total	117,630	77	0.07%
			,		
	60-64	Male	25,450	37	0.15%
		Female	31,904	38	0.12%
		Total	57,354	75	0.13%
	65-69	Male	20.905	76	0.259/
	00-09		30,895		0.25%
		Female Total	38,228	96 172	0.25% 0.25%
		Total	69,123	172	0.25%
	70-74	Male	26,551	117	0.44%
		Female	33,558	162	0.48%
		Total	60,109	279	0.46%
	75-79	Male	14,820	106	0.72%
		Female	20,271	196	0.97%
		Total	35,091	302	0.86%
	80-84	Male	5,586	89	1.59%
		Female	9,276	219	2.36%
		Total	14,862	308	2.07%
	Ages 85+	Male	1,364	34	2.49%
		Female	3,649	130	3.56%
		Total	5,013	164	3.27%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination Period	Attained Age Group	Gender	Exposure	Claims	Rate
90	Less than 40	Molo	120 750	20	0.01%
90	Less man 40	Female	138,758 161,654	14	0.01%
		Total	300,412	34	0.01%
		Total	300,412	34	0.0176
	40-49	Male	141,226	44	0.03%
		Female	168,165	36	0.02%
		Total	309,391	80	0.03%
	50-59	Male	157,661	68	0.04%
		Female	185,558	84	0.05%
		Total	343,219	152	0.04%
			0.0,2.0	.02	0.0 . , 0
	60-64	Male	86,128	85	0.10%
		Female	118,250	114	0.10%
		Total	204,378	199	0.10%
	65-69	Male	113,287	145	0.13%
	05-09	Female	154,378	208	0.13%
		Total	267,665	353	0.13%
		Total	207,000	333	0.1370
	70-74	Male	109,983	225	0.20%
		Female	141,596	349	0.25%
		Total	251,579	574	0.23%
	75-79	Male	62,136	315	0.51%
		Female	82,520	504	0.61%
		Total	144,656	819	0.57%
	80-84	Male	25,554	219	0.86%
		Female	40,104	483	1.20%
		Total	65,658	702	1.07%
	Ages 85+	Male	6,752	103	1.53%
	5	Female	13,021	291	2.23%
		Total	19,773	394	1.99%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination	Attained Age				
Period	Group	Gender	Exposure	Claims	Rate
100	Less than 40	Male	3,394	0	0.00%
		Female	3,739	0	0.00%
		Total	7,133	-	0.00%
	40-49	Male	4,280	0	0.00%
		Female	6,810	1	0.01%
		Total	11,090	1	0.01%
	50-59	Male	22,979	8	0.03%
	00 00	Female	48,129	15	0.03%
		Total	71,108	23	0.03%
			,		
	60-64	Male	45,133	18	0.04%
		Female	80,001	62	0.08%
		Total	125,134	80	0.06%
	65-69	Male	111,603	131	0.12%
		Female	161,014	217	0.13%
		Total	272,617	348	0.13%
	70-74	Male	165,006	403	0.24%
		Female	235,132	682	0.29%
		Total	400,138	1,085	0.27%
	75-79	Male	154,395	805	0.52%
		Female	233,452	1,449	0.62%
		Total	387,847	2,254	0.58%
	80-84	Male	98,212	943	0.96%
		Female	165,021	1,925	1.17%
		Total	263,233	2,868	1.09%
	۸ ۵-		45 50 1	40.4	4.0007
	Ages 85+	Male	45,564	484	1.06%
		Female	102,305	1,245	1.22%
		Total	147,869	1,729	1.17%

Appendix D-3 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Gender

Elimination Period	Attained Age Group	Gender	Exposure	Claims	Rate
101-730	Less than 40	Male	11,437	6	0.05%
101 100	2000 man 10	Female	12,285	8	0.07%
		Total	23,722	14	0.06%
	40-49	Male	22,138	20	0.09%
		Female	27,831	20	0.07%
		Total	49,969	40	0.08%
	50-59	Male	40,571	20	0.05%
	00 00	Female	47,601	46	0.10%
		Total	88,172	66	0.07%
	60-64	Male	23,985	24	0.10%
		Female	22,987	17	0.07%
		Total	46,972	41	0.09%
	65-69	Male	21,179	19	0.09%
		Female	20,735	24	0.12%
		Total	41,914	43	0.10%
	70-74	Male	15,683	24	0.15%
		Female	18,780	53	0.28%
		Total	34,463	77	0.22%
	75-79	Male	10 427	33	0.32%
	75-79	Female	10,437 13,999	33 78	0.56%
		Total	24,436	111	0.36%
		Total	24,430	111	0.4576
	80-84	Male	4,408	42	0.95%
		Female	7,470	96	1.29%
		Total	11,878	138	1.16%
	Ages 85+	Male	1,353	18	1.33%
	Ayes out	Female	3,803	58	1.53%
		Total	5,603 5,156	76	1.47%
		iolai	3,130	10	1.41 70

Appendix D-4
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, Duration, and Issue Year

Elimination Period	Attained Age Duration Group	Issue Year Group	Exposure	Claims	Rate
0 1	Less than 40	1984-87	4	-	0.00%
		1988-91	43	-	0.00%
		1992-95	83	-	0.00%
		1996-99	166	-	0.00%
			296	-	0.00%
	40-49	1984-87	44	-	0.00%
		1988-91	216	-	0.00%
		1992-95	469	-	0.00%
		1996-99	496	-	0.00%
			1,225	-	0.00%
	50-59	1984-87	501	1	0.20%
		1988-91	5,699	9	0.16%
		1992-95	3,113	2	0.06%
		1996-99	2,586	-	0.00%
			11,899	12	0.10%
	60-64	1984-87	2,386	16	0.67%
		1988-91	15,246	45	0.30%
		1992-95	5,449	4	0.07%
		1996-99	3,599	-	0.00%
			26,680	65	0.24%
	65-69	1984-87	12,568	119	0.95%
		1988-91	42,367	190	0.45%
		1992-95	14,517	21	0.14%
		1996-99	8,483	-	0.00%
			77,935	330	0.42%
	70-74	1984-87	18,224	205	1.12%
		1988-91	50,825	431	0.85%
		1992-95	13,421	33	0.25%
		1996-99	7,703	1	0.01%
			90,173	670	0.74%

	75-79	1984-87	15,579	314	2.02%
		1988-91	39,714	689	1.73%
		1992-95	7,711	38	0.49%
		1996-99	5,798	30	0.00%
		1990-99	3,790	-	0.0076
			68,802	1,041	1.51%
	80-84	1984-87	8,745	224	2.56%
		1988-91	22,110	459	2.08%
		1992-95	2,501	8	0.32%
		1996-99	1,165	-	0.00%
			34,521	691	2.00%
	Ages 85+	1984-87	2,892	21	0.73%
		1988-91	6,259	66	1.05%
		1992-95	186	-	0.00%
		1996-99	1	-	0.00%
			9,338	87	0.93%
2	Less than 40	1984-87	2	-	0.00%
		1988-91	22	-	0.00%
		1992-95	28	-	0.00%
		1996-99	28	-	0.00%
			80	-	0.00%
	40-49	1984-87	25	-	0.00%
		1988-91	130	-	0.00%
		1992-95	154	-	0.00%
		1996-99	118	-	0.00%
			427	-	0.00%
	E0 E0	1004.07	201	4	0.220/
	50-59	1984-87	301	1	0.33%
		1988-91	2,078	5	0.24%
		1992-95	1,203	-	0.00%
		1996-99	666	-	0.00%
			4,248	6	0.14%
	60-64	1984-87	1,355	8	0.59%
		1988-91	6,035	18	0.30%
		1992-95	2,366	1	0.04%
		1996-99	1,156	-	0.00%
			10,912	27	0.25%

	65-69	1984-87	8,296	80	0.96%
		1988-91	21,645	178	0.82%
		1992-95	8,042	12	0.15%
		1996-99	3,467	-	0.00%
			,		
			41,450	270	0.65%
	70-74	1984-87	13,827	168	1.22%
		1988-91	32,375	340	1.05%
		1992-95	9,346	33	0.35%
		1996-99	3,052	-	0.00%
			58,600	541	0.92%
	75-79	1984-87	11,935	240	2.01%
		1988-91	27,334	548	2.00%
		1992-95	5,513	49	0.89%
		1996-99	2,172	-	0.00%
			46,954	837	1.78%
	80-84	1984-87	6,844	203	2.97%
		1988-91	15,747	463	2.94%
		1992-95	2,221	10	0.45%
		1996-99	682	-	0.00%
			25,494	676	2.65%
	Ages 85+	1984-87	2,657	42	1.58%
		1988-91	5,644	93	1.65%
		1992-95	181	-	0.00%
		1996-99	-	-	0.00%
			8,482	135	1.59%
•		100107			0.000/
3	Less than 40		2	-	0.00%
		1988-91	11	-	0.00%
		1992-95	12	-	0.00%
		1996-99	14	-	0.00%
			20		0.000/
			39	-	0.00%
	40-49	100/ 07	19		0.000/
	40-43	1984-87		-	0.00%
		1988-91	75 01	-	0.00%
		1992-95	91 52	-	0.00%
		1996-99	52	-	0.00%
			237		0.00%
			231	-	0.00%

50-59	1984-87 1988-91 1992-95 1996-99	210 1,021 736 263	- 3 1	0.00% 0.29% 0.14% 0.00%	
		2,230	4	0.18%	
60-64	1984-87 1988-91 1992-95 1996-99	772 2,948 1,444 471	7 15 1 -	0.91% 0.51% 0.07% 0.00%	
		5,635	23	0.41%	
65-69	1984-87 1988-91 1992-95 1996-99	5,768 12,626 5,074 1,560	56 109 9 -	0.97% 0.86% 0.18% 0.00%	
70-74	1984-87 1988-91 1992-95	11,118 23,261 7,290	162 284 25	1.46% 1.22% 0.34%	
	1996-99	1,235 42,904	- 471	0.00%	
75-79	1984-87 1988-91 1992-95 1996-99	9,972 21,189 4,368 813	219 426 31	2.20% 2.01% 0.71% 0.00%	
		36,342	676	1.86%	
80-84	1984-87 1988-91 1992-95 1996-99	5,821 12,525 1,973 275	197 361 21 -	3.38% 2.88% 1.06% 0.00%	
		20,594	579	2.81%	
Ages 85+	1984-87 1988-91 1992-95 1996-99	2,496 4,898 181 -	48 105 - -	1.92% 2.14% 0.00% 0.00%	
		7,575	153	2.02%	

					0.000/
4	Less than 40		1	=	0.00%
		1988-91	3	-	0.00%
		1992-95	9	-	0.00%
			13	-	0.00%
	40-49	1984-87	15	-	0.00%
		1988-91	35	-	0.00%
		1992-95	63	-	0.00%
			113	-	0.00%
	50-59	1984-87	156	-	0.00%
		1988-91	467	1	0.21%
		1992-95	516	2	0.39%
			1,139	3	0.26%
	60-64	1984-87	475	8	1.68%
	00-04	1988-91	1,374	5	0.36%
			946	2	
		1992-95	340	2	0.21%
			2,795	15	0.54%
	65-69	1984-87	3,939	37	0.94%
		1988-91	6,610	57	0.86%
		1992-95	3,666	10	0.27%
			14,215	104	0.73%
	70-74	1984-87	8,963	141	1.57%
		1988-91	15,702	193	1.23%
		1992-95	5,935	25	0.42%
			30,600	359	1.17%
	75-79	1984-87	8,487	200	2.36%
		1988-91	15,758	294	1.87%
		1992-95	3,594	35	0.97%
			27,839	529	1.90%
	80-84	1984-87	5,075	224	4.41%
		1988-91	9,662	293	3.03%
		1992-95	1,737	30	1.73%
			16,474	547	3.32%

	Ages 85+	1984-87	2,356	49	2.08%
	J	1988-91	4,040	59	1.46%
		1992-95	181	-	0.00%
		1992-90	101	_	0.0076
			6,577	108	1.64%
			0,077	100	1.0470
5	Less than 40	1984-87	-	-	0.00%
		1988-91	2	-	0.00%
		1992-95	3	_	0.00%
		1002 00	0		0.0070
			5	-	0.00%
	40-49	1984-87	1	-	0.00%
		1988-91	27	-	0.00%
		1992-95	30	_	0.00%
		.002 00			0.0070
			58	-	0.00%
	50-59	1984-87	40	-	0.00%
		1988-91	261	1	0.38%
		1992-95	291	-	0.00%
			592	1	0.17%
	60-64	1984-87	117	1	0.85%
		1988-91	816	1	0.12%
		1992-95	575	1	0.17%
			1,508	3	0.20%
	65-69	1984-87	1,217	16	1.31%
		1988-91	3,887	44	1.13%
		1992-95	1,908	7	0.37%
			7,012	67	0.96%
	70-74	1984-87	4,565	88	1.93%
		1988-91	11,585	156	1.35%
		1992-95	4,286	25	0.58%
			20,436	269	1.32%
	75 70	1001 ==	:		
	75-79	1984-87	5,274	121	2.29%
		1988-91	12,977	231	1.78%
		1992-95	2,573	33	1.28%
			00.00:	00-	4.0504
			20,824	385	1.85%

	80-84	1984-87	3,180	125	3.93%
		1988-91	8,328	265	3.18%
		1992-95	1,313	17	1.29%
			12,821	407	3.17%
	Ages 85+	1984-87	1,767	37	2.09%
		1988-91	3,964	33	0.83%
		1992-95	178	-	0.00%
			5,909	70	1.18%
6	Less than 40	1984-87	-	-	0.00%
		1988-91	1	-	0.00%
		1992-95	2	-	0.00%
			3	-	0.00%
	40-49	1984-87	-	-	0.00%
		1988-91	20	1	5.00%
		1992-95	27	-	0.00%
			47	1	2.13%
	50-59	1984-87	7	-	0.00%
		1988-91	139	1	0.72%
		1992-95	183	-	0.00%
			329	1	0.30%
	60-64	1984-87	30	1	3.33%
		1988-91	438	2	0.46%
		1992-95	312	-	0.00%
			780	3	0.38%
	65-69	1984-87	343	7	2.04%
		1988-91	1,627	19	1.17%
		1992-95	813	3	0.37%
			2,783	29	1.04%
	70-74	1984-87	2,828	41	1.45%
		1988-91	7,380	113	1.53%
		1992-95	2,563	19	0.74%
			12,771	173	1.35%

75-79	1984-87	3,971	60	1.51%
	1988-91	10,219	193	1.89%
	1992-95	1,572	22	1.40%
		15,762	275	1.74%
80-84	1984-87	2,441	71	2.91%
	1988-91	6,872	243	3.54%
	1992-95	822	27	3.28%
		10,135	341	3.36%
Ages 85+	1984-87	1,537	30	1.95%
	1988-91	3,877	67	1.73%
	1992-95	168	3	1.79%
		5,582	100	1.79%
7 Less than 40	1984-87	_	_	0.00%
, Legg than 40	1988-91	_	_	0.00%
	1992-95	_	_	0.00%
	1002 00			
		-	-	0.00%
40-49	1984-87	-	-	0.00%
	1988-91	15	-	0.00%
	1992-95	14	-	0.00%
		29	-	0.00%
50-59	1984-87	4	-	0.00%
	1988-91	96	-	0.00%
	1992-95	70	-	0.00%
		170	-	0.00%
60-64	1984-87	23	-	0.00%
	1988-91	242	-	0.00%
	1992-95	124	-	0.00%
		389	-	0.00%
65-69	1984-87	229	3	1.31%
	1988-91	734	8	1.09%
	1992-95	342	-	0.00%
		1,305	11	0.84%

		70-74	1984-87	2,209	35	1.58%
			1988-91	4,069	70	1.72%
			1992-95	991	12	1.21%
				7,269	117	1.61%
		75-79	1984-87	3,495	61	1.75%
			1988-91	7,651	190	2.48%
			1992-95	670	18	2.69%
				11,816	269	2.28%
		80-84	1984-87	2,183	47	2.15%
			1988-91	5,557	199	3.58%
			1992-95	352	24	6.82%
				8,092	270	3.34%
		Ages 85+	1984-87	1,489	22	1.48%
			1988-91	3,603	130	3.61%
			1992-95	111	1	0.90%
				5,203	153	2.94%
0	1	All Ages	1984-87	60,943	900	1.48%
			1988-91	182,479	1,889	1.04%
			1992-95	47,450	106	0.22%
			1996-99	29,997	1	0.00%
				320,869	2,896	0.90%
	2	All Ages	1984-87	45,242	742	1.64%
			1988-91	111,010	1,645	1.48%
			1992-95	29,054	105	0.36%
			1996-99	11,341	-	0.00%
				196,647	2,492	1.27%

Appendix D-4
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, Duration, and Issue Year

Eliminatio Perio		Duration	Attained Age Group	Issue Yea Group		Claims	Rate
1 0110	<i>,</i>	Baradon	Огоар	O.our	ZAPOGGIO	Ciaii i i	rato
20	1		Less than 40	1984-87	19	-	0.00%
				1988-91	36	-	0.00%
				1992-95	71	-	0.00%
				1996-99	48	-	0.00%
					174	-	0.00%
			40-49	1984-87	57	-	0.00%
				1988-91	1,590	1	0.06%
				1992-95	2,334	1	0.04%
				1996-99	578	-	0.00%
					4,559	2	0.04%
			50-59	1984-87	504	-	0.00%
				1988-91	10,869	4	0.04%
				1992-95	13,919	11	0.08%
				1996-99	2,744	3	0.11%
					28,036	18	0.06%
			60-64	1984-87	2,402	5	0.21%
				1988-91	21,412	33	0.15%
				1992-95	22,328	18	0.08%
				1996-99	2,651	2	0.08%
					48,793	58	0.12%
			65-69	1984-87	10,872	38	0.35%
				1988-91	54,919	101	0.18%
				1992-95	40,401	52	0.13%
				1996-99	3,543	8	0.23%
					109,735	199	0.18%
			70-74	1984-87	19,024	91	0.48%
				1988-91	75,142	269	0.36%
				1992-95	35,624	97	0.27%
				1996-99	2,424	7	0.29%
					132,214	464	0.35%

	75-79	1984-87	22,415	181	0.81%	
		1988-91	63,617	432	0.68%	
		1992-95	21,412	154	0.72%	
		1996-99	1,383	12	0.87%	
			108,827	779	0.72%	
	80-84	1984-87	13,994	65	0.46%	
		1988-91	35,606	330	0.93%	
		1992-95	7,949	92	1.16%	
		1996-99	381	6	1.57%	
			57,930	493	0.85%	
			37,930	493	0.03 /6	
	Ages 85+	1984-87	6,983	8	0.11%	
		1988-91	12,855	40	0.31%	
		1992-95	1,200	6	0.50%	
		1996-99	20	-	0.00%	
			21,058	54	0.26%	
2	Less than	40 1984-87	8	-	0.00%	
_	2000 11.01.1	1988-91	30	-	0.00%	
		1992-95	26	-	0.00%	
		1996-99	7	-	0.00%	
			71	-	0.00%	
	40-49	1984-87	41	-	0.00%	
		1988-91	1,181	-	0.00%	
		1992-95	1,104	-	0.00%	
		1996-99	210	-	0.00%	
			2,536	-	0.00%	
	50-59	1984-87	342	-	0.00%	
		1988-91	8,312	6	0.07%	
		1992-95	7,521	6	0.08%	
		1996-99	1,034	1	0.10%	
			17,209	13	0.08%	
	60-64	1984-87	1,728	7	0.41%	
		1988-91	16,389	32	0.20%	
		1992-95	12,017	13	0.11%	
		1996-99	995	1	0.10%	
			31,129	53	0.17%	

	65-69	1984-87	8,150	40	0.49%
		1988-91	44,289	126	0.28%
		1992-95	25,034	57	0.23%
		1996-99	1,390	5	0.36%
			78,863	228	0.29%
	70-74	1984-87	15,990	108	0.68%
	70 74	1988-91	65,461	311	0.48%
		1992-95	23,952	116	0.48%
		1996-99	999	11	1.10%
		1990-99	333		1.1070
			106,402	546	0.51%
	75-79	1984-87	19,796	147	0.74%
		1988-91	55,874	447	0.80%
		1992-95	14,952	138	0.92%
		1996-99	503	4	0.80%
			91,125	736	0.81%
	80-84	1984-87	13,250	110	0.83%
		1988-91	32,726	342	1.05%
		1992-95	5,964	85	1.43%
		1996-99	108	2	1.85%
			52,048	539	1.04%
	Ages 85+	1984-87	6,943	11	0.16%
	· ·	1988-91	12,630	58	0.46%
		1992-95	1,029	21	2.04%
		1996-99	2	-	0.00%
			20,604	90	0.44%
3	Less than 40	1984-87	6	-	0.00%
		1988-91	26	-	0.00%
		1992-95	7	-	0.00%
		1996-99	4	-	0.00%
			43	-	0.00%
	40-49	1984-87	35	-	0.00%
		1988-91	875	1	0.11%
		1992-95	464	1	0.22%
		1996-99	124	-	0.00%
			1,498	2	0.13%
			1,430	2	5.1570

50-59	1984-87	225	-	0.00%
	1988-91	6,369	4	0.06%
	1992-95	3,725	2	0.05%
	1996-99	546	1	0.18%
		10,865	7	0.06%
60-64	1984-87	1,260	3	0.24%
	1988-91	12,954	23	0.18%
	1992-95	5,977	8	0.13%
	1996-99	502	4	0.80%
		20,693	38	0.18%
65-69	1984-87	6,207	41	0.66%
	1988-91	36,750	128	0.35%
	1992-95	12,254	38	0.31%
	1996-99	694	3	0.43%
		55,905	210	0.38%
70-74	1984-87	13,840	93	0.67%
	1988-91	58,383	280	0.48%
	1992-95	13,986	76	0.54%
	1996-99	567	3	0.53%
		86,776	452	0.52%
75 70	1001.07	40.400	450	0.000/
75-79	1984-87	18,100	159	0.88%
	1988-91	50,858	445	0.87%
	1992-95	9,061	107	1.18%
	1996-99	285	6	2.11%
		70.004	747	0.000/
		78,304	717	0.92%
80-84	1984-87	12,645	160	1.27%
00 04	1988-91	30,527	423	1.39%
	1992-95	3,810	83	2.18%
	1996-99	60	3	5.00%
	1000 00	00	3	3.0070
		47,042	669	1.42%
		17,012	000	11.1270
Ages 85+	1984-87	6,904	25	0.36%
.9 00	1988-91	12,287	99	0.81%
	1992-95	763	14	1.83%
	1996-99	-	-	0.00%
		19,954	138	0.69%
		•		_

_			_		
4	Less than 40		6	-	0.00%
		1988-91	22	-	0.00%
		1992-95	2	-	0.00%
			30	-	0.00%
	40-49	1984-87	31	_	0.00%
		1988-91	546	1	0.18%
		1992-95	222		0.00%
		1002 00			0.0070
			799	1	0.13%
	50-59	1984-87	152	-	0.00%
		1988-91	4,814	4	0.08%
		1992-95	1,554	3	0.19%
			6,520	7	0.11%
	00.04	1001.07	000	•	0.050/
	60-64	1984-87	808	2	0.25%
		1988-91	10,408	19	0.18%
		1992-95	1,817	6	0.33%
			13,033	27	0.21%
	65-69	1984-87	4,411	27	0.61%
		1988-91	29,962	93	0.31%
		1992-95	3,516	15	0.43%
			37,889	135	0.36%
	70-74	1984-87	11,506	77	0.67%
		1988-91	51,212	250	0.49%
		1992-95	5,578	44	0.79%
			68,296	371	0.54%
	75 70	1004 07	16,314	165	1.01%
	75-79	1984-87		165	
		1988-91	45,783	453	0.99%
		1992-95	3,799	47	1.24%
			65,896	665	1.01%
	80-84	1984-87	11,883	182	1.53%
		1988-91	27,980	472	1.69%
		1992-95	1,598	39	2.44%
			41,461	693	1.67%

	Ages 85+	1984-87	6,826	40	0.59%
		1988-91	11,758	146	1.24%
		1992-95	482	11	2.28%
			19,066	197	1.03%
5	Less than 40		6	-	0.00%
		1988-91	16	-	0.00%
		1992-95	-	-	0.00%
			22	-	0.00%
	10.40	1004.07	20		0.000/
	40-49	1984-87	28	-	0.00%
		1988-91	242	-	0.00%
		1992-95	137	-	0.00%
			407	_	0.00%
			407	_	0.0078
	50-59	1984-87	103	1	0.97%
		1988-91	2,826	1	0.04%
		1992-95	996	1	0.10%
				•	
			3,925	3	0.08%
	60-64	1984-87	544	5	0.92%
		1988-91	6,584	12	0.18%
		1992-95	1,214	3	0.25%
			8,342	20	0.24%
	65-69	1984-87	2,717	22	0.81%
		1988-91	18,917	53	0.28%
		1992-95	2,355	11	0.47%
					0.000/
			23,989	86	0.36%
	70-74	1984-87	9,006	106	1.18%
	70-74	1988-91	9,000 37,491	192	0.51%
		1992-95	4,420	31	0.70%
		1992-95	4,420	31	0.7076
			50,917	329	0.65%
			30,011	320	5.5070
	75-79	1984-87	14,263	143	1.00%
		1988-91	36,399	318	0.87%
		1992-95	3,085	32	1.04%
			53,747	493	0.92%

	80-84	1984-87	10,798	208	1.93%
		1988-91	23,063	461	2.00%
		1992-95	1,363	41	3.01%
			,		
			35,224	710	2.02%
	Ages 85+	1984-87	6,634	53	0.80%
		1988-91	11,050	141	1.28%
		1992-95	459	11	2.40%
			18,143	205	1.13%
6	Less than 40	1984-87	5	-	0.00%
		1988-91	12	-	0.00%
		1992-95	-	-	0.00%
			17	-	0.00%
	40-49	1984-87	24	-	0.00%
		1988-91	124	-	0.00%
		1992-95	88	-	0.00%
			236	-	0.00%
	50-59	1984-87	84	-	0.00%
		1988-91	1,589	4	0.25%
		1992-95	698	1	0.14%
			2,371	5	0.21%
	60-64	1984-87	381	2	0.52%
		1988-91	3,535	5	0.14%
		1992-95	797	-	0.00%
			4,713	7	0.15%
	65-69	1984-87	1,739	17	0.98%
		1988-91	9,921	29	0.29%
		1992-95	1,565	5	0.32%
			13,225	51	0.39%
			•		
	70-74	1984-87	7,192	67	0.93%
		1988-91	23,965	159	0.66%
		1992-95	3,440	12	0.35%
			, -		
			34,597	238	0.69%

	75-79	1984-87	12,719	132	1.04%
		1988-91	26,992	332	1.23%
		1992-95	2,406	36	1.50%
			•		
			42,117	500	1.19%
			,		
	80-84	1984-87	9,877	192	1.94%
		1988-91	17,561	347	1.98%
		1992-95	1,126	29	2.58%
		1002 00	1,120	20	2.0070
			28,564	568	1.99%
			20,001	000	1.0070
	Ages 85+	1984-87	6,400	104	1.63%
	, igua aa .	1988-91	9,878	182	1.84%
		1992-95	425	16	3.76%
		1002 00	420	10	0.7070
			16,703	302	1.81%
			10,100	002	1.0170
7	Less than 40	1984-87	5	_	0.00%
•	2000 11011 10	1988-91	5	_	0.00%
		1992-95	-	_	0.00%
		1002 00			0.0070
			10	_	0.00%
					0.0070
	40-49	1984-87	16	_	0.00%
	10 10	1988-91	56	_	0.00%
		1992-95	49	_	0.00%
		1002 00	40		0.0070
			121	_	0.00%
			.2.		0.0070
	50-59	1984-87	36	_	0.00%
		1988-91	950	1	0.11%
		1992-95	424	1	0.24%
		1002 00	721	'	0.2470
			1,410	2	0.14%
			1,110	_	0.1170
	60-64	1984-87	173	2	1.16%
	00 0 1	1988-91	1,653	8	0.48%
		1992-95	459	_	0.00%
		1002 00	400		0.0070
			2,285	10	0.44%
			2,200	10	0.77/0
	65-69	1984-87	1,156	9	0.78%
	30 00	1988-91	4,404	19	0.43%
		1992-95	935	3	0.43%
		.552 55	333	3	0.02/0
			6,495	31	0.48%
			0,433	31	0.4070

70-74	1984-87	5,750	47	0.82%
	1988-91	12,607	104	0.82%
	1992-95	2,275	17	0.75%
		20,632	168	0.81%
75 70	1004.07	44 225	104	1.000/
75-79	1984-87	11,335	124	1.09%
	1988-91	17,880	241	1.35%
	1992-95	1,681	24	1.43%
		20.006	200	1.260/
		30,896	389	1.26%
80-84	1984-87	8,959	164	1.83%
	1988-91	12,409	290	2.34%
	1992-95	807	18	2.23%
		22,175	472	2.13%
Ages 85+	1984-87	6,057	130	2.15%
7.g00 00 .	1988-91	8,266	275	3.33%
		•	_	
	1992-95	322	16	4.97%
		14,645	421	2.87%
		,		

Appendix D-4
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, Duration, and Issue Year

Elimination		Attained Age	Issue Year			
Period	Duration	Group	Group	Exposure	Claims	Rate
30	1	Less than 40	1984-87	-	-	0.00%
			1988-91	106	-	0.00%
			1992-95	1,173	3	0.26%
			1996-99	1,379	-	0.00%
				2,658	3	0.11%
		40-49	1984-87	-	-	0.00%
			1988-91	152	-	0.00%
			1992-95	1,421	1	0.07%
			1996-99	2,555	-	0.00%
				4,128	1	0.02%
		50-59	1984-87	12	-	0.00%
			1988-91	865	-	0.00%
			1992-95	3,285	4	0.12%
			1996-99	10,178	2	0.02%
				14,340	6	0.04%
		60-64	1984-87	19	-	0.00%
			1988-91	1,645	5	0.30%
			1992-95	5,183	5	0.10%
			1996-99	10,627	2	0.02%
				17,474	12	0.07%
		65-69	1984-87	45	1	2.22%
			1988-91	4,281	9	0.21%
			1992-95	16,632	7	0.04%
			1996-99	20,033	2	0.01%
				40,991	19	0.05%
		-0 - 4	10015			0.0551
		70-74	1984-87	36	-	0.00%
			1988-91	5,993	28	0.47%
			1992-95	17,171	16	0.09%
			1996-99	15,163	7	0.05%
				00		0.4657
				38,363	51	0.13%

	75-79	1984-87	34	-	0.00%
		1988-91	4,798	29	0.60%
		1992-95	10,347	26	0.25%
		1996-99	8,757	5	0.06%
			23,936	60	0.25%
	80-84	1984-87	25	-	0.00%
	00 0 .	1988-91	2,613	34	1.30%
		1992-95	5,434	41	0.75%
		1996-99	3,413	3	0.09%
		1550 55	0,410	J	0.0070
			11,485	78	0.68%
	Ages 85+	1984-87	9	-	0.00%
	-	1988-91	925	12	1.30%
		1992-95	2,517	33	1.31%
		1996-99	618	1	0.16%
			4,069	46	1.13%
2	Less than 40) 1984-87	-	-	0.00%
		1988-91	50	-	0.00%
		1992-95	771	1	0.13%
		1996-99	340	-	0.00%
			1,161	1	0.09%
	40-49	1984-87	-	-	0.00%
		1988-91	86	-	0.00%
		1992-95	1,093	2	0.18%
		1996-99	548	-	0.00%
			1,727	2	0.12%
			.,	_	
	50-59	1984-87	8	-	0.00%
		1988-91	593	-	0.00%
		1992-95	2,231	3	0.13%
		1996-99	2,129	1	0.05%
			4,961	4	0.08%
			·		
	60-64	1984-87	15	-	0.00%
		1988-91	1,176	2	0.17%
		1992-95	3,068	2	0.07%
		1996-99	2,946	-	0.00%
			7,205	4	0.06%
			1,200	7	0.0070

	65-69	1984-87	38	1	2.63%
		1988-91	3,275	13	0.40%
		1992-95	10,328	14	0.14%
		1996-99	8,023	1	0.01%
			21,664	29	0.13%
	70-74	1984-87	28	_	0.00%
	10 14	1988-91	5,054	18	0.36%
		1992-95	13,054	26	0.20%
		1992-93	6,707	3	0.20%
		1990-99	0,707	3	0.0476
			24,843	47	0.19%
	75-79	1984-87	25	-	0.00%
		1988-91	4,101	31	0.76%
		1992-95	8,016	31	0.39%
		1996-99	3,901	3	0.08%
			16,043	65	0.41%
	80-84	1984-87	16	1	6.25%
		1988-91	2,119	31	1.46%
		1992-95	4,114	45	1.09%
		1996-99	1,754	3	0.17%
			8,003	80	1.00%
	Ages 85+	1984-87	9	-	0.00%
	-	1988-91	852	11	1.29%
		1992-95	2,294	52	2.27%
		1996-99	302	1	0.33%
			0.457	0.4	4.050/
			3,457	64	1.85%
3	Less than 4	0 1984-87	-	-	0.00%
		1988-91	28	-	0.00%
		1992-95	364	-	0.00%
		1996-99	82	-	0.00%
			474	_	0.00%
	40-49	1984-87	-	-	0.00%
		1988-91	59	-	0.00%
		1992-95	591	1	0.17%
		1996-99	219	-	0.00%
			869	1	0.12%

50-59	1984-87	7	-	0.00%	
	1988-91	441	-	0.00%	
	1992-95	1,652	1	0.06%	
	1996-99	813	2	0.25%	
		2,913	3	0.10%	
60-64	1984-87	14	-	0.00%	
	1988-91	929	6	0.65%	
	1992-95	2,297	3	0.13%	
	1996-99	1,231	1	0.08%	
		4,471	10	0.22%	
65-69	1984-87	34	-	0.00%	
	1988-91	2,709	9	0.33%	
	1992-95	7,601	14	0.18%	
	1996-99	3,734	1	0.03%	
		14,078	24	0.170/	
		14,076	24	0.17%	
70-74	1984-87	23	-	0.00%	
	1988-91	4,509	16	0.35%	
	1992-95	11,136	19	0.17%	
	1996-99	3,321	1	0.03%	
		•			
		18,989	36	0.19%	
75-79	1984-87	24	-	0.00%	
	1988-91	3,659	23	0.63%	
	1992-95	6,830	34	0.50%	
	1996-99	1,984	-	0.00%	
		40.40=		0.4007	
		12,497	57	0.46%	
80-84	1984-87	12	-	0.00%	
00 0 1	1988-91	1,865	27	1.45%	
	1992-95	3,487	52	1.49%	
	1996-99	963	1	0.10%	
	1000 00	303		0.1070	
		6,327	80	1.26%	
Ages 85+	1984-87	9	-	0.00%	
	1988-91	796	22	2.76%	
	1992-95	2,055	51	2.48%	
	1996-99	187	-	0.00%	
				0.4657	
		3,047	73	2.40%	

4	Less than 4	0 1984-87	-	-	0.00%
		1988-91	20	-	0.00%
		1992-95	278	-	0.00%
			298	-	0.00%
	40-49	1984-87	-	-	0.00%
		1988-91	46	-	0.00%
		1992-95	484	-	0.00%
			530	_	0.00%
	50-59	1984-87	_	_	0.00%
	00 00	1988-91	312	1	0.32%
		1992-95	1,431	2	0.14%
		1992-95	1,431	2	0.1476
			1 740	2	0.470/
			1,743	3	0.17%
	00.04	4004.07	0		0.000/
	60-64	1984-87	2	-	0.00%
		1988-91	667	1	0.15%
		1992-95	1,933	3	0.16%
			2,602	4	0.15%
	65-69	1984-87	1	-	0.00%
		1988-91	1,983	8	0.40%
		1992-95	6,188	15	0.24%
			8,172	23	0.28%
	70-74	1984-87	18	-	0.00%
		1988-91	3,879	21	0.54%
		1992-95	9,825	34	0.35%
			13,722	55	0.40%
	75-79	1984-87	22	-	0.00%
		1988-91	3,250	29	0.89%
		1992-95	5,970	37	0.62%
			9,242	66	0.71%
			,		
	80-84	1984-87	9	_	0.00%
	00 0 .	1988-91	1,688	22	1.30%
		1992-95	2,976	43	1.44%
		1002 00	2,010	70	1.77/0
			4,673	65	1.39%
			7,073	UJ.	1.33/0

	Ages 85+	1984-87	9	-	0.00%
		1988-91	710	16	2.25%
		1992-95	1,863	71	3.81%
			2,582	87	3.37%
5	Less than 40	1984-87	-	-	0.00%
		1988-91	15	-	0.00%
		1992-95	114	-	0.00%
			129	-	0.00%
	40-49	1984-87	-	-	0.00%
		1988-91	36	-	0.00%
		1992-95	243	-	0.00%
			279	-	0.00%
	50-59	1984-87	-	-	0.00%
		1988-91	190	-	0.00%
		1992-95	693	-	0.00%
			883	-	0.00%
	60-64	1984-87	2	-	0.00%
		1988-91	413	2	0.48%
		1992-95	946	3	0.32%
			1,361	5	0.37%
	65-69	1984-87	-	-	0.00%
		1988-91	1,342	5	0.37%
		1992-95	2,688	12	0.45%
			4,030	17	0.42%
	70-74	1984-87	16	-	0.00%
		1988-91	2,975	11	0.37%
		1992-95	6,107	24	0.39%
			9,098	35	0.38%
	75-79	1984-87	21	-	0.00%
		1988-91	2,593	35	1.35%
		1992-95	3,646	33	0.91%
			6,260	68	1.09%

	80-84	1984-87	7	-	0.00%
		1988-91	1,307	2	
		1992-95	1,893	39	
		1002 00	1,000	0.	2.0070
			3,207	60	6 2.06%
			3,207	0.	2.0070
	Ages 85+	1984-87	9	_	0.00%
	Age3 001	1988-91	519	2:	
		1992-95		69	
		1992-93	1,465	O:	9 4.71%
			1,993	9	1 4.57%
			1,993	9	4.57 /6
6	Less than 40	108/1-87	-	_	0.00%
U	Less man 40	1988-91	11		0.00%
				_	
		1992-95	29	-	0.00%
			40		0.000/
			40	-	0.00%
	40-49	1004 07			0.009/
	40-49	1984-87	-	-	0.00%
		1988-91	24	-	0.00%
		1992-95	99	-	0.00%
			400		0.000/
			123	-	0.00%
	E0 E0	1004.07			0.000/
	50-59	1984-87	-	-	0.00%
		1988-91	156		1 0.64%
		1992-95	306		1 0.33%
			400	,	0 400/
			462	,	2 0.43%
	00.04	4004.07	4		0.000/
	60-64	1984-87	1	-	0.00%
		1988-91	318	-	0.00%
		1992-95	445	=	0.00%
			764	=	0.00%
	05.00	4004.07			2 2221
	65-69	1984-87	-	-	0.00%
		1988-91	878		5 0.57%
		1992-95	1,024	•	4 0.39%
			1,902	,	9 0.47%
		400: ==			
	70-74	1984-87	15	-	0.00%
		1988-91	2,168		8 0.37%
		1992-95	3,133	1	5 0.48%
			5,316	23	3 0.43%

	75-79	1984-87	19	-	0.00%
	70 70	1988-91	1,945	2:	
		1992-95	1,993	30	0 1.51%
			0.057	-	0 40404
			3,957	5	3 1.34%
	00.04	1001.07	_		0.000/
	80-84	1984-87	7	-	
		1988-91	1,034	2	
		1992-95	1,034	20	0 1.93%
			2,075	4	5 2.17%
	Ages 85+	1984-87	8	-	0.00%
		1988-91	379	19	9 5.01%
		1992-95	950	7:	2 7.58%
			1,337	9	1 6.81%
7	Less than 40	1984-87	-	-	0.00%
		1988-91	8	-	0.00%
		1992-95	8	-	0.00%
			16	-	0.00%
	40-49	1984-87	-	-	0.00%
		1988-91	21	_	0.00%
		1992-95	31		1 3.23%
			52		1 1.92%
			02		
	50-59	1984-87	_	_	0.00%
		1988-91	141	_	0.00%
		1992-95	80	_	0.00%
		1002 00	00		0.0070
			221	_	0.00%
			221		0.0070
	60-64	1984-87	_	_	0.00%
	00 04	1988-91	243		1 0.41%
		1992-95	150		
		1992-90	150		1 0.67%
			202		2 0 540/
			393	•	2 0.51%
	CE CO	1004.07			0.000/
	65-69	1984-87	-	-	0.00%
		1988-91	564		2 0.35%
		1992-95	310	2	2 0.65%
			a= :		
			874	•	4 0.46%

70-74	1984-87	11	-	0.00%	
	1988-91	1,346	16	1.19%	
	1992-95	889	16	1.80%	
		2,246	32	1.42%	
75-79	1984-87	15	-	0.00%	
	1988-91	1,266	19	1.50%	
	1992-95	570	14	2.46%	
		1,851	33	1.78%	
		•			
80-84	1984-87	5	-	0.00%	
	1988-91	717	15	2.09%	
	1992-95	336	21	6.25%	
		1,058	36	3.40%	
		,			
Ages 85+	1984-87	6	-	0.00%	
-	1988-91	214	16	7.48%	
	1992-95	358	55	15.36%	
		578	71	12.28%	
		370	, ,	.2.2370	

Appendix D-4
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, Duration, and Issue Year

Elimination	Attained Age	Issue Year			
Period	Duration Group	Group	Exposure	Claims	Rate
90 1	Less than 40		-	-	0.00%
		1988-91	14,066	1	0.01%
		1992-95	43,713	9	0.02%
		1996-99	113,588	11	0.01%
			171,367	21	0.01%
	40-49	1984-87	1	-	0.00%
		1988-91	15,134	4	0.03%
		1992-95	42,184	10	0.02%
		1996-99	81,129	13	0.02%
			138,448	27	0.02%
	50-59	1984-87	1,770	4	0.23%
		1988-91	22,720	12	0.05%
		1992-95	41,780	16	0.04%
		1996-99	84,095	19	0.02%
			150,365	51	0.03%
	60-64	1984-87	5,499	9	0.16%
		1988-91	22,455	25	0.11%
		1992-95	20,208	18	0.09%
		1996-99	35,397	7	0.02%
			83,559	59	0.07%
	65-69	1984-87	8,682	10	0.12%
		1988-91	29,077	35	0.12%
		1992-95	27,118	21	0.08%
		1996-99	38,928	14	0.04%
			103,805	80	0.08%
	70-74	1984-87	8,446	22	0.26%
		1988-91	22,971	45	0.20%
		1992-95	23,439	24	0.10%
		1996-99	28,833	16	0.06%
			83,689	107	0.13%

	75-79	1984-87	4,325	43	0.99%
		1988-91	12,487	70	0.56%
		1992-95	13,743	29	0.21%
		1996-99	17,047	18	0.11%
			,		
			47,602	160	0.34%
			,		
	80-84	1984-87	1,794	7	0.39%
		1988-91	4,897	27	0.55%
		1992-95	6,108	27	0.44%
		1996-99	7,219	13	0.18%
			-,		
			20,018	74	0.37%
	Ages 85+	1984-87	21	_	0.00%
	9	1988-91	948	2	0.21%
		1992-95	2,392	21	0.88%
		1996-99	1,346	2	0.15%
		1000 00	1,040	_	0.1070
			4,707	25	0.53%
			1,101	20	0.0070
2	Less than 40	1984-87	_	_	0.00%
_	2000 (11011 10	1988-91	11,177	1	0.01%
		1992-95	27,175	4	0.01%
		1996-99	23,589	1	0.00%
		1550 55	25,505	'	0.0070
			61,941	6	0.01%
			01,041	Ū	0.0170
	40-49	1984-87	1	_	0.00%
	10 10	1988-91	13,743	7	0.05%
		1992-95	32,291	9	0.03%
		1996-99	20,696	3	0.03%
		1990-99	20,030	3	0.0176
			66,731	19	0.03%
			00,731	13	0.0070
	50-59	1984-87	1,345	2	0.15%
	30 33	1988-91	17,553	11	0.06%
		1992-95	30,874	12	0.04%
		1992-99	22,947	10	0.04%
		1990-99	22,341	10	0.0478
			72,719	35	0.05%
			12,119	33	0.03/0
	60-64	1984-87	4,802	9	0.19%
	JU U T	1988-91	16,538	25	0.15%
		1992-95	12,371	4	0.13%
		1992-95			
		1990-99	10,342	8	0.08%
			44.052	46	0.400/
			44,053	46	0.10%

	65-69	1984-87	7,624	22	0.29%
		1988-91	22,215	31	0.14%
		1992-95	15,768	15	0.10%
		1996-99	13,641	7	0.05%
			59,248	75	0.13%
	70-74	1984-87	7,820	15	0.19%
		1988-91	18,987	64	0.34%
		1992-95	16,514	25	0.15%
		1996-99	11,018	14	0.13%
			54,339	118	0.22%
	75 70	100107	0.000	20	0.740/
	75-79	1984-87	3,939	28	0.71%
		1988-91	10,230	85	0.83%
		1992-95	9,723	22	0.23%
		1996-99	6,532	15	0.23%
			30,424	150	0.49%
	80-84	1984-87	1,758	21	1.19%
		1988-91	4,430	35	0.79%
		1992-95	4,759	43	0.90%
		1996-99	2,849	12	0.42%
			13,796	111	0.80%
	Ages 85+	1984-87	21	_	0.00%
	/ (gco co)	1988-91	916	4	0.44%
		1992-95	2,189	25	1.14%
		1996-99	514	3	0.58%
			3,640	32	0.88%
•		1001.07			0.000/
3	Less than 40		-	-	0.00%
		1988-91	8,984	1	0.01%
		1992-95	17,169	1	0.01%
		1996-99	7,835	2	0.03%
			33,988	4	0.01%
	40-49	1984-87	1	-	0.00%
		1988-91	12,481	3	0.02%
		1992-95	23,611	9	0.04%
		1996-99	8,993	3	0.03%
			45,086	15	0.03%

50-59	1984-87	1,100	1	0.09%	
	1988-91	15,237	16	0.11%	
	1992-95	23,871	4	0.02%	
	1996-99	11,544	6	0.05%	
		51,752	27	0.05%	
60-64	1984-87	4,310	5	0.12%	
	1988-91	13,708	22	0.16%	
	1992-95	9,713	11	0.11%	
	1996-99	4,882	4	0.08%	
		32,613	42	0.13%	
65-69	1984-87	6,693	13	0.19%	
	1988-91	18,529	36	0.19%	
	1992-95	12,751	18	0.14%	
	1996-99	6,022	7	0.12%	
		43,995	74	0.17%	
70-74	1984-87	7,242	21	0.29%	
	1988-91	16,288	59	0.36%	
	1992-95	14,576	22	0.15%	
	1996-99	5,136	9	0.18%	
		43,242	111	0.26%	
75-79	1984-87	3,573	20	0.56%	
	1988-91	8,712	81	0.93%	
	1992-95	8,716	36	0.41%	
	1996-99	2,992	8	0.27%	
		23,993	145	0.60%	
80-84	1984-87	1,690	21	1.24%	
	1988-91	3,907	40	1.02%	
	1992-95	4,296	40	0.93%	
	1996-99	1,315	9	0.68%	
		11,208	110	0.98%	
Ages 85+	1984-87	21	-	0.00%	
5	1988-91	904	8	0.88%	
	1992-95	2,039	32	1.57%	
	1996-99	278	1	0.36%	
		3,242	41	1.26%	

Less than 40	1984-87	-	_	0.00%
	1988-91	5,420	-	0.00%
	1992-95	13,734	1	0.01%
		•		
		19,154	1	0.01%
10.10	4004.07	4		0.000/
40-49	1984-87	0.400	-	0.00%
	1988-91	9,489	3	0.03%
	1992-95	21,506	2	0.01%
		30,996	5	0.02%
50-59	1984-87	944	_	0.00%
	1988-91	11,796	7	0.06%
	1992-95	22,260	8	0.04%
		35,000	15	0.04%
60-64	1984-87	3,931	5	0.13%
	1988-91	10,839	12	0.11%
	1992-95	9,028	7	0.08%
		23,798	24	0.10%
65-69	1984-87	5,996	12	0.20%
	1988-91	14,679	22	0.15%
	1992-95	11,698	16	0.14%
				0.450/
		32,373	50	0.15%
70-74	1984-87	6,778	18	0.27%
	1988-91	13,573	42	0.31%
	1992-95	13,764	20	0.15%
		34,115	80	0.23%
75.70	1004.07	2 200	20	0.070/
75-79	1984-87	3,288	22	0.67%
	1988-91	7,280	55	0.76%
	1992-95	8,162	34	0.42%
		18,730	111	0.59%
80-84	1984-87	1,584	19	1.20%
	1988-91	3,277	52	1.59%
	1992-95	4,001	54	1.35%
		8,862	125	1.41%

	Ages 85+	1984-87	21	-	0.00%
	9	1988-91	823	18	2.19%
		1992-95	1,910	47	2.46%
			,-		
			2,754	65	2.36%
5	Less than 40	1984-87	-	-	0.00%
		1988-91	3,078	1	0.03%
		1992-95	6,923	1	0.01%
			10,001	2	0.02%
	40-49	1984-87	1	-	0.00%
		1988-91	5,660	2	0.04%
		1992-95	13,434	6	0.04%
			19,095	8	0.04%
			004		0.4004
	50-59	1984-87	861	1	0.12%
		1988-91	6,690	2	0.03%
		1992-95	13,350	10	0.07%
			20,901	13	0.06%
			20,001	10	0.0070
	60-64	1984-87	3,655	4	0.11%
		1988-91	3,956	7	0.18%
		1992-95	5,541	4	0.07%
			13,152	15	0.11%
	65-69	1984-87	5,552	11	0.20%
		1988-91	5,414	15	0.28%
		1992-95	7,142	11	0.15%
			40.400	27	0.000/
			18,108	37	0.20%
	70-74	1984-87	6,418	11	0.17%
		1988-91	5,563	37	0.67%
		1992-95	9,216	24	0.26%
			2,		
			21,197	72	0.34%
	75-79	1984-87	3,070	30	0.98%
		1988-91	3,703	36	0.97%
		1992-95	5,290	49	0.93%
			12,063	115	0.95%

	80-84	1984-87	1,454	28	1.93%
		1988-91	1,628	35	2.15%
		1992-95	2,567	46	1.79%
		1992-95	2,307	40	1.7370
			5,649	109	1.93%
	Ages 85+	1984-87	20	_	0.00%
	7.g00 00 .	1988-91	783	23	2.94%
		1992-95	1,392	47	3.38%
		1002 00	1,002	7,	3.3070
			2,195	70	3.19%
6	Less than 40	1984-87	-	-	0.00%
		1988-91	1,862	-	0.00%
		1992-95	2,953	-	0.00%
			4,815	-	0.00%
	40-49	1984-87	1	-	0.00%
		1988-91	3,691	2	0.05%
		1992-95	4,642	1	0.02%
			8,334	3	0.04%
	50-59	1984-87	3	-	0.00%
		1988-91	4,055	4	0.10%
		1992-95	5,025	-	0.00%
			9,083	4	0.04%
			0,000	·	0.0170
	60-64	1984-87	10	1	10.00%
		1988-91	2,366	4	0.17%
		1992-95	2,424	2	0.08%
			4,800	7	0.15%
	65-69	1984-87	13	4	30.77%
		1988-91	3,028	11	0.36%
		1992-95	2,968	7	0.24%
			6,009	22	0.37%
	70-74	1984-87	6	6	100.00%
		1988-91	3,529	17	0.48%
		1992-95	4,353	17	0.39%
			7,888	40	0.51%

75-79	1984-87	7	7	100.00%
	1988-91	2,615	16	0.61%
	1992-95	2,772	38	1.37%
		5,394	61	1.13%
00.04	4004.07	0	7	000 000/
80-84	1984-87	3	7	233.33%
	1988-91	1,226	26	2.12%
	1992-95	1,418	39	2.75%
		2,647	72	2.72%
		2,047	12	2.12/0
Ages 85+	1984-87	4	1	25.00%
	1988-91	607	13	2.14%
	1992-95	823	36	4.37%
	1002 00	020	30	4.57 /0
		1,434	50	3.49%
7 Less than 40	1984-87	_	_	0.00%
7 2000 111011 10				
	1988-91	306	-	0.00%
	1992-95	192	-	0.00%
		498	-	0.00%
40.40	100107			0.000/
40-49	1984-87	1	-	0.00%
	1988-91	756	1	0.13%
	1992-95	342	1	0.29%
		1 000	2	0.100/
		1,099	2	0.18%
50-59	1984-87	-	-	0.00%
	1988-91	1,538	-	0.00%
	1992-95	466	1	0.21%
	1002 00	400		0.2170
		2,004	1	0.05%
60-64	1984-87	1	_	0.00%
	1988-91	1,013	1	0.10%
			'	
	1992-95	410	-	0.00%
		1,424	1	0.07%
CE CO	1004.07	•		0.000/
65-69	1984-87	2	-	0.00%
	1988-91	1,527	3	0.20%
	1992-95	768	1	0.13%
		2,297	4	0.17%
		2,231	4	0.17/0

1 2,231 1,267	- 7 12	0.00% 0.31% 0.95%
1,267		
	12	0.95%
3,499	19	0.54%
4	-	0.00%
1,963	12	0.61%
933	14	1.50%
2,900	26	0.90%
2	-	0.00%
1,002	12	1.20%
516	25	4.84%
1,520	37	2.43%
4	-	0.00%
503	10	1.99%
312	29	9.29%
819	39	4.76%
	4 1,963 933 2,900 2 1,002 516 1,520 4 503 312	4 - 1,963 12 933 14 2,900 26 2 - 1,002 12 516 25 1,520 37 4 - 503 10 312 29

Appendix D-4
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, Duration, and Issue Year

Elimination Period	Attained Age Duration Group	Issue Year Group	Exposure	Claims	Rate
100 1	Less than 40	1984-87	<u>-</u>	<u>-</u>	0.00%
	2000 111011 10	1988-91	16	_	0.00%
		1992-95	1,517	_	0.00%
		1996-99	2,084	_	0.00%
		.000 00	_,00.		0.0070
			3,617	-	0.00%
	40-49	1984-87	3	-	0.00%
		1988-91	533	-	0.00%
		1992-95	2,619	-	0.00%
		1996-99	2,447	1	0.04%
			5,602	1	0.02%
	50-59	1984-87	125	-	0.00%
		1988-91	5,472	-	0.00%
		1992-95	14,744	1	0.01%
		1996-99	15,751	1	0.01%
			36,092	2	0.01%
	60-64	1984-87	846	1	0.12%
		1988-91	11,805	7	0.06%
		1992-95	25,789	11	0.04%
		1996-99	22,731	6	0.03%
			61,171	25	0.04%
	65-69	1984-87	6,319	19	0.30%
		1988-91	29,588	20	0.07%
		1992-95	48,014	25	0.05%
		1996-99	32,748	21	0.06%
			116,669	85	0.07%
	70-74	1984-87	14,358	56	0.39%
		1988-91	42,631	54	0.13%
		1992-95	47,620	61	0.13%
		1996-99	26,795	42	0.16%
			131,404	213	0.16%

	75-79	1984-87	17,625	78	0.44%
		1988-91	38,594	168	0.44%
		1992-95	32,159	93	0.29%
		1996-99	14,786	45	0.30%
		.000 00	,,, 00		0.0070
			103,164	384	0.37%
	80-84	1984-87	11,991	50	0.42%
		1988-91	26,238	184	0.70%
		1992-95	17,035	72	0.42%
		1996-99	4,779	27	0.56%
			,		
			60,043	333	0.55%
	Ages 85+	1984-87	5,957	3	0.05%
		1988-91	13,358	36	0.27%
		1992-95	3,468	10	0.29%
		1996-99	464	7	1.51%
			23,247	56	0.24%
2	Less than 40	1984-87	-	_	0.00%
		1988-91	5	_	0.00%
		1992-95	1,063	_	0.00%
		1996-99	833	_	0.00%
			1,901	-	0.00%
	40-49	1984-87	2	-	0.00%
		1988-91	405	-	0.00%
		1992-95	1,345	-	0.00%
		1996-99	888	-	0.00%
			2,640	-	0.00%
	F0 F0	1001.07	70		0.000/
	50-59	1984-87	76	-	0.00%
		1988-91	4,214	1	0.02%
		1992-95	6,542	2	0.03%
		1996-99	4,465	4	0.09%
			15,297	7	0.05%
	60-64	1984-87	520	1	0.19%
		1988-91	9,122	1	0.01%
		1992-95	10,212	5	0.05%
		1996-99	7,050	10	0.14%
			26,904	17	0.06%
			- /		· · -

	65-69	1984-87	4,246	17	0.40%
		1988-91	23,638	28	0.12%
		1992-95	22,037	27	0.12%
		1996-99	12,505	15	0.12%
			62,426	87	0.14%
	70-74	1984-87	11,455	48	0.42%
		1988-91	36,332	74	0.20%
		1992-95	25,415	43	0.17%
		1996-99	11,422	48	0.42%
			84,624	213	0.25%
	75-79	1984-87	14,825	115	0.78%
		1988-91	32,963	165	0.50%
		1992-95	18,194	69	0.38%
		1996-99	6,677	51	0.76%
			72,659	400	0.55%
	80-84	1984-87	11,056	59	0.53%
		1988-91	22,251	239	1.07%
		1992-95	9,846	72	0.73%
		1996-99	2,262	36	1.59%
			45,415	406	0.89%
	Ages 85+	1984-87	5,865	10	0.17%
		1988-91	12,859	79	0.61%
		1992-95	2,664	17	0.64%
		1996-99	293	6	2.05%
			04.004		0.500/
			21,681	112	0.52%
2	Loop than 10	1004.07			0.000/
3	Less than 40	1988-91	-	-	0.00%
			5	-	0.00%
		1992-95	717	-	0.00%
		1996-99	290	-	0.00%
			1,012		0.00%
			1,012	-	0.00%
	40-49	1984-87	2	_	0.00%
	10 70	1988-91	293	_	0.00%
		1992-95	805	-	0.00%
		1996-99	435	_	0.00%
		1000 00	733		J.00 /0
			1,535	_	0.00%
			1,000		0.0070

50-59	1984-87	51	-	0.00%	
	1988-91	3,197	3	0.09%	
	1992-95	3,868	3	0.08%	
	1996-99	1,965	4	0.20%	
		,			
		9,081	10	0.11%	
60-64	1984-87	287	1	0.35%	
	1988-91	7,247	4	0.06%	
	1992-95	5,940	5	0.08%	
	1996-99	2,802	2	0.07%	
		16,276	12	0.07%	
65-69	1984-87	2,802	14	0.50%	
	1988-91	19,678	27	0.14%	
	1992-95	12,454	22	0.18%	
	1996-99	5,237	9	0.17%	
		40,171	72	0.18%	
70-74	1984-87	9,523	45	0.47%	
	1988-91	32,238	78	0.24%	
	1992-95	16,332	51	0.31%	
	1996-99	5,296	25	0.47%	
		63,389	199	0.31%	
75-79	1984-87	13,043	96	0.74%	
	1988-91	29,647	160	0.54%	
	1992-95	12,265	69	0.56%	
	1996-99	3,385	40	1.18%	
		58,340	365	0.63%	
80-84	1984-87	10,370	80	0.77%	
	1988-91	20,253	220	1.09%	
	1992-95	6,435	64	0.99%	
	1996-99	1,183	25	2.11%	
		38,241	389	1.02%	
Ages 85+	1984-87	5,819	13	0.22%	
	1988-91	12,364	110	0.89%	
	1992-95	1,803	18	1.00%	
	1996-99	163	7	4.29%	
		20,149	148	0.73%	

4	Less than 40	1984-87	-	-	0.00%
		1988-91	2	-	0.00%
		1992-95	358	-	0.00%
			360	-	0.00%
	40-49	1984-87	1	-	0.00%
		1988-91	149	-	0.00%
		1992-95	547	-	0.00%
			697	-	0.00%
	50-59	1984-87	32	-	0.00%
		1988-91	2,308	-	0.00%
		1992-95	2,666	1	0.04%
			5,006	1	0.02%
	60-64	1984-87	172	1	0.58%
	00 04	1988-91	5,792	6	0.10%
		1992-95	3,674	4	0.10%
		1992-95	3,074	7	0.1170
			9,638	11	0.11%
	65-69	1984-87	1,647	8	0.49%
		1988-91	16,122	14	0.09%
		1992-95	7,183	14	0.19%
			24,952	36	0.14%
	70-74	1984-87	7,796	31	0.40%
		1988-91	27,958	64	0.23%
		1992-95	10,614	41	0.39%
			46,368	136	0.29%
	75-79	1984-87	11,542	92	0.80%
		1988-91	26,287	120	0.46%
		1992-95	8,095	61	0.75%
			45,924	273	0.59%
	80-84	1984-87	9,643	98	1.02%
		1988-91	18,063	193	1.07%
		1992-95	3,656	58	1.59%
			31,362	349	1.11%

	Ages 85+	1984-87	5,748	13	0.23%
	9	1988-91	11,671	140	1.20%
		1992-95	757	8	1.06%
		1002 00	101	O	1.0070
			18,176	161	0.89%
			10,170	101	0.0070
5	Less than 40	1984-87	-	-	0.00%
		1988-91	1	_	0.00%
		1992-95	186	_	0.00%
		1002 00			0.0070
			187	-	0.00%
					0.0070
	40-49	1984-87	1	-	0.00%
		1988-91	72	-	0.00%
		1992-95	274	_	0.00%
		1002 00	2		0.0070
			347	_	0.00%
	50-59	1984-87	16	-	0.00%
		1988-91	1,397	2	0.14%
		1992-95	1,393	-	0.00%
			1,222		0.007
			2,806	2	0.07%
			,		
	60-64	1984-87	90	-	0.00%
		1988-91	3,584	5	0.14%
		1992-95	2,049	4	0.20%
			5,723	9	0.16%
	65-69	1984-87	774	6	0.78%
		1988-91	9,895	15	0.15%
		1992-95	3,946	12	0.30%
			14,615	33	0.23%
	70-74	1984-87	5,777	25	0.43%
		1988-91	19,850	54	0.27%
		1992-95	6,752	28	0.41%
			32,379	107	0.33%
	75-79	1984-87	9,781	58	0.59%
		1988-91	20,180	109	0.54%
		1992-95	5,286	51	0.96%
			35,247	218	0.62%
			•		

	80-84	1984-87	8,718	112	1.28%	
		1988-91	13,933	174	1.25%	
		1992-95	2,509	52	2.07%	
		1002 00	2,000	32	2.07 70	
			25,160	338	1.34%	
			25,100	330	1.5470	
	Ages 85+	1984-87	5,616	28	0.50%	
	7.g00 00 .	1988-91	9,552	123	1.29%	
		1992-95	573	12	2.09%	
		1002 00	373	12	2.0370	
			15,741	163	1.04%	
			10,7 11	100	1.0 170	
6	Less than 40	1984-87	-	-	0.00%	
-		1988-91	1	_	0.00%	
		1992-95	36	-	0.00%	
		1002 00	30		0.0070	
			37	_	0.00%	
			0.		0.0070	
	40-49	1984-87	1	-	0.00%	
		1988-91	41	_	0.00%	
		1992-95	120	-	0.00%	
		1002 00	.20		0.0070	
			162	-	0.00%	
					0.0070	
	50-59	1984-87	10	-	0.00%	
		1988-91	749	-	0.00%	
		1992-95	810	-	0.00%	
			1,569	-	0.00%	
			·			
	60-64	1984-87	55	-	0.00%	
		1988-91	1,754	2	0.11%	
		1992-95	1,151	3	0.26%	
			2,960	5	0.17%	
	65-69	1984-87	392	1	0.26%	
		1988-91	4,868	9	0.18%	
		1992-95	2,280	3	0.13%	
			7,540	13	0.17%	
	70-74	1984-87	4,379	15	0.34%	
		1988-91	11,518	40	0.35%	
		1992-95	4,469	15	0.34%	
			,	-		
			20,366	70	0.34%	
			,	-		

	75-79	1984-87	8,389	48	0.57%
		1988-91	13,819	86	0.62%
		1992-95	3,537	38	1.07%
			-,		
			25,745	172	0.67%
					0.0.7
	80-84	1984-87	7,787	82	1.05%
		1988-91	9,883	146	1.48%
		1992-95	1,714	27	1.58%
			,		
			19,384	255	1.32%
	Ages 85+	1984-87	5,450	46	0.84%
	-	1988-91	7,254	117	1.61%
		1992-95	422	14	3.32%
			13,126	177	1.35%
			,		
7	Less than 40	1984-87	-	-	0.00%
		1988-91	-	-	0.00%
		1992-95	19	_	0.00%
			_		
			19	_	0.00%
	40-49	1984-87	-	_	0.00%
		1988-91	26	-	0.00%
		1992-95	52	_	0.00%
			78	-	0.00%
	50-59	1984-87	10	_	0.00%
		1988-91	455	-	0.00%
		1992-95	361	-	0.00%
			826	-	0.00%
	60-64	1984-87	40	-	0.00%
		1988-91	808	-	0.00%
		1992-95	564	-	0.00%
			1,412	-	0.00%
	65-69	1984-87	307	-	0.00%
		1988-91	1,946	9	0.46%
		1992-95	1,143	3	0.26%
			,		
			3,396	12	0.35%
			, -		

70-74	1984-87	3,431	12	0.35%
	1988-91	5,003	30	0.60%
	1992-95	2,405	13	0.54%
		10,839	55	0.51%
75-79	1984-87	7,328	45	0.61%
	1988-91	8,029	58	0.72%
	1992-95	2,081	15	0.72%
		17,438	118	0.68%
80-84	1984-87	7,051	78	1.11%
	1988-91	5,891	99	1.68%
	1992-95	1,024	38	3.71%
		13,966	215	1.54%
Ages 85+	1984-87	5,239	52	0.99%
	1988-91	4,936	98	1.99%
	1992-95	265	8	3.02%
		10,440	158	1.51%

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination Period	Attained Age Group	Benefit Period	Exposure	Claims	Rate
0	Less than 40	1-4	124	-	0.00%
		5+	16	-	0.00%
		Unlimited	98	-	0.00%
		Unknown	84	-	0.00%
		Total	322	-	0.00%
	40-49	1-4	882	2	0.23%
		5+	30	-	0.00%
		Unlimited	501	-	0.00%
		Unknown	256	-	0.00%
		Total	1,669	2	0.12%
		Total	1,009	2	0.1270
	50-59	1-4	9,242	21	0.23%
	00 00	5+	1,024	2	0.20%
		Unlimited	7,046	5	0.07%
		Unknown	1,019	-	0.00%
			,		
		Total	18,331	28	0.15%
	60-64	1-4	25,719	98	0.38%
		5+	4,188	25	0.60%
		Unlimited	13,940	14	0.10%
		Unknown	1,263	1	0.08%
		Total	45,110	138	0.31%
	65-69	1-4	104,551	678	0.65%
		5+	19,923	197	0.99%
		Unlimited	32,161	128	0.40%
		Unknown	2,504	1	0.04%
		Total	159,139	1,004	0.63%
	70-74	1-4	177,362	1,996	1.13%
		5+	44,835	586	1.31%
		Unlimited	36,401	221	0.61%
		Unknown	1,806	2	0.11%
		Total	260,404	2,805	1.08%

75-79	1-4	172,112	3,642	2.12%
	5+	50,106	875	1.75%
	Unlimited	21,225	194	0.91%
	Unknown	837	1	0.12%
	Total	244,280	4,712	1.93%
80-84	1-4	111,269	3,570	3.21%
	5+	29,609	646	2.18%
	Unlimited	3,555	44	1.24%
	Unknown	164	-	0.00%
	Total	144,597	4,260	2.95%
Ages 85+	1-4	50,576	1,356	2.68%
	5+	11,521	222	1.93%
	Unlimited	38	-	0.00%
	Unknown	-	-	0.00%
	Total	62,135	1,578	2.54%

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination Period	Attained Age Group	Benefit Period	Exposure	Claims	Rate
7-19	Less than 40	1-4	-	-	0.00%
		5+	-	_	0.00%
		Unlimited	15	-	0.00%
		Unknown	2	-	0.00%
		Total	17	-	0.00%
	40-49	1-4	4	-	0.00%
		5+	-	-	0.00%
		Unlimited	17	-	0.00%
		Unknown	11	-	0.00%
		Total	32	-	0.00%
	50-59	1-4	24	-	0.00%
		5+	-	-	0.00%
		Unlimited	1,587	6	0.38%
		Unknown	81	-	0.00%
		Total	1,692	6	0.35%
	60-64	1-4	47	-	0.00%
		5+	-	-	0.00%
		Unlimited	4,079	14	0.34%
		Unknown	90	-	0.00%
		Total	4,216	14	0.33%
	65-69	1-4	161	1	0.62%
		5+	-	_	0.00%
		Unlimited	22,572	61	0.27%
		Unknown	221	-	0.00%
		Total	22,954	62	0.27%
	70-74	1-4	354	2	0.56%
		5+	-	-	0.00%
		Unlimited	40,281	159	0.39%
		Unknown	220	-	0.00%
		Total	40,855	161	0.39%

75-79	1-4	379	-	0.00%
	5+	-	-	0.00%
	Unlimited	36,224	230	0.63%
	Unknown	95	-	0.00%
	Total	36,698	230	0.63%
80-84	1-4	122	1	0.82%
	5+	-	-	0.00%
	Unlimited	26,907	292	1.09%
	Unknown	21	-	0.00%
	Total	27,050	293	1.08%
Ages 85+	1-4	35	-	0.00%
	5+	-	-	0.00%
	Unlimited	13,299	180	1.35%
	Unknown	-	-	0.00%
	Total	13,334	180	1.35%

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination Period	Attained Age Group	Benefit Period	Exposure	Claims	Rate
20	Less than 40	1-4	74	_	0.00%
20	Loco man ro	5+	217	_	0.00%
		Unlimited	66	-	0.00%
		Unknown	4	-	0.00%
			•		0.0070
		Total	361	-	0.00%
	40-49	1-4	1,866	-	0.00%
		5+	4,470	4	0.09%
		Unlimited	3,843	1	0.03%
		Unknown	8	-	0.00%
		Total	10,187	5	0.05%
	50-59	1-4	18,350	12	0.07%
		5+	24,201	21	0.09%
		Unlimited	27,644	24	0.09%
		Unknown	458	-	0.00%
		Total	70,653	57	0.08%
	60-64	1-4	45,759	91	0.20%
		5+	30,191	49	0.16%
		Unlimited	48,920	58	0.12%
		Unknown	664	1	0.15%
		Total	125,534	199	0.16%
	65-69	1-4	143,942	433	0.30%
		5+	64,003	189	0.30%
		Unlimited	104,106	278	0.27%
		Unknown	906	3	0.33%
		Total	312,957	903	0.29%
	70-74	1-4	264,267	1,543	0.58%
		5+	96,976	529	0.55%
		Unlimited	121,222	521	0.43%
		Unknown	649	1	0.15%
		Total	483,114	2,594	0.54%

75-79	1-4	296,542	3,222	1.09%
	5+	91,540	851	0.93%
	Unlimited	73,185	578	0.79%
	Unknown	348	4	1.15%
	Total	461,615	4,655	1.01%
80-84	1-4	215,877	3,784	1.75%
	5+	48,763	700	1.44%
	Unlimited	24,674	304	1.23%
	Unknown	224	4	1.79%
	Total	289,538	4,792	1.66%
Ages 85+	1-4	115,300	2,174	1.89%
	5+	18,199	260	1.43%
	Unlimited	2,120	12	0.57%
	Unknown	11	-	0.00%
	Total	135 630	2 446	1.80%
	IUlai	135,630	2,446	1.00%

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

	Attained Age	Benefit	_	01.	5.
Period	Group	Period	Exposure	Claims	Rate
30-50	Less than 40	1-4	190	-	0.00%
		5+	263	-	0.00%
		Unlimited	1,476	2	0.14%
		Unknown	30	-	0.00%
		Total	1,959	2	0.10%
	40-49	1-4	459	-	0.00%
		5+	568	-	0.00%
		Unlimited	3,568	4	0.11%
		Unknown	193	=	0.00%
		Total	4,788	4	0.08%
			,		
	50-59	1-4	2,372	1	0.04%
		5+	2,954	1	0.03%
		Unlimited	11,014	12	0.11%
		Unknown	829	-	0.00%
		Total	17,169	14	0.08%
	60-64	1-4	6,016	9	0.15%
	00-04	5+	4,649	17	0.13%
		Unlimited	10,625	9	0.08%
		Unknown	1,238	-	0.00%
		Olikilowii	1,230		0.0076
		Total	22,528	35	0.16%
	65-69	1-4	26,027	44	0.17%
		5+	11,695	34	0.29%
		Unlimited	18,015	39	0.22%
		Unknown	2,876	-	0.00%
		Tatal	50.040	447	0.000/
		Total	58,613	117	0.20%
	70-74	1-4	46,403	136	0.29%
		5+	18,189	64	0.35%
		Unlimited	17,605	66	0.37%
		Unknown	2,001	=	0.00%
		Total	84,198	266	0.32%

75-79	1-4	34,543	247	0.72%
	5+	12,391	93	0.75%
	Unlimited	10,604	56	0.53%
	Unknown	845	1	0.12%
	Total	58,383	397	0.68%
80-84	1-4	20,228	278	1.37%
	5+	5,595	85	1.52%
	Unlimited	4,577	54	1.18%
	Unknown	275	-	0.00%
	Total	30,675	417	1.36%
Ages 85+	1-4	10,178	233	2.29%
	5+	1,869	59	3.16%
	Unlimited	937	51	5.44%
	Unknown	24	1	4.17%
	Total	13,008	344	2.64%

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination	Attained Age	Benefit			
Period	Group	Period	Exposure	Claims	Rate
			40		0.000/
60	Less than 40		43	-	0.00%
		5+	50,166	22	0.04%
		Unlimited	2,922	5	0.17%
		Unknown	15	-	0.00%
		Total	53,146	27	0.05%
	10.10	4.4	200		0.000/
	40-49	1-4	380	-	0.00%
		5+	73,342	42	0.06%
		Unlimited	5,486	3	0.05%
		Unknown	31	-	0.00%
		Total	79,239	45	0.06%
	50-59	1-4	1,248	_	0.00%
	00 00	5+	90,818	49	0.05%
		Unlimited	11,680	9	0.08%
		Unknown	177	1	0.56%
		OTIKITOWIT	111	!	0.5070
		Total	103,923	59	0.06%
	60-64	1-4	1,847	-	0.00%
		5+	33,369	37	0.11%
		Unlimited	12,005	22	0.18%
		Unknown	211	-	0.00%
		Total	47,432	59	0.12%
		Total	47,432	39	0.1270
	65-69	1-4	3,266	4	0.12%
		5+	31,119	79	0.25%
		Unlimited	16,621	56	0.34%
		Unknown	471	-	0.00%
		Total	51,477	139	0.27%
	70-74	1-4	3,202	10	0.31%
	*	5+	23,278	83	0.36%
		Unlimited	14,988	106	0.71%
		Unknown	345	-	0.00%
		Total	41,813	199	0.48%

75-79	1-4	2,248	9	0.40%	
	5+	8,913	41	0.46%	
	Unlimited	9,379	122	1.30%	
	Unknown	138	1	0.72%	
	Total	20,678	173	0.84%	
80-84	1-4	635	9	1.42%	
	5+	1,571	24	1.53%	
	Unlimited	3,921	79	2.01%	
	Unknown	52	-	0.00%	
	Total	6,179	112	1.81%	
Ages 85+	1-4	110	-	0.00%	
	5+	413	8	1.94%	
	Unlimited	406	17	4.19%	
	Unknown	-	-	0.00%	
	Total	929	25	2.69%	

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination	Attained Age	Benefit			
Period	Group	Period	Exposure	Claims	Rate
90	Less than 40	1_1	10 155	2	0.02%
90	Less than 40	5+	10,155 32,076	13	0.02 %
		Unlimited	27,583	8	0.04%
		Unknown	27,303	0	0.00%
		OTIKITOWIT	23	-	0.00 /6
		Total	69,837	23	0.03%
	40-49	1-4	12,835	4	0.03%
		5+	74,163	19	0.03%
		Unlimited	34,742	13	0.04%
		Unknown	124	-	0.00%
		Total	121,864	36	0.03%
	50-59	1-4	41,946	40	0.10%
		5+	89,338	27	0.03%
		Unlimited	46,764	27	0.06%
		Unknown	857	-	0.00%
		Total	178,905	94	0.05%
	60-64	1-4	67,643	102	0.15%
	00 04	5+	28,994	20	0.07%
		Unlimited	34,016	18	0.05%
		Unknown	1,281	-	0.00%
		• • • • • • • • • • • • • • • • • • • •	.,_0.		0.0070
		Total	131,934	140	0.11%
	65-69	1-4	108,020	200	0.19%
		5+	29,202	33	0.11%
		Unlimited	37,968	38	0.10%
		Unknown	3,063	-	0.00%
			-,		
		Total	178,253	271	0.15%
	70-74	1-4	116,981	335	0.29%
		5+	26,663	61	0.23%
		Unlimited	30,588	68	0.22%
		Unknown	2,912	-	0.00%
		Total	177,144	464	0.26%

75-79	1-4	67,744	527	0.78%	
	5+	15,389	86	0.56%	
	Unlimited	16,194	76	0.47%	
	Unknown	1,256	-	0.00%	
	Total	100,583	689	0.69%	
80-84	1-4	32,879	394	1.20%	
	5+	6,569	88	1.34%	
	Unlimited	6,033	81	1.34%	
	Unknown	384	-	0.00%	
	Total	45,865	563	1.23%	
Ages 85+	1-4	7,660	131	1.71%	
	5+	2,733	52	1.90%	
	Unlimited	2,109	52	2.47%	
	Unknown	4	-	0.00%	
	Total	12,506	235	1.88%	

Appendix D-5
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination Period	Attained Age	Benefit	Evposuro	Claims	Poto
renou	Group	Period	Exposure	Cidil115	Rate
100	Less than 40	1-4	79	_	0.00%
		5+	108	-	0.00%
		Unlimited	932	-	0.00%
		Unknown	-	-	0.00%
		Total	1,119	-	0.00%
	40-49	1-4	1,643	-	0.00%
		5+	2,241	-	0.00%
		Unlimited	4,516	1	0.02%
		Unknown	-	-	0.00%
		Total	9.400	4	0.010/
		Total	8,400	1	0.01%
	50-59	1-4	18,696	9	0.05%
		5+	19,807	6	0.03%
		Unlimited	29,416	7	0.02%
		Unknown	95	-	0.00%
		Total	68,014	22	0.03%
	60-64	1-4	43,462	27	0.06%
		5+	29,733	21	0.07%
		Unlimited	46,409	25	0.05%
		Unknown	103	1	0.97%
		Total	110 707	7.1	0.069/
		Total	119,707	74	0.06%
	65-69	1-4	118,332	163	0.14%
		5+	56,184	117	0.21%
		Unlimited	87,119	59	0.07%
		Unknown	195	-	0.00%
		Total	261,830	339	0.13%
			000 = 15	=05	0.0==:
	70-74	1-4	208,748	562	0.27%
		5+	81,902	316	0.39%
		Unlimited	95,065	170	0.18%
		Unknown	137	-	0.00%
		Total	385,852	1,048	0.27%

75-79	1-4	234,297	1,445	0.62%
	5+	76,121	499	0.66%
	Unlimited	59,734	217	0.36%
	Unknown	68	-	0.00%
	Total	370,220	2,161	0.58%
80-84	1-4	184,202	2,099	1.14%
	5+	43,392	542	1.25%
	Unlimited	23,485	121	0.52%
	Unknown	15	1	6.67%
	Total	251,094	2,763	1.10%
Ages 85+	1-4	116,102	1,368	1.18%
	5+	21,867	239	1.09%
	Unlimited	1,898	7	0.37%
	Unknown	1	-	0.00%
	Total	139,868	1,614	1.15%

Appendix D-5 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination Period	Attained Age Group	Benefit Period	Exposure	Claims	Rate
101-730	Less than 40	1-4	32	1	3.13%
		5+	16,513	12	0.07%
		Unlimited	670	1	0.15%
		Unknown	3	-	0.00%
		Total	17,218	14	0.08%
	40-49	1-4	120	-	0.00%
		5+	44,038	40	0.09%
		Unlimited	957	-	0.00%
		Unknown	1	-	0.00%
		Total	45,116	40	0.09%
	50-59	1-4	694	-	0.00%
		5+	81,129	66	0.08%
		Unlimited	2,402	-	0.00%
		Unknown	232	-	0.00%
		Total	84,457	66	0.08%
	60-64	1-4	1,483	-	0.00%
		5+	41,624	38	0.09%
		Unlimited	2,096	2	0.10%
		Unknown	362	-	0.00%
		Total	45,565	40	0.09%
	65-69	1-4	4,244	2	0.05%
		5+	32,700	37	0.11%
		Unlimited	3,116	2	0.06%
		Unknown	520	-	0.00%
		Total	40,580	41	0.10%
	70-74	1-4	8,086	22	0.27%
		5+	21,515	47	0.22%
		Unlimited	3,351	5	0.15%
		Unknown	349	-	0.00%
		Total	33,301	74	0.22%

75-79	1-4	9,358	49	0.52%	
	5+	12,275	50	0.41%	
	Unlimited	1,921	8	0.42%	
	Unknown	141	1	0.71%	
	Total	23,695	108	0.46%	
80-84	1-4	6,363	66	1.04%	
	5+	4,713	59	1.25%	
	Unlimited	277	1	0.36%	
	Unknown	35	2	5.71%	
	Total	11,388	128	1.12%	
Ages 85+	1-4	3,354	39	1.16%	
	5+	1,370	26	1.90%	
	Unlimited	129	4	3.10%	
	Unknown	-	-	0.00%	
	Total	4,853	69	1.42%	

Appendix D-5 SOA 1984-99 Long Term Care Intercompany Study Incidence Rates by Elimination Period, Attained Age, and Benefit Period

Elimination	Attained Age	Benefit			
Period	Group	Period	Exposure	Claims	Rate
All Periods	Less than 40	1-4	10,697	3	0.03%
		5+	99,359	47	0.05%
		Unlimited	33,762	16	0.05%
		Unknown	161	-	0.00%
		Total	143,979	66	0.05%
	40-49	1-4	18,189	6	0.03%
		5+	198,852	105	0.05%
		Unlimited	53,630	22	0.04%
		Unknown	624	-	0.00%
		Total	271,295	133	0.05%
	50-59	1-4	92,572	83	0.09%
		5+	309,271	172	0.06%
		Unlimited	137,553	90	0.07%
		Unknown	3,748	1	0.03%
		Total	543,144	346	0.06%
	60-64	1-4	191,976	327	0.17%
		5+	172,748	207	0.12%
		Unlimited	172,090	162	0.09%
		Unknown	5,212	3	0.06%
		Total	542,026	699	0.13%
	65-69	1-4	508,543	1,525	0.30%
		5+	244,826	686	0.28%
		Unlimited	321,678	661	0.21%
		Unknown	10,756	4	0.04%
		Total	1,085,803	2,876	0.26%
	70-74	1-4	825,403	4,606	0.56%
		5+	313,358	1,686	0.54%
		Unlimited	359,501	1,316	0.37%
		Unknown	8,419	3	0.04%
		Total	1,506,681	7,611	0.51%

75-79	1-4	817,223	9,141	1.12%	
	5+	266,735	2,495	0.94%	
	Unlimited	228,466	1,481	0.65%	
	Unknown	3,728	8	0.21%	
	Total	1,316,152	13,125	1.00%	
80-84	1-4	571,575	10,201	1.78%	
	5+	140,212	2,144	1.53%	
	Unlimited	93,429	976	1.04%	
	Unknown	1,170	7	0.60%	
	Total	006 206	12 220	1.650/	
	Total	806,386	13,328	1.65%	
Ages 85+	1-4	303,315	5,301	1.75%	
	5+	57,972	866	1.49%	
	Unlimited	20,936	323	1.54%	
	Unknown	40	1	2.50%	
	T-4-1	000 000	0.404	4.700/	
	Total	382,263	6,491	1.70%	

Appendix D-6

SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period	-	Benefit Per Day	Exposure	Claims	Rate
0	Less than 40	< \$100	137	-	0.00%
		\$100	55	-	0.00%
		>\$100	211	-	0.00%
		Total	403	-	0.00%
	40-49	< \$100	664	2	0.30%
		\$100	407	-	0.00%
		> \$100	799	-	0.00%
		Total	1,870	2	0.11%
	50-59	< \$100	7,077	15	0.21%
		\$100	2,715	3	0.11%
		> \$100	3,943	2	0.05%
		Total	13,735	20	0.15%
	60-64	< \$100	20,447	66	0.32%
		\$100	5,267	9	0.17%
		> \$100	4,772	7	0.15%
		Total	30,486	82	0.27%
	65-69	< \$100	88,187	612	0.69%
		\$100	15,727	47	0.30%
		> \$100	10,512	20	0.19%
		Total	114,426	679	0.59%
	70-74	< \$100	175,766	1,879	1.07%
		\$100	18,750	114	0.61%
		> \$100	9,714	49	0.50%
		Total	204,230	2,042	1.00%
	75-79	< \$100	184,185	3,205	1.74%
		\$100	12,567	116	0.92%
		> \$100	5,640	35	0.62%
		Total	202,392	3,356	1.66%
	80-84	< \$100	110,297	2,755	2.50%
		\$100	4,858	74	1.52%
		> \$100	1,769	12	0.68%
		Total	116,924	2,841	2.43%
	Ages 85+	< \$100	52,241	1,118	2.14%
		\$100	1,138	12	1.05%
		>\$100	140	1	0.71%
		Total	53,519	1,131	2.11%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period		Benefit Per Day	Exposure	Claims	Rate
7-19	Less than 40	< \$100	3	-	0.00%
		\$100	3	-	0.00%
		> \$100	29	-	0.00%
		Total	35	-	0.00%
	40-49	< \$100	33	-	0.00%
		\$100	23	-	0.00%
		> \$100	74	-	0.00%
		Total	130	-	0.00%
	50-59	< \$100	538	-	0.00%
		\$100	337	-	0.00%
		>\$100	1,876	6	0.32%
		Total	2,751	6	0.22%
	60-64	< \$100	1,483	1	0.07%
		\$100	757	_	0.00%
		>\$100	4,302	13	0.30%
		Total	6,542	14	0.21%
	65-69	< \$100	8,438	1	0.01%
		\$100	3,463	2	0.06%
		> \$100	22,766	61	0.27%
		Total	34,667	64	0.18%
	70-74	< \$100	15,104	9	0.06%
		\$100	5,249	4	0.08%
		>\$100	39,433	159	0.40%
		Total	59,786	172	0.29%
	75-79	< \$100	14,749	10	0.07%
		\$100	5,190	5	0.10%
		> \$100	33,998	229	0.67%
		Total	53,937	244	0.45%
	80-84	< \$100	11,148	10	0.09%
		\$100	4,382	2	0.05%
		>\$100	24,577	295	1.20%
		Total	40,107	307	0.77%
	Ages 85+	< \$100	3,921	7	0.18%
	-	\$100	1,587	4	0.25%
		> \$100	13,154	180	1.37%
		Total	18,662	191	1.02%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period	I Group	Benefit Per Day	Exposure	Claims	Rate
20	Less than 40	< \$100	102	-	0.00%
		\$100	56	-	0.00%
		> \$100	228	-	0.00%
		Total	386	-	0.00%
	40-49	< \$100	2,862	-	0.00%
		\$100	3,251	1	0.03%
		>\$100	4,144	5	0.12%
		Total	10,257	6	0.06%
	50-59	< \$100	27,943	21	0.08%
		\$100	25,490	21	0.08%
		>\$100	18,586	18	0.10%
		Total	72,019	60	0.08%
	60-64	< \$100	72,142	134	0.19%
		\$100	42,017	56	0.13%
		> \$100	17,384	23	0.13%
			,		
		Total	131,543	213	0.16%
	65-69	< \$100	226,082	699	0.31%
		\$100	80,184	195	0.24%
		>\$100	24,672	80	0.32%
		Total	330,938	974	0.29%
	70-74	< \$100	410,629	2,382	0.58%
		\$100	88,787	351	0.40%
		> \$100	23,932	129	0.54%
		Total	523,348	2,862	0.55%
	75-79	<\$100	452,143	4,605	1.02%
		\$100	63,851	462	0.72%
		>\$100	13,741	114	0.83%
		Total	529,735	5,181	0.98%
	80-84	< \$100	303,614	4,981	1.64%
		\$100	23,977	337	1.41%
		>\$100	4,831	71	1.47%
		Total	332,422	5,389	1.62%
	Ages 85+	< \$100	159,272	3,048	1.91%
		\$100	6,650	112	1.68%
		> \$100	1,420	8	0.56%
		Total	167,342	3,168	1.89%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age		_		_
Elimination Period	Group	Benefit Per Day	Exposure	Claims	Rate
30-50	Less than 40	< \$100	3,614	3	0.08%
		\$100	864	1	0.12%
		>\$100	426	-	0.00%
		Total	4,904	4	0.08%
	40-49	<\$100	4,328	1	0.02%
		\$100	1,696	3	0.18%
		>\$100	2,091	1	0.05%
		Total	8,115	5	0.06%
	50-59	< \$100	11,526	11	0.10%
		\$100	5,464	4	0.07%
		> \$100	10,102	4	0.04%
		Total	27,092	19	0.07%
	60-64	<\$100	17,529	31	0.18%
		\$100	7,803	8	0.10%
		>\$100	11,361	5	0.04%
		Total	36,693	44	0.12%
	65-69	<\$100	53,342	94	0.18%
		\$100	22,230	25	0.11%
		> \$100	22,579	17	0.08%
		Total	98,151	136	0.14%
	70-74	< \$100	78,849	240	0.30%
		\$100	24,275	33	0.14%
		> \$100	19,318	28	0.14%
		Total	122,442	301	0.25%
	75-79	<\$100	60,877	375	0.62%
		\$100	14,246	39	0.27%
		>\$100	8,802	30	0.34%
		Total	83,925	444	0.53%
	80-84	< \$100	33,853	446	1.32%
		\$100	6,459	30	0.46%
		> \$100	3,246	24	0.74%
		Total	43,558	500	1.15%
	Ages 85+	< \$100	15,988	510	3.19%
		\$100	1,704	38	2.23%
		> \$100	975	16	1.64%
		Total	18,667	564	3.02%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period	Group	Benefit Per Day	Exposure	Claims	Rate
60	Less than 40	< \$100	32,916	14	0.04%
		\$100	5,105	2	0.04%
		>\$100	27,202	14	0.05%
		Total	65,223	30	0.05%
	40-49	< \$100	37,628	13	0.03%
		\$100	14,921	12	0.08%
		>\$100	37,985	26	0.07%
		Total	90,534	51	0.06%
	50-59	< \$100	45,821	42	0.09%
		\$100	22,619	11	0.05%
		> \$100	49,252	24	0.05%
		Total	117,692	77	0.07%
	60-64	< \$100	26,015	45	0.17%
		\$100	13,030	14	0.11%
		> \$100	18,337	16	0.09%
		Total	57,382	75	0.13%
	65-69	< \$100	35,903	93	0.26%
		\$100	17,720	32	0.18%
		>\$100	15,524	47	0.30%
		Total	69,147	172	0.25%
	70-74	< \$100	36,226	193	0.53%
		\$100	14,457	54	0.37%
		>\$100	9,433	32	0.34%
		Total	60,116	279	0.46%
	75-79	<\$100	24,751	238	0.96%
		\$100	6,798	40	0.59%
		> \$100	3,546	24	0.68%
		Total	35,095	302	0.86%
	80-84	< \$100	11,871	259	2.18%
		\$100	2,116	32	1.51%
		> \$100	878	17	1.94%
		Total	14,865	308	2.07%
	Ages 85+	< \$100	4,215	146	3.46%
		\$100	580	14	2.41%
		>\$100	218	4	1.83%
		Total	5,013	164	3.27%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period	Group Group	Benefit Per Day	Exposure	Claims	Rate
90	Less than 40	< \$100	247,236	17	0.01%
		\$100	26,911	4	0.01%
		>\$100	28,134	13	0.05%
		Total	302,281	34	0.01%
	40-49	< \$100	212,981	43	0.02%
		\$100	37,190	16	0.04%
		>\$100	61,070	21	0.03%
		Total	311,241	80	0.03%
	50-59	< \$100	215,913	109	0.05%
		\$100	49,786	17	0.03%
		> \$100	79,197	26	0.03%
		Total	344,896	152	0.04%
	60-64	< \$100	137,572	160	0.12%
		\$100	32,409	18	0.06%
		> \$100	35,286	21	0.06%
		Total	205,267	199	0.10%
	65-69	<\$100	185,332	293	0.16%
		\$100	43,531	36	0.08%
		>\$100	39,789	24	0.06%
		Total	268,652	353	0.13%
	70-74	< \$100	185,809	489	0.26%
		\$100	36,441	50	0.14%
		> \$100	29,919	35	0.12%
		Total	252,169	574	0.23%
	75-79	< \$100	112,995	717	0.63%
		\$100	19,248	64	0.33%
		>\$100	12,757	38	0.30%
		Total	145,000	819	0.56%
	80-84	< \$100	54,282	628	1.16%
		\$100	7,451	43	0.58%
		>\$100	4,028	31	0.77%
		Total	65,761	702	1.07%
	Ages 85+	< \$100	16,988	348	2.05%
		\$100	1,886	31	1.64%
		> \$100	961	15	1.56%
		Total	19,835	394	1.99%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age	•			
Elimination Period	l Group	Benefit Per Day	Exposure	Claims	Rate
100	Less than 40	< \$100	6,523	-	0.00%
		\$100	299	-	0.00%
		> \$100	311	-	0.00%
		Total	7,133	-	0.00%
	40-49	< \$100	4,629	-	0.00%
		\$100	2,806	1	0.04%
		> \$100	3,648	-	0.00%
		Total	11,083	1	0.01%
	50-59	< \$100	20,196	5	0.02%
		\$100	26,893	10	0.04%
		> \$100	24,111	8	0.03%
		Total	71,200	23	0.03%
	60-64	< \$100	46,432	26	0.06%
		\$100	46,841	31	0.07%
		> \$100	31,559	23	0.07%
		Total	124,832	80	0.06%
	65-69	< \$100	135,910	207	0.15%
		\$100	85,956	81	0.09%
		> \$100	48,269	56	0.12%
		Total	270,135	344	0.13%
	70-74	< \$100	252,277	713	0.28%
		\$100	96,539	207	0.21%
		> \$100	47,209	149	0.32%
		Total	396,025	1,069	0.27%
	75-79	< \$100	289,304	1,710	0.59%
		\$100	66,319	320	0.48%
		> \$100	27,135	153	0.56%
		Total	382,758	2,183	0.57%
	80-84	< \$100	221,045	2,387	1.08%
		\$100	29,690	295	0.99%
		>\$100	8,644	99	1.15%
		Total	259,379	2,781	1.07%
	Ages 85+	< \$100	136,692	1,603	1.17%
		\$100	8,805	87	0.99%
		>\$100	1,250	14	1.12%
		Total	146,747	1,704	1.16%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period	Group	Benefit Per Day	Exposure	Claims	Rate
101-730	Less than 40	< \$100	7,037	1	0.01%
		\$100	7,118	5	0.07%
		> \$100	9,567	8	0.08%
		Total	23,722	14	0.06%
	40-49	< \$100	11,151	-	0.00%
		\$100	16,982	23	0.14%
		> \$100	21,837	17	0.08%
		Total	49,970	40	0.08%
	50-59	< \$100	16,803	1	0.01%
		\$100	34,815	40	0.11%
		> \$100	36,598	25	0.07%
		Total	88,216	66	0.07%
	60-64	< \$100	11,483	10	0.09%
		\$100	20,652	15	0.07%
		> \$100	14,901	16	0.11%
		Total	47,036	41	0.09%
	65-69	< \$100	14,914	12	0.08%
		\$100	17,221	18	0.10%
		> \$100	9,843	13	0.13%
		Total	41,978	43	0.10%
	70-74	< \$100	18,830	44	0.23%
		\$100	10,823	22	0.20%
		> \$100	4,893	11	0.22%
		Total	34,546	77	0.22%
	75-79	< \$100	17,640	81	0.46%
		\$100	4,919	28	0.57%
		>\$100	1,917	2	0.10%
		Total	24,476	111	0.45%
	80-84	< \$100	10,007	112	1.12%
		\$100	1,316	18	1.37%
		> \$100	575	8	1.39%
		Total	11,898	138	1.16%
	Ages 85+	< \$100	4,577	65	1.42%
		\$100	432	10	2.31%
		> \$100	147	1	0.68%
		Total	5,156	76	1.47%

Appendix D-6
SOA 1984-99 Long Term Care Intercompany Study
Incidence Rates by Elimination Period, Attained Age, and Maximum Benefit Per Day

	Attained Age				
Elimination Period	l Group	Benefit Per Day	Exposure	Claims	Rate
All Periods	Less than 40	< \$100	297,568	35	0.01%
		\$100	40,411	12	0.03%
		>\$100	66,108	35	0.05%
		Total	404,087	82	0.02%
	40-49	< \$100	274,276	59	0.02%
		\$100	77,276	56	0.07%
		> \$100	131,648	70	0.05%
		Total	483,200	185	0.04%
	50-59	< \$100	345,817	204	0.06%
		\$100	168,119	106	0.06%
		> \$100	223,665	113	0.05%
		Total	737,601	423	0.06%
	60-64	< \$100	333,103	473	0.14%
		\$100	168,776	151	0.09%
		> \$100	137,902	124	0.09%
		Total	639,781	748	0.12%
	65-69	< \$100	748,108	2,011	0.27%
		\$100	286,032	436	0.15%
		>\$100	193,954	318	0.16%
		Total	1,228,094	2,765	0.23%
	70-74	< \$100	1,173,490	5,949	0.51%
		\$100	295,321	835	0.28%
		> \$100	183,851	592	0.32%
		Total	1,652,662	7,376	0.45%
	75-79	< \$100	1,156,644	10,941	0.95%
		\$100	193,138	1,074	0.56%
		> \$100	107,536	625	0.58%
		Total	1,457,318	12,640	0.87%
	80-84	< \$100	756,117	11,578	1.53%
		\$100	80,249	831	1.04%
		>\$100	48,548	557	1.15%
		Total	884,914	12,966	1.47%
	Ages 85+	< \$100	393,894	6,845	1.74%
		\$100	22,782	308	1.35%
		> \$100	18,265	239	1.31%
		Total	434,941	7,392	1.70%

Appendix D-7
SOA 1984-99 Long Term Care Intercompany Study
Comparison of Incidence Rates to 1985 NNHS
Incidence Rates by Elimination Period and Attained Age

Elimination Period	Attained Age Group	Exposure	Claims	Rate	Both Sexes Rate	Study/Survey
0	Less than 60	23,332	30	0.13%	0.11%	1.169
	60-64	49,149	139	0.28%	0.27%	1.047
	65-69	171,082	1,005	0.59%	0.59%	0.996
	70-74	271,377	2,810	1.04%	1.32%	0.784
	75-79	251,739	4,718	1.87%	3.01%	0.623
	80-84	147,237	4,261	2.89%	6.20%	0.467

Incidence Rates by Elimination Period and Attained Age - Females

Elimination Period	Attained Age Group	Exposure	Claims	Rate	Both Sexes Rate	Study/Survey
0	Less than 60	16,250	19	0.12%	0.08%	1.462
	60-64	34,424	99	0.29%	0.27%	1.065
	65-69	110,818	642	0.58%	0.72%	0.805
	70-74	168,757	1,717	1.02%	1.36%	0.748
	75-79	160,126	2,969	1.85%	3.02%	0.614
	80-84	97,645	2,861	2.93%	6.65%	0.441

Incidence Rates by Elimination Period and Attained Age - Males

Elimination Period	Attained Age Group	Exposure	Claims	Rate	Both Sexes Rate	Study/Survey
0	Less than 60	7,082	11	0.16%	0.14%	1.109
	60-64	14,723	40	0.27%	0.27%	1.006
	65-69	60,264	363	0.60%	0.43%	1.401
	70-74	102,618	1,093	1.07%	1.28%	0.832
	75-79	91,613	1,749	1.91%	2.99%	0.639
	80-84	49,592	1,400	2.82%	5.36%	0.527

Appendix E-1 SOA 1984-99 Long Term Care Intercompany Study Percentage Persisting at Least n Days by Elimination Period

Number N			0 Day Elimination Period				7-50 Day Elimination Period				60-150 Day Elimination Period					
Page									.					.		Percentage
1,746 1,766 1,466 148 148 149	Days															Persisting n Days
1,746 1,766 1,466 148 148 149	1	1.764	12.777	14.541	27	99.81%	1.716	19.260	20.976	72	99.66%	2.241	10.644	12.885	10	99.92%
1,744 12,611 13,775 128 77.09 17.10 19.007 20.0021 142 17.00 10.000 12.000 1	2															99.80
1.784 1.285 1.28																99.64
1,764 1,274																99.48
1,794																99.27 99.07
1,746	7				166	95.10				137						98.87
1.764		-														98.65
11 1,744																98.42 98.17
1.76																97.94
1,776	12	1,764	11,520	13,284	130	90.46	1,712	17,797	19,509	114	92.48	2,228	10,379	12,606	19	97.79
1.78																97.58
1.78																97.37 97.14
1,782		-														96.91
19	17								18,888					12,470		96.72
1,781																96.50
1,799																96.23 96.06
1.752 1.75																94.96
1.75 8.846 10.597 65 7.51 1,667 14.681 16.48 71 78.63 2.190 9.044 11.834 32 32 33 34 34 35 34 34 35 34 34																93.95
14																93.01 91.97
1,743 8,291 1,0034 53 68,77 1,690 14,150 1,640 77 75,26 2,164 9,386 11,1569 17 17 18 18 18 18 18 18		-														90.91
Bo	50				53	68.77				77	75.26				17	90.08
Fig. 1,766 7,712 9,447 41 64.86 1.679 12,033 14,881 62 70.81 2,167 9,061 11,216 17 17,77 7,553 8,279 18 83.27 1,676 12,338 14,612 59 68.42 2,147 8,861 10,987 7 7 7,775																89.14
1.727 7.583 8.279 18																88.30 87.47
To 1,725																86.68
1.716	75		7,413	9,138							68.42					85.98
100		-														85.17
120																84.39 83.54
180																79.47
1.1 1.50	150		6,138	7,775	13	54.16	1,615	10,243	11,858	23		1,907	7,563	9,467	12	75.76
1,426																72.73
1,366		-														69.89 67.11
1,240																64.65
1,191		-														62.32
1,099																60.32 58.53
420 1,061 3,635 4,695 5 40,65 1,125 5,904 7,027 7 39,72 1,248 4,404 5,651 3 450 1,014 3,490 4,500 3 39,88 1,071 5,657 6,724 4 38,62 1,182 4,221 5,400 3 510 935 3,244 4,177 1 38,38 984 5,272 6,251 4 36,66 1,095 3,927 5,018 2 570 869 3,132 4,029 0 37,58 941 5,080 6,018 5 3,631 1,041 3,785 4,824 4 600 850 2,982 3,810 2 36,22 896 4,914 5,810 8 34,72 992 3,631 4,439 4 600 850 2,982 3,813 3,624 4,819 4,788 5,613 10 33,81 4,239 4 4,899 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>56.54</td></th<>																56.54
480 973 3,350 4,318 2 39.05 1,027 5,443 6,470 6 37.53 1,131 4,078 5,209 6 510 935 3,244 4,177 1 38.38 984 5,272 6,251 4 36.66 1,095 3,927 5,018 2 570 869 3,048 3,917 1 36.92 896 4,914 5,810 8 34.72 992 3,631 4,620 6 600 850 2,962 3,810 2 36.23 857 4,788 5,613 10 33.81 935 3,504 4,439 4 660 76 2,804 3,579 1 34.83 795 4,439 5,233 8 31.94 859 3,240 4,098 3 690 731 2,724 3,453 1 34.16 757 4,292 5,048 2 31.11 817 3,126 3,940																54.82
510 935 3,244 4,177 1 38,38 984 5,272 6,251 4 36,66 1,095 3,927 5,018 2 540 897 3,132 4,029 0 37,58 941 5,000 6,018 5 35,63 1,041 3,785 4,824 4 600 850 2,962 3,810 2 36,23 867 4,758 5,613 10 33,81 935 3,504 4,439 4 630 813 2,881 3,690 2 35,52 827 4,589 5,416 2 32,86 898 3,377 4,272 5 690 771 2,724 3,453 1 34,16 757 4,292 5,048 2 31,11 817 3,126 3,940 2 720 707 2,664 3,370 2 33,59 723 4,151 4,873 8 30,24 70 3,033 3,783																53.28
540 897 3,132 4,029 0 37.58 941 5,080 6,018 5 35.63 1,041 3,785 4,824 4 570 869 3,048 3,917 1 36.92 886 4,914 5,810 8 34.72 992 3,631 4,620 6 600 850 2,962 3,810 2 36.23 857 4,758 5,613 10 33.81 935 3,504 4,439 4 630 813 2,881 3,690 2 35.52 827 4,589 5,416 2 32.86 898 3,377 4,4272 5 660 776 2,804 3,579 1 34.83 795 4,439 5,233 8 31.94 859 3,240 4,098 3 690 731 2,724 3,453 1 34.16 757 4,292 5,048 2 31.11 817 3,126 3,724																52.01 50.64
600 850 2,962 3,810 2 36,23 857 4,758 5,613 10 33,81 935 3,504 4,439 4 630 813 2,881 3,690 2 35,52 827 4,589 5,416 2 32,86 898 3,377 4,272 5 660 776 2,804 3,579 1 34,83 795 4,439 5,233 8 31,94 859 3,240 4,098 3 690 731 2,724 3,453 1 34,16 757 4,292 5,048 2 31,11 817 3,126 3,940 2 720 707 2,664 3,370 2 33,59 723 4,151 4,873 8 30,24 780 30,03 3,783 4 750 659 2,527 3,181 1 33,01 692 3,841 4,631 4 29,39 734 2,626 3,354																49.22
630 813 2,881 3,690 2 35.52 827 4,589 5,416 2 32.86 898 3,377 4,272 5 660 776 2,804 3,579 1 34.83 795 4,439 5,233 8 31.94 859 3,240 4,098 3 690 731 2,724 3,453 1 34.16 757 4,292 5,048 2 31.11 817 3,126 3,940 2 750 659 2,527 3,181 1 33.01 692 3,841 4,531 4 29.39 734 2,626 3,354 5 780 629 2,422 3,050 1 32.40 656 3,654 4,308 4 28.58 690 2,471 3,158 5 810 609 2,344 2,950 0 31.84 626 3,520 4,142 4 27.85 654 2,372 3,025 <																47.69
660 776 2,804 3,579 1 34.83 795 4,439 5,233 8 31.94 859 3,240 4,098 3 690 731 2,724 3,453 1 34.16 757 4,292 5,048 2 31.11 817 3,126 3,940 2 750 659 2,527 3,181 1 33.01 692 3,841 4,531 4 29.39 734 2,626 3,354 5 780 629 2,422 3,050 1 32.40 656 3,654 4,308 4 28.58 690 2,471 3,158 5 810 609 2,344 2,950 0 31.84 626 3,520 4,142 4 27.85 654 2,372 3,025 1 840 584 2,280 2,863 1 31.27 591 3,403 3,993 6 27.11 629 2,283 2,911 <																46.44 45.12
690 731 2,724 3,453 1 34.16 757 4,292 5,048 2 31.11 817 3,126 3,940 2 720 707 2,664 3,370 2 33.59 723 4,151 4,873 8 30.24 780 3,003 3,783 4 750 659 2,527 3,181 1 33.01 692 3,841 4,531 4 29.39 734 2,626 3,354 5 780 629 2,422 3,050 1 32.40 666 3,654 4,308 4 28.58 690 2,471 3,158 5 810 609 2,344 2,950 0 31.84 626 3,520 4,142 4 27.85 654 2,372 3,025 1 840 584 2,280 2,863 1 31.27 551 3,493 3,993 6 27.11 629 2,283 2,911 <																45.12 43.73
750 659 2,527 3,181 1 33.01 692 3,841 4,531 4 29.39 734 2,626 3,354 5 780 629 2,422 3,050 1 32.40 666 3,654 4,308 4 28.88 690 2,471 3,158 5 810 609 2,344 2,950 0 31.84 626 3,520 4,142 4 27.85 654 2,372 3,025 1 840 584 2,280 2,863 1 31.27 591 3,403 3,993 6 27.11 629 2,283 2,911 4 870 553 2,211 2,762 0 30.72 552 3,298 3,849 6 26.46 588 2,192 2,778 0 900 524 2,148 2,668 1 30.13 521 3,193 3,714 7 25.80 564 2,134 2,698 <																42.56
780 629 2,422 3,050 1 32.40 656 3,654 4,308 4 28.58 690 2,471 3,158 5 810 609 2,344 2,950 0 31.84 626 3,520 4,142 4 27.85 654 2,372 3,025 1 840 584 2,280 2,863 1 31.27 591 3,403 3,993 6 27.11 629 2,283 2,911 4 870 553 2,211 2,762 0 30.72 552 3,298 3,849 6 26.46 588 2,192 2,778 0 900 524 2,148 2,668 1 30.13 521 3,193 3,714 7 25.80 564 2,134 2,698 0 930 492 2,093 2,583 7 29.55 489 3,062 3,551 1 24.99 537 2,059 2,596 <																41.23
810 609 2,344 2,950 0 31.84 626 3,520 4,142 4 27.85 654 2,372 3,025 1 840 584 2,280 2,863 1 31.27 591 3,403 3,993 6 27.11 629 2,283 2,911 4 870 553 2,211 2,762 0 30.72 552 3,298 3,849 6 26.46 588 2,192 2,778 0 900 524 2,148 2,668 1 30.13 521 3,193 3,714 7 25.80 564 2,134 2,698 0 930 492 2,093 2,583 7 29.55 489 3,062 3,551 1 24.99 537 2,059 2,596 3 960 463 2,036 2,497 0 29.10 481 2,961 3,421 2 24.33 505 1,990 2,494 <																39.87 38.74
840 584 2,280 2,863 1 31,27 591 3,403 3,993 6 27,11 629 2,283 2,911 4 870 553 2,211 2,762 0 30.72 552 3,298 3,849 6 26,46 588 2,192 2,778 0 900 524 2,148 2,688 1 30.13 521 3,193 3,714 7 25.80 564 2,134 2,698 0 930 492 2,093 2,583 7 29.55 489 3,062 3,551 1 24.99 537 2,059 2,596 3 960 463 2,036 2,497 0 29.10 461 2,961 3,421 2 24.33 505 1,990 2,494 0 990 440 1,975 2,415 3 28.48 437 2,864 3,300 6 23.67 471 1,928 2,399 <																38.74
900 524 2,148 2,668 1 30.13 521 3,193 3,714 7 25.80 564 2,134 2,698 0 930 492 2,093 2,583 7 29.55 489 3,062 3,551 1 24.99 537 2,059 2,596 3 960 463 2,036 2,497 0 29.10 461 2,961 3,421 2 24.33 505 1,990 2,494 0 990 440 1,975 2,415 3 28.48 437 2,864 3,300 6 23.67 471 1,928 2,399 2 1020 417 1,908 2,324 2 27.85 417 2,767 3,183 0 23.07 451 1,851 2,302 5 1050 399 1,857 2,255 1 27.33 389 2,684 3,072 4 22.49 418 1,774 2,190																36.84
930																35.92
960 463 2,036 2,497 0 29.10 461 2,961 3,421 2 24.33 505 1,990 2,494 0 990 440 1,975 2,415 3 28.48 437 2,864 3,300 6 23.67 471 1,928 2,399 2 1020 417 1,908 2,324 2 27.85 417 2,767 3,183 0 23.07 451 1,851 2,302 5 1050 399 1,857 2,255 1 27.33 389 2,684 3,072 4 22.49 418 1,774 2,190 3 1080 380 1,797 2,176 2 26.67 366 2,565 2,930 4 21.66 395 1,684 2,078 0 1095 372 1,763 1,924 0 26.31 354 2,507 2,645 3 21.25 384 1,655 1,932																35.25 34.25
990 440 1,975 2,415 3 28.48 437 2,864 3,300 6 23.67 471 1,928 2,399 2 1020 417 1,908 2,324 2 27.85 417 2,767 3,183 0 23.07 451 1,851 2,302 5 1050 399 1,867 2,255 1 27.33 389 2,684 3,072 4 22.49 418 1,774 2,190 3 1080 380 1,797 2,176 2 26.67 366 2,565 2,930 4 21.66 395 1,684 2,078 0 1095 372 1,763 1,924 0 26.31 354 2,507 2,645 3 21.25 384 1,655 1,932 2 1460 195 755 948 1 22.55 177 1,064 1,207 5 15.32 202 642 824																33.42
1050 399 1,857 2,255 1 27.33 389 2,684 3,072 4 22.49 418 1,774 2,190 3 1080 380 1,797 2,176 2 26.67 366 2,565 2,930 4 21.66 395 1,684 2,078 0 1095 372 1,763 1,924 0 26.31 35 2,507 2,645 3 21.25 384 1,655 1,932 2 1460 195 755 948 1 22.55 177 1,064 1,207 5 15.32 202 642 824 1 1825 115 509 618 0 19.68 97 455 547 0 9.61 98 315 409 0															2	32.61
1080 380 1,797 2,176 2 26.67 366 2,565 2,930 4 21.66 395 1,684 2,078 0 1095 372 1,763 1,924 0 26.31 354 2,507 2,645 3 21.25 384 1,655 1,932 2 1460 195 755 948 1 22.55 177 1,064 1,207 5 15.32 202 642 824 1 1825 115 509 618 0 19,68 97 455 547 0 9,61 98 315 409 0																31.57
1095 372 1,763 1,924 0 26.31 354 2,507 2,645 3 21.25 384 1,655 1,932 2 1460 195 755 948 1 22.55 177 1,064 1,207 5 15.32 202 642 824 1 1825 115 509 618 0 19,68 97 455 547 0 9,61 98 315 409 0																30.60 29.42
1460 195 755 948 1 22.55 177 1,064 1,207 5 15.32 202 642 824 1 1825 115 509 618 0 19.68 97 455 547 0 9.61 98 315 409 0																28.97
			755		1		177	1,064	1,207	5				824	1	21.09
219U 70 177 253 U 19:22 56 154 206 U 8:38 42 78 118 U																14.41
2555 51 100 151 0 18.85 35 62 97 0 7.45 20 28 48 0																12.77 11.38

Appendix E-2 SOA Long Term Care Intercompany Study Percentage Persisting at Least n Days by Gender

			Female					Male		
		Number of		Number	Percentage		Number of		Number	Percentage
Days	Number of Claims Open	Claims Closed	Beginning Exposure	Terminating on Day n	Persisting n Days	Number of Claims Open	Claims Closed	Beginning Exposure	Terminating on Day n	Persisting n Days
1	4,036	27,947	31,983	57	99.82%	1,717	14,793	16,510	56	99.66%
2	4,036	27,890	31,925	134	99.40	1,717	14,737	16,452	86	99.14
3	4,035	27,756	31,788	149	98.94	1,715	14,651	16,365	87	98.61
4 5	4,032 4,031	27,607 27,414	31,638 31,443	193 168	98.33 97.81	1,714 1,714	14,564 14,466	16,278 16,180	98 109	98.02 97.36
6	4,029	27,414	31,274	192	97.01	1,714	14,357	16,071	103	96.74
7	4,028	27,054	31,081	198	96.59	1,714	14,255	15,967	130	95.95
8	4,027	26,856	30,882	205	95.95	1,712	14,125	15,837	118	95.24
9 10	4,026 4,025	26,651	30,676	211 220	95.29 94.60	1,712 1,711	14,007	15,718	101 98	94.63 94.03
10	4,025	26,440 26,220	30,465 30,245	186	94.00	1,711	13,906 13,808	15,617 15,518	98	93.48
12	4,025	26,034	30,059	173	93.48	1,710	13,717	15,426	90	92.94
13	4,025	25,861	29,884	186	92.89	1,709	13,627	15,335	103	92.31
14	4,023	25,675	29,696	198	92.27	1,708	13,524	15,231	97	91.72
15 16	4,021 4,021	25,477 25,295	29,498 29,315	182 175	91.71 91.16	1,707 1,707	13,427 13,304	15,134 15,011	123 83	90.98 90.48
17	4,020	25,120	29,140	178	90.60	1,707	13,221	14,928	97	89.89
18	4,020	24,942	28,961	157	90.11	1,707	13,124	14,831	96	89.31
19	4,019	24,785	28,803	180	89.55	1,707	13,028	14,734	82	88.81
20 25	4,018 4,011	24,605 23,810	28,622 27,820	148 147	89.08 86.60	1,706 1,698	12,946 12,514	14,650 14,211	83 77	88.31 85.72
30	3,996	23,120	27,116	132	84.49	1,693	12,167	13,860	99	83.48
35	3,990	22,489	26,477	119	82.55	1,691	11,802	13,491	61	81.50
40	3,980	21,875	25,854	119	80.63	1,688	11,516	13,204	49	79.84
45 50	3,973 3,963	21,319 20.866	25,290 24,828	97 101	78.95 77.52	1,687 1,682	11,247 11,011	12,933 12,693	53 46	78.18 76.79
55	3,963	20,445	24,398	89	76.24	1,681	10,756	12,435	39	75.28
60	3,950	20,043	23,993	80	75.01	1,672	10,558	12,230	45	74.04
65	3,944	19,661	23,603	84	73.80	1,665	10,354	12,017	36	72.86
70	3,930	19,316	23,243	57 47	72.80	1,657	10,170	11,827	33 24	71.76
75 80	3,918 3,908	19,021 18,737	22,938 22,642	47 58	71.90 70.98	1,652 1,647	9,971 9,806	11,622 11,449	36	70.60 69.52
85	3,895	18,457	22,350	59	70.09	1,639	9,664	11,303	31	68.69
90	3,883	18,179	22,059	52	69.24	1,634	9,512	11,144	28	67.78
120	3,775	16,851	20,621	42	65.08	1,587	8,756	10,342	27	63.17
150 180	3,655 3,520	15,853 15,044	19,506 18,560	27 19	61.97 59.41	1,529 1,463	8,129 7,626	9,656 9,084	21 24	59.35 56.23
210	3,371	14,328	17,693	24	57.10	1,382	7,125	8,506	19	53.13
240	3,236	13,674	16,904	22	54.98	1,308	6,739	8,044	12	50.75
270	3,106	13,110	16,213	18	53.15	1,241	6,410	7,650	8	48.69
300 330	2,980 2,865	12,613 12,171	15,589 15,031	20 13	51.51 50.06	1,179 1,103	6,107 5,840	7,281 6,942	9 11	46.74 45.00
360	2,729	11,706	14,432	17	48.49	1,063	5,575	6,637	9	43.29
390	2,590	9,977	12,540	6	47.08	1,000	4,858	5,848	14	41.70
420	2,493	9,405	11,894	7	45.90	956	4,561	5,517	8	40.35
450 480	2,384 2,291	9,058 8,749	11,434 11,036	6 7	44.91 43.94	897 853	4,333 4,145	5,227 4,997	4 7	39.01 37.77
510	2,291	8,501	10,706	4	43.14	815	3,964	4,997	3	36.55
540	2,116	8,232	10,345	4	42.16	776	3,786	4,560	5	35.31
570	2,027	7,981	10,006	8	41.23	743	3,633	4,375	7	34.19
600	1,945	7,760 7,541	9,702 9,402	12	40.38	709	3,484	4,192	4	33.06 31.83
630 660	1,866 1,793	7,541 7,317	9,402	5 7	39.54 38.63	684 649	3,323 3,183	4,005 3,832	5	31.83
690	1,700	7,103	8,798	2	37.81	616	3,055	3,670	3	29.73
720	1,638	6,902	8,539	7	36.96	583	2,932	3,514	7	28.73
750	1,556	6,334	7,880	7	36.04	540	2,673	3,210	3	27.83
780 810	1,476 1,406	6,018 5,802	7,491 7,202	8 2	35.18 34.42	510 494	2,539 2,442	3,046 2,934	2	27.02 26.33
840	1,343	5,632	6,973	7	33.69	472	2,341	2,812	4	25.53
870	1,267	5,457	6,720	3	33.01	437	2,251	2,687	3	24.82
900	1,175	5,254	6,428	5	32.14	410	2,134	2,544	6	23.81
930 960	1,134 1,070	5,141 5,006	6,274 6,074	7 1	31.59 31.02	394 369	2,080 1,988	2,473 2,355	4	23.37 22.58
990	1,070	4,852	5,858	5	30.30	351	1,988	2,355	6	21.95
1020	961	4,688	5,648	5	29.54	334	1,845	2,178	2	21.30
1050	903	4,556	5,456	7	28.91	312	1,766	2,077	1	20.58
1080	857	4,374	5,228	2	28.03	293	1,679	1,972	4	19.73
1095 1460	831 438	4,292 1,856	4,727 2,252	5 5	27.59 21.63	288 142	1,640 608	1,790 736	0	19.39 13.61
1825	240	986	1,213	0	15.87	71	293	362	0	9.40
2190	139	334	469	0	14.72	35	75	108	0	8.29
2555	88	155	243	0	13.70	18	35	53	0	7.77

Appendix E-3 SOA 1984-99 Long Term Care Intercompany Study Percentage Persisting at Least n Days by Attained Age

Days Persisting n Days Persis	-	1			1	
Days Persisting n Days Persis						
Days Days Days Days Days 1 99.71% 99.78% 99.74% 99.82% 99.91% 2 99.32 99.31 99.27 99.46 99.39 3 99.12 98.61 98.79 99.21 98.95 4 98.83 97.81 98.2 98.77 98.4 98.67 5 98.34 96.93 97.67 98.4 98.61 99.71 19 86.62 97.11 99.24 98.79 99.24 93.34 96.2 97.11 19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.91 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 79.64 80.35 79.64		Percentage	Percentage	Percentage	Percentage	Percentage
1 99.71% 99.78% 99.74% 99.82% 99.91% 2 99.32 99.31 99.27 99.46 99.39 3 99.12 98.61 98.79 99.21 98.95 4 98.83 97.81 98.2 98.77 98.7 5 98.34 96.93 97.67 98.4 98.6 10 94.04 92.74 94.49 96.2 97.11 19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 80 69.61 </td <td></td> <td>Persisting n</td> <td>Persisting n</td> <td>Persisting n</td> <td>Persisting n</td> <td>Persisting n</td>		Persisting n				
2 99.32 99.31 99.27 99.46 99.39 3 99.12 98.61 98.79 99.21 98.95 4 98.83 97.81 98.2 98.77 98.77 5 98.34 96.93 97.67 98.4 98.6 10 94.04 92.74 94.49 96.2 97.11 19 38.96 86.74 89.39 92.04 93.34 20 38.77 86.15 88.9 91.71 93.17 25 36.23 83.04 86.41 39.73 91.94 30 33.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 85 68.33	Days	Days	Days	Days	Days	Days
3 99.12 98.61 98.79 99.21 98.95 4 98.83 97.81 98.2 98.77 98.77 5 98.34 96.93 97.67 98.4 98.6 10 94.04 92.74 94.49 96.2 97.11 19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33	1	99.71%	99.78%	99.74%	99.82%	99.91%
4 98.83 97.81 98.2 98.77 98.4 98.6 5 98.34 96.93 97.67 98.4 98.6 10 94.04 92.74 94.49 96.2 97.11 19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 150	2	99.32	99.31	99.27	99.46	99.39
5 98.34 96.93 97.67 98.4 98.6 10 94.04 92.74 94.49 96.2 97.11 19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 <td>3</td> <td>99.12</td> <td>98.61</td> <td>98.79</td> <td>99.21</td> <td>98.95</td>	3	99.12	98.61	98.79	99.21	98.95
10 94.04 92.74 94.49 96.2 97.11 19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 <td>4</td> <td>98.83</td> <td>97.81</td> <td>98.2</td> <td>98.77</td> <td>98.77</td>	4	98.83	97.81	98.2	98.77	98.77
19 88.96 86.74 89.39 92.04 93.34 20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89	5	98.34	96.93	97.67	98.4	98.6
20 88.77 86.15 88.9 91.71 93.17 25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17	10	94.04	92.74	94.49	96.2	97.11
25 86.23 83.04 86.41 89.73 91.94 30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31	19	88.96	86.74	89.39	92.04	93.34
30 83.79 80.32 84.33 88.07 90.27 60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 150 57.41 54.58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25	20	88.77	86.15	88.9	91.71	93.17
60 74.02 69.08 75.16 79.87 82.02 65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.16	25	86.23	83.04	86.41	89.73	91.94
65 72.84 67.63 73.98 78.79 81.67 70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.1	30	83.79	80.32	84.33	88.07	90.27
70 71.77 66.64 72.95 77.76 80.35 75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.3	60	74.02	69.08	75.16	79.87	82.02
75 70.88 65.51 71.99 76.83 79.64 80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.	65	72.84	67.63	73.98	78.79	81.67
80 69.61 64.54 71 75.92 79.02 85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 960 23.08 23.98 29 30.98 26.14 990 22.28	70	71.77	66.64	72.95	77.76	80.35
85 68.33 63.47 70.21 75.13 78.14 90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 <td>75</td> <td>70.88</td> <td>65.51</td> <td>71.99</td> <td>76.83</td> <td>79.64</td>	75	70.88	65.51	71.99	76.83	79.64
90 67.34 62.48 69.38 74.3 77.25 120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,050 21.61 </td <td>80</td> <td>69.61</td> <td>64.54</td> <td>71</td> <td>75.92</td> <td>79.02</td>	80	69.61	64.54	71	75.92	79.02
120 62.4 58 65.13 70.25 72.53 150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,080 21.	85	68.33	63.47	70.21	75.13	78.14
150 57.41 54.58 61.9 66.97 68.3 180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,080	90	67.34	62.48	69.38	74.3	77.25
180 53.58 51.79 59.22 64.18 65.29 360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 <	120	62.4	58	65.13	70.25	72.53
360 38.89 40.69 47.8 51.77 52.44 750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,460 15.86 16.37 19.38 20.23 12.52 1,825	150	57.41	54.58	61.9	66.97	68.3
750 27.17 28.26 34.19 37.28 35.43 780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,460 15.86 16.37 19.38 20.23 12.52 1,825 </td <td>180</td> <td>53.58</td> <td>51.79</td> <td>59.22</td> <td>64.18</td> <td>65.29</td>	180	53.58	51.79	59.22	64.18	65.29
780 26.31 27.73 33.29 36.07 33.97 810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 </td <td>360</td> <td>38.89</td> <td>40.69</td> <td>47.8</td> <td>51.77</td> <td>52.44</td>	360	38.89	40.69	47.8	51.77	52.44
810 25.55 27.04 32.55 35.36 32.42 840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	750	27.17	28.26	34.19	37.28	35.43
840 25.16 26.44 31.8 34.11 31.63 870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	780	26.31	27.73	33.29	36.07	33.97
870 24.39 25.94 31.09 33.09 30.82 900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	810	25.55	27.04	32.55	35.36	32.42
900 23.87 25.42 30.4 32.57 29.14 930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	840	25.16	26.44	31.8	34.11	31.63
930 23.48 24.63 29.62 31.71 26.75 960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	870	24.39	25.94	31.09	33.09	30.82
960 23.08 23.98 29 30.98 26.14 990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	900	23.87	25.42	30.4	32.57	29.14
990 22.28 23.45 28.3 30.04 25.48 1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	930	23.48	24.63	29.62	31.71	26.75
1,020 22.02 22.91 27.51 29.27 24.82 1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	960	23.08	23.98	29	30.98	26.14
1,050 21.61 22.34 26.81 28.58 24.48 1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	990	22.28	23.45	28.3	30.04	25.48
1,080 21.19 21.6 25.86 27.94 22.73 1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	1,020	22.02	22.91	27.51	29.27	24.82
1,095 21.04 21.33 25.41 27.38 22.37 1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	1,050	21.61	22.34	26.81	28.58	24.48
1,460 15.86 16.37 19.38 20.23 12.52 1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	1,080	21.19	21.6	25.86	27.94	22.73
1,825 12.19 12.49 14.2 10.17 3.37 2,190 12.19 11.29 13.12 7.78 .	1,095	21.04	21.33	25.41	27.38	22.37
2,190 12.19 11.29 13.12 7.78	1,460	15.86	16.37	19.38	20.23	12.52
	1,825	12.19	12.49	14.2	10.17	3.37
2,555 11.66 10.01 12.78 5.14.	2,190	12.19	11.29	13.12	7.78	
	2,555	11.66	10.01	12.78	5.14	

Appendix E-4
SOA 1984-99 Long Term Care Intercompany Study

		Per	centage Persist	ting at Least n D	Days - LTC Int	ercompany Stu	udy versus 1985	5 National Nurs	sing Home Sur	vey		
		Age 55-64		Age 65-74			Age 75-84		Age 85+			
	Current	1985 NH	Ratio Study/	Current	1985 NH	Ratio Study/	Current	1985 NH	Ratio Study/	Current	1985 NH	Ratio Study/
Days	Study	Survey	Survey	Study	Survey	Survey	Study	Survey	Survey	Study	Survey	Survey
0	100%	100%	1.000	100%	100%	1.000	100%	100%	1.000	100%	100%	1.000
10	94.0	93.3	1.008	92.7	91.3	1.015	94.5	91.5	1.033	96.3	90.5	1.064
20	88.8	84.7	1.048	86.2	83.8	1.029	88.9	83.2	1.069	91.9	82.3	1.117
30	83.8	80.1	1.046	80.3	76.7	1.047	84.3	75.6	1.116	88.4	76.7	1.152
60	74.0	67.6	1.095	69.1	63.9	1.081	75.2	63.9	1.176	80.2	65.3	1.228
90	67.3	59.1	1.139	62.5	55.3	1.130	69.4	55.8	1.243	74.7	57.3	1.304
121	62.4	53.2	1.172	57.9	49.3	1.173	65.0	50.0	1.300	70.5	51.6	1.366
151	57.3	49.1	1.168	54.5	45.1	1.207	61.8	45.8	1.351	67.1	47.4	1.415
182	53.6	46.0	1.164	51.6	42.1	1.226	59.1	42.6	1.388	64.1	44.3	1.449
212	49.4	43.8	1.129	49.1	40.0	1.230	56.5	40.1	1.410	61.6	41.8	1.472
243	46.4	42.0	1.105	46.9	38.3	1.223	54.4	38.1	1.428	59.3	39.9	1.485
273	43.7	40.6	1.077	44.8	37.1	1.210	52.5	36.5	1.440	57.3	38.3	1.494
304	42.2	39.3	1.074	43.1	36.0	1.197	50.7	35.0	1.448	55.5	37.0	1.500
334	40.3	38.1	1.058	41.9	35.1	1.192	49.2	33.8	1.456	53.8	35.8	1.503
365	38.8	36.9	1.051	40.3	34.3	1.176	47.4	32.6	1.452	51.5	34.7	1.485
547	32.2	29.4	1.095	33.9	29.0	1.170	40.6	26.8	1.514	44.7	28.7	1.555
730	27.3	24.2	1.128	28.8	23.2	1.243	34.7	22.1	1.575	38.2	23.3	1.640
912	23.6	21.6	1.093	25.1	19.1	1.319	30.0	18.0	1.665	31.9	18.5	1.727
1095	21.0	19.5	1.078	21.3	16.2	1.320	25.4	14.6	1.742	26.8	14.7	1.821
1277	18.4	17.4	1.060	19.1	13.7	1.398	22.7	11.9	1.900	23.1		
1460	15.9			16.4	11.6	1.406	19.4	9.8	1.980	19.3		
1642	13.6			13.9	10.3	1.348	16.0	7.9	2.032	11.2		

APPENDIX F-1

SOA 1984-99 Long Term Care Intercompany Study

Lapse Rates by Issue Year Group, Policy Type and Duration

(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Policy Type

			Individual			Group			All Types	
Issue Year Group	Duration	Exposure	Lapses	Rate	Exposure	Lapses	Rate	Exposure	Lapses	Rate
1984-87	1	154,066	16,932	10.99%	34,279	3,743	10.91%	188,345	20,675	10.97%
100101	2	134,640	12,609	9.36%	,	2,728		,	15,337	
	3	120,065	12,481	10.39%		1,625		,	14,106	
	4	105,485	13,010	12.33%	,	1,284		,	14,294	
	5	90,471	9,294		,	1,019		,	10,313	
	6	79,071	5,322			91			5,413	
	7	69,632	4,147	5.95%		25			4,172	
	8	54,073	3,716					,	3,752	
	9	35,420	2,773					,	2,773	
	10	28,462	2,075						2,075	
	11	23,709	1,679			1				
	12	19,899	1,469		2	0	0.00%	19,901	1,469	
	13	8,029	658	8.19%	. 1	0	0.00%	8,030	658	8.19%
	14	1,156	133	11.50%			-	1,156	133	11.50%
	15	1	0	0.00%				1	0	0.00%
	Total	924,179	86,298	9.33%	142,324	10,552	7.41%	1,066,503	96,850	9.08%
1988-91	1	530,954	61,585	11.59%	200,359	23,450	11.70%	731,313	85,035	11.62%
.000 0 .	2	459,632	38,854			12,093			50,947	
	3	406,924	27,353			8,466		,	35,819	
	4	350,091	18,028		,	4,867		,	22,895	
	5	258,741	12,132		,	2,175		,	14,307	
	6	175,858	9,157	5.20%		1,366			10,523	
	7	111,048	6,305		,	704		,	7,009	
	8	86,645	4,266			488	1.45%	120,120	4,754	3.95%
	9	64,556	2,782	4.30%	24,776	324	1.30%	89,332	3,106	3.47%
	10	43,517	1,835	4.21%	1,061	37	3.48%	44,578	1,872	4.19%
	11	19,604	854	4.35%	794	7	0.88%	20,398	861	4.22%
	Total	2,507,570	183,151	7.30%	853,597	53,977	6.32%	3,361,167	237,128	7.05%
1992-95	1	509,135	50,555	9.92%	212,634	30,813	14.49%	721,769	81,368	11.27%
	2	348,201	26,249	7.53%		18,247		,	44,496	
	3	230,663	16,760	7.26%		11,850			28,610	
	4	157,445	10,602	6.73%	116,562	8,843	7.58%	274,007	19,445	7.09%
	5	95,520	5,185	5.42%	83,872	5,629	6.71%	179,392	10,814	6.02%
	6	54,957	2,688	4.89%	49,858	3,464	6.94%	104,815	6,152	5.86%
	7	24,815	1,078	4.34%	12,581	608	4.83%	37,396	1,686	4.50%
	Total	1,420,736	113,117	7.96%	778,365	79,454	10.20%	2,199,101	192,571	8.75%
1996-98	1	299,059	29,929		,	34,977		,	64,906	
	2	156,118	11,649		,	12,681		,	24,330	
	3	69,014	4,158	6.02%	36,282	3,864	10.64%	105,296	8,022	7.61%
	Total	524,191	45,736	8.72%	297,723	51,522	17.30%	821,914	97,258	11.83%
Grand Total		5,376,676	428,302	7.97%	2,072,009	195,505	9.44%	7,448,685	623,807	8.37%

APPENDIX F-2

SOA 1984-99 Long Term Care Intercompany Study

Lapse Rates by Issue Age Group and Duration
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Age Group	Duration	Exposure	Lapses	Rate
Under 50	1	345,736	60,283	17.43%
	2	233,711	•	
	3	163,700		
	4	119,199		
	5	85,091	5,928	
	6	56,797	3,654	6.43%
	7	25,246	1,010	4.00%
	8	17,856	385	2.15%
	9	13,982	238	1.70%
	10	1,044	51	4.88%
	11	531	11	2.07%
	12	12		0.00%
	13	3		
	14	2		
	15	1	0	0.00%
	Total	1,062,911	127,952	12.03%
50-54	1	105,767	10,668	10.08%
00 04	2	76,117		
	3	56,092		
	4	40,546		
	5	28,372		
	6	19,012		
	7	10,599		
	8	7,673		
	9	6,036		
	10	1,307		
	11	610		
	12	27	2	7.40%
	13	1	0	0.00%
	Total	352,159	24,727	7.02%
55-59	1	155,548	14,292	9.18%
	2	112,948	7,741	6.85%
	3	85,255	5,000	5.86%
	4	63,301	2,985	
	5	43,454		
	6	26,865		
	7	15,303		
	8	10,495		
	9	7,570		2.36%
	10	3,167		
	11	1,786		
	12	497		
	13	132		
	14	12	0	0.00%
	Total	526,333	33,851	6.43%

60-64	1	325,808	32,084	9.84%
	2	241,614	18,808	7.78%
	3	183,412	12,710	6.92%
	4	136,823	8,179	5.97%
	5	95,448	4,636	4.85%
	6	59,766	2,630	4.40%
	7	36,437	1,535	4.21%
	8	24,598	1,047	4.25%
	9	17,571	644	3.66%
	10	11,812	449	3.80%
	11	7,449	272	3.65%
	12	3,509	181	5.15%
	13	1,142	57	4.99%
	14	104	13	12.50%
	17	104	10	12.0070
	Total	1,145,493	83,245	7.26%
65-69	1	506,380	51,043	10.07%
00 00	2	385,868	29,945	7.76%
	3	298,843	20,957	7.01%
	4	228,838	14,763	6.45%
	5	165,074	9,289	5.62%
	6	110,020	5,629	5.11%
	7	71,659	3,696	5.15%
	8	48,778	2,548	5.22%
	9			
		34,480	1,776	5.15%
	10	24,570	1,130	4.59%
	11	15,371	758	4.93%
	12	7,708	444	5.76%
	13	3,209	201	6.26%
	14	445	36	8.08%
	Total	1,901,243	142,215	7.48%
70-74	1	371,927	42,831	11.51%
	2	276,706	22,782	8.23%
	3	212,098	15,367	7.24%
	4	159,847	10,789	6.74%
	5	115,352	6,946	6.02%
	6	78,809	4,318	5.47%
	7	52,249	3,006	5.75%
	8	35,814	2,011	5.61%
	9	24,826	1,423	5.73%
	10	17,295	962	5.56%
	11	10,268	658	6.40%
	12	4,575	358	7.82%
	13	1,990	183	9.19%
	14	299	34	11.37%
	•		3.	70
	Total	1,362,055	111,668	8.19%

75-79	1	229,620	30,253	13.17%
	2	167,916	14,805	8.81%
	3	127,932	9,364	7.31%
	4	96,761	6,268	6.47%
	5	70,640	4,159	5.88%
	6	49,895	2,756	5.52%
	7	34,448	1,916	5.56%
	8	24,332	1,481	6.08%
	9	16,673	1,030	6.17%
	10	11,422	840	7.35%
	11	6,677	516	7.72%
	12	2,968	316	10.64%
	13	1,312	148	11.28%
	14	234	35	14.95%
	Total	840,830	73,887	8.78%
80-84	1	72,070	10,094	14.00%
	2	50,908	4,524	8.88%
	3	37,734	2,806	7.43%
	4	27,368	1,902	6.94%
	5	19,213	1,456	7.57%
	6	12,720	1,116	8.77%
	7	7,933	764	9.63%
	8	5,042	559	11.08%
	9	3,331	424	12.72%
	10	2,237	323	14.43%
	11	1,300	244	18.76%
	12	541	126	23.29%
	13	216	55	25.46%
	14	55	12	21.81%
	14	33	12	21.01/0
	Total	240,668	24,405	10.14%
85-89	1	3,832	406	10.59%
	2	2,821	211	7.47%
	3	2,294	151	6.58%
	4	1,862	133	7.14%
	5	1,460	156	10.68%
	6	1,042	146	14.01%
	7	658	111	16.86%
	8	364	78	21.42%
	9	250	70	28.00%
	10	166	48	28.91%
	11	108	23	21.29%
	12	60	20	33.33%
	13	23	11	47.82%
	14	5	3	60.00%
	Total	14,945	1,567	10.48%

00		400	00	0.070/
90 and Over	1	430	30	6.97%
	2	377	32	8.48%
	3	333	31	9.30%
	4	283	34	12.01%
	5	228	39	17.10%
	6	169	46	27.21%
	7	100	34	34.00%
	8	53	15	28.30%
	9	36	9	25.00%
	10	23	12	52.17%
	11	10	5	50.00%
	12	4	1	25.00%
	13	2	2	100.00%
	Total	2,048	290	14.16%
All Ages	1	2,117,118	251,984	11.90%
_	2	1,548,986	135,110	8.72%
	3	1,167,693	86,557	7.41%
	4	874,828	56,634	6.47%
	5	624,332	35,434	5.67%
	6	415,095	22,088	5.32%
	7	254,632	12,867	5.05%
	8	175,005	8,506	4.86%
	9	124,755	5,879	4.71%
	10	73,043	3,947	5.40%
	11	44,110	2,541	5.76%
	12	19,901	1,469	7.38%
	13	8,030	658	8.19%
	14	1,156	133	11.50%
	15	1,100	0	0.00%
	10	'	O	0.0070
	Total	7,448,685	623,807	8.37%

APPENDIX F-3

SOA 1984-99 Long Term Care Intercompany Study

Lapse Rates by Type of Underwriting, Policy Type and Duration (Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Policy Type

			Inividual			Group			All Types	
Type of Underwriting	Duration	Exposure	Lapses	Rate	Exposure	Lapses	Rate	Exposure	Lapses	Rate
Full	1	1,173,180	116,052	9.89%	116,621	11,019	9.44%	1,289,801	127,071	9.85%
i uii	2	855,562	62,438	7.29%		5,470	5.97%		,	
	3	630,104	40,198	6.37%	75.532		5.16%			
	4	451,075	25,747	5.70%	-,	-,	3.10%			
	5	310,257	15,874	5.11%			3.11%			
	6	204,745	11,186	5.46%						
	7	126,540	6,887	5.44%		401	2.07%		7,288	
	8	80,071	4,154	5.18%						
	9	53,358	2,535	4.75%		134				
	10	33,077	1,664	5.03%						
	11	14,101	784	5.55%	796					
	12	1,877	264							
	13	974	152			ŭ		974		
	14	422	63	14.92%		-	•	422		
	15	1	0	0.00%				1		
	Total	3,935,344	287,998	7.31%	470,158	25,885	5.50%	4,405,502	313,883	7.12%
Simplified	1	206,468	35,905	17.39%	101,069	12,027	11.89%	307,537	47,932	15.58%
	2	164,437	22,510	13.68%	76,686	6,027	7.85%	241,123	28,537	11.83%
	3	137,821	16,332	11.85%	63,119	3,709	5.87%	200,940	20,041	9.97%
	4	117,510	11,908	10.13%	52,227	2,530	4.84%	169,737	14,438	8.50%
	5	100,862	7,781	7.71%	24,126	980	4.06%	124,988	8,761	7.00%
	6	79,695	3,869	4.85%	2,984	83	2.78%	82,679	3,952	4.77%
	7	58,839	3,086	5.24%	2,121	28	1.32%	60,960	3,114	5.10%
	8	43,613	2,557	5.86%	2,087	19	0.91%	45,700	2,576	5.63%
	9	30,960	1,885	6.08%	2,019	23	1.13%	32,979	1,908	5.78%
	10	24,497	1,264	5.15%	•	-		24,497	1,264	5.15%
	11	16,621	811	4.87%	•	-		16,621	811	4.87%
	12	8,998	451	5.01%				8,998	451	5.01%
	13	3,980	228	5.72%	•	-		3,980	228	5.72%
	14	443	33	7.44%		•	•	443	33	7.44%
	Total	994,744	108,620	10.91%	326,438	25,426	7.78%	1,321,182	134,046	10.14%
Guaranteed	1	ė			369,112		17.13%			
	2		•	•	252,770					
	3	•		•	177,916		9.36%			
	4	•		•	128,783	,		,		
	5	•		•	93,552					
	6		•	•	60,984		5.78%			
	7		•	•	25,508					
	8		•	•	18,699					
	9	•		•	15,719		1.06%			
	10		•	•	2					
	11		•	•	1				0	
	12		•	•	1				0	
	13				1	0	0.00%	1	0	0.00%
	Total				1,143,048	131,492	11.50%	1,143,048	131,492	11.50%
Other	1	27,156	2,119	7.80%	36,924	6,641	17.98%	64,080	8,760	13.67%
	2	14,057	767	5.45%	29,329		10.33%			
	3	6,675			,	,				
	4	3,438		3.17%						
	5	1,979			12,573					
	6	504	13		7,523					
	7	9	0	0.00%			2.32%			
	8	1	0	0.00%	809					
	Total	53,819	3,369	6.25%	132,069	12,623	9.55%	185,888	15,992	8.60%

APPENDIX F-4
SOA 1984-99 Long Term Care Intercompany Study
Lapse Rates by Gender and Duration
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Gender	Duration	Exposure	Lapses	Rate
Male	1	847,342	99,895	11.78%
Wale	2	616,936		8.61%
	3	462,610		
	4	342,595		
	5	241,598		
	6	159,086	•	
	7	92,843		4.74%
	8	62,555		
	9	44,738		
	10	23,800		
	11	14,012	821	5.85%
	12	5,992	450	7.51%
	13	2,148	181	8.42%
	14	260	33	12.69%
	15	1	0	0.00%
		2,916,516	240,969	8.26%
Female	1	1,263,337	151,126	11.96%
	2	929,092		8.77%
	3	703,821	52,973	
	4	531,431	34,982	
	5	382,280		
	6	255,832		
	7	161,782		
	8	112,447		
	9	80,016		4.89%
	10	49,242	2,718	5.51%
	11	30,098	1,720	5.71%
	12	13,909	1,019	7.32%
	13	5,882	477	8.10%
	14	896	100	11.16%
	Total	4,520,065	381,065	8.43%
All Genders	1	2,110,679	251,021	11.89%
	2	1,546,028		
	3	1,166,431	86,352	
	4	874,026	56,511	6.46%
	5	623,878		5.67%
	6	414,918		
	7	254,625		
	8	175,002	8,506	4.86%
	9	124,754	5,879	4.71%
	10	73,042	3,947	5.40%
	11	44,110		5.76%
	12	19,901	1,469	7.38%
	13	8,030	658	8.19%
	14	1,156	133	11.50%
	15	1	0	0.00%
	Total	7,436,581	622,034	8.36%

APPENDIX F-5
SOA 1984-99 Long Term Care Intercompany Study
Lapse Rates by Elimination Period and Duration
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Elimination Perio	d Duration	Exposure	Lapses	Rate
0	1	175,162	22,868	13.05%
	2	133,489		
	3	106,739		
	4	84,365	6,318	7.48%
	5	64,197		
	6	46,558	2,601	5.58%
	7	33,190	1,981	5.96%
	8	24,850	1,359	5.46%
	9	18,087	1,002	5.53%
	10	12,842	564	4.39%
	11	6,848	278	4.05%
	12	2,405	118	4.90%
	13	991	43	4.33%
	14	75	9	12.00%
	Total	709,798	63,261	8.91%
7-19	1	74,844	9,776	13.06%
	2	51,356		
	3	33,448		13.31%
	4	21,274		
	5	12,794	1,741	13.60%
	6	8,069		
	7	4,869	565	11.60%
	8	2,295	230	10.02%
	9	770	53	6.88%
	Total	209,719	27,031	12.88%
20	1	462,887	52,240	11.28%
	2	377,135	30,565	8.10%
	3	303,262	22,333	7.36%
	4	238,467	15,799	6.62%
	5	182,278	10,421	5.71%
	6	131,475	6,966	5.29%
	7	88,753	4,872	5.48%
	8	62,335	3,412	5.47%
	9	45,973	2,370	5.15%
	10	34,367	1,790	
	11	21,367		
	12	10,383		
	13	3,693		
	14	331	35	
	15	1	0	0.00%
	Total	1,962,707	153,108	7.80%

00	4	404 500	44.570	44.070/
30	1	131,583	14,570	11.07%
	2	88,245	7,689	8.71%
	3	62,992	4,688	7.44%
	4	43,208	2,578	5.96%
	5	27,240	1,346	4.94%
	6 7	15,976	782 291	4.89%
	8	7,289	173	3.99%
	9	3,921 2,396	82	4.41% 3.42%
	10	1,163	38	3.42 %
	11	271	5	1.84%
		27.1	Ü	1.0470
	Total	384,284	32,242	8.39%
31-50	1	12,099	2,708	22.38%
0.00	2	5,817	1,073	18.44%
	3	3,141	549	17.47%
	4	1,789	281	15.70%
	5	860	91	10.58%
	6	299	17	5.68%
	7	168	3	1.78%
	8	159	5	3.14%
	9	133	6	4.51%
	10	28	1	3.57%
	Total	24,493	4,734	19.32%
	Total	24,493	4,734	19.32 /0
60	1	140,932	13,604	9.65%
	2	104,224	6,915	6.63%
	3	77,488	4,175	5.38%
	4	57,935	2,559	4.41%
	5	46,066	2,258	4.90%
	6	38,265	1,833	4.79%
	7	15,847	620	3.91%
	8	4,878	90	1.84%
	9	171	8	4.67%
	10	7	0	0.00%
	11	7	0	0.00%
	Total	485,820	32,062	6.59%
90	1	603,510	83,892	13.90%
	2	404,867	40,490	10.00%
	3	287,708	21,675	7.53%
	4	205,126	12,041	5.87%
	5	122,361	6,454	5.27%
	6	50,404	2,822	5.59%
	7	16,060	512	3.18%
	8	10,436	233	2.23%
	9	6,953	144	2.07%
	10	2,144	51	2.37%
	11	1,387	11	0.79%
	12	3	0	0.00%
	13	2	0	0.00%
	Total	1,710,961	168,325	9.83%

100	1	447,225	46,158	10.32%
	2	326,955	24,913	7.61%
	3	243,800	16,763	6.87%
	4	179,418	11,046	6.15%
	5	130,076	7,036	5.40%
	6	89,384	4,183	4.67%
	7	57,169	2,686	4.69%
	8	37,300	1,967	5.27%
	9	25,142	1,346	5.35%
	10	18,230	925	5.07%
	11	11,485	637	5.54%
	12	5,443	348	6.39%
	13	•	163	
	14	2,372		6.87%
	14	329	26	7.90%
	Total	1,574,328	118,197	7.50%
101-359	1	56,716	4,762	8.39%
	2	46,567	3,303	7.09%
	3	39,687	2,568	6.47%
	4	34,600	2,061	5.95%
	5	30,870	1,018	3.29%
	6	28,166	795	2.82%
	7	26,060	504	1.93%
	8	24,524	397	1.61%
	9	21,482	291	1.35%
	10	1,230	76	6.17%
	11	324	19	5.86%
	12			
	12	26	3	11.53%
	Total	310,252	15,797	5.09%
360-365	1	3,632	1,225	33.72%
	2	1,986	420	21.14%
	3	1,323	210	15.87%
	4	1,012	235	23.22%
	5	631	78	12.36%
	6	476	59	12.39%
	7	206	20	9.70%
	8	100	9	9.00%
	9	75	2	2.66%
	10	41	1	2.43%
	Total	9,482	2,259	23.82%
730	1	2	0	0.00%
	Total	2	0	0.00%

Unknown	1	8,526	181	2.12%
	2	8,345	233	2.79%
	3	8,105	459	5.66%
	4	7,634	670	8.77%
	5	6,959	929	13.34%
	6	6,023	998	16.56%
	7	5,021	813	16.19%
	8	4,207	631	14.99%
	9	3,573	575	16.09%
	10	2,991	501	16.75%
	11	2,421	340	14.04%
	12	1,641	246	14.99%
	13	972	152	15.63%
	14	421	63	14.96%
	Total	66,839	6,791	10.16%
All Periods	1	2,117,118	251,984	11.90%
	2	1,548,986	135,110	8.72%
	3	1,167,693	86,557	7.41%
	4	874,828	56,634	6.47%
	5	624,332	35,434	5.67%
	6	415,095	22,088	5.32%
	7	254,632	12,867	5.05%
	8	175,005	8,506	4.86%
	9	124,755	5,879	4.71%
	10	73,043	3,947	5.40%
	11	44,110	2,541	5.76%
	12	19,901	1,469	7.38%
	13	8,030	658	8.19%
	14	1,156	133	11.50%
	15	1	0	0.00%
	Total	7,448,685	623,807	8.37%

APPENDIX F-6
SOA 1984-99 Long Term Care Intercompany Study
Lapse Rates by Benefit Period and Duration
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Benefit Period	Duration	Exposure	Lapses	Rate
Limited	1	1,677,058	211,087	7 12.58%
	2	1,234,746	113,465	9.18%
	3	942,299	74,072	7.86%
	4	713,387	48,787	6.83%
	5	521,441	30,946	5.93%
	6	356,934	19,445	5.44%
	7	232,012	11,660	5.02%
	8	164,567	7,967	4.84%
	9	118,997	5,694	4.78%
	10	70,282	3,855	5.48%
	11	43,045	2,508	5.82%
	12	19,900	1,469	7.38%
	13	8,029	658	8.19%
	14	1,156	133	3 11.50%
	15	1	(0.00%
	Total	6,103,854	531,746	8.71%
Unlimited	1	427,425	·	
	2	304,554	20,467	6.72%
	3	219,693	12,012	5.46%
	4	158,646	7,684	4.84%
	5	102,390	4,448	4.34%
	6	58,142	2,638	4.53%
	7	22,615	1,205	5.32%
	8	10,436	539	5.16%
	9	5,757	185	3.21%
	10	2,760		
	11	1,064	33	3.10%
	Total	1,313,482	88,581	6.74%

APPENDIX F-7 SOA 1984-99 Long Term Care Intercompany Study Lapse Rates by Benefit Escalator Clause and Duration (Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Benefit Escalator Clause	Duration	Exposure	Lapses	Rate
Future Purchase Option	1	507,663	47,742	9.40%
· atalo · atomaco option	2	399,886	28,724	
	3	315,456	18,795	
	4	245,267	11,312	
	5	170,675	6,456	
	6	101,351	3,957	
	7	56,882	1,312	
	8	44,565	796	
	9	33,432	552	1.65%
	10	6,945	176	
	11	2,824	44	1.55%
	12	1	0	
	Total	1,884,947	119,866	6.35%
Benefits Increase Annually, Premiums Level	1	427,663	49,378	11.54%
,	2	276,852	22,673	
	3	185,258	12,345	
	4	115,535	6,039	
	5	69,415	2,972	
	6	36,540	1,217	
	7	12,006	385	
	8	3,944	91	
	9	1,281	17	
	10	377	6	
	11	202	2	
	12	1	0	
	13	1	0	
	Total	1,129,075	95,125	8.42%
Benefits Increase Annually, Premiums increase	1	17,123	1,246	7.27%
	2	15,119	960	6.34%
	3	12,663	640	5.05%
	4	10,504	386	
	5	8,511	407	4.78%
	6	6,137	351	5.71%
	7	4,610	309	6.70%
	8	3,608	193	5.34%
	9	2,705	114	4.21%
	10	1,756	77	
	11	630	20	3.17%
	Total	83,366	4,703	5.64%

Maria	4	4 044 045	4.44.004	40.040/
None	1	1,041,215	144,204	13.84%
	2	758,572	77,335	10.19%
	3	575,306	48,392	8.41%
	4	435,267	32,858	7.54%
	5	317,450	20,709	6.52%
	6	221,423	12,505	5.64%
	7	142,675	7,787	5.45%
	8	96,494	5,164	5.35%
	9	64,594	3,311	5.12%
	10	44,355	2,059	4.64%
	11	24,566	1,119	4.55%
	12	9,114	453	4.97%
	13	3,980	228	5.72%
	14	443	33	7.44%
	Total	3,735,454	356,157	9.53%
Unknown	1	123,454	9,414	7.62%
	2	98,557	5,418	5.49%
	3	79,010	6,385	8.08%
	4	68,255	6,039	8.84%
	5	58,281	4,890	8.39%
	6	49,644	4,058	8.17%
	7	38,459	3,074	7.99%
	8	26,394	2,262	8.57%
	9	22,743	1,885	8.28%
	10	19,610	1,629	8.30%
	11	15,888	1,356	8.53%
	12	10,785	1,016	9.42%
	13	4,049	430	10.61%
	14	713	100	14.02%
	15	1	0	0.00%
	Total	615,843	47,956	7.78%
All Clauses	1	2,117,118	251,984	11.90%
	2	1,548,986	135,110	8.72%
	3	1,167,693	86,557	7.41%
	4	874,828	56,634	6.47%
	5	624,332	35,434	5.67%
	6	415,095	22,088	5.32%
	7	254,632	12,867	5.05%
	8	175,005	8,506	4.86%
	9	124,755	5,879	4.71%
	10	73,043	3,947	5.40%
	11	44,110	2,541	5.76%
	12	19,901	1,469	7.38%
	13	8,030	658	8.19%
	14	1,156	133	11.50%
	15	1	0	0.00%
	Total	7,448,685	623,807	8.37%

APPENDIX F-8
SOA 1984-99 Long Term Care Intercompany Study
Lapse Rates by Premium Mode and Duration
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Premium Mode	Duration	Exposure	Lapses	Rate
Annually	1	609,800	72,266	11.85%
•	2	451,194		
	3	344,714		
	4	259,943		
	5	186,205		
	6	131,765	7,163	5.43%
	7	87,042	4,749	5.45%
	8	61,417	3,365	5.47%
	9	46,159	2,432	5.26%
	10	34,104	1,683	4.93%
	11	20,581	1,135	5.51%
	12	9,376	671	7.15%
	13	3,751	309	8.23%
	14	571	54	9.45%
	15	1	0	0.00%
	Total	2,246,623	183,782	8.18%
Semi-annually	1	133,892	14,702	10.98%
Com amadany	2	102,678		
	3	78,840		
	4	58,833		
	5	42,822		
	6	30,093	•	
	7	19,760		
	8	14,054		
	9	10,768		
	10	8,103		
	11	5,217		
	12	2,592		
	13	977		
	14	168		
	Total	508,797	42,656	8.38%
Quarterly	1	217,706	27,080	12.43%
,	2	165,202		
	3	126,421	10,380	
	4	94,853		
	5	69,441	4,736	
	6	47,006		
	7	28,501	1,681	
	8	19,054		
	9	13,167		
	10	9,261		
	11	5,548		
	12	2,591	211	
	13	1,004		
	14	102		
	Total	799,857	72,346	9.04%

Monthly, Including Monthly EFT	1	952,560	122,548	12.86%
,, ,	2	679,843	66,112	9.72%
	3	507,311	41,304	8.14%
	4	375,605	25,763	6.85%
	5	265,462	15,248	5.74%
	6	167,168	9,141	5.46%
	7	97,701	4,240	4.33%
	8	70,618	2,636	3.73%
	9	52,447	1,918	3.65%
	10	20,605	1,042	5.05%
	11	12,301	637	5.17%
	12	5,252	350	6.66%
	13	2,259	165	7.30%
	14	308	37	12.01%
	Total	3,209,440	291,141	9.07%

APPENDIX F-9
SOA 1984-99 Long Term Care Intercompany Study
Lapse Rates by Duration and Quarter
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Duration	Quarter	Exposure	Lapses	Rate
1	1	2,117,118	47,932	2.26%
•	2	2,047,388		
	3	1,984,855		
	4	1,933,039		
		,,,,,,,,,,	,	
	Total	2,117,118	251,984	11.90%
2	1	1,548,986	29,534	1.90%
	2	1,505,152	28,455	1.89%
	3	1,462,745	23,670	1.61%
	4	1,426,105	53,451	3.74%
	Total	1,548,986	135,110	8.72%
•		4.407.000	40.000	4.500/
3	1	1,167,693		
	2	1,139,976		
	3	1,113,486		
	4	1,087,479	34,549	3.17%
	Total	1,167,693	86,557	7.41%
4	1	874,828	12,288	1.40%
	2	852,814		
	3	832,055		
	4	807,549		
	Total	874,828	56,634	6.47%
5	1	624,332	7,446	1.19%
· ·	2	607,272		
	3	591,891	6,311	
	4	577,744		
	Total	624,332	35,434	5.67%
		,	•	
6	1	415,095	4,676	1.12%
	2	403,167	4,879	1.21%
	3	390,981	3,848	0.98%
	4	381,629	8,685	2.27%
	Total	415,095	22,088	5.32%
7	1	254,632	2,645	1.03%
•	2	247,819		
	3	241,249		
	4	235,055		
	·	200,000	5,130	2.2070
	Total	254,632	12,867	5.05%

8	1	175,005	1,799	1.02%
	2	170,042	1,819	1.06%
	3	165,215	1,574	0.95%
	4	160,869	3,314	2.06%
	Total	175,005	8,506	4.86%
		,	-,	
9	1	124,755	1,257	1.00%
	2	121,968	1,307	1.07%
	3	119,861	1,080	0.90%
	4	117,890	2,235	1.89%
	Total	124,755	5,879	4.71%
10	1	73,043	834	1.14%
	2	71,612	859	1.19%
	3	70,126	717	1.02%
	4	68,780	1,537	2.23%
	T. (-)	70.040	0.047	F 400/
	Total	73,043	3,947	5.40%
11	1	44,110	511	1.15%
	2	43,212	557	1.28%
	3	42,243	498	1.17%
	4	41,341	975	2.35%
	Total	44,110	2,541	5.76%
40	4	40.004	000	4.440/
12	1	19,901	282	1.41%
	2 3	19,456 18,921	350 259	1.79%
	4	18,489	578	1.36% 3.12%
	4	10,409	370	3.1270
	Total	19,901	1,469	7.38%
13	1	8,030	120	1.49%
	2	7,841	157	2.00%
	3	7,604	120	1.57%
	4	7,417	261	3.51%
	Total	8,030	658	8.19%
14	1	1,156	23	1.98%
	2	1,124	38	3.38%
	3	1,079	25	2.31%
	4	1,048	47	4.48%
	Total	1,156	133	11.50%
15	1	1	0	0.00%
-	2	1	0	0.00%
	3	1	0	0.00%
	4	1	0	0.00%
	Total	4	0	0.009/
	Total	1	0	0.00%

APPENDIX F-10
SOA 1984-99 Long Term Care Intercompany Study
Lapse Rates by Distribution Type and Duration
(Excludes Those Companies who do not Distinguish Between Deaths and Lapses)

Distribution Type	Duration	Exposure	Lapses	Rate
Company Agent	1	506,670	44,671	8.81%
. , ,	2	394,440	23,833	
	3	326,155	17,067	5.23%
	4	273,551	11,297	4.12%
	5	211,847	7,712	3.64%
	6	140,146	5,667	4.04%
	7	67,941	2,314	
	8	47,457	1,507	
	9	34,097	1,089	
	10	7,732		
	11	4,945		8.71%
	12	1,760		
	13 14	972	152 63	
		421	03	14.96%
	Total	2,018,134	116,759	5.78%
Independent Agent (Broker)	1	419,024	50,462	12.04%
	2	317,852	29,068	9.14%
	3	254,327		7.85%
	4	187,784	13,787	7.34%
	5	141,526		
	6	113,121	6,876	
	7	91,096		5.45%
	8	62,771	3,296	
	9	46,751	2,316	
	10	35,555	1,778	
	11	21,412	1,246	
	12	9,154		
	13 14	3,075	278 37	
		291		
	Total	1,703,739	144,242	8.46%
Agent, Type Unknown	1	729,669	80,852	11.08%
	2	536,507	47,008	8.76%
	3	382,282		8.19%
	4	265,619	21,431	8.06%
	5	192,013		
	6	132,968		
	7	91,636		
	8	64,180		5.74%
	9	43,544	2,467	5.66%
	10	29,751	1,475	4.95%
	11 12	17,749	863	
	13	8,984 3,980		5.02% 5.72%
	14	443		
	Total	2,499,325	215,612	8.62%
Direct Mail	1	94,094	11,601	12.32%
	2	69,859	5,656	8.09%
	3	56,670		
	4	48,029		
	5	21,784		
	6	719	23	3.19%
	Total	291,155	23,894	8.20%

Table of Contents - Appendix G

Summary	<u>Appendix</u>	<u>Coverage</u>	<u>Page</u>
Di agnosi s ICD9 Mappi ng	Appendi x G-1		1
Diagnosis Summary	Appendi x G-2	Nursing Home Home Care/ADC/Other	2 3
Diagnosis by Claim Status	Appendi x G-3	Nursing Home Home Care/ADC/Other	4 6
Diagnosis by Gender	Appendi x G-4	Nursing Home Home Care/ADC/Other	8 10
Diagnosis by Attained Age	Appendi x G-5	Nursing Home Home Care/ADC/Other	12 18
Diagnosis by Duration	Appendi x G-6	Nursing Home Home Care/ADC/Other	24 31
Diagnosis by Incurral Year	Appendi x G-7	Nursing Home Home Care/ADC/Other	38 42
Diagnosis by Closed Status	Appendi x G-8	Nursing Home Home Care/ADC/Other	46 51
Diagnosis by Issue Year	Appendi x G-9	Nursing Home Home Care/ADC/Other	56 60
Diagnosis by Underwriting Type	Appendi x G-10	Nursing Home Home Care/ADC/Other	64 70
Diagnosis by Benefit Period Type	Appendi x G-11	Nursing Home Home Care/ADC/Other	76 79
Diagnosis by Average HC Visits	Appendi x G-12	Home Care/ADC	82

Appendi x: G - 1

ICD-9-CM CODES BY DIAGNOSIS CATEGORIES

DIAGNOSIS CATEGORY

ICD- 9- CM CODES INCLUDED

ALZHEI MER'S	290-294, 331, 797
ARTHRI TI S	710-739
CANCER	141-239, V10, V16
CIRCULATORY	390-398, 410-417, 420-429, 440-459
CONGENITAL	742 - 756
DI ABETES	250
DI GESTI VE SYSTEM	530-579
ENDOCRI NE, I MMUNI TY SYSTEM	242 - 249, 251 - 289
GENI TOURI NARY SYSTEM	580-618
HYPERTENSI ON	401 - 405
INJURY	800-996
MENTAL	295 - 319
ILL-DEFINED AND MISCELLANEOUS CONDITIONS	780 - 796, 798 - 799
NERVOUS SYSTEM AND SENSE ORGANS	323-330, 332-380
RESPIRATORY	011, 012, 460-496, 500-519
SKIN AND SUBCUTANEOUS TISSUE	680-709
PREGNANCY DISORDERS	620-674, 759-772
STROKE	430-438
ALL OTHER	ALL OTHER CODES NOT DEFINED ELSEWHERE

Appendi x: G - 2 Nursing Home Claims: Diagnosis Category Summary

Di agnosi s Category	Tally	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
Al zhei mer's	5, 787	3, 603, 256	\$289, 052, 513	\$49, 949	622. 6	\$80
Arthritis Cancer	2, 008 2, 774	766, 920 472, 858	\$54, 305, 238 \$34, 500, 635	\$27, 044 \$12, 437	381. 9 170. 5	\$71 \$73
Circulatory	4, 015	1, 716, 453	\$121, 061, 884	\$30, 152	427. 5	\$71
Congenital Di abetes	20 611	4, 114 303, 129	\$187, 400 \$21, 152, 534	\$9, 370 \$34, 620	205. 7 496. 1	\$46 \$70
Digestive System	684	268, 862	\$18, 166, 748	\$26, 560	393. 1	\$68
Endocrine, Immunity System Genitourinary System	447 516	200, 761 175, 087	\$12, 912, 374 \$12, 580, 096	\$28, 887 \$24, 380	449. 1 339. 3	\$64 \$72
Hypertension	458	274, 059	\$16, 297, 294	\$35, 584	598. 4	\$5 9
Ill-Defined and Misc Conditions	1, 450	591, 140	\$42, 221, 089	\$29, 118	407. 7	\$71
I nj ury Mental	4, 179 895	1, 522, 422 563, 244	\$100, 226, 818 \$35, 874, 278	\$23, 983 \$40, 083	364. 3 629. 3	\$66 \$64
Nervous System and Sense Organs	1, 459	701, 578	\$60, 957, 614	\$41, 780	480. 9	\$87
Pregnancy Di sorders Respi ratory	45 1, 84 4	17, 636 603, 783	\$920, 604 \$40, 643, 192	\$20, 458 \$22, 041	391. 9 327. 4	\$52 \$67
Skin and Subcutaneous Tissue	191	69, 787	\$4, 500, 501	\$23, 563	365. 4	\$64
Stroke Other/Unknown	4, 078 13, 875	1, 831, 193 3, 892, 698	\$130, 555, 268 \$240, 246, 415	\$32, 015 \$17, 315	449. 0 280. 6	\$71 \$62
Total	45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendi x: G - 2

Home Health Care/ADC/Other Claims: Diagnosis Category Summary

Di agnosi s			Total	Average Cl ai m	Average	Average Per
Category	Tal l y	Vi si ts	Payments	Payments	Visits	Visit
Al zhei mer's	769	159, 488	\$11, 493, 397	\$14, 946	207. 4	\$72
Arthritis	450	54, 709	\$3, 523, 268	\$7, 829	121.6	\$64
Cancer	697	56, 187	\$3, 561, 181	\$5, 109	80. 6	\$63
Circulatory	506	66, 416	\$3, 761, 750	\$7, 434	131. 3	\$57
Congeni tal "	5	350	\$39, 289	\$7, 858	70. 0	\$112
Diabetes	52	5, 472	\$356, 064	\$6, 847	105. 2	\$65
Digestive System	89	5, 856	\$436, 126	\$4, 900	65. 8	\$74
Endocrine, Immunity System	47	4, 163	\$363, 567	\$7, 735	88. 6	\$87
Geni touri nary System	47	2, 795	\$208, 154	\$4, 429	59. 5	\$74
Hypertensi on "	42	2, 562	\$330, 694	\$7, 874	61.0	\$129
Ill-Defined and Misc Conditions	148	16, 366	\$1, 122, 838	\$7, 587	110. 6	\$69
I nj ury	706	77, 776	\$4, 676, 212	\$6, 624	110. 2	\$60
Mental	63	4, 768	\$554, 298	\$8, 798	75. 7	\$116
Nervous System and Sense Organs	292	79, 412	\$5, 931, 020	\$20, 312	272. 0	\$75
Pregnancy Di sorders	14	221	\$62, 463	\$4, 462	15. 8	\$283
Respiratory	187	20, 095	\$1,600,944	\$8, 561	107. 5	\$80
Skin and Subcutaneous Tissue	28	3, 817	\$269, 015	\$9,608	136. 3	\$70
Stroke	538	85, 968	\$6, 439, 790	\$11, 970	159. 8	\$75
Other/Unknown	1, 115	74, 063	\$8, 766, 716	\$7, 863	66. 4	\$118
Total	5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendix: G - 3

Nursing Home Claims: Status Type and Diagnosis Summary

Cl ai m	Status			Total	Average Cl ai m	Avorago	Average Per
Status	Category	Tally	Days	Payments	Payments	Average Days	Day
Status	category	Tarry	Days	rayments	rayments	Days	vay
Closed	Al zhei mer's	4, 890	2, 971, 348	\$238, 122, 415	\$48, 696	607. 6	\$80
	Arthritis	1, 868	671, 908	\$48, 170, 460	\$25, 787	359. 7	\$72
	Cancer	2, 709	447, 246	\$32, 569, 605	\$12, 023	165. 1	\$73
	Ci rcul atory	3, 677	1, 486, 349	\$104, 117, 174	\$28, 316	404. 2	\$70
	Congeni tal "	18	3, 151	\$147, 320	\$8, 184	175. 1	\$47
	Di abetes	567	272, 109	\$18, 652, 952	\$32, 898	479. 9	\$69
	Digestive System	641	233, 939	\$15, 672, 617	\$24, 450	365. 0	\$67
	Endocrine, Immunity System	411	178, 724	\$11, 478, 751	\$27, 929	434. 9	\$64
	Geni touri nary System	486	156, 623	\$11, 098, 801	\$22, 837	322. 3	\$71
	Hypertensi on	417	244, 841	\$14, 600, 329	\$35, 013	587 . 1	\$60
	Ill-Defined and Misc Conditions	1, 304	485, 494	\$34, 731, 976	\$26, 635	372. 3	\$72
	I nj ury	3, 823	1, 257, 275	\$81, 732, 819	\$21, 379	328. 9	\$65
	Mental	839	514, 730	\$32, 752, 316	\$39, 037	613. 5	\$64
	Nervous System and Sense Organs	1, 261	609, 295	\$51, 143, 270	\$40, 558	483. 2	\$84
	Pregnancy Di sorders	44	16, 691	\$863, 884	\$19, 634	379. 3	\$52
	Respi ratory	1, 722	538, 478	\$36, 325, 546	\$21, 095	312. 7	\$67
	Skin and Subcutaneous Tissue	180	64, 697	\$4, 154, 865	\$23, 083	359. 4	\$64
	Stroke	3, 743	1, 624, 763	\$114, 450, 909	\$30, 577	434. 1	\$70
	Other/Unknown	11, 509	2, 713, 121	\$166, 528, 230	\$14, 469	235. 7	\$61
	Status Total	40, 109	14, 490, 782	\$1, 017, 314, 239	<i>\$25, 364</i>	361. 3	\$70

Appendix: G - 3

Nursing Home Claims: Status Type and Diagnosis Summary

Cl ai m Status	Status Category	Tal l y	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
0pen	Al zhei mer' s	897	631, 908	\$50, 930, 098	\$56, 778	704. 5	\$81
-	Arthritis	140	95, 012	\$6, 134, 778	\$43, 820	678. 7	\$65 \$75
	Cancer	65	25, 612	\$1, 931, 030	\$29, 708	394. 0	
	Ci rcul atory	338	230, 104	\$16, 944, 710	\$50, 132	680. 8	\$74
	Congeni tal Č	2	963	\$40, 080	\$20, 040	481. 5	\$42
	Di abetes	44	31, 020	\$2, 499, 582	\$56, 809	705. 0	\$81
	Digestive System	43	34, 923	\$2, 494, 131	\$58, 003	812. 2	\$71
	Endocrine, Immunity System	36 30	22, 037	\$1, 433, 623	\$39, 823	612. 1	\$65
	Geni touri nary System	30	18, 464	\$1, 481, 295	\$49, 377	615. 5	\$80
	Hypertension	41	29, 218	\$1, 696, 965	\$41, 389	712. 6	\$58
	Ill-Defined and Misc Conditions	146	105, 646	\$7, 489, 113	\$51, 295	723. 6	\$71
	Injury	356	265, 147	\$18, 493, 999	\$51, 949	744. 8	\$70
	Mental	56	48, 514	\$3, 121, 962	\$55, 749	866. 3	\$64
	Nervous System and Sense Organs	198	92, 283	\$9, 814, 344	\$49, 567	466. 1	\$106
	Pregnancy Di sorders	1	945	\$56, 720	\$56, 720	945. 0	\$60
	Respi ratory	122	65, 305	\$4, 317, 646	\$35, 391	535. 3	\$66
	Skin and Subcutaneous Tissue	11	5, 090	\$345, 636	\$31, 421	462. 7	\$68
	Stroke	335	206, 430	\$16, 104, 359	\$48 , 073	616. 2	\$78
	Other/Unknown	2, 366	1, 179, 577	\$73, 718, 185	\$31, 157	498. 6	\$62
	Status Total	5, 227	3, 088, 198	\$219, 048, 256	\$41, 907	<i>590. 8</i>	\$71
	Type Total	45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendix: G - 3

Home Health Care/ADC/Other Claims: Status Type and Diagnosis Summary

Cl ai m	Status	Di agnosi s			Average Total	Average Cl ai m	Average Per
Status	Category	Tally	Vi si ts	Payments	<i>Payments</i>	Vi si ts	Vi si t
Closed	Al zhei mer' s	560	95, 819	\$6, 193, 253	\$11, 059	171. 1	\$65
	Arthri ti s	402	35, 853	\$2, 041, 570	\$5, 079	89. 2	\$57
	Cancer	660	47, 891	\$2, 757, 488	\$4, 178	72. 6	\$58
	Ci rcul atory	457	44, 887	\$2, 768, 180	\$6, 057	98. 2	\$62
	Congeni tal *	5	350	\$39, 289	\$7, 858	70. 0	\$112
	Di abetes	47	4, 976	\$317, 525	\$6, 756	105. 9	\$64
	Digestive System	84	5, 333	\$343, 123	\$4, 085	63. 5	\$64
	Endocrine, İmmunity System	44 43	4, 157	\$324, 014	\$7, 364	94. 5	\$78
	Geni touri nary System		1, 278	\$143, 496	\$3, 337	29. 7	\$112
	Hypertensi on	38	1, 296	\$234, 392	\$6, 168	34. 1	\$181
	Ill-Defined and Misc Conditions	136	14, 074	\$840, 018	\$6, 177	103. 5	\$60
	I nj ury	660	57, 131	\$3, 197, 541	\$4, 845	86. 6	\$56
	Mental	56	3, 395	\$369, 110	\$6, 591	60. 6	\$109
	Nervous System and Sense Organs	210	35, 127	\$2, 586, 277	\$12, 316	167. 3	\$74
	Pregnancy Di sorders	14	221	\$62, 463	\$4, 462	15. 8	\$283
	Respi ratory	171	16, 011	\$1, 235, 894	\$7, 227	93. 6	\$77
	Skin and Subcutaneous Tissue	24	952	\$123, 575	\$5, 149	39. 7	\$130
	Stroke	452	61, 188	\$4, 377, 926	\$9, 686	135. 4	\$72
	Other/Unknown	935	50, 846	\$7, 415, 139	\$7, 931	54. 4	\$146
	Status Total	4, 998	480, 785	\$35, 370, 273	\$7, 077	<i>96. 2</i>	\$74

Appendix: G - 3

Home Health Care/ADC/Other Claims: Status Type and Diagnosis Summary

Claim Status	Status Category	Di agnosi s Tal l y	Visits	Payments	Average Total Payments	Average Claim Visits	Average Per Vi si t
0pen	Al zhei mer's	209	63, 669	\$5, 300, 144	\$25, 360	304. 6	\$83
	Arthritis	48	18, 856	\$1, 481, 698	\$30, 869	392. 8	\$79
	Cancer	37	8, 296	\$803, 693	\$21, 721	224. 2	\$97
	Circulatory	49	21, 529	\$993, 570	\$20, 277	439. 4	\$46
	Diabetes	5	496	\$38, 539	\$7, 708	99. 2	\$78
	Digestive System	5	523	\$93, 003	\$18, 601	104. 6	\$178
	Endocrine, Immunity System Genitourinary System	3 4	1, 517	\$39, 553 \$64, 658	\$13, 184 \$16, 165	2. 0 379. 3	\$6, 592 \$43
	Hypertension Ill-Defined and Misc Conditions	12 12	1, 266 2, 292	\$96, 302 \$282, 820	\$24, 076 \$23, 568	316. 5 191. 0	\$76 \$123
	Injury	46	20, 645	\$1, 478, 671	\$32, 145	448. 8	\$72
	Mental	7	1, 373	\$185, 188	\$26, 455	196. 1	\$135
	Nervous System and Sense Organs	82	44, 285	\$3, 344, 743	\$40, 790	540. 1	\$76
	Respiratory	16	4, 084	\$365, 050	\$22, 816	255. 3	\$89
	Skin and Subcutaneous Tissue	4	2, 865	\$145, 440	\$36, 360	716. 3	\$51
	Stroke	86	24, 780	\$2, 061, 864	\$23, 975	288. 1	\$83
	Other/Unknown	180	23, 217	\$1, 351, 577	\$7, 509	129. 0	\$58
	Status Total	797	239, 699	\$18, 126, 513	\$22, 743	300. 8	\$76
	Type Total	5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendix: G - 4

Nursing Home Claims: Gender and Diagnosis Summary

Gender	Di agnosi s Category	Tally	Days	Total Payments	Average Total Payment	Average Cl ai m Days	Average Per Day
Female	Alzheimer's Arthritis Cancer Circulatory Congenital Diabetes Digestive System Endocrine, Immunity System Genitourinary System Hypertension Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Gender Total	3, 665 1, 630 1, 654 2, 572 11 391 487 334 275 361 970 3, 442 607 735 38 1, 090 133 2, 500 9, 106 30, 001	2, 454, 653 633, 201 295, 136 1, 166, 268 2, 067 195, 757 194, 471 154, 309 102, 888 218, 867 419, 236 1, 282, 218 409, 423 389, 907 15, 206 387, 587 56, 236 1, 202, 338 2, 605, 036 12, 184, 804	\$198, 150, 995 \$44, 553, 159 \$21, 449, 227 \$82, 165, 460 \$94, 040 \$13, 461, 288 \$13, 175, 095 \$9, 739, 350 \$7, 280, 817 \$12, 986, 087 \$29, 678, 295 \$83, 519, 265 \$26, 078, 091 \$33, 130, 323 \$783, 494 \$26, 185, 825 \$3, 677, 189 \$84, 409, 657 \$158, 535, 338 \$849, 052, 995	\$54, 066 \$27, 333 \$12, 968 \$31, 946 \$8, 549 \$34, 428 \$27, 054 \$29, 160 \$26, 476 \$35, 973 \$30, 596 \$24, 265 \$42, 965 \$42, 965 \$42, 965 \$42, 961 \$24, 024 \$27, 648 \$33, 764 \$17, 410 \$28, 301	669. 8 388. 5 178. 4 453. 4 187. 9 500. 7 399. 3 462. 0 374. 1 606. 3 432. 2 372. 5 674. 5 530. 5 400. 2 355. 6 422. 8 480. 9 286. 1 406. 1	\$81 \$70 \$73 \$70 \$45 \$69 \$68 \$63 \$71 \$59 \$71 \$65 \$64 \$85 \$52 \$68 \$65 \$70 \$61 \$70

Appendix: G - 4

Nursing Home Claims: Gender and Diagnosis Summary

Gender	Di agnosi s Category	Tally	Days	Total Payments	Average Total Payment	Average Cl ai m Days	Average Per Day
Mal e	Al zhei mer's	2, 122	1, 148, 603	\$90, 901, 518	\$42, 838	541. 3	\$79
	Arthritis	378	133, 719	\$9, 752, 079	\$25, 799	353. 8	\$73
	Cancer	1, 120	177, 722	\$13, 051, 408	\$11, 653	158. 7	\$73
	Circulatory	1, 443	550, 185	\$38, 896, 424	\$26, 955	381. 3	\$71
	Congeni tal	9	2, 047	\$93, 360	\$10, 373	227. 4	\$46
	Di abetes	220	107, 372	\$7, 691, 246	\$34, 960	488. 1	\$72
	Digestive System	197	74, 391	\$4, 991, 653	\$25, 338	377. 6	\$67
	Endocrine, Immunity System	113	46, 452	§3 , 173, 024	\$28, 080	411. 1	\$68
	Genitourinary System	241	72, 199	\$5, 299, 279	\$21, 989	299. 6	\$73
	Hypertension	97	55, 192	\$3, 311, 207	\$34, 136	569. 0	\$60
	Ill-Defined and Misc Conditions	480	171, 904	\$12, 542, 794	\$26, 131	358. 1	\$73
	I nj ury	737	240, 204	\$16, 707, 553	\$22, 670	325. 9	\$70
	Mental	288	153, 821	\$9, 796, 187	\$34, 015	534. 1	\$64
	Nervous System and Sense Organs	724	311, 671	\$27, 827, 291	\$38, 435	430. 5	\$89
	Pregnancy Di sorders	7	2, 430	\$137, 110	\$19, 587	347. 1	\$56
	Respi ratory	754	216, 196	\$14, 457, 367	\$19, 174	286. 7	\$67
	Skin and Subcutaneous Tissue	58	13, 551	\$823, 312	\$14, 195	233. 6	\$61
	Stroke	1, 578	628, 855	\$46, 145, 611	\$29, 243	398. 5	\$73
	Other/Unknown	4, 769	1, 287, 662	\$81, 711, 077	\$17, 134	270.0	\$63
	Gender Total	15, 335	5, 394, 176	\$387, 309, 500	\$25, 257	351.8	\$72
	Total	45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendi x: G - 4

Home Health Care/ADC/Other Claims: Gender and Diagnosis Summary

	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Gender	Category	Tal l y	Vi si ts	<i>Payments</i>	Payments	Vi si ts	Vi si t
Femal e	Al zhei mer's	478	109, 728	\$7, 965, 412	\$16, 664	229. 6	\$73
	Arthritis	368	44, 203	\$2, 790, 884	\$7, 584	120. 1	\$63
	Cancer	441	33, 915	\$2, 352, 276	\$5, 334	76. 9	\$69
	Ci rcul atory	317	43, 795	\$2, 651, 322	\$8, 364	138. 2	\$61
	Congeni tal *	5	350	\$39, 289	\$7, 858	70. 0	\$112
	Di abetes	33	3, 448	\$269, 174	\$8, 157	104. 5	\$78
	Digestive System	62	4, 868	\$346, 783	\$5, 593	78. 5	\$71
	Endocrine, Immunity System	38	2, 781	\$318, 586	\$8, 384	73. 2	\$115
	Geni touri nary System	31	2, 009	\$130, 435	\$4, 208	64. 8	\$65
	Hypertensi on The Hypertensi o	31	1, 883	\$187, 342	\$6, 043	60. 7	\$99
	Ill-Defined and Misc Conditions	102	14, 542	\$907, 922	\$8, 901	142. 6	\$62
	Inj ury	585	60, 016	\$3, 633, 144	\$6, 211	102. 6	\$61
	Mental	52	3, 132	\$501, 182	\$9, 638	60. 2	\$160
	Nervous System and Sense Organs	163	40, 952	\$3, 111, 741	\$19,090	251. 2	\$76
	Pregnancy Di sorders	14	221	\$62, 463	\$4, 462	15. 8	\$283
	Respi ratory	133	15, 694	\$1, 325, 060	\$9, 963	118. 0	\$84
	Skin and Subcutaneous Tissue	21	1, 692	\$143, 114	\$6, 815	80. 6	\$85
	Stroke	313	50, 026	\$3, 890, 005	\$12, 428	159. 8	\$78
	Other/Unknown	764	48, 364	\$6, 178, 006	\$8, 086	63. 3	\$128
	Gender Total	3, 951	481, 619	\$36, 804, 140	\$9, 315	121. 9	\$76

Appendi x: G - 4

Home Health Care/ADC/Other Claims: Gender and Diagnosis Summary

	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Gender	Category	Tal l y	Vi si ts	Payments	Payments	Vi si ts	Vi si t
Male	Al zhei mer's	291	49, 760	\$3, 527, 985	\$12, 124	171. 0	\$71
	Arthritis	82	10, 506	\$732, 384	\$8, 932	128. 1	\$70
	Cancer	256	22, 272	\$1, 208, 905	\$4,722	87. 0	\$54
	Ci rcul atory	189	22, 621	\$1, 110, 428	\$5, 875	119. 7	\$49
	Di abetes	19	2, 024	\$86, 890	\$4, 573	106. 5	\$43
	Digestive System	27	988	\$89, 343	\$3, 309	36. 6	\$90
	Endocrine, Immunity System	9	1, 382	\$44, 981	\$4, 998	153. 6	\$33
	Geni touri nary System	16 11	786	\$77, 719	\$4, 857	49. 1	\$99
	Hypertensi on Table 1		679	\$143, 352	\$13, 032	61. 7	\$211
	Ill-Defined and Misc Conditions	46	1, 824	\$214, 916	\$4,672	39. 7	\$118
	Inj ury	121	17, 760	\$1, 043, 068	\$8, 620	146. 8	\$59
	Mental	11	1, 636	\$53, 116	\$4, 829	148. 7	\$32
	Nervous System and Sense Organs	129	38, 460	\$2, 819, 279	\$21, 855	298. 1	\$73
	Respiratory	54	4, 401	\$275, 884	\$5, 109	81. 5	\$63
	Skin and Subcutaneous Tissue	7	2, 125	\$125, 901	\$17, 986	303. 6	\$59
	Stroke	225	35, 942	\$2, 549, 785	\$11, 332	159. 7	\$71
	Other/Unknown	351	25, 699	\$2, 588, 710	\$7, 375	73. 2	\$101
	Gender Total	1, 844	238, 865	\$16, 692, 646	\$9, 052	129. 5	\$70
	Total	5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendix: G - 5

Nursing Home Claims: Diagnosis Category by Attained Age Summary

	Av	erage	Average	Average			
Di agnos i s Category	Attained Age Band	Age Band Tally	Days	Payments	Total Paynent	Claim Days	Per Day
Al zhei mer's	00- 64	89	43, 381	\$6, 825, 695	\$76, 693	487. 4	\$157
Alzheimer's	65- 69	256	190, 776	\$18, 023, 691	\$70, 405	745. 2	\$94
Al zhei mer's	70- 74	815	578, 512	\$49, 716, 030	\$61,001	709.8	\$86
Al zhei mer's	75- 79	1, 616	1, 069, 796	\$84, 303, 653	\$52, 168	662. 0	\$79
Al zhei mer's	80- 84	1, 883	1, 186, 211	\$91, 735, 165	\$48, 718	630. 0	\$77
Al zhei mer's	85- 89	965	469, 472	\$34, 362, 662	\$35, 609	486. 5	\$73
Al zhei mer's	90+	163 5, 787	65, 108 3, 603, 256	\$4, 085, 617 \$289, 052, 513	\$25, 065	399. 4 <i>622</i> . <i>6</i>	\$63 <i>\$80</i>
Diagnosis Category Sub-Total		3, 767	3, 003, 230	3289, 032, 313	\$49, 949	022. 0	300
Arthri ti s	00- 64	31	3, 455	\$331, 080	\$10, 680	111. 5	\$96
Arthritis	65- 69	85	29, 794	\$2, 345, 959	\$27, 600	350. 5	\$79
Arthritis	70- 74	276	86, 606	\$6, 432, 015	\$23, 304	313. 8	\$74
Arthritis	75- 79	500	182, 832	\$13, 033, 408	\$26, 067	365. 7	\$71
Arthritis	80- 84	696	306, 019	\$21, 853, 883	\$31, 399	439. 7	\$71
Arthritis	85-89	354	134, 320	\$9, 015, 353	\$25, 467	379. 4	\$67
Arthritis	90+	66	23, 894	\$1, 293, 540	\$19,599	362. 0	\$54
Diagnosis Category Sub-Total		2, 008	<i>766, 920</i>	\$54, 305, 238	\$27, 044	381. 9	\$71
Cancer	00- 64	148	7, 390	\$1, 106, 324	\$7, 475	49. 9	\$150
Cancer	65- 69	236	29, 660	\$2, 745, 646	\$11,634	125. 7	\$93
Cancer	70- 74	579	78, 587	\$5, 774, 039	\$9, 972	135. 7	\$73
Cancer	75- 79	835	154, 334	\$10, 770, 199	\$12, 898	184. 8	\$70
Cancer	80- 84	640	132, 245	\$9, 372, 566	\$14, 645	206. 6	\$71
Cancer	85-89	281	60, 426	\$4, 170, 970	\$14, 843	215. 0	\$69
Cancer	90+	55	10, 216	\$560, 891	\$10, 198	185. 7	\$55
Diagnosis Category Sub-Total		2, 774	472, 858	<i>\$34, 500, 635</i>	\$12, 437	170. 5	\$73

Appendix: G - 5

Nursing Home Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Days	Payments	Average Total Paynent	Average Claim Days	Average Per Day
Ci rcul atory	00- 64	42	14, 270	\$1, 953, 907	\$46, 522	339. 8	\$137
Ci rcul atory	65- 69	120	56, 728	\$4, 857, 935	\$40, 483	472. 7	\$86
Circulatory	70- 74	432	187, 646	\$14, 268, 853	\$33, 030	434. 4	\$76
Circulatory	75- 79 80- 84	1, 002 1, 363	437, 242 627, 058	\$31, 642, 592 \$43, 147, 792	\$31, 579 \$31, 656	436. 4 460. 1	\$72 \$69
Ci rcul atory Ci rcul atory	85- 89	1, 303 847	329, 892	\$21, 661, 543	\$25, 574	389. 5	\$66
Circulatory	90+	209	63, 617	\$3, 529, 262	\$16, 886	304. 4	\$55
Diagnosis Category Sub-Total		4, 015	1, 716, 453	\$121, 061, 884	\$30, 152	427. 5	\$71
Congenital	00- 64	1	6	\$600	\$600	6. 0	\$100
Congeni tal	65- 69	4	113	\$8, 560	\$2, 140	28. 3	\$76
Congeni tal	70- 74	2	1, 089	\$43, 690	\$21, 845	544. 5	\$40
Congenital	75- 79	7	2, 007	\$92, 800	\$13, 257	286. 7	\$46
Congeni tal	80- 84 85- 89	$\frac{3}{3}$	212 687	\$9, 495 \$32, 255	\$3, 165 \$10, 752	70. 7 229. 0	\$45 \$47
Congenital Diagnosis Category Sub-Total	65- 69	20	4, 114	\$187, 400	\$9, 370	205. 7	\$46
Di abetes	00- 64	18	5, 116	\$368, 100	\$20, 450	284. 2	\$72
Di abetes	65- 69	20	6, 154	\$350, 567	\$17, 528	307. 7	\$57
Di abetes	70- 74	.96	52, 217	\$3, 549, 094	\$36, 970	543. 9	\$68
Diabetes	75- 79	190	98, 214	\$6, 913, 179	\$36, 385	516. 9	\$70
Di abetes	80- 84	188	97, 131	\$6, 763, 135	\$35, 974	516. 7	\$70
Di abetes Di abetes	85- 89 90+	84 15	40, 654 3, 643	\$2, 967, 539 \$240, 920	\$35, 328 \$16, 061	484. 0 242. 9	\$73 \$66
Di agnosi s Category Sub-Total	30+	611	303, 129	\$21, 152, 534	\$34, 620	496. 1	\$70
Digestive System	00- 64	7	674	\$40, 610	\$5, 801	96. 3	\$60
Digestive System	65- 69	27	5, 489	\$491, 522	\$18, 205	203. 3	\$90
Digestive System	70- 74	93	28, 646	\$2, 273, 573	\$24, 447	308. 0	\$79
Digestive System	75- 79	178	73, 761	\$4, 925, 871	\$27, 673	414. 4	\$67
Digestive System	80- 84	212	98, 972	\$6, 394, 838	\$30, 164	466. 8	\$65
Digestive System	85- 89	130 37	51, 166	\$3, 324, 405	\$25, 572	393. 6 274. 4	\$65
Diğestive System Diagnosis Category Sub-Total	90+	684	10, 154 <i>268</i> , <i>862</i>	\$715, 929 \$18, 166, 748	\$19, 349 <i>\$26, 560</i>	274. 4 393. 1	\$71 <i>\$68</i>
Diagnosis Category Sub-Total		004	200, 002	910, 100, 7 40	320, 300	333. I	\$UO

Appendi x: G - 5

Nursing Home Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Days	Payments	Average Total Paynent	Average Claim Days	Average Per Day
Endocrine, Immunity System	00- 64	3	1, 168	\$59, 410	\$19, 803	389. 3	\$51
Endocrine, Immunity System	65- 69	14	4, 375	\$436, 911	\$31, 208	312. 5	\$100
Endocrine, Immunity System	70- 74	41	24, 607	\$1, 757, 524	\$42, 866	600. 2	\$71
Endocrine, Immunity System	75- 79	105	61, 551	\$3, 882, 162	\$36, 973	586 . 2	\$63
Endocrine, Immunity System	80- 84	136	57, 728	\$3, 841, 602	\$28, 247	424. 5	\$67
Endocrine, Immunity System	85- 89	121	44, 044	\$2, 582, 903	\$21, 346	364 . 0	\$59
Endocrine, Immunity System	90+	27	7, 288	\$351, 862	\$13, 032	269 . 9	\$48
Diagnosis Category Sub-Total		447	200, 761	\$12, 912, 374	<i>\$28, 887</i>	449. 1	\$64
Genitourinary System	00- 64	16	5, 706	\$734, 595	\$45, 912	356. 6	\$129
Geni touri nary System	65- 69	25	14, 668	\$1, 183, 346	\$47, 334	586 . 7	\$81
Geni touri nary System	70- 74	62	19, 909	\$1, 430, 910	\$23, 079	321. 1	\$72
Geni touri nary System	75- 79	134	38, 445	\$2, 639, 853	\$19, 700	286. 9	\$69
Geni touri nary System	80- 84	163	61, 503	\$4, 103, 275	\$25, 173	377. 3	\$67
Geni touri nary System	85-89	89	27, 369	\$2, 115, 502	\$23, 770	307. 5	\$77
Geni touri nary System	90+	27	7, 487	\$372, 615	\$13, 801	277. 3	\$50
Diagnosis Category Sub-Total		516	175, 087	\$12, 580, 096	\$24, 380	339. 3	\$72
Hypertensi on	00- 64	4	1, 605	\$117, 633	\$29, 408	401. 3	\$73
Hypertensi on	65- 69	10	3, 964	\$236, 492	\$23, 649	396. 4	\$60
Hypertensi on	70- 74	54	28, 755	\$1, 861, 393	\$34, 470	532 . 5	\$65
Hypertensi on	75- 79	113	81, 045	\$5, 080, 707	\$44, 962	717. 2	\$63
Hypertensi on	80- 84	163	113, 689	\$6, 491, 329	\$39, 824	697. 5	\$57
Hypertensi on	85- 89	81	34, 742	\$1, 984, 917	\$24, 505	428. 9	\$57
Hypertension	90+	33	10, 259	\$524, 823	\$15, 904	310. 9	\$51
Diagnosis Category Sub-Total		458	<i>274, 059</i>	<i>\$16, 297, 294</i>	\$35, 5 84	598. 4	\$59

Appendi x: G - 5

Nursing Home Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Days	Payments	Average Total Paynent	Average Claim Days	Average Per Day
Ill-Defined and Misc Conditions	00- 64	13	1, 468	\$73, 949	\$5, 688	112. 9	\$50
Ill-Defined and Misc Conditions	65- 69	55	21, 178	\$1, 468, 841	\$26, 706	385. 1	\$69
Ill-Defined and Misc Conditions	70- 74	175	82, 620	\$5, 760, 071	\$32, 915	472. 1	\$70
Ill-Defined and Misc Conditions	75- 79	344	130, 167	\$9, 512, 912	\$27, 654	378. 4	\$73
Ill-Defined and Misc Conditions	80- 84	463	207, 210	\$14, 900, 734	\$32, 183	447. 5	\$72
Ill-Defined and Misc Conditions	85- 89	320	125, 521	\$8, 941, 246	\$27, 941	392. 3	\$71
Ill-Defined and Misc Conditions	90+	80	22, 976	\$1, 563, 336	\$19, 542	287. 2	\$68
Diagnosis Category Sub-Total		1, 450	<i>591, 140</i>	\$42, 221, 089	<i>\$29, 118</i>	407. 7	\$71
Injury	00- 64	44	10, 256	\$584, 289	\$13, 279	233. 1	\$57
Inj ury	65- 69	146	44, 700	\$3, 474, 322	\$23, 797	306. 2	\$78
I nji ury	70- 74	479	147, 559	\$10, 827, 243	\$22, 604	308. 1	\$73
I nj ury	75- 79	1, 007	361, 719	\$24, 218, 876	\$24, 051	359. 2	\$67
I nj ury	80- 84	1, 360	558, 488	\$36, 801, 391	\$27, 060	410. 7	\$66
I nji ury	85- 89	901	329, 011	\$20, 357, 907	\$22, 595	365. 2	\$62
I nj ury	90+	242	70, 689	\$3, 962, 790	\$16, 375	292. 1	\$56
Diagnosis Category Sub-Total		4, 179	1, 522, 422	\$100, 226, 818	<i>\$23, 983</i>	<i>364. 3</i>	\$66
Mental	00- 64	12	7, 620	\$721, 802	\$60, 150	635. 0	\$95
Mental	65- 69	52	39, 111	\$3, 317, 542	\$63, 799	752 . 1	\$85
Mental	70- 74	161	119, 423	\$8, 176, 248	\$50, 784	741.8	\$68
Mental	75- 79	251	159, 941	\$10, 063, 201	\$40, 092	637. 2	\$63
Mental	80- 84	293	183, 048	\$10, 433, 992	\$35, 611	624. 7	\$57
Mental	85- 89	111	49, 389	\$2, 908, 731	\$26, 205	444. 9	\$59
Mental	90+	15	4, 712	\$252, 762	\$16, 851	314. 1	\$54
Diagnosis Category Sub-Total		895	563, 244	\$35, 874, 278	\$40, 083	<i>629. 3</i>	\$64

Appendix: G - 5

Nursing Home Claims: Diagnosis Category by Attained Age Summary

Di agnos i s Category	Attai ned Age Band	Age Band Tally	Days	Paynents	Average Total Paynent	Average Claim Days	Average Per Day
Nervous System and Sense Organs	00- 64	214	22, 204	\$14, 756, 809	\$68, 957	103. 8	\$665
Nervous System and Sense Organs	65- 69	108	49, 519	\$4, 029, 083	\$37, 306	458. 5	\$81
Nervous System and Sense Organs	70- 74	238	145, 265	\$10, 776, 379	\$45, 279	610. 4	\$74
Nervous System and Sense Organs	75- 79	400	235, 958	\$15, 857, 872	\$39, 645	589. 9	\$67
Nervous System and Sense Organs	80- 84	326	164, 135	\$10, 429, 754	\$31, 993	503. 5	\$64
Nervous System and Sense Organs	85- 89	152	73, 647	\$4, 498, 396	\$29, 595	484. 5	\$61
Nervous System and Sense Organs	90+	21	10, 850	\$609, 321	\$29, 015	516. 7	\$56 <i>\$87</i>
Diagnosis Category Sub-Total		1, 459	701, 578	\$60, 957, 614	\$41, 780	480. 9	307
Pregnancy Disorders	00- 64	4	72	\$11, 284	\$2, 821	18. 0	\$157
Pregnancy Disorders	65- 69	3	1, 536	\$106, 870	\$35, 623	512. 0	\$70
Pregnancy Di sorders	70- 74	6	4, 195	\$222, 590	\$37, 098	699. 2	\$53
Pregnancy Disorders	75- 79	10	2, 344	\$105, 420	\$10, 542	234. 4	\$45
Pregnancy Disorders	80- 84	10	4, 526	\$222, 180	\$22, 218	452. 6	\$49
Pregnancy Disorders	85- 89	11	4, 932	\$251, 600	\$22, 873	448. 4	\$51
Pregnancy Disorders	90+	1	31	\$660	\$660	31.0	\$21
Diagnosis Category Sub-Total		45	17, 636	\$920, 604	<i>\$20, 458</i>	391. 9	\$52
Respiratory	00- 64	21	2, 249	\$320, 769	\$15, 275	107. 1	\$143
Respiratory	65-69	77	32, 379	\$2, 472, 802	\$32, 114	420. 5	\$76
Respiratory	70- 74	235	69, 875	\$5, 070, 874	\$21, 578	297. 3	\$73
Respi ratory	75- 79	548	169, 549	\$11, 882, 319	\$21, 683	309. 4	\$70
Respiratory	80- 84	571	210, 054	\$13, 752, 817	\$24, 085	367. 9	\$65
Respiratory	85-89	308	93, 545	\$5, 728, 094	\$18, 598	303. 7	\$61
Respiratory	90+	84	26, 132	\$1, 415, 517	\$16, 851	311. 1	\$54
Diagnosis Category Sub-Total		1, 844	603, 783	\$40, 643, 192	<i>\$22, 041</i>	327. 4	\$67
Skin and Subcutaneous Tissue	00- 64	2	53	\$3, 986	\$1, 993	26. 5	\$75
Skin and Subcutaneous Tissue	65- 69	8	1, 056	\$75, 028	\$9, 379	132. 0	\$71
Skin and Subcutaneous Tissue	70- 74	27	9, 630	\$680, 174	\$25, 192	356. 7	\$71
Skin and Subcutaneous Tissue	75- 79	52	24, 564	\$1, 634, 503	\$31, 433	472. 4	\$67
Skin and Subcutaneous Tissue	80- 84	58	23, 714	\$1, 414, 706	\$24, 391	408. 9	\$60
Skin and Subcutaneous Tissue	85- 89	37	9, 808	\$639, 444	\$17, 282	265. 1	\$65
Skin and Subcutaneous Tissue	90+	7	962	\$52, 660	\$7, 523	137. 4	\$55
Diagnosis Category Sub-Total	: - - - C	191	69, 787	\$4, 500, 501	\$23, 563	<i>365. 4</i>	\$64

Society of Actuaries Long Term Care Committee 1984 - 1999 Intercompany Experience Study

Appendix: G - 5

Nursing Home Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attai ned Age Band	Age Band Tally	Days	Paynents	Average Tota l Paynent	Average Claim Days	Average Per Day
Stroke	00- 64	88	18, 715	\$3, 142, 701	\$35, 713	212. 7	\$168
Stroke	65- 69	176	83, 833	\$8, 259, 852	\$46, 931	476. 3	\$99
Stroke	70- 74	612	289, 123	\$21, 920, 421	\$35, 818	472. 4	\$76
Stroke	75- 79	1, 130	527, 603	\$36, 876, 890	\$32, 634	466. 9	\$70
Stroke	80-84	1, 295	592, 786	\$40, 592, 421	\$31, 345	457. 7	\$68
Stroke	85- 89	668	283, 249	\$17, 855, 425	\$26, 730	424. 0	\$63
Stroke	90+	109	35, 884	\$1, 907, 558	\$17, 501	329. 2	\$53

Diagnosis Category Sub-Total		4, 078	1, 831, 193	\$130, 555, 268	\$32, 015	449. 0	\$71
Other/Unknown Other/Unknown Other/Unknown Other/Unknown Other/Unknown Other/Unknown Other/Unknown Other/Unknown Diagnosis Category Sub-Total	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89 90+	280 741 2, 168 3, 899 4, 119 2, 141 527 13, 875	65, 117 181, 162 570, 350 1, 123, 350 1, 209, 936 607, 884 134, 899 3, 892, 698	\$5, 882, 136 \$13, 156, 276 \$39, 206, 406 \$71, 245, 867 \$70, 811, 485 \$33, 152, 686 \$6, 791, 559 \$240, 246, 415	\$21, 008 \$17, 755 \$18, 084 \$18, 273 \$17, 191 \$15, 485 \$12, 887 \$17, 315	232. 6 244. 5 263. 1 288. 1 293. 7 283. 9 256. 0 280. 6	\$90 \$73 \$69 \$63 \$59 \$55 \$50 \$62
Total		45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendi x: G - 5

Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Visits	Payments	Average Total Paynents	Average Claim Visits	Average Per Vi si t
Al zhei mer's	00- 64	41	12, 871	\$818, 804	\$19, 971	313. 9	\$64
Alzheimer's	65- 69	56	14, 874	\$1, 013, 067	\$18, 090	265. 6	\$68
Al zhei mer's	70- 74	121	24, 428	\$1, 841, 421	\$15, 218	201. 9	\$75
Al zhei mer's	75- 79	204	36, 739	\$2, 910, 335	\$14, 266	180. 1	\$79
Al zhei mer's	80- 84	215	34, 352	\$2, 468, 928	\$11, 483	159. 8	\$72
Al zhei mer's	85-89	108	25, 738	\$1, 857, 718	\$17, 201	238. 3	\$72
Al zhei mer's	90+	24	10, 486	\$583, 124	\$24, 297	436. 9	\$56
Diagnosis Category Sub-Total		769	159, 488	\$11, 493, 397	\$14, 946	207. 4	\$72
Arthritis	00- 64	35	4, 552	\$201, 118	\$5, 746	130. 1	\$44
Arthri ti s	65- 69	42	5, 405	\$484, 405	\$11, 533	128. 7	\$90
Arthri ti s	70- 74	90	3, 774	\$247, 887	\$2, 754	41. 9	\$66
Arthritis	75- 79	109	8, 277	\$694, 392	\$6, 371	75. 9	\$84
Arthritis	80- 84	110	18, 401	\$1, 078, 947	\$9, 809	167. 3	\$59
Arthritis	85-89	49	7, 839	\$589, 560	\$12, 032	160. 0	\$75
Arthritis	90+	15	6, 461	\$226, 959	\$15, 131	430. 7	\$35
Diagnosis Category Sub-Total		450	54, 709	\$3, 523, 268	\$7, 829	121. 6	\$64
Cancer	00- 64	136	14, 131	\$769, 667	\$5, 659	103. 9	\$54
Cancer	65-69	112	9, 356	\$528, 457	\$4, 718	83. 5	\$56
Cancer	70- 74	163	12, 864	\$916, 161	\$5, 621	78. 9	\$71
Cancer	75- 79	142	9, 969	\$575, 040	\$4,050	70. 2	\$58
Cancer	80- 84	99	4, 969	\$489, 178	\$4, 941	50. 2	\$98
Cancer	85-89	37	3, 807	\$226, 963	\$6, 134	102. 9	\$60
Cancer	90+	8	1, 091	\$55, 715	\$6, 964	136. 4	\$51
Diagnosis Category Sub-Total		697	<i>56, 187</i>	\$3, 561, 181	<i>\$5, 109</i>	<i>80. 6</i>	\$63

Appendix: G - 5

Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Visits	Paynents	Average Total Payments	Average Claim Visits	Average Per Visit
Ci rcul atory	00- 64	25	6, 899	\$196, 931	\$7, 877	276. 0	\$29
Ci rcul atory	65- 69	57	5, 480	\$177, 436	\$3, 113	96. 1	\$32
Circulatory	70- 74	89	5, 461	\$556, 536	\$6, 253	61. 4	\$102
Circulatory	75- 79	132	15, 063	\$650, 100	\$4, 925	114. 1	\$43
Ci rcul atory	80- 84 85- 89	108 75	16, 435 11, 411	\$965, 967 \$832, 033	\$8, 944 \$11, 094	152. 2 152. 1	\$59 \$73
Ci rcul atory Ci rcul atory	90+	20	5, 667	\$382, 747	\$11, 094 \$19, 137	283. 4	\$68
Diagnosis Category Sub-Total	30+	506	66, 416	\$3, 761, 750	\$7, 434	131. 3	\$57
Congeni tal	75- 79	1	0	\$1, 186	\$1, 186	0. 0	0
Congenital	80- 84	$\bar{4}$	350	\$38, 103	\$9, 526	87. 5	\$109
Diagnosis Category Sub-Total		5	350	\$39, 289	\$7, 858	70. 0	\$112
Di abetes	00- 64	9	1, 014	\$43, 906	\$4, 878	112. 7	\$43
Di abetes	65- 69	2	419	\$40, 292	\$20, 146	209. 5	\$96
Di abetes	70- 74	9	311	\$68, 526	\$7,614	34. 6	\$220
Di abetes	75- 79	15	2, 207	\$118, 139	\$7, 876	147. 1	\$54
Di abetes	80- 84 85- 89	13 3	1, 211 47	\$52, 224 \$28, 044	\$4, 017 \$9, 348	93. 2 15. 7	\$43
Di abetes Di abetes	90+	ა 1	263	\$4, 933	\$4, 933	263. 0	\$597 \$19
Diagnosis Category Sub-Total	30+	52	5, 472	\$356, 064	\$6, 847	105. 2	\$65
Digestive System	00- 64	10	2, 051	\$110, 533	\$11, 053	205. 1	\$54
Digestive System	65- 69	6	45	\$5, 038	\$840	7. 5	\$112
Digestive System	70- 74	20	689	\$63, 525	\$3, 176	34. 5	\$92
Digestive System	75- 79	21	1, 509	\$71, 250	\$3, 393	71. 9	\$47
Digestive System	80- 84	16	331	\$76, 803	\$4, 800	20. 7	\$232
Digestive System	85- 89	12	445	\$71, 469	\$5, 956	37. 1	\$161
Digestive System Piagnesis Catagony Sub Total	90+	4 89	786 5, 856	\$37, 508 \$436, 126	\$9, 377 \$4, 900	196. 5 65. 8	\$48 <i>\$74</i>
Diagnosis Category Sub-Total		09	<i>J, 6</i> 30	9 4 50, 120	<i>34, 900</i>	<i>03. 6</i>	3/4

Appendix: G - 5

Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Visits	Payments	Average Total Payments	Average Claim Visits	Average Per Visit
Endocrine, Immunity System	00- 64	2	1, 303	\$53, 360	\$26, 680	651. 5	\$41
Endocrine, Immunity System	65- 69	8	666	\$84, 528	\$10, 566	83. 3	\$127
Endocrine, Immunity System	70- 74	6 10	153 244	\$34, 253	\$5, 709	25. 5	\$224
Endocrine, Immunity System	75- 79 80- 84	10	498	\$70, 893 \$26, 333	\$7, 089 \$2, 633	24. 4 49. 8	\$291 \$53
Endocrine, Immunity System Endocrine, Immunity System	85- 89	10	1, 299	\$20, 333 \$94, 200	\$2, 633 \$8, 564	118. 1	\$73
Diagnosis Category Sub-Total	00-00	47	4, 163	\$363, 567	\$7, 735	88. 6	\$87
Diagnosis category bub rotar		17	1, 100	<i>4000, 001</i>	<i>\$1,100</i>	00. 0	<i>407</i>
Genitourinary System	00- 64	5	215	\$36, 818	\$7, 364	43. 0	\$171
Geni touri nary System	65- 69	6	1, 634	\$72, 071	\$12,012	272. 3	\$44
Geni touri nary System	70- 74	8	22	\$26, 192	\$3, 274	2.8	\$1, 191
Geni touri nary System	75- 79	13	461	\$19, 368	\$1, 490	35. 5	\$42
Genitourinary System	80- 84	8	199	\$32, 844	\$4, 106	24. 9	\$165
Genitourinary System	85- 89	5	183	\$19,601	\$3, 920	36. 6	\$107
Genitourinary System	90+	2	81	\$1, 260	\$630	40. 5	\$16
Diagnosis Category Sub-Total		47	2, 795	<i>\$208, 154</i>	\$4, 429	<i>59. 5</i>	\$74
Hypertensi on	65- 69	3	588	\$48, 297	\$16, 099	196. 0	\$82
Hypertension	70- 74	5	79	\$9, 692	\$1, 938	15. 8	\$123
Hypertension	75- 79	15	318	\$114, 164	\$7, 611	21. 2	\$359
Hypertensi on	80- 84	13	1, 577	\$115, 787	\$8, 907	121. 3	\$73
Hypertensi on	85- 89	6	0	\$42, 754	\$7, 126	0. 0	0
Diagnosis Category Sub-Total		42	2, 562	\$330, 694	\$7, 874	<i>61. 0</i>	\$1 2 9
Ill-Defined and Misc Conditions	00- 64	1	54	\$3, 780	\$3, 780	54. 0	\$70
Ill-Defined and Misc Conditions	65- 69	$\bar{7}$	94	\$10, 939	\$1, 563	13. 4	\$116
Ill-Defined and Misc Conditions	70- 74	26	1, 237	\$91, 302	\$3, 512	47. 6	\$74
Ill-Defined and Misc Conditions	75- 79	33	2, 027	\$134, 188	\$4,066	61. 4	\$66
Ill-Defined and Misc Conditions	80- 84	47	4, 814	\$358, 526	\$7, 628	102. 4	\$74
Ill-Defined and Misc Conditions	85- 89	22	3, 795	\$231, 412	\$10, 519	172. 5	\$61
Ill-Defined and Misc Conditions	90+	12	4, 345	\$292, 691	\$24, 391	362. 1	\$67
Diagnosis Category Sub-Total		148	16, 366	\$1, 122, 838	<i>\$7. 587</i>	110. 6	\$69

Appendix: G - 5

Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary

Di agnos i s Category	Attai ned Age Band	Age Band Tally	Visits	Paynents	Average Total Payments	Average Claim Visits	Average Per Visit
Injury	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89 90+	48 58 117 160 195 96 32 706	13, 848 3, 133 9, 215 11, 562 17, 841 11, 607 10, 570 77, 776	\$770, 003 \$207, 296 \$684, 894 \$790, 439 \$1, 046, 089 \$758, 804 \$418, 687 \$4, 676, 212	\$16, 042 \$3, 574 \$5, 854 \$4, 940 \$5, 365 \$7, 904 \$13, 084 \$6, 624	288. 5 54. 0 78. 8 72. 3 91. 5 120. 9 330. 3 110. 2	\$56 \$66 \$74 \$68 \$59 \$65 \$40 \$60
Mental Mental Mental Mental Mental Mental Diagnosis Category Sub-Total	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89	3 8 12 19 19 2 63	1, 473 219 190 1, 847 1, 039 0 4, 768	\$34, 760 \$34, 336 \$27, 770 \$154, 670 \$277, 251 \$25, 511 \$554, 298	\$11, 587 \$4, 292 \$2, 314 \$8, 141 \$14, 592 \$12, 756 \$8, 798	491. 0 27. 4 15. 8 97. 2 54. 7 0. 0 75. 7	\$24 \$157 \$146 \$84 \$267 0 \$116
Nervous System and Sense Organs Organs Category Sub-Total	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89 90+	117 30 36 52 30 25 2 292	47, 061 7, 323 4, 989 10, 358 4, 054 4, 846 781 79, 412	\$3, 223, 991 \$402, 416 \$663, 682 \$810, 512 \$412, 574 \$380, 435 \$37, 410 \$5, 931, 020	\$27, 555 \$13, 414 \$18, 436 \$15, 587 \$13, 752 \$15, 217 \$18, 705 \$20, 312	402. 2 244. 1 138. 6 199. 2 135. 1 193. 8 390. 5 272. 0	\$69 \$55 \$133 \$78 \$102 \$79 \$48 <i>\$75</i>
Pregnancy Di sorders Di agnosis Category Sub-Total	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89	6 1 1 3 1 2 14	221 0 0 0 0 0 0 221	\$13, 549 \$631 \$5, 810 \$36, 253 \$1, 740 \$4, 480 \$62, 463	\$2, 258 \$631 \$5, 810 \$12, 084 \$1, 740 \$2, 240 \$4, 462	36. 8 0. 0 0. 0 0. 0 0. 0 0. 0 15. 8	\$61 0 0 0 0 0 \$283

Society of Actuaries Long Term Care Committee 1984 - 1999 Intercompany Experience Study

Appendi x: G - 5

Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary

Di agnosi s Category	Attained Age Band	Age Band Tally	Visits	Payments	Average Total Paynents	Average Claim Visits	Average Per Visit
Respi ratory	00- 64	12	842	\$53, 056	\$4, 421	70. 2	\$63
Respi ratory	65- 69	12	1, 411	\$32, 051	\$2, 671	117. 6	\$23
Respi ratory	70- 74	44	6, 264	\$495, 393	\$11, 259	142. 4	\$79
Respi ratory	75- 79	41	5, 304	\$395, 489	\$9, 646	129. 4	\$75
Respi ratory	80- 84	48	2, 574	\$372, 786	\$7, 766	53. 6	\$145
Respi ratory	85- 89	23	643	\$160, 112	\$6, 961	28. 0	\$249

Respiratory Diagnosis Category Sub-Total	90+	7 187	3, 057 20, 095	\$92, 057 \$1, 600, 944	\$13, 151 \$8, 561	436. 7 107. 5	\$30 \$80
Skin and Subcutaneous Tissue	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89 90+	2 7 4 5 4 4 2 28	10 39 2, 281 207 1, 280 0 0 3, 817	\$1, 254 \$7, 304 \$111, 910 \$17, 035 \$55, 820 \$68, 884 \$6, 808 \$269, 015	\$627 \$1, 043 \$27, 978 \$3, 407 \$13, 955 \$17, 221 \$3, 404 \$9, 608	5. 0 5. 6 570. 3 41. 4 320. 0 0. 0 0. 0 136. 3	\$125 \$187 \$49 \$82 \$44 0 0 \$70
Stroke Stroke Stroke Stroke Stroke Stroke Stroke Diagnosis Category Sub-Total	00- 64 65- 69 70- 74 75- 79 80- 84 85- 89 90+	53 51 95 146 120 59 14 538	11, 539 9, 030 17, 142 18, 204 15, 665 9, 151 5, 237 85, 968	\$826, 276 \$463, 177 \$1, 323, 892 \$1, 479, 862 \$1, 387, 028 \$621, 506 \$338, 049 \$6, 439, 790	\$15, 590 \$9, 082 \$13, 936 \$10, 136 \$11, 559 \$10, 534 \$24, 146 \$11, 970	217. 7 177. 1 180. 4 124. 7 130. 5 155. 1 374. 1 159. 8	\$72 \$51 \$77 \$81 \$89 \$68 \$65 \$75

Appendi x: G - 5

Home Health Care/ADC/Other Claims: Diagnosis Category by Attained Age Summary

Di agnos i s Category	Attained Age Band	Age Band Tally	Visits	P ayn e nts	Average Total Payments	Average Claim Visits	Average Per Visit
Other/Unknown	00- 64	121	17, 929	\$1, 083, 117	\$8, 951	148. 2	\$60
Other/Unknown	65- 69	119	5, 451	\$1, 475, 229	\$12, 397	45. 8	\$271
Other/Unknown	70- 74	254	14, 848	\$1, 713, 578	\$6, 746	58 . 5	\$115
Other/Unknown	75- 79	282	17, 608	\$1, 825, 649	\$6, 474	62. 4	\$104
Other/Unknown	80- 84	210	12, 549	\$1, 888, 518	\$8, 993	59. 8	\$150
Other/Unknown	85-89	102	4, 377	\$653, 148	\$6, 403	42. 9	\$149
Other/Unknown	90+	27	1, 301	\$127, 477	\$4, 721	48. 2	\$98
Diagnosis Category Sub-Total		1, 115	74, 063	<i>\$8, 766, 716</i>	\$7, 863	<i>66. 4</i>	\$118
Total		5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendi x: G - 6

Di agnosi s Category	Durati on	Tally	Days	Total Payments	Average Cl ai m Payment	Average Days	Average Per Day
Al zhei mer' s	1	536	396, 825	\$32, 691, 775	\$60, 992	740. 3	\$82
Al zhei mer's	2 3	752	526, 443	\$43, 553, 743	\$57, 917	700. 1	\$83
Al zhei mer's	3	822	583, 995	\$46, 683, 068	\$56, 792	710. 5	\$80
Al zhei mer's	4	785	491, 834	\$40, 167, 718	\$51, 169	626. 5	\$82
Alzhei mer's	5	659	401, 470	\$32, 649, 441	\$49, 544	609. 2	\$81
Al zhei mer's	6 7	570	350, 305	\$29, 194, 740	\$51, 219	614. 6	\$83
Alzhei mer's Alzhei mer's	8	495	293, 703	\$23, 676, 882	\$47, 832	593. 3 549. 4	\$81
Al zhei mer's Al zhei mer's	9+	346 822	190, 076 368, 605	\$15, 026, 429 \$25, 408, 717	\$43, 429 \$30, 911	349. 4 448. 4	\$79 \$69
Diagnosis Category Sub-Total	3 T	5. 787	3, 603, 256	\$289, 052, 513	\$49, 949	622. 6	\$80
Diagnosis category bub rotar		0, 707	0, 000, 200	\$200, 002, 010	010, 010	022. 0	ψOU
Arthritis	1	231	101, 639	\$7, 842, 171	\$33, 949	440. 0	\$77
Arthritis	2	296	130, 307	\$9, 245, 123	\$31, 234	440. 2	\$71
Arthri ti s	3	294	127, 415	\$9, 325, 569	\$31, 720	433. 4	\$73
Arthritis	4	258	103, 975	\$6, 698, 509	\$25, 963	403. 0	\$64
Arthritis	5	238	79, 042	\$5, 767, 884	\$24, 235	332. 1	\$73
Arthritis	6	192	65, 096	\$4, 411, 276	\$22, 975	339. 0	\$68
Arthritis	7	151	59, 044	\$3, 989, 883	\$26, 423	391. 0	\$68
Arthritis	8	119	33, 552	\$2, 533, 534	\$21, 290	281. 9	\$76
Arthritis Diagnosis Category Sub-Total	9+	229 2, 008	66, 850 766, 920	\$4, 491, 289 \$54, 305, 238	\$19, 613 <i>\$27</i> , <i>044</i>	291. 9 381. 9	\$67 \$71
Diagnosis Category Sub-total		۵, 000	700, 320	334, 303, 238	327, 044	361. 9	3/1
Cancer	1	345	69, 843	\$5, 295, 970	\$15, 351	202. 4	\$76
Cancer	$ar{2}$	444	82, 790	\$5, 857, 797	\$13, 193	186. 5	\$71
Cancer	$\frac{\overline{2}}{3}$	430	81, 411	\$5, 802, 177	\$13, 493	189. 3	\$71
Cancer	4	377	60, 179	\$4, 329, 315	\$11, 484	159. 6	\$72
Cancer	4 5 6	333	56, 379	\$4, 163, 715	\$12, 504	169. 3	\$74
Cancer	6	242	33, 895	\$2, 575, 438	\$10, 642	140. 1	\$76
Cancer	7	177	29, 818	\$2, 386, 575	\$13, 483	168. 5	\$80
Cancer	8	142	18, 606	\$1, 398, 477	\$9, 848	131. 0	\$75
Cancer	9+	284	39, 937	\$2, 691, 171	\$9, 476	140.6	\$67
Diagnosis Category Sub-Total		2, 774	472, 858	\$34, 500, 635	\$12, 437	170. 5	\$73

Appendi x: G - 6

Di agnosi s Category	Durati on	Tal l y	Days	Total Payments	Average Cl ai m Payment	Average Days	Average Per Day
Ci rcul atory	1	492	257, 053	\$19, 104, 486	\$38, 830	522. 5	\$74
Ci rcul atory	2 3	485	265, 604	\$19, 553, 399	\$40, 316	547. 6	\$74
Ci rcul atory	3	470	223, 305	\$15, 578, 653	\$33, 146	475. 1	\$70
Ci rcul atory	4	495	223, 320	\$15, 466, 858	\$31, 246	451. 2	\$69
Ci rcul atory	5	449	189, 700	\$13, 116, 352	\$29, 212	422. 5	\$69
Ci rcul atory	6	360	136, 626	\$9, 227, 413	\$25, 632	379. 5	\$68
Ci rcul atory	7	302	116, 425	\$8, 011, 769	\$26, 529	385. 5	\$69
Ci rcul atory	8	279	108, 809	\$8, 034, 093	\$28, 796	390. 0	\$74
Ci rcul atory	9+	683	195, 611	\$12, 968, 861	\$18, 988	286. 4	\$66
Diagnosis Category Sub-Total		4, 015	1, 716, 453	<i>\$121, 061, 884</i>	\$30, 152	<i>427.</i> 5	\$71
Congeni tal	1	1	173	\$6, 975	\$6, 975	173. 0	\$40
Congenital	2	6	955	\$50, 540	\$8, 423	175. 0 159. 2	\$53
Congeni tal	$\tilde{3}$	6	2, 135	\$86, 370	\$14, 395	355. 8	\$40
Congeni tal	4	2	Σ, 133 22	\$860	\$430	11. 0	\$39
Congenital	6	ĩ	116	\$7, 800	\$7, 800	116. 0	\$67
Congenital	8	i	329	\$10, 475	\$10, 475	329. 0	\$32
Congeni tal	9+	3	384	\$24, 380	\$8, 127	128. 0	\$63
Diagnosis Category Sub-Total	0.	20	4, 114	\$187, 400	\$9, 370	205. 7	\$46
g and a second of							, -
Di abetes	1	78	45, 418	\$3, 110, 268	\$39, 875	582 . 3	\$68
Di abetes	2 3	78	45, 581	\$3, 129, 241	\$40, 118	584 . 4	\$69
Diabetes	3	85	48, 641	\$3, 103, 674	\$36, 514	572. 2	\$64
Di abetes	4	73	29, 877	\$2, 399, 754	\$32, 873	409. 3	\$80
Di abetes	5	70	35, 675	\$2, 499, 485	\$35, 707	509. 6	\$70
Di abetes	6	54	29, 736	\$1, 902, 465	\$35, 231	550. 7	\$64
Di abetes	7	58	24, 563	\$1, 771, 771	\$30, 548	423. 5	\$72
Di abetes	8	36	14, 974	\$1, 143, 908	\$31, 775	415. 9	\$76
Diabetes	9+	79	28, 664	\$2, 091, 968	\$26, 481	362. 8	\$73
Diagnosis Category Sub-Total		611	303, 129	<i>\$21, 152, 534</i>	<i>\$34, 620</i>	<i>496.</i> 1	\$70

Appendix: G - 6

Di agnosi s Category	Durati on	Tally	Days	Total Payments	Average Claim Payment	Average Days	Average Per Day
Digestive System	1	64	28, 402	\$1, 983, 576	\$30, 993	443.8	\$70
Digestive System	2 3	87	36, 600	\$2, 569, 709	\$29, 537	420. 7	\$70
Digestive System		91	34, 205	\$2, 144, 539	\$23, 566	375. 9	\$63
Digestive System	4	84	38, 063	\$2, 518, 079	\$29, 977	453. 1	\$66
Digestive System	5	65	21, 579	\$1, 391, 431	\$21, 407	332. 0	\$64
Digestive System	6 7	73	32, 056	\$2, 268, 097	\$31, 070	439. 1	\$71
Digestive System Digestive System	8	60 49	23, 740 23, 674	\$1, 799, 128 \$1, 605, 123	\$29, 985 \$32, 758	395. 7 483. 1	\$76 \$ 68
Digestive System	9+	111	30, 543	\$1, 887, 066	\$17, 001	275. 2	\$62
Diagnosis Category Sub-Total	01	684	268, 862	\$18, 166, 748	\$26, 560	393. 1	\$68
2149-0010 04008017 0410 10041		001	200, 002	¥10, 100, 710	420, 000	000.1	ţ CC
Endocrine, Immunity System	1	48	26, 627	\$2, 136, 068	\$44, 501	554. 7	\$80
Endocrine, Immunity System	2	34	21, 313	\$1, 400, 826	\$41, 201	626. 9	\$66
Endocrine, Immunity System	3	40	23, 337	\$1, 405, 393	\$35, 135	583. 4	\$60
Endocrine, Immunity System	4	47	23, 526	\$1, 478, 327	\$31, 454	500. 6	\$63
Endocrine, Immunity System	4 5 6 7	40	20, 102	\$1, 283, 148	\$32, 079	502. 6	\$64
Endocrine, Immunity System Endocrine, Immunity System	6 7	50 39	23, 322 14, 716	\$1, 253, 639 \$992, 945	\$25, 073 \$25, 460	466. 4 377. 3	\$54 \$67
Endocrine, Immunity System	8	41	15, 872	\$988, 933	\$23, 400 \$24, 120	387. 1	\$62
Endocrine, Immunity System Endocrine, Immunity System	9+	108	31, 946	\$1, 973, 095	\$18, 269	295. 8	\$62
Diagnosis Category Sub-Total	01	447	200, 761	\$12, 912, 374	\$28, 887	449. 1	\$6 4
Genitourinary System	1	37	14, 794	\$1, 449, 747	\$39, 182	399. 8	\$98
Genitourinary System	2 3	52	23, 548	\$1, 523, 662	\$29, 301	452. 8	\$65
Genitourinary System	3	68	25, 640	\$1, 665, 956	\$24, 499	377. 1	\$65
Genitourinary System Genitourinary System	4 5	72 64	24, 416 24, 230	\$1, 797, 716 \$1, 613, 711	\$24, 968 \$25, 214	339. 1 378. 6	\$74 \$67
Geni touri nary System	6	43	15, 725	\$1, 013, 711 \$1, 206, 442	\$28, 057	365. 7	\$77
Geni touri nary System	7	42	7, 683	\$513, 523	\$12, 227	182. 9	\$67
Geni touri nary System	8	$3\tilde{7}$	14, 458	\$1, 220, 272	\$32, 980	390. 8	\$84
Geni touri nary System	9+	101	24, 593	\$1, 589, 067	\$15, 733	243. 5	\$65
Diagnosis Category Sub-Total		516	175, 087	\$12, 580, 096	<i>\$24, 380</i>	339. 3	\$72

Appendix: G - 6

Di agnosi s Cat egory	Durati on	Tal l y	Days	Total Payments	Average Cl ai m Payment	Average Days	Average Per Day
		-	40.001	00 000 700	050 400	004.1	070
Hypertensi on	1	51	42, 031	\$3, 030, 508	\$59, 422	824. 1	\$72
Hypertensi on	2 3	51 58	34, 652	\$2, 078, 050	\$40, 746	679. 5	\$60
Hypertensi on			41, 860	\$2, 501, 189	\$43, 124	721. 7	\$60
Hypertensi on	4	67	41, 474	\$2, 530, 300	\$37, 766	619. 0 576. 9	\$61
Hypertensi on Hypertensi on	5 6	52 42	29, 999 27, 954	\$1, 754, 506 \$1, 352, 274	\$33, 741 \$32, 197	665. 6	\$58 \$48
Hypertensi on	7	36	14, 565	\$777, 142	\$21, 587	404. 6	\$53
Hypertensi on	8	27	15, 582	\$847, 180	\$31, 377	577. 1	\$54
Hypertensi on	9+	74	25, 942	\$1, 426, 145	\$19, 272	350. 6	\$55
Diagnosis Category Sub-Total	J T	458	274, 059	\$16, 297, 294	\$35, 584	598. 4	\$59
Diagnosis category bas rotar		100	271,000	010, 207, 201	000, 001	000. 1	000
Ill-Defined and Misc Conditions	1	182	81, 118	\$5, 451, 765	\$29, 955	445. 7	\$67
Ill-Defined and Misc Conditions	$ar{2}$	129	67, 661	\$4, 241, 103	\$32, 877	524. 5	\$63
Ill-Defined and Misc Conditions	3	135	59, 902	\$4, 370, 744	\$32, 376	443. 7	\$73
Ill-Defined and Misc Conditions	$ar{4}$	163	73, 918	\$5, 419, 226	\$33, 247	453. 5	\$73
Ill-Defined and Misc Conditions	5	162	62, 853	\$4, 329, 759	\$26, 727	388. 0	\$69
Ill-Defined and Misc Conditions	6	131	58, 954	\$4, 469, 838	\$34, 121	450.0	\$76
Ill-Defined and Misc Conditions	7	128	58, 886	\$4, 387, 254	\$34, 275	460. 0	\$75
Ill-Defined and Misc Conditions	8	108	39, 971	\$3, 013, 776	\$27, 905	370. 1	\$75
Ill-Defined and Misc Conditions	9+	312	87, 877	\$6, 537, 624	\$20, 954	281. 7	\$74
Diagnosis Category Sub-Total		1, 450	591, 140	\$42, 221, 089	\$29, 118	407. 7	\$71
I nj ury	1	489	174, 760	\$12, 425, 781	\$25, 411	357. 4	\$71
Injury	$\dot{2}$	484	203, 453	\$13, 388, 964	\$27, 663	420. 4	\$66
Injury	3	489	196, 516	\$12, 538, 642	\$25, 641	401. 9	\$64
Injury	4	490	183, 138	\$12, 049, 331	\$24, 590	373. 8	\$66
Injury	$\bar{5}$	438	167, 910	\$11, 570, 166	\$26, 416	383. 4	\$69
Injury	6	382	138, 800	\$8, 693, 263	\$22, 757	363. 4	\$63
I nj ury	7	344	128, 535	\$8, 431, 305	\$24, 510	373. 6	\$66
I nji ury	8	298	101, 562	\$6, 700, 367	\$22, 484	340.8	\$66
I nji ury	9+	765	227, 748	\$14, 428, 999	\$18, 861	297. 7	\$63
Diagnosis Category Sub-Total		4, 179	1, 522, 422	\$100, 226, 818	\$23, 983	<i>364. 3</i>	\$66

Appendi x: G - 6

Di agnosi s	D	m 11	D.	Total	Average Claim	Average	Average Per
Category	Durati on	Tal l y	Days	<i>Payments</i>	Payment	Days	Day
Mental	1	118	99, 424	\$7, 191, 930	\$60, 949	842. 6	\$72
Mental	2	142	95, 662	\$6, 910, 203	\$48, 663	673. 7	\$72
Mental	2 3	171	120, 398	\$7, 107, 696	\$41, 565	704. 1	Š 59
Mental	4	138	76, 732	\$4, 795, 000	\$34, 746	556. 0	\$62
Mental	5	97	54, 286	\$3, 210, 385	\$33, 097	559. 6	\$59
Mental	6	73	37, 754	\$2, 063, 668	\$28, 269	517. 2	\$55
Mental	7	56	35, 125	\$1, 938, 021	\$34, 608	627 . 2	\$55
Mental	8	30	12, 210	\$674, 268	\$22, 476	407. 0	\$55
Mental	9+	70	31, 653	\$1, 983, 107	\$28, 330	452. 2	\$63
Diagnosis Category Sub-Total		895	<i>563, 244</i>	\$35, 874, 278	\$40, 083	<i>629. 3</i>	\$64
Nervous System and Sense Organs	1	201	109, 422	\$12, 612, 599	\$62, 749	544. 4	\$115
Nervous System and Sense Organs	$\overset{1}{2}$	178	96, 887	\$9, 329, 674	\$52, 414	544. 3	\$96
Nervous System and Sense Organs	3	175	93, 697	\$8, 040, 424	\$45, 945	535. 4	\$86
Nervous System and Sense Organs	4	210	106, 694	\$8, 766, 069	\$41, 743	508. 1	\$82
Nervous System and Sense Organs	5	165	73, 428	\$6, 055, 662	\$36, 701	445. 0	\$82
Nervous System and Sense Organs	6	126	56, 586	\$4, 184, 521	\$33, 210	449. 1	\$74
Nervous System and Sense Organs	7	119	44, 256	\$4, 101, 332	\$34, 465	371.9	\$93
Nervous System and Sense Organs	8	108	46, 724	\$3, 308, 305	\$30, 632	432. 6	\$71
Nervous System and Sense Organs	9+	177	73, 884	\$4, 559, 028	\$25, 757	417. 4	\$62
Diagnosis Category Sub-Total		1, 459	701, 578	\$60, 957, 614	<i>\$41, 780</i>	<i>480. 9</i>	\$87
Duagnanay Di gandana	1	e	1 001	0121 010	001 007	303. 5	\$72
Pregnancy Di sorders Pregnancy Di sorders	$\overset{1}{2}$	6 5	1, 821 1, 506	\$131, 019 \$82, 070	\$21, 837 \$16, 414	303. 5 301. 2	\$72 \$54
Pregnancy Disorders	3	7	3, 893	\$190, 615	\$27, 231	556. 1	\$49
Pregnancy Disorders		9	2, 795	\$137, 380	\$15, 264	310. 6	\$49
Pregnancy Disorders	4 5	$\overset{\mathtt{o}}{4}$	$\tilde{1}, 707$	\$73, 870	\$18, 468	426. 8	\$43
Pregnancy Disorders	6	3	3, 510	\$175, 550	\$58, 517	1, 170. 0	\$50
Pregnancy Disorders	7	4	929	\$37, 790	\$9, 448	232. 3	\$41
Pregnancy Disorders	8	1	32	\$1, 280	\$1, 280	32. 0	\$40
Pregnancy Di sorders	9+	6	1, 443	\$91, 030	\$15, 172	240. 5	\$63
Diagnosis Category Sub-Total		45	17, 636	<i>\$920, 604</i>	<i>\$20, 458</i>	391. 9	<i>\$52</i>

Appendix: G - 6

Di agnosi s Category	Durati on	Tally	Days	Total Payments	Average Cl ai m Payment	Average Days	Average Per Day
Respiratory	1	139	65, 715	\$4, 341, 608	\$31, 235	472. 8	\$66
<u>Respi</u> ratory	2	180	76, 893	\$5, 332, 475	\$29, 625	427. 2	\$69
Respiratory	3	215	72, 919	\$5, 102, 418	\$23, 732	339. 2	\$70
Respi ratory	4	210	69, 421	\$4, 689, 845	\$22, 333	330. 6	\$68
Respi ratory	5	167	56, 259	\$3, 793, 327	\$22, 715	336. 9	\$67
Respiratory	6	179	52, 939	\$3, 600, 491	\$20, 114	295. 7	\$68
Respiratory	7	173	54, 640	\$3, 957, 851	\$22, 878	315. 8	\$72
Respiratory	8 9+	150	51, 418	\$3, 541, 669	\$23, 611	342. 8	\$69
Respiratory	9+	431	103, 579	\$6, 283, 508	\$14, 579	240. 3	\$61
Diagnosis Category Sub-Total		1, 844	603, 783	\$40, 643, 192	\$22, 041	327. 4	\$67
Skin and Subcutaneous Tissue	1	22	6, 409	\$401, 048	\$18, 229	291. 3	\$63
Skin and Subcutaneous Tissue	2	15	7, 406	\$425, 994	\$28, 400	493. 7	\$58
Skin and Subcutaneous Tissue	2 3	20	10, 120	\$709, 711	\$35, 486	506. 0	\$70
Skin and Subcutaneous Tissue	4	21	6, 816	\$448, 721	\$21, 368	324. 6	\$66
Skin and Subcutaneous Tissue	5	20	12, 357	\$802, 016	\$40, 101	617. 9	\$65
Skin and Subcutaneous Tissue	6	27	11, 079	\$691, 370	\$25,606	410. 3	\$62
Skin and Subcutaneous Tissue	7	11	3, 345	\$290, 058	\$26, 369	304. 1	\$87
Skin and Subcutaneous Tissue	8	13	1, 978	\$119, 440	\$9, 188	152. 2	\$60
Skin and Subcutaneous Tissue	9+	42	10, 277	\$612, 143	\$14, 575	244. 7	\$60
Diagnosis Category Sub-Total		191	69, 787	<i>\$4, 500, 501</i>	<i>\$23, 563</i>	365. 4	\$64
Stroke	1	426	233, 846	\$18, 438, 671	\$43, 283	548. 9	\$79
Stroke	$\hat{2}$	532	275, 662	\$20, 204, 776	\$37, 979	518. 2	\$73
Stroke	3	524	266, 538	\$19, 332, 090	\$36, 893	508. 7	\$73
Stroke	4	554	248, 560	\$16, 513, 092	\$29, 807	448. 7	\$66
Stroke	5	469	201, 704	\$14, 797, 125	\$31, 550	430. 1	\$73
Stroke	6	389	162, 239	\$11, 818, 133	\$30, 381	417. 1	\$73
Stroke	7	319	140, 800	\$9, 255, 543	\$29, 014	441. 4	\$66
Stroke	8	265	102, 565	\$7, 408, 416	\$27, 956	387. 0	\$72
Stroke	9+	600	199, 279	\$12, 787, 422	\$21, 312	332. 1	\$64
Diagnosis Category Sub-Total		4, 078	1, 831, 193	<i>\$130, 555, 268</i>	<i>\$32, 015</i>	<i>449. 0</i>	\$71

Appendi x: G - 6

Di agnosi s Category	Durati on	Tally	Days	Total Payments	Average Claim Payment	Average Days	Average Per Day
Other/Unknown	1	2, 911	809, 885	\$48, 107, 939	\$16, 526	278. 2	\$59
Other/Unknown	2	2, 426	663, 776	\$41, 427, 978	\$17,077	273.6	\$62
Other/Unknown	3	1, 884	489, 818	\$32, 699, 437	\$17, 356	260. 0	\$67
Other/Unknown	4	1, 327	360, 667	\$24, 090, 620	\$18, 154	271.8	\$67
Other/Unknown	5	1, 034	315, 485	\$20, 138, 667	\$19, 476	305. 1	\$64
Other/Unknown	6	805	220, 464	\$13, 565, 019	\$16, 851	273. 9	\$62
Other/Unknown	7	707	213, 424	\$13, 249, 634	\$18, 741	301.9	\$62
Other/Unknown	8	692	238, 618	\$14, 099, 629	\$20, 375	344. 8	\$59
Other/Unknown	9+	2, 089	580, 561	\$32, 867, 492	\$15, 734	277. 9	\$57
Diagnosis Category Sub-Total		13, 875	3, 892, 698	\$240, 246, 415	\$17, 315	<i>280. 6</i>	\$62
Total		45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendix: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s				Total	Average Cl ai m	Average	Average Per
Category	Durati on	Tal l y	Vi si ts	Payments	<i>Payments</i>	Vi si ts	Vi si t
Al zhei mer' s	1	93	30, 529	\$1, 762, 548	\$18, 952	328. 3	\$58
Al zhei mer's	$\overline{2}$	131	38, 905	\$2, 074, 756	\$15, 838	297. 0	\$53
Al zhei mer's	3	145	34, 802	\$2, 738, 382	\$18, 885	240. 0	\$79
Al zhei mer's	4	115	19, 704	\$1, 599, 728	\$13, 911	171. 3	\$81
Al zhei mer's	5	85	14, 460	\$1, 552, 861	\$18, 269	170. 1	\$107
Al zhei mer's	6	82	8, 802	\$927, 593	\$11, 312	107. 3	\$105
Al zhei mer's	7	52	5, 954	\$538, 440	\$10, 355	114. 5	\$90
Al zhei mer's	8	20	2, 483	\$120, 199	\$6, 010	124. 2	\$48
Al zhei mer's	9	46	3, 849	\$178, 890	\$3, 889	83. 7	\$46
Diagnosis Category Sub-Total		769	159, 488	\$11, 493, 397	<i>\$14, 946</i>	207. 4	\$72
Arthritis	1	151	16, 786	\$1, 137, 610	\$7, 534	111. 2	\$68
Arthritis	$\overline{2}$	101	12, 669	\$654, 355	\$6, 479	125. 4	\$52
Arthritis	$\tilde{3}$	73	13, 412	\$752, 649	\$10, 310	183. 7	\$56
Arthritis	4	44	4, 333	\$399, 287	\$9, 075	98. 5	\$92
Arthritis	5	25	1, 913	\$166, 959	\$6, 678	76. 5	\$87
Arthritis	6 7	22	2, 828	\$172,046	\$7,820	128. 5	\$61
Arthritis		15	1, 725	\$160, 332	\$10, 689	115. 0	\$93
Arthritis	8	10	841	\$63, 383	\$6, 338	84. 1	\$75
Arthri ti s	9	9	202	\$16, 647	\$1,850	22. 4	\$82
Diagnosis Category Sub-Total		450	<i>54, 709</i>	\$3, 523, 268	\$7, 829	121. 6	\$64
Cancer	1	172	18, 145	\$1, 153, 835	\$6, 708	105. 5	\$64
Cancer	$ar{2}$	147	12, 680	\$774, 155	\$5, 266	86. 3	\$61
Cancer	3	141	11, 346	\$674, 522	\$4, 784	80. 5	\$59
Cancer	4	90	8, 048	\$458, 347	\$5, 093	89. 4	\$57
Cancer	5	64	2, 270	\$188, 600	\$2, 947	35. 5	\$83
Cancer	6	37	1, 612	\$121, 809	\$3, 292	43. 6	\$76
Cancer	7	20	545	\$106, 632	\$5, 332	27. 3	\$196
Cancer	8	15	1, 235	\$57, 447	\$3, 830	82 . 3	\$47
Cancer	9	11	306	\$25, 834	\$2, 349	27. 8	\$84
Diagnosis Category Sub-Total		697	<i>56, 187</i>	\$3, 561, 181	<i>\$5, 109</i>	<i>80. 6</i>	\$63

Appendix: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s Category	Durati on	Tal l y	Visits	Total Payments	Average Claim Payments	Average Vi si ts	Average Per Vi si t
Ci rcul atory	1	125	17, 448	\$871, 712	\$6, 974	139. 6	\$50
Ci rcul atory	2	105	13, 040	\$567, 243	\$5, 402	124. 2	\$44
Ci rcul atory	3	78	12, 421	\$817, 551	\$10, 481	159. 2	\$66
Ci rcul atory	4	71	11, 300	\$565, 831	\$7, 969	159. 2	\$50
Ci rcul atory	5	51	4, 293	\$395, 937	\$7, 763	84. 2	\$92
Ci rcul atory	6	29	3, 864	\$339, 779	\$11, 717	133. 2	\$88
Ci rcul atory	7	15	1, 257	\$112, 539	\$7, 503	83. 8	\$90
Ci rcul atory	8	13	1, 679	\$49, 930	\$3, 841	129. 2	\$30 \$37
Circulatory	9	19	1, 114	\$41, 228	\$2, 170	58. 6	\$37
Diagnosis Category Sub-Total		<i>506</i>	66, 416	\$3, 761, 750	<i>\$7, 434</i>	131. 3	\$57
Congeni tal	1	2	0	\$1, 270	\$635	0.0	
Congeni tal	$\bar{3}$	ī	0	\$19, 389	\$19, 389	0. 0	
Congeni tal	4	1	350	\$18, 250	\$18, 250	350. 0	\$52
Congeni tal	5	1	0	\$380	\$380	0. 0	, -
Diagnosis Category Sub-Total		5	350	\$39, 289	<i>\$7, 858</i>	70. O	\$112
Di abetes	1	14	2, 744	\$63, 659	\$4, 547	196. 0	\$23
Di abetes	2	6	575	\$53, 621	\$8, 937	95. 8	\$93
Di abetes	$\tilde{3}$	ğ	1, 359	\$153, 019	\$17,002	151. 0	\$113
Di abetes	4	8	436	\$13, 692	\$1,712	54. 5	\$31
Di abetes	5	3	1	\$2, 230	\$743	0. 3	\$2, 230
Di abetes	6	5	124	\$32, 487	\$6, 497	24. 8	\$262
Diabetes	7	3	233	\$16, 250	\$5, 417	77. 7	\$70
Di abetes	8	2	0	\$7, 813	\$3, 907	0. 0	
Di abetes	9	2 52	0	\$13, 293	\$6, 647	0. 0	
Diagnosis Category Sub-Total		52	5, 472	\$356, 064	\$6, 847	<i>105. 2</i>	\$65

Appendix: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s				Total	Average Cl ai m	Average	Average Per
Category	Durati on	Tally	Vi si ts	Payments	Payments	Visits	Vi si t
		•					
igestive System	1	31	2, 107	\$81, 187	\$2,619	68. 0	\$39
Digestive System	2	18 17	1, 553 508	\$129, 286	\$7, 183	86. 3	\$83
Digestive System Digestive System	3 1	4	187	\$83, 748 \$13, 257	\$4, 926 \$3, 314	29. 9 46. 8	\$165 \$71
Digestive System Digestive System	5	3	380	\$24, 635	\$8, 212	126. 7	\$65
Digestive System	5 6	8	715	\$27, 309	\$3, 414	89. 4	\$38
Digestive System	ž	$\overset{\circ}{4}$	406	\$41, 953	\$10, 488	101. 5	\$103
Digestive System	8	2 2	0	\$30, 171	\$15, 086	0. 0	,
Digestive System	9		Ŏ	\$4, 580	\$2, 290	0. 0	
Diagnosis Category Sub-Total		89	5, 856	\$436, 126	\$4, 900	<i>65.</i> 8	\$74
Endocrine, Immunity System	1	11	1, 482	\$122, 421	\$11, 129	134. 7	\$83
Endocrine, Immunity System	2	5	1, 103	\$44, 716	\$8, 943	220. 6	\$41
Endocrine, Immunity System	3	9	210	\$60, 453	\$6, 717	23. 3	\$288
Endocrine, Immunity System	4	5	211	\$9, 610	\$1, 922	42. 2	\$46
Endocrine, Immunity System	5	7	376	\$41, 152	\$5, 879	53. 7	\$109
Endocrine, Immunity System	6	5	191	\$32, 899	\$6, 580	38. 2	\$172
Endocrine, Immunity System	7	2	90	\$15, 696	\$7, 848	45. 0	\$174
Endocrine, Immunity System	8 9	1	0	\$18,020	\$18, 020	0.0	007
Endocri ne, Immuni ty System Diagnosis Category Sub-Total	9	$\frac{2}{47}$	500 4, 163	\$18, 600 \$363, 567	\$9, 300 <i>\$7, 735</i>	250. 0 88. 6	\$37 \$87
bragnosis category sub-total		47	4, 103	3303, 307	\$7,733	<i>88.</i> 0	367
Genitourinary System	1	12	1, 638	\$109, 958	\$9, 163	136. 5	\$67
Geni touri nary System	2	9	470	\$18, 338	\$2, 038	52. 2	\$39
Geni touri nary System	3	7	174	\$48, 649	\$6, 950	24. 9	\$280
Genitourinary System	4 5	5	270	\$10, 865	\$2, 173	54. 0	\$40
Genitourinary System	5	I	0	\$2, 518	\$2, 518	0. 0	
Genitourinary System	6	3	0	\$5, 409	\$1,803	0.0	
Genitourinary System Genitourinary System	8	5 1	0 60	\$6, 389 \$3, 000	\$1, 278 \$3, 000	0. 0 60. 0	\$50
Genitourinary System	9	4	183	\$3, 000 \$3, 028	\$3,000 \$757	45. 8	\$17
Diagnosis Category Sub-Total	3	47	2, 795	\$208, 154	\$4, 429	59. 5	\$74

Appendix: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s	Durati on	Tolly	Visits	Total	Average Claim	Average Vi si ts	Average Per Vi si t
Category	Dui ati on	Tally	VISILS	<i>Payments</i>	<i>Payments</i>	VISILS	VISIL
Hypertensi on	1	6	352	\$66, 608	\$11, 101	58. 7	\$189
Hypertension	2	9	1, 841	\$109, 956	\$12, 217	204. 6	\$60
Hypertension	3	4	123	\$5, 154	\$1, 289	30. 8	\$42
Hypertensi on	4	7	174	\$15, 537	\$2, 220	24. 9	\$89
Hypertensi on	5 6	4	0	\$24, 725	\$6, 181	0.0	
Hypertension	6	6	26	\$88, 046	\$14, 674	4. 3	\$3, 386
Hypertension	7	3	0	\$14, 741	\$4, 914	0. 0	
Hypertension	8	1	0	\$1,746	\$1, 746	0.0	001
Hypertensi on	9	2	46	\$4, 181	\$2,091	23. 0	\$91
Diagnosis Category Sub-Total		42	2, 562	\$330, 694	\$7, 874	<i>61. 0</i>	<i>\$129</i>
Ill-Defined and Misc Conditions	1	31	3, 706	\$188, 653	\$6, 086	119. 5	\$51
Ill-Defined and Misc Conditions	2	21	1, 599	\$171, 005	\$8, 143	76. 1	\$107
Ill-Defined and Misc Conditions	3	25	3, 098	\$197, 501	\$7, 900	123. 9	\$64
Ill-Defined and Misc Conditions	4	24	3, 153	\$157, 915	\$6, 580	131. 4	\$50
Ill-Defined and Misc Conditions	5	17	497	\$48, 396	\$2, 847	29. 2	\$97
Ill-Defined and Misc Conditions	6	. 7	811	\$156, 909	\$22, 416	115. 9	\$193
Ill-Defined and Misc Conditions	7	11	1, 856	\$27, 032	\$2, 457	168. 7	\$15
Ill-Defined and Misc Conditions	8	6	503	\$130, 231	\$21, 705	83. 8	\$259
Ill-Defined and Misc Conditions	9	6	1, 143	\$45, 196	\$7, 533	190. 5	\$40
Diagnosis Category Sub-Total		148	16, 366	\$1, 122, 838	\$7, 587	110. 6	\$69
Inj ury	1	207	33, 559	\$1, 732, 951	\$8, 372	162. 1	\$52
Inj ury	$\hat{2}$	144	15, 150	\$1, 031, 212	\$7, 161	105. 2	\$68
Inj ury	3	106	7, 675	\$472, 391	\$4, 457	72. 4	\$62
Inj ury	4	86	6, 461	\$526, 835	\$6, 126	75. 1	\$82
I nji ury	5	61	5, 719	\$443, 503	\$7, 271	93. 8	\$78
Injury	6	38	3, 984	\$237, 801	\$6, 258	104. 8	\$60
I nj ury	7	27	2, 514	\$153, 902	\$5, 700	93. 1	\$61
Į nj ury	8	20	1, 413	\$34, 867	\$1, 743	70. 7	\$25
Injury	9	17	1, 301	\$42, 750	\$2, 515	76. 5	\$33
Diagnosis Category Sub-Total		706	77, 776	<i>\$4, 676, 212</i>	<i>\$6, 624</i>	110. 2	\$60

Appendix: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s Category	Durati on	Tally	Visits	Total Payments	Average Claim Payments	Average Vi si ts	Average Per Vi si t
Mental Mental	1 2	10 20	979	\$229, 260	\$22, 926	97. 9 56. 3	\$234 \$100
Mental	3	20 15	1, 125 1, 995	\$112, 597 \$130, 117	\$5, 630 \$8, 674	133. 0	\$100 \$65
Mental		5	1, 333 89	\$130, 117 \$8, 697	\$1, 739	17.8	\$98
Mental	4 5	8	167	\$11, 939	\$1, 492	20. 9	\$71
Mental	6	5	413	\$61, 688	\$12, 338	82. 6	\$149
Diagnosis Category Sub-Total		63	4, 768	\$554, 298	\$8, 798	75. 7	\$116
Nervous System and Sense Organs	1	74	32, 773	\$2, 450, 169	\$33, 110	442. 9	\$75
Nervous System and Sense Organs	$\overline{2}$	67	22, 150	\$1, 564, 511	\$23, 351	330.6	\$71
Nervous System and Sense Organs	3	51	7, 678	\$602, 648	\$11, 817	150. 5	\$78
Nervous System and Sense Organs	4	37	9, 011	\$577, 458	\$15, 607	243. 5	\$64
Nervous System and Sense Organs	5	27	4, 754	\$387, 057	\$14, 335	176. 1	\$81
Nervous System and Sense Organs	6	13	1, 203	\$152, 296	\$11, 715	92. 5	\$127
Nervous System and Sense Organs	7	8	571	\$119, 568	\$14, 946	71. 4	\$209
Nervous System and Sense Organs	8	9	1, 022	\$52, 027	\$5, 781	113. 6	\$51
Nervous System and Sense Organs	9	6	250	\$25, 286	\$4, 214	41. 7	\$101
Diagnosis Category Sub-Total		292	79, 412	\$5, 931, 020	\$20, 312	<i>272.</i> 0	\$75
Pregnancy Disorders	1	5	221	\$42,005	\$8, 401	44. 2	\$190
Pregnancy Disorders	2	1	0	\$520	\$520	0. 0	
Pregnancy Disorders	3	1	0	\$263	\$263	0.0	
Pregnancy Disorders	4	2	0	\$4, 110	\$2, 055	0.0	
Pregnancy Disorders	6	1	0	\$1, 740	\$1,740	0. 0	
Pregnancy Disorders	7	2	0	\$8, 705	\$4, 353	0.0	
Pregnancy Disorders	9	2	0	\$5, 120	\$2, 560	0. 0	
Diagnosis Category Sub-Total		14	221	<i>\$62, 463</i>	\$4, 462	15. 8	<i>\$283</i>

Appendix: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s Category	Durati on	Tally	Vi si ts	Total Payments	Average Claim Payments	Average Vi si ts	Average Per Vi si t
Respi ratory	1	37	3, 641	\$308, 699	\$8, 343	98. 4	\$85
Respiratory	2 3	30	3, 257	\$295, 538	\$9, 851	108. 6	\$91
Respiratory	3	33	4, 058	\$229, 452	\$6, 953	123. 0	\$57
Respi ratory	4	23	2, 033	\$192, 330	\$8, 362	88. 4	\$95
Respiratory	5 6	19	2, 285	\$181, 137	\$9, 534	120. 3	\$79
Respi ratory	6	18	2, 339	\$167, 994	\$9, 333	129. 9	\$72
Respiratory	7	14	884	\$80, 141	\$5, 724	63. 1	\$91
Respiratory	8	6	830	\$103, 285	\$17, 214	138. 3	\$124
Respiratory	9	7	768	\$42, 368	\$6, 053	109. 7	\$55
Diagnosis Category Sub-Total		187	20, 095	\$1, 600, 944	\$8, 561	107. 5	\$80
Skin and Subcutaneous Tissue	1	7	22	\$7, 860	\$1, 123	3. 1	\$357
Skin and Subcutaneous Tissue	2	6	2, 075	\$124, 150	\$20, 692	345. 8	\$60
Skin and Subcutaneous Tissue	$\tilde{3}$	3	92	\$60, 278	\$20, 093	30. 7	\$655
Skin and Subcutaneous Tissue	4	3	604	\$21, 289	\$7, 096	201. 3	\$35
Skin and Subcutaneous Tissue	5	3	10	\$7, 748	\$2, 583	3. 3	\$775
Skin and Subcutaneous Tissue	6	1	718	\$31, 150	\$31, 150	718. 0	\$43
Skin and Subcutaneous Tissue	8	1	214	\$10, 700	\$10, 700	214. 0	\$50
Skin and Subcutaneous Tissue	9	3	79	\$5, 750	\$1, 917	26. 3	\$73
Skin and Subcutaneous Tissue	9+	1	3	\$90	\$90	3. 0	\$30
Diagnosis Category Sub-Total		28	3, 817	<i>\$269, 015</i>	<i>\$9, 608</i>	136. 3	\$70
Stroke	1	126	33, 636	\$1, 968, 195	\$15, 621	267. 0	\$59
Stroke	1 2	122	21, 042	\$1, 403, 803	\$11, 507	172. 5	\$67
Stroke	$\tilde{3}$	82	10. 566	\$1, 014, 426	\$12, 371	128. 9	\$96
Stroke	4	69	8, 506	\$788, 318	\$11, 425	123. 3	\$93
Stroke	5	59	9, 288	\$723, 757	\$12, 267	157. 4	\$78
Stroke	6	32	419	\$288, 525	\$9, 016	13. 1	\$689
Stroke	7	18	983	\$168, 601	\$9, 367	54. 6	\$172
Stroke	8	14	734	\$41, 753	\$2, 982	52. 4	\$57
Stroke	9	15	704	\$41,062	\$2, 737	46. 9	\$58
Stroke	9+	1	90	\$1, 350	\$1, 350	90. 0	\$15
Diagnosis Category Sub-Total		<i>538</i>	85, 968	<i>\$6, 439, 790</i>	\$11, 970	159. 8	\$75

Appendi x: G - 6

Home Health Care/ADC/Other Claims: Diagnosis Category by Duration Summary

Di agnosi s Category	Durati on	Tally	Visits	Total Payments	Average Claim Payments	Average Vi si ts	Average Per Vi si t
Other/Unknown	1	202	19, 709	\$2, 562, 638	\$12,686	97. 6	\$130
Other/Unknown	2	180	15, 812	\$1, 487, 683	\$8, 265	87. 8	\$94
Other/Unknown	3	158	11, 428	\$1, 267, 797	\$8, 024	72. 3	\$111
Other/Unknown	4	164	9, 602	\$986, 176	\$6, 013	58 . 5	\$103
Other/Unknown	5	159	8, 402	\$1, 187, 215	\$7, 467	52. 8	\$141
Other/Unknown	6	88	2, 967	\$601, 899	\$6, 840	33. 7	\$203
Other/Unknown	7	62	2, 671	\$365, 253	\$5, 891	43. 1	\$137
Other/Unknown	8	52	872	\$132, 957	\$2, 557	16. 8	\$152
Other/Unknown	9	47	1, 953	\$142, 828	\$3, 039	41. 6	\$73
Other/Unknown	9+	3	647	\$32, 270	\$10, 757	215. 7	\$50
Diagnosis Category Sub-Total		1, 115	74, 063	\$8, 766, 716	<i>\$7, 863</i>	<i>66. 4</i>	\$118
Total		5, 795	720, 484	\$53, 496, 786	\$9, 232	124.3	\$74

Appendi x: G - 7

Incurred	Year	Di agnosi s			Average Total	Average Cl ai m	Average Per
Year	Category	Tal ly	Days	<i>Payments</i>	Payment	Days	Day
1984 - 1987	Al zhei mer's	38	43, 377	\$3, 066, 480	\$80, 697	1, 141. 5	\$71
	Arthri ti s	12	8, 642	\$524, 110	\$43, 676	720. 2	\$61
	Cancer	29	11, 742	\$879, 853	\$30, 340	404. 9	\$75
	Ci rcul atory	67	51, 914	\$3, 276, 825	\$48, 908	774.8	\$63
	Di abetes	5	5, 022	\$379, 570	\$75, 914	1, 004. 4	\$76
	Digestive System	6	7, 156	\$406, 375	\$67, 729	1, 192. 7	\$57
	Endocrine, İmmunity System	11	8, 533	\$635, 735	\$57, 794	775. 7	\$75
	Genitouri nary System	2	2, 017	\$100, 870	\$50, 435	1, 008. 5	\$50
	Hypertensi on	4	5, 087	\$280, 510	\$70, 128	1, 271. 8	\$55
	Ill-Defined and Misc Conditions	9	11, 508	\$558, 180	\$62,020	1, 278. 7	\$49
	Inj ury	63	23, 322	\$1, 711, 830	\$27, 172	370. 2	\$73
	Mental	17	16, 429	\$924, 430	\$54, 378	966. 4	\$56
	Nervous System and Sense Organs	28	32, 338	\$1, 825, 155	\$65, 184	1, 154. 9	\$56
	Pregnancy Di sorders	2	1, 507	\$105, 130	\$52, 565	753. 5	\$70
	Respi ratory	12	8, 818	\$531, 925	\$44, 327	734. 8	\$60
	Skin and Subcutaneous Tissue	2	174	\$10, 440	\$5, 220	87. 0	\$60
	Stroke	29	15, 362	\$955, 306	\$32, 942	529. 7	\$62
	Other/Unknown	952	325, 408	\$16, 535, 926	\$17, 370	341. 8	\$51
	Incurred Year Sub-Total	1, 288	<i>578, 356</i>	\$32, 708, 650	\$25, 395	449. 0	\$57

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tal l y	Days	Payments	Average Total Payment	Average Cl ai m Days	Average Per Day
	Year Category Al zhei mer's Arthritis Cancer Ci rcul atory Congenital Di abetes Di gesti ve System Endocrine, Immunity System Genitourinary System Hypertension Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Di sorders Respi ratory Skin and Subcutaneous Tissue Stroke		Days 1, 076, 940 329, 977 185, 669 688, 799 3, 109 118, 681 90, 097 66, 511 77, 062 137, 860 177, 207 507, 596 290, 689 279, 433 10, 570 194, 576 23, 353 570, 927	Payments \$83, 440, 421 \$22, 553, 881 \$12, 918, 035 \$48, 579, 247 \$134, 505 \$7, 869, 871 \$5, 954, 174 \$4, 529, 057 \$5, 362, 329 \$8, 970, 814 \$11, 847, 945 \$32, 830, 802 \$18, 670, 789 \$22, 449, 549 \$540, 360 \$13, 131, 985 \$1, 420, 304 \$39, 999, 816		Claim Days 814. 6 593. 5 236. 2 552. 4 310. 9 618. 1 455. 0 639. 5 478. 6 796. 9 455. 5 427. 6 794. 2 684. 9 704. 7 429. 5 486. 5 601. 6	
	Other/Unknown Incurred Year Sub-Total	7, 018 15, 582	1, 640, 930 6, 469, 986	\$100, 347, 613 \$441, 551, 497	\$14, 299 \$28, 337	233. 8 415. 2	\$61 \$68

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tal l y	Days	Paynents	Average Total Paynent	Average Claim Days	Average Per Day
1992 - 1995	Al zhei mer's	2, 597	1, 587, 939	\$127, 046, 380	\$48, 920	611. 5	\$80
	Arthritis	1, 082	315, 291	\$22, 698, 567	\$20, 978	291. 4	\$72
	Cancer	1, 384	204, 335	\$14, 247, 143	\$10, 294	147. 6	\$70
	Ci rcul atory	1, 654	645, 333	\$44, 301, 928	\$26, 785	390. 2	\$69
	Congeni tal	7	614	\$36, 940	\$5, 277	87. 7	\$60
	Di abetes	296	137, 717	\$9, 686, 014	\$32, 723	465. 3	\$70
	Digestive System	318	121, 351	\$7, 928, 338	\$24, 932	381.6	\$65
	Endocrine, Immunity System	174	76, 492	\$4, 363, 521	\$25, 078	439. 6	\$57
	Geni touri nary System	206	57, 238	\$4, 076, 474	\$19, 789	277. 9	\$71
	Hypertensi on The Control of the Con	165	86, 805	\$4, 489, 442	\$27, 209	526 . 1	\$52
	Ill-Defined and Misc Conditions	593	261, 608	\$19, 061, 756	\$32, 145	441. 2	\$73
	Injury	1, 773	651, 305	\$41, 903, 352	\$23, 634	367. 3	\$64
	Mental	408	208, 974	\$13, 433, 031	\$32, 924	512. 2	\$64
	Nervous System and Sense Organs	624	262, 977	\$24, 737, 376	\$39, 643	421. 4	\$94
	Pregnancy Di sorders	18	4, 068	\$172, 855	\$9, 603	226. 0	\$42
	Respi ratory	796	261, 024	\$17, 405, 005	\$21, 866	327. 9	\$67
	Skin and Subcutaneous Tissue	75	32, 008	\$2, 195, 857	\$29, 278	426. 8	\$69
	Stroke	2, 084	889, 535	\$61, 302, 115	\$29, 416	426. 8	\$69
	Other/Unknown	2, 709	960, 700	\$62, 151, 250	\$22, 943	354. 6	\$65
	Incurred Year Sub-Total	16, 963	6, 765, 314	\$481, 237, 344	\$28, 370	<i>398. 8</i>	\$71

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tal ly	Days	Payments	Average Total Paynent	Average Claim Days	Average Per Day
1996 - 1999	Al zhei mer's	1, 830	895, 000	\$75, 499, 232	\$41, 256	489. 1	\$84
	Arthritis	358	113, 010	\$8, 528, 680	\$23, 823	315. 7	\$75
	Cancer	575	71, 112	\$6, 455, 604	\$11, 227	123. 7	\$91
	Ci rcul atory	1, 047	330, 407	\$24, 903, 884	\$23, 786	315. 6	\$75
	Congeni tal "	3	391	\$15, 955	\$5, 318	130. 3	\$41
	Di abetes	118	41, 709	\$3, 217, 079	\$27, 263	353. 5	\$77
	Digestive System	162	50, 258	\$3, 877, 861	\$23, 937	310. 2	\$77
	Endocrine, Immunity System	158	49, 225	\$3, 384, 061	\$21, 418	311.6	\$69
	Geni touri nary System	147	38, 770	\$3, 040, 423	\$20, 683	263. 7	\$78
	Hypertensi on Table 1	116	44, 307	\$2, 556, 528	\$22, 039	382. 0	\$58
	Ill-Defined and Misc Conditions	459	140, 817	\$10, 753, 208	\$23, 427	306. 8	\$76
	Injury	1, 156	340, 199	\$23, 780, 834	\$20, 572	294. 3	\$70
	Mental	104	47, 152	\$2, 846, 028	\$27, 366	453. 4	\$60
	Nervous System and Sense Organs	399	126, 830	\$11, 945, 534	\$29, 939	317. 9	\$94
	Pregnancy Di sorders	10	1, 491	\$102, 259	\$10, 226	149. 1	\$69
	Respi ratory	583	139, 365	\$9, 574, 277	\$16, 422	239. 0	\$69
	Skin and Subcutaneous Tissue	66	14, 252	\$873, 900	\$13, 241	215. 9	\$61
	Stroke	1, 016	355, 369	\$28, 298, 031	\$27, 852	349. 8	\$80
	Other/Unknown	3, 196	965, 660	\$61, 211, 626	§19, 153	302. 1	\$63
	Incurred Year Sub-Total	11, 503	3, 765, 324	\$280, 865, 004	\$24, 417	<i>327. 3</i>	\$75
	Total	45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	<i>387. 7</i>	\$70

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tal ly	Visits	Payments	Average Total Paynents	Average Claim Visits	Average Per Vi si t
1984 - 1987	Al zhei mer's	1	1, 244	\$24, 940	\$24, 940	1, 244. 0	\$20
	Arthritis	1	13	\$336	\$336	13. 0	\$26
	Cancer	2	1, 500	\$33, 795	\$16, 898	750. 0	\$23
	Ci rcul atory	1	231	\$4,620	\$4,620	231.0	\$20
	Hypertensi on	1	180	\$3,600	\$3,600	180. 0	\$20
	Ill-Defined and Misc Conditions	1	120	\$3,000	\$3,000	120. 0	\$25
	Mental	1	0	\$680	\$680	0. 0	\$ 0
	Nervous System and Sense Organs	1	156	\$3, 120	\$3, 120	156. 0	\$20
	Unknown/Other	19	2, 724	\$64, 248	\$3, 381	143. 4	\$24
	Incurred Year Sub-Total	28	6. 168	\$138, 339	S4. 941	220. 3	<i>\$22</i>

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tal l y	Visits	Paynents -	Average Total Paynents	Average Claim Visits	Average Per Visit
1988 - 1991	Al zhei mer's	90	28, 220	\$1, 014, 924	\$11, 277	313. 6	\$36
	Arthritis	36	4, 107	\$161, 277	\$4, 480	114. 1	\$39
	Cancer	102	10, 973	\$450, 866	\$4, 420	107. 6	\$41
	Ci rcul atory	89	19, 692	\$608, 498	\$6, 837	221. 3	\$31
	Di abetes	6	582	\$17, 659	\$2, 943	97. 0	\$30
	Digestive System	10	171	\$20, 228	\$2, 023	17. 1	\$118
	Endocrine, Immunity System	8	1, 549	\$87, 615	\$10, 952	193. 6	\$57
	Geni touri nary System	11	1, 956	\$83, 614	\$7, 601	177. 8	\$43
	Hypertensi on The Hypertensi o	3	727	\$41, 535	\$13, 845	242. 3	\$57
	Ill-Defined and Misc Conditions	19 90	2, 013	\$84, 062	\$4, 424	105. 9	\$42
	Inj ury	90	12, 409	\$443, 644	\$4,929	137. 9	\$36
	Mental	21	3, 099	\$164, 208	\$7, 819	147. 6	\$53
	Nervous System and Sense Organs	49	15, 640	\$807, 390	\$16, 477	319. 2	\$52
	Respi ratory	14	2, 905	\$112, 136	\$8, 010	207. 5	\$39
	Skin and Subcutaneous Tissue	4	0	\$7, 630	\$1, 908	0. 0	\$ 0
	Stroke	40	8, 509	\$489, 695	\$12, 242	212. 7	\$58
	Unknown/Other	191	22, 732	\$2, 430, 796	\$12, 727	119. 0	\$107
	Incurred Year Sub-Total	<i>783</i>	135, 284	\$7, 025, 777	\$8, 973	172.8	<i>\$52</i>

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tally	Visits	Payments	Average Total Paynents	Average Claim Visits	Average Per Visit
1992 - 1995	Al zhei mer's	338	69, 061	\$4, 551, 423	\$13, 466	204. 3	\$66
	Arthritis	312	31, 208	\$2, 015, 442	\$6, 460	100. 0	\$65
	Cancer	362	21, 110	\$1, 393, 274	\$3, 849	58 . 3	\$66
	Ci rcul atory	289	26, 435	\$1, 726, 691	\$5, 975	91. 5	\$65
	Congeni tal "	4	350	\$38, 909	\$9, 727	87. 5	\$111
	Di abetes	30	2, 932	\$192, 864	\$6, 429	97. 7	\$66
	Digestive System	58	3, 777	\$270, 531	\$4, 664	65. 1	\$72
	Endocrine, Immunity System	28	2, 249	\$171, 349	\$6, 120	80. 3	\$76
	Geni touri nary System	21	497	\$87, 231	\$4, 154	23. 7	\$176
	Hypertensi on	23 80	1, 609	\$157, 729	\$6, 858	70. 0	\$98
	Ill-Defined and Misc Conditions		6, 347	\$454, 702	\$5, 684	79. 3	\$72
	I nj ury	410	35, 772	\$2, 485, 046	\$6, 061	87.2	\$69
	Mental	33	1, 256	\$325, 477	\$9, 863	38. 1	\$259
	Nervous System and Sense Organs	143	36, 423	\$2, 815, 684	\$19, 690	254. 7	\$77
	Pregnancy Di sorders	9	45	\$44, 606	\$4, 956	5. 0	\$991
	Respi ratory	108	11, 970	\$954, 023	\$8, 834	110. 8	\$80
	Skin and Subcutaneous Tissue	12	2, 353	\$139, 445	\$11, 620	196. 1	\$59
	Stroke	335	54, 675	\$3, 574, 158	\$10, 669	163. 2	\$65
	Unknown/Other	531	35, 743	\$4, 174, 770	\$7, 862	67. 3	\$117
	Incurred Year Sub-Total	3, 126	<i>343, 812</i>	<i>\$25, 573, 3</i> 54	\$8, 181	110. 0	\$74

Appendi x: G - 7

Incurred Year	Year Category	Di agnosi s Tal l y	Visits	P aynents	Average Total Paynents	Average Claim Visits	Average Per Visit
1996 - 1999	Al zhei mer' s	340	60, 963	\$5, 902, 110	\$17, 359	179. 3	\$97
	Arthritis	101	19, 381	\$1, 346, 213	\$13, 329	191. 9	\$69
	Cancer	231	22, 604	\$1, 683, 246	\$7, 287	97. 9	\$74
	Ci rcul atory	127	20, 058	\$1, 421, 941	\$11, 196	157. 9	\$71
	Congeni tal "	1	0	\$380	\$380	0. 0	\$ 0
	Di abetes	16	1, 958	\$145, 541	\$9, 096	122. 4	\$74
	Digestive System	21	1, 908	\$145, 367	\$6, 922	90. 9	\$76
	Endocrine, Immunity System	11	365	\$104, 603	\$9, 509	33. 2	\$287
	Genitourinary System	15	342	\$37, 309	\$2, 487	22. 8	\$109
	Hypertension	15	46	\$127, 830	\$8, 522	3. 1	\$2, 779
	Ill-Defined and Misc Conditions	48	7, 886	\$581, 074	\$12, 106	164. 3	\$74
	Inj ury	206	29, 595	\$1, 747, 522	\$8, 483	143. 7	\$59
	Mental	. 8	413	\$63, 933	\$7, 992	51.6	\$155
	Nervous System and Sense Organs	99	27, 193	\$2, 304, 826	\$23, 281	274. 7	\$85
	Pregnancy Di sorders	5	176	\$17, 857	\$3, 571	35. 2	\$101
	Respi ratory	65 12	5, 220	\$534, 785	\$8, 227	80. 3	\$102
	Skin and Subcutaneous Tissue		1, 464	\$121, 940	\$10, 162	122. 0	\$83
	Stroke	163	22, 784	\$2, 375, 937	\$14, 576	139. 8	\$104
	Unknown/Other	374	12, 864	\$2, 096, 902	\$5, 607	34. 4	\$163
	Incurred Year Sub-Total	1, 858	235, 220	\$20, 759, 316	\$11, 173	126. 6	\$88
	Total	5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendi x: G - 8

Claim Status	Status Category	Di agnosi s Tal l y	Days	Payments	Average Total Payments	Average Claim Days	Average Per Day
Benefit Expiry	Al zhei mer's Arthritis Cancer Ci rcul atory Di abetes Di gesti ve System Endocrine, Immunity System Geni touri nary System Hypertensi on Ill-Defi ned and Misc Conditions Injury Mental Nervous System and Sense Organs Respiratory Stroke Other/Unknown Status Sub-Total	172 79 18 62 8 10 7 2 21 6 40 11 34 20 108 335 933	152, 165 81, 314 14, 862 67, 593 9, 496 10, 229 6, 585 2, 190 24, 905 7, 921 37, 834 11, 549 25, 159 18, 759 105, 720 237, 831 814, 112	\$13, 519, 433 \$6, 413, 731 \$882, 731 \$4, 506, 049 \$605, 710 \$736, 016 \$443, 610 \$158, 600 \$1, 778, 691 \$455, 860 \$2, 967, 445 \$1, 074, 930 \$4, 914, 192 \$1, 443, 894 \$8, 191, 633 \$18, 907, 556 \$67, 000, 081	\$78, 601 \$81, 186 \$49, 041 \$72, 678 \$75, 74 \$73, 602 \$63, 373 \$79, 300 \$84, 700 \$75, 977 \$74, 186 \$97, 721 \$144, 535 \$72, 195 \$75, 840 \$71, 811	884. 7 1, 029. 3 825. 7 1, 090. 2 1, 187. 0 1, 022. 9 940. 7 1, 095. 0 1, 186. 0 1, 320. 2 945. 9 1, 049. 9 740. 0 938. 0 978. 9 709. 9 872. 6	\$89 \$79 \$59 \$67 \$64 \$72 \$67 \$71 \$58 \$78 \$93 \$195 \$77 \$77 \$79 \$82
			,	. ,	. , -		

Appendi x: G - 8

Cl ai m	Status	Di agnosi s			Average Total	Average Cl ai m	Average Per
Status	Category	Tally	Days	Payments	Payments	Days	Day
Death	Al zhei mer's	1, 164	558, 260	\$44, 468, 149	\$38, 203	479. 6	\$80
	Arthri ti s	259	114, 089	\$7, 804, 954	\$30, 135	440. 5	\$68
	Cancer	893	106, 840	\$8, 455, 893	\$9, 469	119. 6	\$79
	Ci rcul atory	550	191, 768	\$12, 531, 378	\$22, 784	348. 7	\$65
	Di abetes	95	45, 904	\$2, 933, 784	\$30, 882	483. 2	\$64
	Digestive System	89	31, 630	\$1, 909, 497	\$21, 455	355. 4	\$60
	Endocrine, Immunity System	69	28, 207	\$1, 801, 871	\$26, 114	408.8	\$64
	Genitourinary System	86	22, 569	\$1, 524, 784	\$17, 730	262. 4	\$68
	Hypertensi on	84	53, 821	\$3, 686, 426	\$43, 886	640. 7	\$68
	Ill-Defined and Misc Conditions	110	44, 024	\$2, 894, 007	\$26, 309	400. 2	\$66
	Injury	317	161, 817	\$9, 095, 589	\$28, 693	510. 5	
	Mental	134	71, 901	\$4, 563, 482	\$34, 056	536. 6	\$56 \$63
	Nervous System and Sense Organs	356	141, 134	\$12, 331, 124	\$34, 638	396. 4	\$ 87
	Pregnancy Di sorders	6	3, 331	\$151, 640	\$25, 273	555. 2	\$46
	Respi ratory	346	102, 653	\$6, 370, 803	\$18, 413	296. 7	\$62
	Skin and Subcutaneous Tissue	14	6, 444	\$434, 550	\$31, 039	460. 3	\$67
		832	324, 364			389. 9	
	Stroke Other/Unknown	1, 987		\$23, 368, 275	\$28, 087		\$72
			559, 071	\$39, 537, 885	\$19, 898	281. 4	\$71
	Status Sub-Total	7, 391	2, 567, 827	<i>\$183, 864, 091</i>	<i>\$24, 877</i>	<i>347. 4</i>	\$72

Appendi x: G - 8

Claim	Status	Di agnosi s	D	D	Average Total	Average Claim	Average Per
Status	Category	Tally	Days	Payments	Payments	Days	Day
Recovery	Al zhei mer's	82	13, 609	\$1, 077, 588	\$13, 141	166. 0	\$79
J	Arthri ti s	402	36, 280	\$2, 785, 191	\$6, 928	90. 2	\$77
	Cancer	108	6, 783	\$555, 918	\$5, 147	62. 8	\$82
	Ci rcul atory	167	22, 865	\$1, 669, 075	\$9, 994	136. 9	\$73
	Diabetes	38	6, 945	\$539, 563	\$14, 199	182. 8	\$78
	Digestive System	49	3, 457	\$312, 740	\$6, 382	70. 6	\$90
	Endocrine, Immunity System	13	2, 398	\$164, 773	\$12,675	184. 5	\$69
	Geni touri nary System	17	1, 708	\$261, 386	\$15, 376	100. 5	\$153
	Hypertension	$\overline{14}$	3, 352	\$209, 305	\$14, 950	239. 4	\$62
	Ill-Defined and Misc Conditions	28	3, 667	\$225, 769	\$8,063	131. 0	\$62
	Injury	420	28, 917	\$1, 934, 146	\$4,605	68. 9	\$67
	Mental	14	1, 914	\$114, 239	\$8, 160	136. 7	\$60
	Nervous System and Sense Organs	59	8, 268	\$632, 768	\$10, 725	140. 1	\$77
	Pregnancy Di sorders	2	0	\$6, 329	\$3, 165	0. 0	• • • •
	Respiratory	76	7, 862	\$548, 280	\$7, 214	103. 4	\$70
	Skin and Subcutaneous Tissue	12	426	\$31, 614	\$2, 635	35. 5	\$74
	Stroke	276	39, 548	\$2, 941, 538	\$10, 658	143. 3	\$74
	Other/Unknown	1, 161	74, 262	\$3, 504, 323	\$3, 018	64. 0	\$47
	Status Sub-Total	2, 938	262, 261	\$17, 514, 545	\$5, 961	89. 3	\$67

Appendi x: G - 8

Claim Status	Status Category	Di agnosi s Tal l y	Days	Payments	Average Total Payments	Average Cl ai m Days	Average Per Day
Transfer	Alzheimer's Ill-Defined and Misc Conditions	3	977 19	\$13, 254 \$600	\$4, 418 \$600	325. 7 19. 0	\$14 \$32
	Injury	7	643	\$37, 487	\$5, 35 5	91. 9	\$5 8
	Stroke	7	772	\$47, 889	\$6, 841	110. 3	\$62
	Other/Unknown	35	2, 021	\$94, 704	\$2, 706	57. 7	\$47
	Status Sub-Total	53	4, 432	\$193, 934	<i>\$3, 659</i>	<i>83. 6</i>	\$44

Appendix: G - 8

Nursing Home Claims: Closed Status and Diagnosis Summary

Claim Status	Status Category	Di agnosi s Tal l y	Days	Payments	Average Total Payments	Average Claim Days	Average Per Day
Unknown	Al zhei mer's Arthritis Cancer Ci rcul atory Congenital Di abetes Di gestive System Endocrine, Immunity System Genitourinary System Hypertension Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Status Sub-Total	3, 469 1, 128 1, 690 2, 898 18 426 493 322 381 1, 159 3, 039 680 812 36 1, 280 154 2, 520 7, 991 28, 794	2, 246, 337 440, 225 318, 761 1, 204, 123 3, 151 209, 764 188, 623 141, 534 130, 156 162, 763 429, 863 1, 028, 064 429, 366 434, 734 13, 360 409, 204 57, 827 1, 154, 359 1, 839, 936 10, 842, 150	\$179, 043, 991 \$31, 166, 584 \$22, 675, 063 \$85, 410, 672 \$147, 320 \$14, 573, 895 \$12, 714, 364 \$9, 068, 497 \$9, 154, 031 \$8, 925, 907 \$31, 155, 740 \$67, 698, 152 \$26, 999, 665 \$33, 265, 186 \$705, 915 \$27, 962, 569 \$3, 688, 701 \$79, 901, 574 \$104, 483, 762 \$748, 741, 588	\$51, 613 \$27, 630 \$13, 417 \$29, 472 \$8, 184 \$34, 211 \$25, 790 \$28, 163 \$24, 026 \$29, 953 \$26, 882 \$22, 276 \$39, 705 \$40, 967 \$19, 609 \$21, 846 \$23, 953 \$31, 707 \$13, 075 \$26, 003	647. 5 390. 3 188. 6 415. 5 175. 1 492. 4 382. 6 439. 5 341. 6 546. 2 370. 9 338. 3 631. 4 535. 4 371. 1 319. 7 375. 5 458. 1 230. 3 376. 5	\$80 \$71 \$71 \$71 \$47 \$69 \$67 \$64 \$70 \$55 \$72 \$66 \$63 \$77 \$53 \$68 \$64 \$69 \$57 \$69
	Total	40, 109	14, 490, 782	\$1, 017, 314, 239	\$25, 364	361. 3	\$70

Appendi x: G - 8

Home Health Care/ADC/Other Claims: Closed Status and Diagnosis Summary

Claim Status	Status Category	Di agni si s Tal l y	Vi si ts	<i>Payments</i>	Average Total Payments	Average Claim Visits	Average Per Vi si t
Benefit Expiry	Al zhei mer's	20	16, 918	\$425, 854	\$21, 293	845. 9	\$25
1 3	Arthritis	5	4, 830	\$188, 420	\$37, 684	966. 0	\$39
	Ci rcul atory	4	3, 246	\$60, 785	\$15, 196	811. 5	\$19
	Di abetes "	2	1, 303	\$67, 472	\$33, 736	651. 5	\$52
	Ill-Defined and Misc Conditions	2	2, 248	\$122, 400	\$61, 200	1, 124. 0	\$54
	Injury	12	10, 559	\$295, 570	\$24, 631	879. 9	\$28
	Nervous System and Sense Organs	3	1, 656	\$20, 974	\$6, 991	552. 0	\$13
	Respiratory	2	2, 323	\$76, 450	\$38, 225	1, 161. 5	\$33
	Stroke	11	9, 720	\$299, 841	\$27, 258	883. 6	\$31
	Other/Unknown	25	557	\$413, 005	\$16, 520	22. 3	\$741
	Status Sub-Total	86	<i>53</i> , <i>360</i>	\$1, 970, 771	\$22, 916	<i>620.</i> 5	\$37

Appendix: G - 8

Home Health Care/ADC/Other Claims: Closed Status and Diagnosis Summary

Cl ai m	Status	Di agn <u>i</u> și s		_	Average Total	Average Cl ai m	Average Per
Status	Category	Tally	Vi si ts	Payments	Payments	Vi si ts	Vi si t
Death	Al zhei mer's	85	31, 631	\$1, 465, 975	\$17, 247	372. 1	\$46
	Arthri ti s	26	11, 087	\$376, 457	\$14, 479	426. 4	\$34
	Cancer	240	22, 539	\$1, 241, 369	\$5, 172	93. 9	\$55
	Ci rcul atory	40	10, 210	\$591, 091	\$14, 777	255. 3	\$58
	Di abetes	6	2, 340	\$36, 951	\$6, 159	390. 0	\$16
	Digestive System	4	709	\$20, 323	\$5, 081	177. 3	\$29
	Endocrine, Immunity System	7	804	\$31,020	\$4, 431	114. 9	\$39
	Geni touri nary System	8	208	\$30, 603	\$3, 825	26. 0	\$147
	Hypertensi on	2	0	\$25, 798	\$12, 899	0. 0	
	Ill-Defined and Misc Conditions	15	4, 915	\$175, 928	\$11, 729	327. 7	\$36
	Inj ury	26	12, 393	\$499, 367	\$19, 206	476. 7	\$40
	Mental	3	0	\$19, 780	\$6, 593	0. 0	
	Nervous System and Sense Organs	60	11, 922	\$760, 046	\$12, 667	198. 7	\$64
	Pregnancy Di sorders	2	176	\$12, 502	\$6, 251	88. 0	\$71
	Respi ratory	31	5,671	\$263, 223	\$8, 491	182. 9	\$46
	Skin and Subcutaneous Tissue	1	562	\$19, 560	\$19, 560	562. 0	\$35
	Stroke	$4\bar{3}$	16, 757	\$844, 049	\$19, 629	389. 7	\$50
	Other/Unknown	148	5, 708	\$2, 863, 017	\$19, 345	38. 6	\$502
	Status Sub-Total	747	137, 632	\$9, 277, 059	\$12, 419	184. 2	\$67

Appendi x: G - 8

Home Health Care/ADC/Other Claims: Closed Status and Diagnosis Summary

Claim Status	Status Category	Di agni si s Tal l y	Visits	Payments	Average Total Payments	Average Claim Visits	Average Per Vi si t
Recovery	Al zhei mer's Arthritis Cancer Circul atory Di abetes Di gestive System Endocrine, Immunity System Genitourinary System Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Status Sub-Total	17 114 35 45 1 14 2 5 6 135 2 17 1 13 2 38 85 532	1, 802 8, 345 3, 439 6, 925 22 1, 595 103 104 615 12, 760 142 1, 939 0 885 22 7, 277 3, 848 49, 823	\$96, 497 \$370, 422 \$135, 937 \$236, 743 \$3, 000 \$89, 079 \$2, 920 \$6, 156 \$30, 751 \$615, 415 \$14, 868 \$99, 144 \$1, 390 \$52, 204 \$1, 620 \$371, 541 \$475, 465 \$2, 603, 152	\$5, 676 \$3, 249 \$3, 884 \$5, 261 \$3, 000 \$6, 363 \$1, 460 \$1, 231 \$5, 125 \$4, 559 \$7, 434 \$5, 832 \$1, 390 \$4, 016 \$810 \$9, 777 \$5, 594 \$4, 893	106. 0 73. 2 98. 3 153. 9 22. 0 113. 9 51. 5 20. 8 102. 5 94. 5 71. 0 114. 1 0. 0 68. 1 11. 0 191. 5 45. 3 93. 7	\$54 \$44 \$40 \$34 \$136 \$56 \$28 \$59 \$50 \$48 \$105 \$51 \$51 \$51

Appendi x: G - 8

Home Health Care/ADC/Other Claims: Closed Status and Diagnosis Summary

Status Category	Di agni si s Tal l y	Vi si ts	Payments	Average Total Payments	Average Claim Visits	Average Per Vi si t
Alzheimer's Arthritis Cancer Digestive System Injury Nervous System and Sense Organs Stroke Other/Unknown Status Sub-Total	2 1 1 1 6 1 5 3 20	1, 721 71 126 34 967 19 2, 670 284 5, 892	\$66, 650 \$4, 313 \$8, 200 \$120 \$11, 968 \$770 \$151, 430 \$3, 697 \$247, 148	\$33, 325 \$4, 313 \$8, 200 \$120 \$1, 995 \$770 \$30, 286 \$1, 232 \$12, 357	860. 5 71. 0 126. 0 34. 0 161. 2 19. 0 534. 0 94. 7 294. 6	\$39 \$61 \$65 \$4 \$12 \$41 \$57 \$13 \$42

Appendix: G - 8

Home Health Care/ADC/Other Claims: Closed Status and Diagnosis Summary

Claim Status	Status Category	Di agni si s Tal l y	Visits	Payments	Average Total Payments	Average Claim Visits	Average Per Vi si t
Unknown	Al zhei mer's Arthritis Cancer Circul atory Congenital Di abetes Di gestive System Endocrine, Immunity System Genitourinary System Hypertension Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Status Sub-Total	436 256 384 368 5 38 65 35 30 36 113 481 51 129 11 125 21 355 674 3, 613	43, 747 11, 520 21, 787 24, 506 350 1, 311 2, 995 3, 250 966 6, 296 6, 296 20, 452 3, 253 19, 591 45 7, 132 368 24, 764 40, 449 234, 078	\$4, 138, 277 \$1, 101, 958 \$1, 371, 982 \$1, 879, 561 \$39, 289 \$210, 102 \$233, 601 \$290, 074 \$106, 737 \$208, 594 \$510, 939 \$1, 775, 221 \$334, 462 \$1, 705, 343 \$48, 571 \$844, 017 \$102, 395 \$2, 711, 065 \$3, 659, 955 \$21, 272, 143	\$9, 491 \$4, 305 \$3, 573 \$5, 108 \$7, 859 \$5, 529 \$3, 594 \$8, 288 \$3, 558 \$5, 794 \$4, 522 \$3, 691 \$6, 558 \$13, 220 \$4, 416 \$6, 752 \$4, 876 \$7, 637 \$5, 888	100. 3 45. 0 56. 7 66. 6 70. 0 34. 5 46. 1 92. 9 32. 2 36. 0 55. 7 42. 5 63. 8 151. 9 4. 1 57. 1 17. 5 69. 8	\$95 \$96 \$63 \$77 \$112 \$160 \$78 \$89 \$110 \$161 \$81 \$87 \$103 \$87 \$1,079 \$118 \$278 \$109 \$90 \$91
	Total	4, 998	480, 785	\$35, 370, 273	\$7, 077	<i>96. 2</i>	\$74

Appendi x: G - 9

Issue	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Year	Category	Tal l y	Days	Payments Payments	Payments	Days	Day
1984 - 1987	Alzhei mer's	933	665, 861	\$41, 109, 748	\$44, 062	713. 7	\$62
	Arthritis	476	249, 783	\$13, 972, 403	\$29, 354	524. 8	\$56
	Cancer	542	120, 320	\$7, 435, 723	\$13, 719	222. 0	\$62
	Ci rcul atory	1, 074	523, 439	\$30, 960, 982	\$28, 828	487. 4	\$59
	Congeni tal	5	1, 191	\$63, 280	\$12, 656	238. 2	\$53
	<u>Di</u> abetes	178	88, 709	\$5, 444, 553	\$30, 587	498. 4	\$61
	Digestive System	200	101, 022	\$5, 455, 041	\$27, 275	505. 1	\$54
	Endocrine, Immunity System	153	79, 215	\$4, 614, 371	\$30, 159	517. 7	\$58
	Genitourinary System	154	61, 565	\$3, 540, 172	\$22, 988	399. 8	\$58
	Hypertensi on	150	101, 835	\$5, 915, 798	\$39, 439	678.9	\$58
	Ill-Defined and Misc Conditions	278	123, 965	\$7, 080, 084	\$25, 468	445. 9	\$57
	Injury	1, 155	458, 458	\$24, 467, 832	\$21, 184	396. 9	\$53 \$57
	Mental	312	215, 777	\$12, 207, 133	\$39, 125	691. 6	\$57
	Nervous System and Sense Organs	418	300, 357	\$17, 412, 580	\$41, 657	718. 6	\$58
	Pregnancy Di sorders	22	13, 894	\$737, 610	\$33, 528	631. 5	\$53
	Respi ratory	572	205, 288	\$11, 494, 686	\$20, 096	358. 9	\$56
	Skin and Subcutaneous Tissue	77	30, 333	\$1, 643, 770	\$21, 348	393. 9	\$54
	Stroke	992	483, 919	\$27, 483, 147	\$27, 705	487. 8	\$57
	Other/Unknown	6, 313	1, 675, 691	\$85, 328, 417	\$13, 516	265. 4	\$51
	Issue Year Sub-Total	14, 004	5, 500, 622	\$306, 367, 330	\$21, 877	392. 8	\$56

Appendi x: G - 9

Issue Year	Di agnosi s Category	Tally	Days	Total Payments	Average Cl ai m Payments	Average Days	Average Per Day
1988 - 1991	Al zhei mer's Arthritis Cancer Circul atory Congenital Di abetes Di gestive System Endocrine, Inmunity System Genitourinary System Hypertension Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Issue Year Sub-Total	3, 898 1, 282 1, 820 2, 589 2381 422 261 319 271 1, 063 2, 615 531 792 19 1, 125 877 2, 455 6, 653 26, 596	2, 478, 568 457, 614 314, 355 1, 078, 186 2, 838 197, 157 150, 306 109, 807 106, 529 155, 290 427, 289 950, 478 325, 403 330, 774 3, 670 361, 310 33, 717 1, 122, 074 1, 902, 241 10, 507, 206	\$206, 464, 702 \$36, 561, 626 \$23, 722, 919 \$81, 742, 076 \$118, 190 \$14, 488, 398 \$11, 492, 104 \$7, 474, 306 \$8, 384, 910 \$9, 384, 545 \$32, 465, 352 \$68, 639, 268 \$21, 254, 664 \$35, 058, 147 \$171, 710 \$26, 634, 572 \$2, 419, 612 \$84, 680, 496 \$131, 903, 463 \$803, 061, 060	\$52, 967 \$28, 519 \$13, 035 \$31, 573 \$9, 092 \$38, 027 \$27, 232 \$28, 637 \$26, 285 \$34, 629 \$30, 541 \$26, 248 \$40, 028 \$44, 265 \$9, 037 \$23, 675 \$27, 812 \$34, 493 \$19, 826 \$30, 195	635. 9 357. 0 172. 7 416. 4 218. 3 517. 5 356. 2 420. 7 333. 9 573. 0 402. 0 363. 5 612. 1 417. 6 193. 2 321. 2 387. 6 457. 1 285. 9 395. 1	\$83 \$80 \$75 \$76 \$42 \$73 \$76 \$68 \$79 \$60 \$76 \$72 \$65 \$106 \$47 \$74 \$74 \$75 \$69 \$76

Appendi x: G - 9

Issue	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Year	Category	Tally	Days	Payments	Payments	Days	Day
1992 - 1995	Al zhei mer's	913	448, 544	\$40, 181, 866	\$44, 011	491. 3	\$90
	Arthri ti s	244	59, 162	\$3, 749, 029	\$15, 365	242. 5	\$63
	Cancer	369	36, 179	\$3, 135, 191	\$8, 496	98. 0	\$87
	Ci rcul atory	341	112, 771	\$7, 932, 422	\$23, 262	330. 7	\$70
	Congeni tal "	2	85	\$5, 930	\$2, 965	42. 5	\$70
	Di abetes	49	16, 811	\$1, 208, 656	\$24, 666	343. 1	\$72
	Digestive System	62 32	17, 534	\$1, 219, 603	\$19, 671	282. 8	\$70
	Endocrine, Immunity System		11, 730	\$823, 292	\$25, 728	366. 6	\$70
	Genitourinary System	43	6, 993	\$655, 014	\$15, 233	162. 6	\$94
	Hypertensi on	36	16, 208	\$945, 642	\$26, 268	450. 2	\$58
	Ill-Defined and Misc Conditions	107	39, 523	\$2, 655, 958	\$24, 822	369. 4	\$67
	I nj ury	398	112, 445	\$6, 987, 732	\$17, 557	282. 5	\$62
	Mental	51	22, 369	\$2, 402, 981	\$47, 117	438. 6	\$107
	Nervous System and Sense Organs	223	68 , 485	\$7, 890, 556	\$35, 384	307. 1	\$115
	Pregnancy Disorders	3	72	\$4, 475	\$1, 492	24. 0	\$62
	Respiratory	143	37, 132	\$2, 503, 796	\$17, 509	259. 7	\$67
	Skin and Subcutaneous Tissue	26	5, 416	\$423, 199	\$16, 277	208. 3	\$78
	Stroke	605	221, 397	\$17, 700, 471	\$29, 257	365. 9	\$80
	Other/Unknown	822	296, 177	\$21, 425, 420	\$26, 065	360. 3	\$72
	Issue Year Sub-Total	4, 469	1, 529, 033	\$121, 851, 233	<i>\$27, 266</i>	<i>342.</i> 1	\$80

Appendi x: G - 9

Issue	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Year	Category	Tally	Days	Payments	Payments	Days	Day
1996 - 1999	Al zhei mer's	43	10, 283	\$1, 296, 197	\$30, 144	239. 1	\$126
	Arthritis	6	361	\$22, 180	\$3, 697	60. 2	\$61
	Cancer	43	2, 004	\$206, 802	\$4, 809	46. 6	\$103
	Ci rcul atory	11	2, 057	\$426, 404	\$38, 764	187. 0	\$207
	Di abetes	3	452	\$10, 927	\$3, 642	150. 7	\$24
	Endocrine, Immunity System	1	9	\$405	\$405	9. 0	\$45
	Hypertension	1	726	\$51, 309	\$51, 309	726. 0	\$71
	Ill-Defined and Misc Conditions	2	363	\$19, 695	\$9, 848	181. 5	\$54
	I nj ury	11	1, 041	\$131, 986	\$11, 999	94. 6	\$127
	Mental	1	95	\$9, 500	\$9, 500	95. 0	\$100
	Nervous System and Sense Organs	26	1, 962	\$596, 331	\$22, 936	75. 5	\$304
	Pregnancy Di sorders	1	0	\$6, 809	\$6, 809	0.0	
	Respi ratory	4	53	\$10, 138	\$2, 535	13. 3	\$191
	Skin and Subcutaneous Tissue	1	321	\$13, 920	\$13, 920	321.0	\$43
	Stroke	26	3, 803	\$691, 154	\$26, 583	146. 3	\$182
	Other/Unknown	87	18, 589	\$1, 589, 115	\$18, 266	213. 7	\$85
	Issue Year Sub-Total	267	42, 119	\$5, 082, 872	\$19, 037	157. 7	\$121
	Issue Year Total	45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendi x: G - 9

Issue	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Year	Category	Tal l y	Days	Payments	Payments	Days	Day
1984 - 1987	Al zhei mer' s	15	6, 588	\$198, 040	\$13, 203	439. 2	\$30
	Arthritis	10	2, 403	\$77, 370	\$7, 737	240. 3	\$32
	Cancer	24	5, 086	\$142, 017	\$5, 917	211. 9	\$28
	Ci rcul atory	37	8, 979	\$276, 320	\$7, 468	242. 7	\$31
	Di abetes	4	417	\$13, 501	\$3, 375	104. 3	\$32
	Digestive System	3	168	\$9, 615	\$3, 205	56. 0	\$57
	Endocrine, Immunity System	5	767	\$23, 380	\$4,676	153. 4	\$30
	Geni touri nary System	3	129	\$4, 745	\$1,582	43. 0	\$37
	Hypertension	Ī	180	\$3, 600	\$3, 600	180. 0	\$20
	Ill-Defined and Misc Conditions	3	150	\$8, 875	\$2, 958	50. 0	\$59
	Inj ury	32	2, 822	\$126, 260	\$3, 946	88. 2	\$45
	Mental	11	1, 587	\$45, 194	\$4, 109	144. 3	\$28
	Nervous System and Sense Organs	9	1, 340	\$36, 138	\$4, 015	148. 9	\$27
	Pregnancy Di sorders	3	0	\$12, 065	\$4, 022	0. 0	****
	Respiratory	11	2, 094	\$79, 050	\$7, 186	190. 4	\$38
	Skin and Subcutaneous Tissue	5	296	\$16, 290	\$3, 258	59. 2	\$55
	Stroke	19	2, 834	\$126, 195	\$6, 642	149. 2	\$45
	Other/Unknown	99	14, 179	\$392, 412	\$3, 964	143. 2	\$28
	Issue Year Sub-Total	294	50, 019	\$1, 591, 067	\$5, 412	170. 1	\$32

Appendi x: G - 9

Issue	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Year	Category	Tal l y	Days	Payments	Payments Payments	Days	Day
1988 - 1991	Al zhei mer's	347	54, 432	\$2, 948, 544	\$8, 497	156. 9	\$54
	Arthri ti s	161	8, 731	\$689, 251	\$4, 281	54. 2	\$79
	Cancer	284	13, 419	\$943, 866	\$3, 323	47. 3	\$70
	Ci rcul atory	214	21, 494	\$930, 737	\$4, 349	100. 4	\$43
	Congeni tal *	4	350	\$39, 205	\$9, 801	87. 5	\$112
	Di abetes	20	618	\$79, 304	\$3, 965	30. 9	\$128
	Digestive System	34 24	496	\$158, 263	\$4,655	14. 6	\$319
	Endocrine, Immunity System		1, 842	\$218, 298	\$9, 096	76. 8	\$119
	Geni touri nary System	28	2, 304	\$149, 071	\$5, 324	82 . 3	\$65
	Hypertension	21 73	1, 065	\$79, 548	\$3, 788	50. 7	<u> </u>
	Ill-Defined and Misc Conditions		6, 895	\$396, 114	\$5, 426	94. 5	\$57
	Inj ury	301	20, 514	\$1, 240, 810	\$4, 122	68. 2	\$60
	Mental	34	2, 473	\$258, 650	\$7, 607	72. 7	\$105
	Nervous System and Sense Organs	128	21, 232	\$1, 796, 930	\$14, 039	165. 9	\$85
	Pregnancy Di sorders	4	0	\$35, 109	\$8, 777	0.0	***
	Respi ratory	80	6, 635	\$598, 577	\$7, 482	82. 9	\$90
	Skin and Subcutaneous Tissue	7	13	\$32, 864	\$4, 695	1. 9	\$2, 528
	Stroke	207	19, 864	\$1, 485, 611	\$7, 177	96. 0	\$75
	Other/Unknown	564	39, 833	\$4, 740, 256	\$8, 405	70. 6	\$119
	Issue Year Sub-Total	2, 535	<i>222, 210</i>	\$16, 821, 008	<i>\$6, 636</i>	<i>87. 7</i>	<i>\$76</i>

Appendi x: G - 9

Tally	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
384 265 326 251 1 26 49 18 16 20 70 339 18	90, 590 39, 965 28, 657 34, 938 0 3, 965 4, 936 1, 554 362 1, 317 9, 093 49, 848 708 48, 528	Payments \$7, 593, 827 \$2, 580, 071 \$1, 923, 095 \$2, 528, 498 \$84 \$247, 825 \$244, 164 \$121, 889 \$54, 338 \$247, 546 \$702, 763 \$3, 079, 203 \$250, 454 \$3, 329, 384	\$19, 776 \$9, 736 \$5, 899 \$10, 074 \$84 \$9, 532 \$4, 983 \$6, 772 \$3, 396 \$12, 377 \$10, 039 \$9, 083 \$13, 914 \$25, 415	235. 9 150. 8 87. 9 139. 2 0. 0 152. 5 100. 7 86. 3 22. 6 65. 9 129. 9 147. 0 39. 3 370. 4	\$84 \$65 \$67 \$72 \$63 \$49 \$78 \$150 \$188 \$77 \$62 \$354 \$69
7 92 15 289 419	221 10, 995 3, 416 57, 951 16, 509	\$15, 289 \$905, 765 \$206, 361 \$4, 464, 624 \$3, 421, 986	\$2, 184 \$9, 845 \$13, 757 \$15, 449 \$8, 167	31. 6 119. 5 227. 7 200. 5 39. 4	\$69 \$82 \$60 \$77 \$207 \$79
	384 265 326 251 1 26 49 18 16 20 70 339 18 131 7 92 15 289	384 90, 590 265 39, 965 326 28, 657 251 34, 938 1 0 26 3, 965 49 4, 936 18 1, 554 16 362 20 1, 317 70 9, 093 339 49, 848 18 708 131 48, 528 7 221 92 10, 995 15 3, 416 289 57, 951 419 16, 509	Tally Days Payments 384 90, 590 \$7,593,827 265 39,965 \$2,580,071 326 28,657 \$1,923,095 251 34,938 \$2,528,498 1 0 \$84 26 3,965 \$247,825 49 4,936 \$244,164 18 1,554 \$121,889 16 362 \$54,338 20 1,317 \$247,546 70 9,093 \$702,763 339 49,848 \$3,079,203 18 708 \$250,454 131 48,528 \$3,329,384 7 221 \$15,289 92 10,995 \$905,765 15 3,416 \$206,361 289 57,951 \$4,464,624 419 16,509 \$3,421,986	Total Payments Payments 384 90, 590 \$7, 593, 827 \$19, 776 265 39, 965 \$2, 580, 071 \$9, 736 326 28, 657 \$1, 923, 095 \$5, 899 251 34, 938 \$2, 528, 498 \$10, 074 1 0 \$84 \$84 26 3, 965 \$247, 825 \$9, 532 49 4, 936 \$244, 164 \$4, 983 18 1, 554 \$121, 889 \$6, 772 16 362 \$54, 338 \$3, 396 20 1, 317 \$247, 546 \$12, 377 70 9, 093 \$702, 763 \$10, 039 339 49, 848 \$3, 079, 203 \$9, 083 18 708 \$250, 454 \$13, 914 131 48, 528 \$3, 329, 384 \$25, 415 7 221 \$15, 289 \$2, 184 92 10, 995 \$905, 765 \$9, 845 15 3, 416 \$206, 361 \$13, 757 289 57, 951 \$4, 464, 624 \$15, 449 419 16, 509 \$3, 421, 986 \$8, 167	Tally Days Total Payments Claim Payments Average Days 384 90, 590 \$7,593,827 \$19,776 235.9 265 39,965 \$2,580,071 \$9,736 150.8 326 28,657 \$1,923,095 \$5,899 87.9 251 34,938 \$2,528,498 \$10,074 139.2 1 0 \$84 \$84 0.0 26 3,965 \$247,825 \$9,532 152.5 49 4,936 \$244,164 \$4,983 100.7 18 1,554 \$121,889 \$6,772 86.3 16 362 \$54,338 \$3,396 22.6 20 1,317 \$247,546 \$12,377 65.9 70 9,093 \$702,763 \$10,039 129.9 339 49,848 \$3,079,203 \$9,083 147.0 18 708 \$250,454 \$13,914 39.3 131 48,528 \$3,329,384 \$25,415 370.4

Appendi x: G - 9

Issue Year	Di agnosi s Category	Tally	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
1996 - 1999	Al zhei mer's	23	7, 878	\$752, 986	\$32, 739	342. 5	\$96
	Arthritis	14	3, 610	\$176, 576	\$12, 613	257. 9	\$49
	Cancer	63	9, 025	\$552, 203	\$8, 765	143. 3	\$61
	Ci rcul atory	4	1, 005	\$26, 195	\$6, 549	251. 3	\$26
	Di abetes °	2	472	\$15, 434	\$7, 717	236 . 0	\$33
	Digestive System	3	256	\$24, 084	\$8, 028	85 . 3	\$94
	Ill-Defined and Misc Conditions	2	228	\$15, 086	\$7, 543	114. 0	\$66
	Inj ury	34	4, 592	\$229, 939	\$6, 763	135. 1	\$50
	Nervous System and Sense Organs	24	8, 312	\$768, 568	\$32, 024	346. 3	\$92
	Respi ratory	4	371	\$17, 552	\$4, 388	92. 8	\$47
	Skin and Subcutaneous Tissue	1	92	\$13, 500	\$13, 500	92. 0	\$147
	Stroke	23	5, 319	\$363, 360	\$15, 798	231. 3	\$68
	Other/Unknown	33	3, 542	\$212, 062	\$6, 426	107. 3	\$60
	Issue Year Sub-Total	230	44, 702	\$3, 167, 545	\$13, 772	194. 4	\$71
	Issue Year Total	5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendix: G - 10

Nursing Home Claims: Underwriting Type and Diagnosis Summary

Di agnosi s Total Cl ai m Average Per Underwriting Type Category Tally Days **Payments Payments** Days Day Full Medical 2, 490 1, 344, 303 \$83 Al zhei mer's \$110, 925, 427 \$44, 548 539. 9 289, 515 168, 701 \$20, 654, 017 \$11, 573, 339 \$28, 014, 144 \$22, 329 \$9, 200 Arthritis 925 313. 0 134. 1 \$71 1. 258 **Š**69 Cancer Ci rcul atory 1, 229 425, 028 \$22,794 345.8 \$66 \$23, 810 \$5, 883, 733 \$3, 968 \$27, 623 Congeni tal 105.7 \$38 634 213 431. 2 \$64 Di abetes 91, 854 \$19,744 Digestive System 251 75, 909 \$4, 955, 839 302.4 \$65 Endocrine, Immunity System 157 60, 761 \$3, 928, 018 \$25,019 387.0 \$65 185 42, 583 \$2, 730, 030 \$14, 757 230. 2 \$64 Geni touri nary System 233 138, 972 \$8, 770, 981 \$37,644 596. 4 \$63 Hypertensi on Ill-Defined and Misc Conditions 280 88, 873 \$5, 484, 376 \$19,587 317.4 \$62 \$21, 736, 048 1.403 347, 982 \$15, 493 248. 0 \$62 Inj ury

288

560

640

1, 819

4, 084

16, 092

10

156, 520

229, 398

175, 721

1, 241, 762

5, 616, 181

14, 525 722, 653

487

\$10, 289, 381

\$17, 578, 897 \$29, 994

\$11, 314, 830

\$53, 021, 615

\$88, 917, 672

\$406, 786, 632

\$954, 481

Mental

Stroke Other/Unknown

Respi ratory

Nervous System and Sense Organs

Underwriting Type Sub-Total

Skin and Subcutaneous Tissue

Pregnancy Di sorders

Average

\$35, 727

\$31, 391

\$17,679

\$15,647

\$29, 149

\$21,772

\$25, 279

\$2, 999

543.5

409.6

274.6

238. 1

397. 3

304. 1

349. 0

48. 7

Average

\$66

\$77

\$62

\$64

\$66

\$73

\$72

\$72

Appendi x: G - 10

Nursing Home Claims: Underwriting Type and Diagnosis Summary

Underwriting Type	Di agnosi s Category	Tally	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
Full Medical + Cognitive Testing	Al zhei mer's Arthritis Cancer Ci rcul atory Di abetes Di gestive System Endocrine, Immunity System Genitourinary System Hypertension Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Underwriting Type Sub-Total	111 74 40 68 10 6 8 5 5 12 40 5 15 19 2 114 45 579	44, 004 17, 532 4, 845 15, 978 3, 727 2, 124 1, 865 860 3, 855 1, 496 8, 337 1, 618 5, 706 3, 131 47 38, 804 7, 706 161, 635	\$3, 068, 639 \$1, 303, 436 \$324, 439 \$986, 863 \$223, 404 \$171, 856 \$82, 940 \$46, 115 \$275, 525 \$54, 419 \$488, 684 \$119, 585 \$407, 133 \$169, 299 \$2, 459 \$2, 598, 632 \$654, 426 \$10, 977, 854	\$27, 645 \$17, 614 \$8, 111 \$14, 513 \$22, 340 \$28, 643 \$10, 368 \$9, 223 \$55, 105 \$4, 535 \$12, 217 \$23, 917 \$27, 142 \$8, 910 \$1, 230 \$22, 795 \$14, 543 \$18, 960	396. 4 236. 9 121. 1 235. 0 372. 7 354. 0 233. 1 172. 0 771. 0 124. 7 208. 4 323. 6 380. 4 164. 8 23. 5 340. 4 171. 2 279. 2	\$70 \$74 \$67 \$62 \$60 \$81 \$44 \$54 \$71 \$36 \$59 \$74 \$71 \$54 \$52 \$67 \$85 \$68

Appendi x: G - 10

Nursing Home Claims: Underwriting Type and Diagnosis Summary

v. 1	Di agnosi s	m 11		Total	Average Claim	Average	Average Per
Underwriting Type	Category	Tal l y	Days	Payments	<i>Payments</i>	Days	Day
GI/Actively at Work Requirements	Al zhei mer's	61	24, 936	\$3, 336, 013	\$54, 689	408. 8	\$134
J	Arthritis	17	301	\$263, 733	\$15, 514	17. 7	\$876
	Cancer	76	3, 439	\$623, 871	\$8, 209	45. 3	\$181
	Ci rcul atory	13	2, 722	\$673, 490	\$51, 807	209. 4	\$247
	Di abetes "	7	384	\$55, 610	\$7, 944	54. 9	\$145
	Digestive System	3	700	\$74, 346	\$24, 782	233. 3	\$106
	Endocrine, Immunity System	2	21	\$2, 450	\$1, 225	10. 5	\$117
	Genitourinary System	8	185	\$238, 090	\$29, 761	23. 1	\$1, 287
	Ill-Defined and Misc Conditions	2	329	\$11, 930	\$5, 965	164. 5	\$36
	I nj ury	13	2, 740	\$98, 146	\$7, 550	210. 8	\$36
	Mental	4	1, 340	\$221, 042	\$55, 261	335. 0	\$165
	Nervous System and Sense Organs	196	11, 242	\$14, 146, 068	\$72, 174	57. 4	\$1, 258
	Pregnancy Di sorders	1	0	\$-480	\$-480	0. 0	
	Respiratory	6	0	\$55, 225	\$9, 204	0.0	
	Skin and Subcutaneous Tissue	1	53	\$3,006	\$3,006	53. 0	\$57
	Stroke	65	8, 141	\$1, 990, 206	\$30, 619	125. 2	\$244
	Other/Unknown	65 58	4, 641	\$479, 257	\$8, 263	80. 0	\$103
	Underwriting Type Sub-Total	533	61, 174	\$22, 272, 003	\$41, 786	114. 8	\$364

Appendi x: G - 10

Nursing Home Claims: Underwriting Type and Diagnosis Summary

	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Underwri ti ng Type	Category	Tally	Days	<i>Payments</i>	Payments	Days	Day
Other/None	Al zhei mer's	336	173, 142	\$10, 452, 005	\$31, 107	515. 3	\$60
	Arthritis	90	12, 939	\$745, 124	\$8, 279	143. 8	\$58
	Cancer	161	18, 612	\$1, 037, 704	\$6, 445	115. 6	\$56
	Circulatory	167	47, 985	\$2, 732, 646	\$16, 363	287. 3	\$57
	Congenital	2	85	\$5, 930	\$2, 965	42. 5	\$70
	Di abetes	37	11, 258	\$668, 196	\$18, 059	304. 3	\$59
	Digestive System	29	5, 950	\$262, 465	\$9, 051	205. 2	\$44
	Endocrine, Immunity System	12	2, 777	\$153, 837	\$12, 820	231. 4	\$55
	Geni touri nary System	19	2, 869	\$185, 986	\$9, 789	151. 0	\$65
	Hypertension	15	5, 990	\$350, 395	\$23, 360	399. 3	\$58
	Ill-Defined and Misc Conditions	29	6, 714	\$436, 129	\$15, 039	231. 5	\$65
	I nj ury	171	34, 726	\$1, 976, 006	\$11, 556	203. 1	\$57
	Mental	15	8, 112	\$527, 313	\$35, 154	540. 8	\$65
	Nervous System and Sense Organs	39	21, 480	\$1, 372, 682	\$35, 197	550. 8	\$64
	Respi ratory	37	10, 031	\$472, 445	\$12, 769	271. 1	\$47
	Skin and Subcutaneous Tissue	5	426	\$21, 500	\$4, 300	85. 2	\$50
	Stroke	233	89, 222	\$5, 111, 515	\$21,938	382. 9	\$57
	Other/Unknown	22	4, 345	\$225, 977	\$10, 272	197. 5	\$52
	Underwriting Type Sub-Total	1, 419	456, 663	\$26, 737, 855	\$18, 843	321. 8	\$59

Appendix: G - 10

Nursing Home Claims: Underwriting Type and Diagnosis Summary

Di agnosi s Total Claim Average Per Underwriting Type Category Tally Days Payments 1 4 1 Payments 1 4 1 Days Day 1, 706, 409 362, 624 239, 447 \$138, 842, 932 \$26, 106, 151 \$58, 707 \$34, 578 \$16, 773 Simplified Al zhei mer's 2, 365 755 721. 5 480. 3 \$81 \$72 Arthritis \$18, 232, 638 \$78, 867, 745 \$133, 280 220.3 1.087 \$76 Cancer \$73 Ci rcul atory 2, 250 1.081.842 \$35,052 480.8 3, 011 \$14, 809 \$44 334. 6 Congeni tal 297 172, 464 Di abetes \$12, 634, 724 \$42, 541 580.7 \$73 Digestive System 333 145, 611 \$10, 296, 881 \$30,922 437.3 \$71 Endocrine, Immunity System 233 118, 275 \$7, 608, 994 \$32, 657 507.6 \$64 Genitourinary System 258 110, 158 \$8, 097, 498 \$31, 386 427.0 \$74 170 105, 252 \$5, 700, 872 \$33, 535 619. 1 \$54 Hypertensi on Ill-Defined and Misc Conditions 1.009 438, 836 \$32, 449, 598 \$32, 160 434.9 \$74 2, 166 954, 307 \$65, 857, 047 \$30, 405 440.6 \$69 Inj ury \$22, 422, 030 \$22, 377, 926 Mental 535 527 360, 555 \$41,910 673.9 \$62 Nervous System and Sense Organs 359, 048 \$42, 463 681.3 \$62

Pregnancy Di sorders

Skin and Subcutaneous Tissue

Underwriting Type Sub-Total

Respi ratory

Other/Unknown

Stroke

28

981

103

1, 492

3, 742

18, 340

14, 545

338, 015

752, 910

1, 128, 460

8, 439, 255

47, 486

Average

\$26, 448

\$24, 022

\$29, 749

\$35, 852

\$17, 102

\$32, 415

519.5

344.6

461.0

504.6

301.6

460. 2

\$740, 530

\$23, 565, 741

\$53, 491, 315

\$63, 994, 847

\$594, 484, 924

\$3, 064, 175

Average

\$51

\$70

\$65

\$71

\$57

\$70

Appendi x: G - 10

Nursing Home Claims: Underwriting Type and Diagnosis Summary

Underwriting Type	Di agnosi s Category	Tally	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
Unknown	Al zhei mer's Arthritis Cancer Circul atory Congeni tal Di abetes Di gestive System Endocri ne, Immunity System Genitouri nary System Hypertensi on III - Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Underwriting Type Sub-Total	424 147 152 288 3 47 62 35 41 35 118 386 48 122 6 161 19 355 5, 924 8, 373	310, 462 84, 009 37, 814 142, 898 384 23, 442 38, 568 17, 062 18, 432 19, 990 54, 892 174, 330 35, 099 74, 704 2, 604 76, 885 7, 250 219, 463 1, 505, 784 2, 844, 072	\$22, 427, 497 \$5, 232, 777 \$2, 708, 644 \$9, 786, 996 \$24, 380 \$1, 686, 867 \$2, 405, 361 \$1, 136, 135 \$1, 282, 377 \$1, 199, 521 \$3, 784, 637 \$10, 070, 887 \$2, 294, 927 \$5, 074, 908 \$150, 560 \$5, 065, 652 \$454, 880 \$14, 341, 985 \$85, 974, 236 \$175, 103, 227	\$52, 895 \$35, 597 \$17, 820 \$33, 983 \$8, 127 \$35, 891 \$38, 796 \$32, 461 \$31, 277 \$34, 272 \$32, 073 \$26, 090 \$47, 811 \$41, 598 \$25, 093 \$31, 464 \$23, 944 \$40, 400 \$14, 513 \$20, 913	732. 2 571. 5 248. 8 496. 2 128. 0 498. 8 622. 1 487. 5 449. 6 571. 1 465. 2 451. 6 731. 2 612. 3 434. 0 477. 5 381. 6 618. 2 254. 2 339. 7	\$72 \$62 \$72 \$68 \$63 \$72 \$62 \$67 \$70 \$60 \$69 \$58 \$65 \$65 \$63 \$63 \$65 \$57 \$62

45, 336 17, 578, 980 \$1, 236, 362, 495

\$27, 271

387. 7

\$70

Underwriting Type Total

Appendi x: G - 10

Underwriting Type	Di agnosi s Category	Tal l y	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
onder witting Type	category	lairy	Days	Taylicites	Taylicites	Days	Day
Full Medical	Al zhei mer's	387	17, 473	\$4, 751, 243	\$12, 277	45. 1	\$272
	Arthri ti s	229	9, 440	\$1, 293, 655	\$5, 649	41. 2	\$137
	Cancer	319	8, 247	\$1, 146, 829	\$3, 595	25. 9	\$139
	Ci rcul atory	251	5, 643	\$1, 489, 509	\$5, 934	22. 5	\$264
	Congeni tal "	4	0	\$21, 039	\$5, 260	0. 0	
	Di abetes	27	1,014	\$228, 832	\$8, 475	37. 6	\$226
	Digestive System	52	1, 536	\$201, 927	\$3, 883	29. 5	\$131
	Endocrine, Immunity System	22	210	\$199, 203	\$9, 055	9. 5	\$949
	Geni touri nary System	24	214	\$82, 763	\$3, 448	8. 9	\$387
	Hypertension	29	82	\$215, 375	\$7, 427	2. 8	\$2, 627
	Ill-Defined and Misc Conditions	67	556	\$396, 447	\$5, 917	8. 3	\$713
	I nj ury	348	9, 080	\$1, 703, 013	\$4, 894	26. 1	\$188
	Mental	32	791	\$389, 239	\$12, 164	24. 7	\$492
	Nervous System and Sense Organs	103	5, 880	\$1, 055, 936	\$10, 252	57. 1	\$180
	Pregnancy Di sorders	6	0	\$35, 553	\$5, 926	0. 0	
	Respi ratory	102	4, 126	\$861, 552	\$8, 447	40. 5	\$209
	Skin and Subcutaneous Tissue	12	87	\$77, 865	\$6, 489	7. 3	\$895
	Stroke	298	13, 892	\$2, 821, 106	\$9, 467	46. 6	\$203
	Other/Unknown	649	12, 521	\$6, 412, 081	\$9, 880	19. 3	\$512
	Underwriting Type Sub-Total	2, 961	90, 792	<i>\$23, 383, 167</i>	<i>\$7, 897</i>	<i>30.</i> 7	<i>\$258</i>

Appendi x: G - 10

Underwriting Type	Di agnosi s Category	Tally	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
Full Medical + Cognitive Testing	Al zhei mer' s	35 66	8, 888	\$360, 560	\$10, 302	253. 9	\$41
e e	Arthri ti s	66	3, 997	\$215, 327	\$3, 263	60. 6	\$54
	Cancer	45	1, 689	\$116, 302	\$2, 584	37. 5	\$69
	Ci rcul atory	47	525	\$68, 932	\$1, 467	11. 2	\$131
	Di abetes	8	192	\$15, 565	\$1, 946	24. 0	\$81
	Digestive System	9	22	\$6, 866	\$763	2. 4	\$312
	Endocrine, Immunity System	3	671	\$32, 805	\$10, 935	223. 7	\$49
	Genitourinary System	2	45	\$1, 150	\$575	22. 5	\$26
	Hypertensi on "	3	43	\$2, 765	\$922	14. 3	\$64
	Ill-Defined and Misc Conditions	14	124	\$24, 093	\$1,721	8. 9	\$194
	Injury	$ar{64}$	3, 028	\$144, 348	\$2, 255	47. 3	\$48
	Mental	2	59	\$2, 900	\$1, 450	29. 5	\$49
	Nervous System and Sense Organs	6	1, 166	\$80, 133	\$13, 356	194. 3	\$69
	Pregnancy Di sorders	$\dot{2}$	45	\$2, 088	\$1,044	22. 5	\$46
	Respiratory	14	1, 734	\$116, 143	\$8, 296	123. 9	\$67
	Skin and Subcutaneous Tissue	3	16	\$2, 220	\$740	5. 3	\$139
	Stroke	46	4, 999	\$300, 500	\$6, 533	108. 7	\$60
	Other/Unknown	30	1, 817	\$165, 501	\$5, 517	60. 6	\$91
	Underwriting Type Sub-Total	399	29, 060	\$1, 658, 198	\$4, 156	72. 8	\$57

Appendi x: G - 10

Underwriting Type	Di agnosi s Category	Tal l y	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
GI/Actively at Work Requirements	Al zhei mer's Arthritis Cancer Circul atory Di abetes Di gestive System Endocrine, Immunity System Genitourinary System Ill-Defined and Misc Conditions Injury Mental Nervous System and Sense Organs Pregnancy Disorders Respiratory Skin and Subcutaneous Tissue Stroke Other/Unknown Underwriting Type Sub-Total	39 14 76 7 5 2 4 4 1 17 109 1 7 1 35 82 405	12, 485 2, 919 9, 022 3, 775 472 1, 351 724 210 54 6, 076 0 48, 511 0 785 10 11, 819 14, 167 112, 380	\$580, 719 \$112, 480 \$364, 599 \$65, 246 \$28, 800 \$68, 674 \$29, 095 \$29, 193 \$3, 780 \$333, 025 \$4, 230 \$3, 161, 696 \$1, 390 \$23, 593 \$540 \$720, 966 \$704, 031 \$6, 232, 057	\$14, 890 \$8, 034 \$4, 797 \$9, 321 \$5, 760 \$34, 337 \$7, 274 \$7, 298 \$3, 780 \$19, 590 \$4, 230 \$29, 006 \$1, 390 \$3, 370 \$540 \$20, 599 \$8, 586 \$15, 388	320. 1 208. 5 118. 7 539. 3 94. 4 675. 5 181. 0 52. 5 54. 0 357. 4 0. 0 445. 1 0. 0 112. 1 10. 0 337. 7 172. 8 277. 5	\$47 \$39 \$40 \$17 \$61 \$51 \$40 \$139 \$70 \$55 \$65

Appendi x: G - 10

Underwriting Type	Di agnosi s Category	Tal l v	Days	Total Payments	Average Cl ai m Payments	Average Days	Average Per Day
onder wireing Type	out og or y	14119	zujo	1 11/11/25	1 try menes	zujz	24.9
Other/None	Al zhei mer' s	13	1, 053	\$73, 263	\$5, 636	81. 0	\$70
	Arthritis	16	1, 003	\$36, 149	\$2, 259	62. 7	\$36
	Cancer	33	2,078	\$89, 729	\$2, 719	63. 0	\$43
	Ci rcul atory	21	2, 637	\$65, 446	\$3, 116	125. 6	\$25
	Diabetes	2	150	\$5, 306	\$2, 653	75. 0	\$35
	Digestive System	2	85	\$9, 432	\$4,716	42. 5	\$111
	Endocrine, Immunity System	2	368	\$6, 761	\$3, 381	184. 0	\$18
	Geni touri nary System	3	23	\$1, 321	\$440	7. 7	\$57
	Hypertension	5	304	\$5, 379	\$1,076	60. 8	\$18
	Ill-Defined and Misc Conditions	6	1, 043	\$22, 270	\$3, 712	173. 8	\$21
	Inj ury	25	1, 603	\$62, 740	\$2, 510	64 . 1	\$39
	Nervous System and Sense Organs	5	231	\$12, 046	\$2, 409	46. 2	\$52
	Respiratory	7	1, 346	\$35, 629	\$5, 090	192. 3	\$26
	Skin and Subcutaneous Tissue	1	13	\$720	\$720	13. 0	\$55
	Stroke	29	4, 748	\$312, 143	\$10, 764	163. 7	\$66
	Other/Unknown	13	955	\$54, 503	\$4, 193	73. 0	\$57
	Underwriting Type Sub-Total	183	17, 640	\$792, 837	<i>\$4, 332</i>	<i>96. 4</i>	\$45

Appendi x: G - 10

	Di agnosi s			Total	Average Cl ai m	Average	Average Per
Underwriting Type	Category	Tal l y	Days	Payments	Payments	Days	Day
Simplified	Al zhei mer's	148	32, 900	\$881, 943	\$5, 959	222. 3	\$27
	Arthritis	31	2, 955	\$84, 495	\$2, 726	95. 3	\$29
	Cancer	69	9, 113	\$278, 522	\$4, 037	132. 1	\$31
	Ci rcul atory	101	21, 800	\$644, 012	\$6, 376	215.8	\$30
	Di abetes "	5	528	\$17, 802	\$3, 560	105. 6	\$34
	Digestive System	7	107	\$22, 276	\$3, 182	15. 3	\$208
	Endocrine, Immunity System	7	661	\$42, 868	\$6, 124	94. 4	\$65
	Geni touri nary System	10	1, 957	\$85, 963	\$8, 596	195. 7	\$44
	Hypertensi on Table 1	4	907	\$46, 775	\$11, 694	226. 8	\$52
	Ill-Defined and Misc Conditions	36	5, 309	\$132, 201	\$3,672	147. 5	\$25
	I nj ury	96	9, 915	\$307, 634	\$3, 205	103. 3	\$31
	Mental	26	3, 440	\$121, 642	\$4,679	132. 3	\$35
	Nervous System and Sense Organs	25	6,013	\$236, 737	\$9, 469	240. 5	\$39
	Pregnancy Di sorders	4	0	\$13, 825	\$3, 456	0.0	
	Respiratory	21	1, 363	\$49, 988	\$2, 380	64. 9	\$37
	Skin and Subcutaneous Tissue	4	0	\$10,710	\$2,678	0. 0	
	Stroke	$4\bar{5}$	1, 973	\$142, 239	\$3, 161	43. 8	\$72
	Other/Unknown	259	35, 020	\$972, 403	\$3, 754	135. 2	\$28
	Underwriting Type Sub-Total	898	133, 961	\$4, 092, 035	\$4, 557	149. 2	\$31

Appendi x: G - 10

Underwriting Type	Di agnosi s Category	Tal l y	Days	Total Payments	Average Claim Payments	Average Days	Average Per Day
Unknown	Al zhei mer's	147	86, 689	\$4, 845, 669	\$32, 964	589. 7	\$56
	Arthritis	94	34, 395	\$1, 781, 162	\$18, 949	365. 9	\$52
	Cancer	155	26, 038	\$1, 565, 200	\$10,098	168. 0	\$60
	Ci rcul atory	79	32, 036	\$1, 428, 605	\$18, 084	405. 5	\$45
	Congeni tal	1	350	\$18, 250	\$18, 250	350. 0	\$52
	Di abetes	5	3, 116	\$59, 759	\$11, 952	623. 2	\$19
	Digestive System	17	2, 755	\$126, 951	\$7, 468	162. 1	\$46
	Endocrine, Immunity System	9	1, 529	\$52, 835	\$5, 871	169. 9	\$35
	Geni touri nary System	4	346	\$7, 764	\$1, 941	86. 5	\$22
	Hypertensi on The Hypertensi o	1	1, 226	\$60, 400	\$60, 400	1, 226. 0	\$49
	III-Defined and Misc Conditions	24	9, 280	\$544, 047	\$22,669	386. 7	\$59
	Inj ury	156	48, 074	\$2, 125, 452	\$13, 625	308. 2	\$44
	Mental	2	478	\$36, 287	\$18, 144	239. 0	\$76
	Nervous System and Sense Organs	44	17, 611	\$1, 384, 472	\$31, 465	400. 3	\$79
	Pregnancy Di sorders	1	176	\$9, 607	\$9, 607	176. 0	\$55
	Respiratory	36	10, 741	\$514, 039	\$14, 279	298. 4	\$48
	Skin and Subcutaneous Tissue	7	3, 691	\$176, 960	\$25, 280	527 . 3	\$48
	Stroke	85	48, 537	\$2, 142, 836	\$25, 210	571. 0	\$44
	Other/Unknown	82	9, 583	\$458, 197	\$5, 588	116. 9	\$48 <i>\$52</i>
	Underwriting Type Sub-Total	949	336, 651	\$17, 338, 492	\$18, 270	<i>354. 7</i>	\$52
	Underwriting Type Total	5, 795	720, 484	\$53, 496, 786	<i>\$9, 232</i>	124. 3	\$74

Appendix: G - 11

Nursing Home Claims: Benefit Period Type and Diagnosis Summary

ВР Туре	Di agnosi s Category	Tally	Days	Total Payments	Average Claim Paynents	Average Days	Average Per Day
Li mi ted	Al zhei mer' s	4, 699	2, 902, 619	\$238, 972, 017	\$50, 856	617. 7	\$82
	Arthri ti s	1, 586	625, 839	\$45, 119, 802	\$28, 449	394. 6	\$72
	Cancer	2, 248	386, 237	\$28, 528, 727	\$12, 691	171. 8	\$74
	Ci rcul atory	3, 468	1, 493, 422	\$105, 889, 651	\$30, 533	430. 6	\$71
	Congeni tal	16	3, 715	\$160, 780	\$10, 049	232. 2	\$43
	Di abetes	509	258, 976	\$18, 105, 952	\$35, 572	508. 8	\$70
	Digestive System	571	220, 651	\$14, 966, 307	\$26, 211	386. 4	\$68
	Endocrine, Immunity System	387	172, 285	\$10, 888, 878	\$28, 137	445. 2	\$63
	Geni touri nary System	440	148, 545	\$10, 702, 519	\$24, 324	337. 6	\$72
	Hypertensi on	387	237, 024	\$13, 921, 058	\$35, 972	612. 5	\$59
	Ill-Defined and Misc Conditions	1, 267	515, 837	\$37, 155, 946	\$29, 326	407. 1	\$72
	I nj ury	3, 493	1, 282, 106	\$86, 063, 337	\$24, 639	367. 1	\$67
	Mental	787	493, 144	\$31, 178, 751	\$39, 617	626. 6	\$63
	Nervous System and Sense Organs	1, 212	575, 891	\$52, 220, 446	\$43, 086	475. 2	\$91
	Pregnancy Di sorders	38	15, 003	\$769, 639	\$20, 254	394. 8	\$51
	Respiratory	1, 556	491, 480	\$33, 329, 974	\$21, 420	315. 9	\$68
	Skin and Subcutaneous Tissue	160	60, 566	\$3, 912, 123	\$24, 451	378. 5	\$65
	Stroke	3, 200	1, 421, 801	\$103, 613, 437	\$32, 379	444. 3	\$73
	Other/Unknown	12, 164	3, 323, 269	\$200, 836, 297	\$16, 511	273. 2	\$60
	BP Type Sub-Total	38, 188	14, 628, 410	\$1, 036, 335, 641	\$27, 138	383. 1	\$71

Appendix: G - 11

Nursing Home Claims: Benefit Period Type and Diagnosis Summary

ВР Туре	Di agnosi s Category	Tally	Days	Total Paynents	Average Clai m Paynents	Average Days	Average Per Day
Unknown	Al zhei mer's	511	341, 461	\$23, 674, 553	\$46, 330	668. 2	\$69
	Arthritis	170	89, 781	\$5, 576, 882	\$32, 805	528. 1	\$62
	Cancer	188	44, 084	\$2, 947, 927	\$15, 680	234. 5	\$67
	Ci rcul atory	317	148, 405	\$10, 104, 136	\$31, 874	468. 2	\$68
	Congeni tal Č	3	384	\$24, 380	\$8, 127	128. 0	\$63
	Diabetes	60	27, 850	\$1, 927, 013	\$32, 117	464. 2	\$69
	Digestive System	65	39, 702	\$2, 508, 762	\$38, 596	610. 8	\$63
	Endocrine, Immunity System	38	18, 030	\$1, 180, 411	\$31, 063	474. 5	\$65
	Geni touri nary System	46	19, 152	\$1, 310, 062	\$28, 480	416. 3	\$68
	Hypertensi on	37	18, 651	\$1, 127, 226	\$30, 466	504 . 1	\$60
	Ill-Defined and Misc Conditions	122	52, 024	\$3, 430, 320	\$28, 117	426. 4	\$66
	Inj ury	420	186, 338	\$10, 611, 399	\$25, 265	443. 7	\$57
	Mental	55	36, 362	\$2, 286, 147	\$41, 566	661. 1	\$63
	Nervous System and Sense Organs	144	82, 156	\$5, 519, 089	\$38, 327	570. 5	\$67
	Pregnancy Di sorders	6	2, 604	\$150, 560	\$25, 093	434. 0	\$58
	Respi ratory	163	74, 997	\$4, 978, 804	\$30, 545	460. 1	\$66
	Skin and Subcutaneous Tissue	20	7, 168	\$444, 862	\$22, 243	358. 4	\$62
	Stroke	444	241 , 795	\$15, 523, 415	\$34, 963	544 . 6	\$64
	Other/Unknown	1, 090	349, 774	\$23, 005, 130	\$21, 106	320. 9	\$66
	BP Type Sub-Total	3, 899	1, 780, 718	\$116, 331, 078	<i>\$29, 836</i>	<i>456. 7</i>	\$65

Appendix: G - 11

Nursing Home Claims: Benefit Period Type and Diagnosis Summary

BP Type	Di agnosi s Category	Tally	Days	Total Paynents	Average Cl ai m Paynents	Average Days	Average Per Day
Unlimited	Al zhei mer's	577	359, 176	\$26, 405, 943	\$45, 764	622. 5	\$74
	Arthritis	252	51, 300	\$3, 608, 554	\$14, 320	203. 6	\$70
	Cancer	338	42, 537	\$3, 023, 981	\$8, 947	125. 8	\$71
	Ci rcul atory	230	74, 626	\$5, 068, 097	\$22, 035	324. 5	\$68
	Congeni tal	1	15	\$2, 240	\$2, 240	15. 0	\$149
	Di abetes	$4\bar{2}$	16, 303	\$1, 119, 569	\$26, 656	388. 2	\$69
	Digestive System	48	8, 509	\$691, 679	\$14, 410	177. 3	\$81
	Endocrine, Immunity System	22	10, 446	\$843, 085	\$38, 322	474. 8	
	Geni touri nary System	22 30	7, 390	\$567, 515	\$18, 917	246. 3	\$81 \$77
	Hypertensi on	34	18, 384	\$1, 249, 010	\$36, 736	540. 7	\$68
	Ill-Defined and Misc Conditions	61	23, 279	\$1, 634, 823	\$26, 800	381.6	\$70
	Inj ury	266	53, 978	\$3, 552, 082	\$13, 354	202. 9	\$66
	Mental	53	33, 738	\$2, 409, 380	\$45, 460	636. 6	\$71
	Nervous System and Sense Organs	103	43, 531	\$3, 218, 079	\$31, 243	422. 6	\$74
	Pregnancy Di sorders	1	29	\$405	\$405	29. 0	\$14
	Respi ratory	125	37, 306	\$2, 334, 414	\$18,675	298. 4	\$63
	Skin and Subcutaneous Tissue	11	2, 053	\$143, 516	\$13, 047	186. 6	\$70
	Stroke	434	167, 597	\$11, 418, 416	\$26, 310	386. 2	\$68
	Other/Unknown	621	219, 655	\$16, 404, 988	\$26, 417	353. 7	\$75
	BP Type Sub-Total	3, 249	1, 169, 852	\$83, 695, 776	\$25, 760	360. 1	\$72
	BP Type Total	45, 336	17, 578, 980	\$1, 236, 362, 495	\$27, 271	387. 7	\$70

Appendi x: G - 11

Home Health Care/ADC/Other Claims: Benefit Period Type and Diagnosis Summary

ВР Туре	Di agnosi s Category	Tally	Days	Total Paynents	Average Claim Payments	Average Days	Average Per Day
Li mi ted	Al zhei mer's	344	40, 605	\$3, 278, 394	\$9, 530	118. 0	\$81
	Arthritis	133	9, 507	\$900, 878	\$6, 774	71. 5	\$95
	Cancer	236	14, 753	\$914, 126	\$3, 873	62. 5	\$62
	Ci rcul atory	193	25, 737	\$1, 427, 699	\$7, 397	133. 4	\$55
	Di abetes	21	1, 339	\$206, 870	\$9, 851	63. 8	\$154
	Digestive System	22	525	\$103, 613	\$4,710	23. 9	\$197
	Endocrine, Immunity System	16	1, 131	\$114, 872	\$7, 180	70. 7	\$102
	Geni touri nary System	23	2, 162	\$118, 112	\$5, 135	94. 0	\$55
	Hypertensi on	14	1, 090	\$120, 462	\$8, 604	77. 9	\$111
	Ill-Defined and Misc Conditions	63	6, 806	\$234, 391	\$3, 720	108. 0	\$34
	Inj ury	209	13, 671	\$937, 798	\$4, 487	65. 4	\$69
	Mental	35	4, 059	\$179, 068	\$5, 116	116. 0	\$44
	Nervous System and Sense Organs	148	11, 747	\$1, 576, 185	\$10, 650	79. 4	\$134
	Pregnancy Di sorders	6	0	\$17, 935	\$2, 989	0. 0	
	Respiratory	72	6, 377	\$547, 180	\$7, 600	88. 6	\$86
	Skin and Subcutaneous Tissue	11	57	\$59, 392	\$5, 399	5. 2	\$1,042
	Stroke	193	14, 876	\$1, 767, 213	\$9, 157	77. 1	\$119
	Other/Unknown	596	42, 647	\$5, 317, 922	\$8, 923	71. 6	\$125
	BP Type Sub-Total	2. 335	197. 089	\$17. 822. 110	\$7, 633	84. 4	\$90

Appendi x: G - 11

Home Health Care/ADC/Other Claims: Benefit Period Type and Diagnosis Summary

ВР Туре	Di agnosi s Category	Tally	Days	Total Paynents	Average Cl ai m Payments	Average Days	Average Per Day
Unknown	Al zhei mer' s	206	96, 098	\$4, 913, 342	\$23, 851	466. 5	\$51
	Arthri ti s	149	31, 256	\$1, 292, 582	\$8, 675	209. 8	\$41
	Cancer	214	28, 583	\$1, 294, 400	\$6, 049	133. 6	\$45
	Ci rcul atory	135	31, 748	\$1, 536, 338	\$11, 380	235. 2	\$48
	Congeni tal	1	350	\$18, 250	\$18, 250	350. 0	\$52
	Di abetes	12	2, 227	\$60, 108	\$5, 009	185. 6	\$27
	Digestive System	26	2, 624	\$126, 736	\$4, 874	100. 9	\$48
	Endocrine, İmmunity System	19	2, 867	\$111, 712	\$5, 880	150. 9	\$39
	Geni touri nary System	11	491	\$21, 006	\$1, 910	44. 6	\$43
	Hypertensi on	3	1, 226	\$69, 872	\$23, 291	408. 7	\$57
	Ill-Defined and Misc Conditions	42	9, 449	\$617, 327	\$14, 698	225. 0	\$65
	I nj ury	238	48 , 450	\$2, 136, 037	\$8, 975	203. 6	\$44
	Mental	3	207	\$16, 282	\$5, 427	69. 0	\$79
	Nervous System and Sense Organs	84	37, 335	\$2, 068, 455	\$24, 624	444. 5	\$55
	Pregnancy Di sorders	3	221	\$11, 695	\$3, 898	73. 7	\$53
	Respi ratory	55	11, 790	\$617, 671	\$11, 230	214. 4	\$52
	Skin and Subcutaneous Tissue	11	3, 026	\$148, 269	\$13, 479	275. 1	\$49
	Stroke	156	56 , 350	\$2, 778, 111	\$17, 808	361. 2	\$49
	Other/Unknown	224	25, 025	\$1, 438, 288	\$6, 421	111. 7	\$57
	BP Type Sub-Total	1, 592	<i>389, 323</i>	<i>\$19, 276, 481</i>	<i>\$12, 108</i>	<i>244.</i> 5	\$50

Appendi x: G - 11

Home Health Care/ADC/Other Claims: Benefit Period Type and Diagnosis Summary

BP Type	Diagnosis Category	Tally	Days	Total Paynents	Average Claim Paynents	Average Days	Average Per Day
Unlimited	Al zhei mer's	219	22, 785	\$3, 301, 661	\$15,076	104. 0	\$145
	Arthritis	168	13, 946	\$1, 329, 808	\$7, 916	83. 0	\$95
	Cancer	$\overline{247}$	12, 851	\$1, 352, 655	\$5, 476	52. 0	\$105
	Ci rcul atory	178	8, 931	\$797, 713	\$4, 482	50. 2	\$89
	Congeni tal	4	0	\$21, 039	\$5, 260	0.0	
	Di abetes	19	1, 906	\$89, 086	\$4, 689	100. 3	\$47
	Digestive System	41	2, 707	\$205, 777	\$5, 019	66. 0	\$76
	Endocrine, Immunity System	12	165	\$136, 983	\$11, 415	13. 8	\$830
	Geni touri nary System	13	142	\$69, 036	\$5, 310	10. 9	\$486
	Hypertensi on The Hypertensi o	25	246	\$140, 360	\$5, 614	9. 8	\$571
	Ill-Defined and Misc Conditions	43	111	\$271, 120	\$6, 305	2. 6	\$2, 443
	Inj ury	259	15, 655	\$1, 602, 377	\$6, 187	60. 4	\$102
	Mental	25	502	\$358, 948	\$14, 358	20. 1	\$715
	Nervous System and Sense Organs	60 5	30, 330	\$2, 286, 380	\$38, 106	505. 5	\$75
	Pregnancy Di sorders		0	\$32, 833	\$6, 567	0. 0	
	Respi ratory	60	1, 928	\$436, 093	\$7, 268	32. 1	\$226
	Skin and Subcutaneous Tissue	6	734	\$61, 354	\$10, 226	122. 3	\$84
	Stroke	189	14, 742	\$1, 894, 466	\$10, 024	78. 0	\$129
	Other/Unknown	295	6, 391	\$2, 010, 506	\$6, 815	21. 7	\$315
	BP Type Sub-Total	1, 868	134, 072	\$16, 398, 195	\$8, 778	71.8	\$122
	BP Type Total	5, 795	720, 484	\$53, 496, 786	\$9, 232	124. 3	\$74

Appendi x: G - 12

Average Number of Home Health Care Visits Per Week By Diagnosis

Primary Category	Number of Claims Paid	Servi ce Length	Number of Visits Paid	Average number of Visit Per Week
Al zhei mer's	730	259, 031	158, 447	4. 28
Arthri ti s	367	76, 735	53, 873	4. 91
Cancer	615	58, 955	53, 874	6. 40
Ci rcul atory	398	68, 126	66, 001	6. 78
Congeni tal	5	432	350	5. 67
Di abetes	42	9, 295	5, 472	4. 12
Digestive System	58	7, 916	5, 721	5. 06
Endocrine, Immunity System	44	6, 880	4, 133	4. 21
Genitourinary System	42	7, 297	2, 750	2. 64
Hypertensi on	38	3, 324	2, 546	5. 36
Ill-Defined and Misc Conditions	122	21, 643	16, 058	5. 19
Inj ury	571	108, 428	77, 192	4. 98
Mental	59	10, 050	4, 759	3. 31
Nervous System and Sense Organs	278	202, 942	79, 047	2. 73
Pregnancy Di sorders	12	898	221	1. 72
Respi ratory	164	27, 007	19, 914	5. 16
Skin and Subcutaneous Tissue	23	4, 326	3, 772	6. 10
Stroke	466	151, 646	84, 632	3. 91
Other/Unknown	1, 077	134, 611	72, 634	3. 78
Total	5, 111	1, 159, 542	711, 396	4. 29

Includes Adult Day Care

Appendix H-1 Mortality Rates by Age Groupings

Active and Disabled Lives

Attained	Female	Female	Female	Female	Female	Female
Age	Exposure	Deaths - LTC	Qx - LTC	Qx - 83GAM	Qx - A2000	Qx - SOA
40-49	279,068	285	0.0010	0.0010	0.0010	0.0017
50-59	451,488	1,053	0.0023	0.0027	0.0026	0.0046
60-69	1,471,548	7,524	0.0051	0.0077	0.0067	0.0113
70-79	1,592,530	18,726	0.0118	0.0220	0.0165	0.0252
80-89	409,651	12,222	0.0298	0.0566	0.0450	0.0620
90-99	10,167	538	0.0529	0.1303	0.1166	0.1683
Total	4,214,452	40,348	0.0096	0.0172	0.0135	0.0205

Attained	Male	Male	Male	Male	Male	Male
Age	Exposure	Deaths - LTC	Qx - LTC	Qx - 83GAM	Qx - A2000	Qx - SOA
40-49	219,373	365	0.0017	0.0023	0.0018	0.0026
50-59	316,125	1,104	0.0035	0.0062	0.0045	0.0070
60-69	942,659	7,146	0.0076	0.0174	0.0110	0.0191
70-79	999,265	19,394	0.0194	0.0413	0.0259	0.0420
80-89	196,988	9,999	0.0508	0.0922	0.0582	0.0910
90-99	3,069	231	0.0753	0.1718	0.1174	0.1674
Total	2,677,479	38,239	0.0143	0.0294	0.0186	0.0303

Acive Lives

Attained	Female	Female	Female	Female	Female	Female
Age	Exposure	Deaths - LTC	Qx - LTC	Qx - 83GAM	Qx - A2000	Qx - SOA
40-49	278,848	270	0.0010	0.0010	0.0010	0.0017
50-59	451,268	992	0.0022	0.0027	0.0026	0.0046
60-69	1,471,328	6,967	0.0047	0.0077	0.0067	0.0113
70-79	1,592,310	16,078	0.0101	0.0220	0.0165	0.0253
80-89	409,431	9,594	0.0234	0.0567	0.0450	0.0621
90-99	9,947	408	0.0410	0.1332	0.1192	0.1720
Total	4,213,132	34,309	0.0081	0.0172	0.0136	0.0205

Attained	Male	Male	Male	Male	Male	Male
Age	Exposure	Deaths - LTC		Qx - 83GAM	Qx - A2000	Qx - SOA
40-49	219,153	344	0.0016	0.0023	0.0018	0.0026
50-59	315,905	1,049	0.0033	0.0062	0.0045	0.0070
60-69	942,439	6,734	0.0071	0.0174	0.0110	0.0191
70-79	999,045	17,117	0.0171	0.0413	0.0259	0.0420
80-89	196,768	8,179	0.0416	0.0923	0.0583	0.0911
90-99	2,849	193	0.0677	0.1850	0.1265	0.1804
Total	2,676,159	33,616	0.0126	0.0294	0.0186	0.0303

Qx - LTC: LTC Mortality

Qx - 83GAM: 83 Group Annuity Table Qx - A2000: 2000 Annuity Table

Qx - SOA: 1985-90 Society of Actuaries Life Insurance Table, ultimate rates

Appendix H-2
Total Active Life Mortality and Ultimate (Durations 7-15)

Female LTC Mortality Rates

Total Active Lives Ultimate Active Lives

Male LTC Mortality Rates

		Total Active Lives		Ultimate Active Lives			,		Т
	Attained	Number	Mortality		Mortality	Total/		Attained	
	Age	of Deaths	Rate		Rate	Ultimate		Age	
	40	18	0.000798	1	0.001131	0.71		40	
	41	17	0.000706		0.000000	-		41	
	42	19	0.000751	0	0.000000	-		42	
	43	20	0.000745	0	0.000000	-		43	
	44	19	0.000681	0	0.000000	-		44	
	45 46	27 31	0.000933	0	0.000000	- 1.42		45	
	46	39	0.001039 0.001288	1	0.000734 0.000667	1.42		46 47	
	48	45	0.001288	0	0.000007	1.93		48	
	49	35	0.001443	2	0.000000	1.09		49	
	50	37	0.001034	3	0.001345	0.81		50	
	51	48	0.001362	2	0.000863	1.58		51	
	52	73	0.002039	4	0.001802	1.13		52	
	53	69	0.001807	4	0.001733	1.04		53	
	54	73	0.001780	5	0.002119	0.84		54	
	55	115	0.002598	3	0.001207	2.15		55	
	56	108	0.002272	1	0.000389	5.84		56	
	57	126	0.002437	4	0.001534	1.59		57	
	58	146	0.002534	9	0.003367	0.75		58	
	59	197	0.002989	8	0.002786	1.07		59	
	60	256	0.003405	9	0.003023	1.13		60	
	61	280	0.003278	10	0.003056	1.07		61	
	62	373	0.003773	10	0.002748	1.37		62	
	63	472	0.004223	12	0.003052	1.38		63	
	64	606	0.004201	17	0.003981	1.06		64	
	65 66	713	0.004161	24	0.004813	0.86		65	
	66 67	863 1027	0.004675 0.005287	24 37	0.004050 0.005280	1.15 1.00		66 67	
	68	1027	0.005287	49	0.005260	0.96		68	
	69	1278	0.006208	75	0.007456	0.83		69	
	70	1363	0.006671	137	0.008948	0.75		70	
	71	1440	0.007290	184	0.009431	0.77		71	
	72	1496	0.007932	258	0.012009	0.66		72	
	73	1655	0.009283	319	0.013797	0.67		73	
	74	1626	0.009674	338	0.013962	0.69		74	
	75	1727	0.011098	402	0.015588	0.71		75	
	76	1666	0.011681	410	0.016474	0.71		76	
	77	1673	0.012902	428	0.018529	0.70		77	
	78 70	1699	0.014373	457	0.021603	0.67		78	
	79	1733	0.015839	487	0.025190	0.63		79	
	80	1578	0.016958	482	0.026589	0.64		80	
	81 82	1454 1270	0.018963 0.020110	438 472	0.026815 0.031791	0.71 0.63		81 82	
	83	1194	0.023042	447	0.031731	0.03		83	
	84	1015	0.024161	462	0.036130	0.67		84	
	85	939	0.030587	508	0.039837	0.77		85	
	86	782	0.036397	481	0.047417	0.77		86	
	87	590	0.040232	383	0.051437	0.78		87	
	88	443	0.045689	303	0.055822	0.82		88	
	89	329	0.053228	251	0.063432	0.84		89	
	90	214	0.056360	184	0.064972	0.87		90	
	91	107	0.045824		0.055587	0.82		91	
	92	51	0.036042	43	0.043173	0.83		92	
	93	19	0.021493		0.023689	-		93	
	94	11	0.019643		0.023739	-		94	
	95	4	0.010152	0	0.000000	-		95	
	96	2	0.008230	0	0.000000	-		96	
	97	0	0.000000	0	0.000000	-		97	
	98 99	0	0.000000		0.000000	_		98 99	
L	33	U	0.000000	U	0.000000		l	99	L

	Total Active	Lives	Ultimate Ac			
Attained	Number	Mortality	Number	Mortality	Total/	
Age	of Deaths	Rate	of Deaths	Rate	Ultimate	
40	29	0.001559	1	0.001460	1.07	
41	29	0.001500	0	0.000000	-	
42	33	0.001654	2	0.002601	0.64	
43	28	0.001351	0	0.000000	-	
44	34	0.001580	2	0.002415	0.65	
45	27	0.001232	0	0.000000	-	
46	32	0.001392	1	0.001133	1.23	
47	36	0.001520	1	0.001040	1.46	
48	50	0.002028	0	0.000000	-	
49	46	0.001785	0	0.000000	-	
50	60	0.002198	3	0.002044	1.08	
51	82	0.002934	2	0.001232	2.38	
52	78	0.002808	8	0.004762	0.59	
53	80	0.002790	6	0.003207	0.87	
54	94	0.003147	12	0.005944	0.53	
55	120	0.003855	13	0.006109	0.63	
56	121	0.003747	11	0.005186	0.72	
57	107	0.003158	7	0.003273	0.97	
58	138	0.003802	12	0.005331	0.71	
59	169	0.004146	13	0.005704	0.73	
60	229	0.004995	11	0.004723	1.06	
61	235	0.004568	10	0.004047	1.13	
62	346	0.005872	18	0.006944	0.85	
63	394	0.005879	12	0.004410	1.33	
64	533	0.006024	14	0.004958	1.22	
65	687	0.006223	27	0.008637	0.72	
66	799	0.006593	20	0.005618	1.17	
67	1001 1180	0.007775	32 41	0.008077 0.009055	0.96	
68 69	1330	0.008900 0.009652	39	0.009033	0.98 1.25	
70	1420	0.009032	102	0.007704	0.80	
71	1608	0.010419	151	0.012997	0.86	
72	1732	0.012230	196	0.014100	0.85	
73	1732	0.015032	269	0.021312	0.03	
73 74	1747	0.016368	328	0.021612	0.67	
75	1776	0.018380	402	0.027504	0.67	
76	1777	0.020554	419	0.029613	0.69	
77	1840	0.024188	480	0.037267	0.65	
78	1787	0.026643	492	0.041769	0.64	
79	1702	0.028467	429	0.040714	0.70	
80	1590	0.032010	443	0.046127	0.69	
81	1364	0.034387	417	0.051022	0.67	
82	1222	0.039004	415	0.059201	0.66	
83	1069	0.043586	378	0.063626	0.69	
84	829	0.043747	327	0.062596	0.70	
85	720	0.055101	357	0.073336	0.75	
86	549	0.064158	303	0.080244	0.80	
87	389	0.070484	238	0.090805	0.78	
88	255	0.074978	176	0.098988	0.76	
89	192	0.092308	137	0.108558	0.85	
90	90	0.075885	73	0.085280	0.89	
91	54	0.082317	44	0.097561	-	
92	24	0.059113	18	0.069231	-	
93	14	0.061674	8	0.061538	-	
94	5	0.035211	2	0.027397	-	
95	1	0.011494	1	0.024390	0.47	
96	0	0.000000	0	0.000000	-	
97	1	0.024390	0	0.000000	-	
98	1	0.041667	0	0.000000	-	
99	3	0.187500	1	0.125000	-	

Appendix H-3 (Page 1 of 2)
LTC Disabled Lives Mortaltiy by Claim Age Groupings

		Female						Male					
Age at	Claim			Mortality						Mortality			
Claim	Duration	Exposure	Deaths	Rate	SOA 95	Deaths	A/E	Exposure	Deaths	Rate	SOA 95	Deaths	A/E
Under 50	1	115	11	0.0957	0.1113	13	0.86	116	5	0.0431	0.1368	16	0.32
	2	72	3	0.0417	0.0937	7	0.44	72	1	0.0139	0.0977	7	0.14
	3	55	3	0.0545	0.0449	2	1.22	60	1	0.0167	0.0509	3	0.33
	4	42	1	0.0238	0.0335	1	0.71	41	0	0.0000	0.0433	2	0.00
	5	33	2	0.0606	0.0239	1	2.54	35	0	0.0000	0.0371	1	0.00
	6	24	1	0.0417	0.0191	0	2.19	23	0	0.0000	0.0338	1	0.00
	7-13	23	0 21	0.0000	0.0205	0 25	0.00	23	0 7	0.0000	0.0362	1	0.00 0.23
50-54	Total	364 74	21	0.0577	0.0691 0.1223	25 9	0.84 2.32	370 48	13	0.0189	0.0828	31 7	1.82
30-34	2	40	6	0.2636	0.1223	4	1.44	31	3	0.2708	0.1492	3	0.91
	3	27	0	0.0000	0.1042	1	0.00		2	0.1053	0.1000	1	1.82
	4	22	0	0.0000	0.0342	1	0.00	12	0	0.0000	0.0380	1	0.00
	5	16	1	0.0625	0.0289	0	2.17	10	1	0.1000	0.0432	0	2.32
	6	12	0	0.0020	0.0249	0	0.00	6	0	0.0000	0.0433	0	0.00
	7-13	9	1	0.1111	0.0267	0	4.17	8	0	0.0000	0.0459	0	0.00
	Total	200	29	0.1450	0.0829	17	1.75	134	19	0.1418	0.0986	13	1.44
55-59	1	131	27	0.2061	0.1439	19	1.43	76	25	0.3289	0.1707	13	1.93
	2	61	5	0.0820	0.1149	7	0.71	32	4	0.1250	0.1177	4	1.06
	3	44	2	0.0455	0.0635	3	0.72	17	1	0.0588	0.0651	1	0.90
	4	32	4	0.1250	0.0467	1	2.68	12	1	0.0833	0.0511	1	1.63
	5	22	1	0.0455	0.0343	1	1.32	8	0	0.0000	0.0495	0	0.00
	6	15	1	0.0667	0.0298	0	2.23	6	0	0.0000	0.0530	0	0.00
	7-13	19	2	0.1053	0.0327	1	3.22	2	1	0.5000	0.0568	0	8.80
	Total	324	42	0.1296	0.0987	32	1.31	153	32	0.2092	0.1260	19	1.66
60-64	1	357	106	0.2969	0.1700	61	1.75	229	61	0.2664	0.1927	44	1.38
	2	134	20	0.1493	0.1250	17	1.19	109	12	0.1101	0.1282	14	0.86
	3	74	5	0.0676	0.0722	5	0.94	71	7	0.0986	0.0719	5	1.37
	4	41	6	0.1463	0.0525	2	2.79	54	2	0.0370	0.0539	3	0.69
	5	17	2	0.1176	0.0393	1	2.99	28	3	0.1071	0.0579	2	1.85
	6	9	0	0.0000	0.0385	0	0.00	14	1	0.0714	0.0639	1	1.12
	7-13	5	0	0.0000	0.0405	0	0.00		1	0.0714	0.0640	1	1.12
05.00	Total 1	637 1,356	139	0.2182	0.1352	86 264	1.61	519 782	87	0.1676	0.1322	69 164	1.27 1.55
65-69		538	319 59	0.2353 0.1097	0.1944 0.1342	264 72	1.21 0.82	333	255 48	0.3261 0.1441	0.2102 0.1377	46	1.05
	2	372	24	0.1097	0.1342	30	0.82	198	39	0.1441	0.1377	16	2.50
	4	252	19	0.0043	0.0504	15	1.28	110	11	0.1970	0.0787	6	1.75
	5	154	2	0.0130	0.0494	8	0.26	63	4	0.0635	0.0570	4	1.08
	6	92	3	0.0136	0.0519	5	0.20	27	2	0.0033	0.0567	2	1.16
	7-13	93	3	0.0323	0.0576	5	0.56		1	0.0909	0.0684	1	1.33
	Total	2,857	429	0.1502	0.1394	398	1.08	1,524	360	0.2362	0.1563	238	1.51
70-74	1	3,233	773	0.2391	0.2134	690	1.12	1,943	596	0.3067	0.2225	432	1.38
	2	1,391	147	0.1057	0.1427	198	0.74	849	167	0.1967	0.1464	124	1.34
	3	944	92	0.0975	0.0883	83	1.10	507	85	0.1677	0.0857	43	1.96
	4	579	40	0.0691	0.0654	38	1.06	279	33	0.1183	0.0618	17	1.91
	5	310	24	0.0774	0.0610	19	1.27	127	6	0.0472	0.0674	9	0.70
	6	164	7	0.0427	0.0669	11	0.64	66	7	0.1061	0.0791	5	1.34
	7-13	180	7	0.0389	0.0735	13	0.53	35	0	0.0000	0.0871	3	0.00
	Total	6,801	1,090	0.1603	0.1548	1,053	1.04	3,806	894	0.2349	0.1666	634	1.41

Appendix H-3 (Page 2 of 2)
LTC Disabled Lives Mortaltiy by Claim Age Groupings

		Female				100 E1100 III		Male					
Age at	Claim			Mortality				i		Mortality			
Claim	Duration	Exposure	Deaths	Rate	SOA 95	Deaths	A/E	Exposure	Deaths	Rate	SOA 95	Deaths	A/E
75-79	1	5,573	120	0.0215				3,007	971	0.3229			
	2	2,676	279	0.1043				1,351	276	0.2043			
	3	1,794	221	0.1232				788	149	0.1891			
	4	1,014	84	0.0828				398	61	0.1533			
	5	487	42	0.0862				168	17	0.1012			
	6	274	11	0.0401				84	5	0.0595			
	7-13	279	22	0.0789				50	4	0.0800			
	Total	12,097	779	0.0644				5,846	1,483	0.2537			
80-84	1	6,093	102	0.0167				2,682	901	0.3359			
	2	3,140	354	0.1127				1,177	230	0.1954			
	3	2,019	209	0.1035				648	119	0.1836			
	4	1,121	88	0.0785				290	33	0.1138			
	5		26	0.0468				108	8	0.0741			
	6	292	12	0.0411				46	1	0.0217			
	7-13	266	18	0.0677				34	5	0.1471			
	Total	13,487	809	0.0600				4,985	1,297	0.2602			
85-89	1	2,746	421	0.1533				1,049	299	0.2850			
	2		117	0.0901				422	69	0.1635			
	3		63	0.0856				205	34	0.1659			
	4	328	12	0.0366				68	8	0.1176			
	5		7	0.0483				22	2	0.0909			
	6	57	3	0.0526				8	0	0.0000			
	7-13		2	0.0833				2	0	0.0000			
	Total	5,334	625	0.1172				1,776	412	0.2320			
90 and Ove		818	72	0.0880				217	24	0.1106			
	2		22	0.0753				56	6	0.1071			
	3	_	7	0.0543				19	1	0.0526			
	4	50	3	0.0600				7	1	0.1429			
	5	13	0	0.0000				2	0	0.0000			
	6	0	0	-				1	0	0.0000			
	7-13		0	-				0	0	-			
	Total	1,302	104	0.0799				302	32	0.1060			
Total	1	,	1,972	0.0962				10,149	3,150	0.3104			
	2	,	1,012	0.1050				4,432	816	0.1841			
	3	,	626	0.1011				2,532	438	0.1730			
	4	3,481	257	0.0738				1,271	150	0.1180			
	5	,	107	0.0610				571	41	0.0718			
	6	000	38	0.0405				281	16	0.0569			
	7-13		55	0.0612				179	12	0.0670			
	Total	43,403	4,067	0.0937				19,415	4,623	0.2381			

Appendix H-4 (Page 1 of 2) Female LTC Mortality Rates by Exposure Period

	Total		1984-	1987	1988-	1991	1992-	-1995		-1999
Attained	Number	Mortality	Number	Mortality	Number	Mortality	Number	Mortality		Mortality
Age	of Deaths	Rate	of Deaths	Rate	of Deaths	Rate	of Deaths	Rate	of Deaths	Rate
40	18	0.000798 0.000706	0	-	2	0.011173 0.016949	10	0.001898 0.001461	6	0.000351 0.000326
41 42	17 19	0.000708	0	-	5 5	0.016949	8 7	0.001461	_	0.000326
43	20	0.000731	0	_	3	0.030120	7	0.001218		0.000301
44	19	0.000681	0	_	1	0.006849	10	0.001140		0.000372
45	27	0.000933	0	0.000000	3	0.017241	19	0.003035		0.000222
46	31	0.001039	0	0.000000	4	0.026144	17	0.002767	10	0.000425
47	39	0.001288	0	0.000000	4	0.022346	26	0.004255	9	0.000375
48	45	0.001445	0	0.000000	4	0.022222	23	0.003602	18	0.000732
49	35	0.001094	0	0.000000	2	0.014085	17	0.002571	16	0.000634
50	37	0.001088	0	0.000000	2	0.005764	15	0.001979		0.000767
51	48	0.001362	0	0.000000	8	0.014625	24	0.002834	16	0.000610
52	73	0.002039	1	0.055556	15	0.021368	39	0.004092	18	0.000705
53	69	0.001807	0	0.000000	21	0.024419	29	0.002670		0.000718
54	73	0.001780	0	0.000000	11	0.010536	39	0.003101		0.000840
55 56	115	0.002598	2	0.083333	23	0.017504	60 50	0.004110		0.001059
56 57	108 126	0.002272 0.002437	1	0.027027 0.044444	28	0.018605 0.017713	59 56	0.003448		0.000692
57 58	126 146	0.002437	2	0.000000	33 40	0.017713	56 82	0.002827 0.003458	35 24	0.001167 0.000760
59	197	0.002534	2	0.000000	46	0.017429	109	0.003436	40	0.000760
60	256	0.002303	4	0.027027	67	0.010140	128	0.003732		0.001100
61	280	0.003278	2	0.010870	72	0.015947	152	0.003743		0.001318
62	373	0.003773	6	0.025105	86	0.014245	223	0.004745		0.001272
63	472	0.004223	10	0.030581	124	0.016814	264	0.004941	74	0.001461
64	606	0.004201	18	0.030405	183	0.017259	306	0.004487	99	0.001526
65	713	0.004161	30	0.036900	197	0.015386	373	0.004628	113	0.001465
66	863	0.004675	36	0.044554	245	0.016967	441	0.005064	141	0.001714
67	1027	0.005287	40	0.048960	296	0.019647	513	0.005580	178	0.002060
68	1099	0.005502	32	0.037383	314	0.020688	527	0.005566	226	0.002539
69	1278	0.006208	57	0.064117	349	0.022499	608	0.006215		0.002881
70	1363	0.006671	47	0.055100	349	0.023376	644	0.006647	323	0.003524
71	1440	0.007290	38	0.046569	363	0.025919	695	0.007450		0.003847
72	1496	0.007932	32	0.036322	334	0.025185	713	0.008116		0.004815
73	1655	0.009283	49	0.054933	383	0.030186	776	0.009553		0.005356
74 75	1626	0.009674	45	0.051903	445	0.036312	687	0.009145		0.005625
75 76	1727 1666	0.011098 0.011681	39 42	0.048387 0.057221	392 349	0.035456 0.034019	744 755	0.010723 0.011958		0.007423 0.007592
77	1673	0.011001	52	0.057221	379	0.034019	685	0.011936		0.007392
78	1699	0.012302	55	0.007332	385	0.039337	688	0.011300		0.000939
79	1733	0.015839	55	0.073925	431	0.053157	658	0.013432		0.011421
80	1578	0.016958	29	0.103571	348	0.061593	630	0.015085		0.012589
81			7	0.114754	330	0.083523	595	0.017372		0.013590
82		0.020110	4	0.285714		0.074008		0.019774		0.015587
83		0.023042	1	0.166667		0.094260		0.022163		0.018786
84	1015	0.024161	0	0.000000	120	0.093531	437	0.024501	458	0.020010
85	939	0.030587	0	-	79	0.145221	422	0.034531	438	0.024423
86	782	0.036397	0	-	30	0.138889	359	0.047231		0.028753
87	590	0.040232	0	-	8	0.102564	217	0.049341		0.035823
88	443	0.045689	0	-	4	0.105263	127	0.052610		0.043070
89	329	0.053228	0	-	1	0.055556	75	0.058870		0.051749
90	214	0.056360	0	-	0	0.000000	43	0.065152		0.054755
91	107	0.045824	0	-	0	0.000000	14	0.036939		0.047988
92	51	0.036042	0	-	0	0.000000	5	0.019157		0.040386
93	19 11	0.021493	0	-	1	0.076923	2	0.011173		0.023121
94 95	11 4	0.019643 0.010152	0	-	0	0.100000 0.000000	0 2	0.000000 0.019608		0.023697 0.006969
95 96	2	0.010152	0	-	0	0.000000	1	0.019608		0.006969
96	0	0.000230	0		0	0.000000	0	0.013623		0.000714
98	0	0.000000	0	_ [0	0.000000	0	0.000000		0.000000
99	0	0.000000	0		0	0.000000	0	0.000000		0.000000

Appendix H-4 (Page 2 of 2) Male LTC Mortality Rates by Exposure Period

	Total		1984-	1987	1988-	-1991	1992	-1995		-1999
Attained	Number	Mortality	Number	Mortality	Number	Mortality	Number	Mortality	ll	Mortality
Age	of Deaths	Rate	of Deaths	Rate	of Deaths	Rate	of Deaths	Rate		Rate
40	29	0.001559	0	-	3	0.027778	12	0.003106	14	0.000957
41 42	29 33	0.001500 0.001654	0	0.000000	1	0.007576 0.021898	19 16	0.004630 0.003675		0.000596 0.000906
42	28	0.001654	0	0.000000	3 4	0.021696	14	0.003075		0.000906
44	34	0.001580	0	_	4	0.030334	19	0.003043		0.000623
45	27	0.001332	0	_	1	0.007813	16	0.003343		0.000588
46	32	0.001392	0	_	3	0.024793	13	0.002734	16	0.000883
47	36	0.001520	0	-	8	0.064000	13	0.002816		0.000792
48	50	0.002028	0	0.000000	8	0.054795	21	0.004438		0.001062
49	46	0.001785	0	0.000000	7	0.042169	21	0.004321	18	0.000868
50	60	0.002198	0	0.000000	9	0.038793	25	0.004746	26	0.001193
51	82	0.002934	0	0.000000	13	0.047445	42	0.007484	27	0.001224
52	78	0.002808	0	0.000000	9	0.025424	29	0.004870		0.001864
53	80	0.002790	1	0.166667	11	0.026764	35	0.005473	ll	0.001510
54	94	0.003147	0	0.000000	21	0.042770	23	0.003244		0.002244
55	120	0.003855	1	0.090909	19	0.032258	55	0.006778		0.002008
56 57	121	0.003747	1	0.062500	25	0.034247	50 50	0.005352	45 25	0.002027
57 58	107 138	0.003158 0.003802	1 0	0.052632 0.000000	31 33	0.033226 0.029024	50 54	0.004671 0.004370	25 51	0.001125 0.002238
59	169	0.003802	3	0.107143	54	0.029024	60	0.004370		0.002238
60	229	0.004140	3	0.061224	81	0.037012	76	0.003924	ll	0.002100
61	235	0.004568	3	0.063830	82	0.035839	92	0.004123		0.002030
62	346	0.005872	9	0.113924	109	0.038901	145	0.005503		0.002725
63	394	0.005879	6	0.048780	126	0.035573	151	0.004829		0.003459
64	533	0.006024	12	0.047244	178	0.032643	224	0.005422	119	0.002870
65	687	0.006223	22	0.057292	238	0.033310	267	0.005164	160	0.003127
66	799	0.006593	27	0.071809	274	0.032720	326	0.005708	172	0.003109
67	1001	0.007775	27	0.069948	313	0.035105	448	0.007346		0.003644
68	1180	0.008900	45	0.096154	397	0.043279	488	0.007746		0.004171
69	1330	0.009652	52	0.106122	456	0.047283	543	0.008257	279	0.004508
70	1420	0.010419	60	0.125523	470	0.050273	604	0.009296		0.004651
71	1608	0.012250	48	0.098563	498	0.056707	723	0.011568		0.005698
72 73	1732 1728	0.013991	54 51	0.116883	510 492	0.061210	781 767	0.013301		0.006876
73 74	1747	0.015032 0.016368	51 58	0.116972 0.126915	492	0.062405 0.065232	767 799	0.014246 0.016126		0.007918 0.008163
75	1776	0.018380	57	0.120913	485	0.003232	757	0.016120		0.000103
76	1777	0.020554	63	0.169811	466	0.080000	781	0.010071	ll	0.010042
77	1840	0.024188	55	0.150273	437	0.080242	809	0.023071		0.015315
78	1787	0.026643	65	0.175676	412	0.083048	802	0.026044		0.016415
79	1702	0.028467	64	0.176796	430	0.096326	701	0.025344	ll	0.018569
80	1590	0.032010	31	0.223022	388	0.124719	662	0.028636	509	0.021842
81		0.034387	19	0.260274		0.140898	599	0.032197	448	0.023736
82		0.039004	5	0.208333		0.144192		0.038625		0.028739
83		0.043586	0	0.000000		0.177778		0.043262		0.031990
84	829	0.043747	0	0.000000		0.158708	404	0.047235	ll	0.032218
85	720	0.055101	0	0.000000		0.223602	353	0.062082		0.041797
86	549	0.064158	0	-		0.285714	268	0.078340	ll	0.049233
87 88	389	0.070484	0	-	11 4	0.220000	164 87	0.083631		0.061003
88 89	255 192	0.074978 0.092308	0		0	0.235294 0.000000	65	0.081081 0.114236	ll	0.070965 0.084498
90	90	0.092308	0		0	0.000000	26	0.114230		0.064496
91	54	0.073883	0	-	0	0.000000	10	0.063694		0.089431
92	24	0.059113	0	-	0	0.000000	2	0.020619	ll	0.072607
93	14	0.061674	0	-	0	0.000000	3	0.042857		0.071429
94	5	0.035211	0	-	0	0.000000	1	0.022222	ll	0.042553
95	1	0.011494	0	-	0	0.000000	0	0.000000	1	0.018519
96	0	0.000000	0	-	0	0.000000	0	0.000000		0.000000
97	1	0.024390	0	-	0	-	1	0.076923		0.000000
98	1	0.041667	0	-	0	-	0	0.000000		0.062500
99	3	0.187500	0	-	1	1.000000	0	0.000000	2	0.181818

Appendix H-5 (Page 1 of 2) Female LTC Mortality Rates

	Active Lives		Disable	ed Lives	Total L	ives	
Attained	Number	Mortality	Number	Mortality	Number	Mortality	Disabled/
Age	of Deaths	Rate	of Deaths	Rate	of Deaths	Rate	Active
40	18	0.000798	0	0.000000	18	0.000798	0.00
41 42	17 19	0.000706 0.000751	0 1	0.000000 0.062500	17 20	0.000706 0.000791	0.00 83.19
43	20	0.000731	2	0.002300	20	0.000791	134.31
44	19	0.000743	2	0.105263	21	0.0000753	154.52
45	27	0.000933	1	0.062500	28	0.000968	66.96
46	31	0.001039	1	0.040000	32	0.001073	38.49
47	39	0.001288	2	0.083333	41	0.001354	64.72
48	45	0.001445	2	0.068966	47	0.001509	47.74
49	35	0.001094	4	0.129032	39	0.001219	117.95
50	37	0.001088	3	0.103448	40	0.001177	95.06
51	48	0.001362	2	0.042553	50	0.001419	31.25
52	73	0.002039	6	0.125000	79	0.002207	61.29
53	69	0.001807	10	0.208333	79	0.002069	115.27
54	73	0.001780	3	0.061224	76	0.001853	34.39
55	115	0.002598	4	0.081633	119	0.002688	31.42
56	108	0.002272	12	0.210526	120	0.002524	92.67
57	126	0.002437	7	0.114754	133	0.002572	47.09
58	146	0.002534	5	0.068493	151	0.002621	27.03
59	197	0.002989	9	0.107143	206	0.003125	35.85
60	256	0.003405	18	0.174757	274	0.003644	51.33
61	280	0.003278	19	0.174312	299	0.003500	53.18
62 63	373 472	0.003773	23 26	0.172932	396 498	0.004005 0.004455	45.84 36.65
64	606	0.004223 0.004201	26 51	0.154762 0.218884	498 657	0.004455	52.10
65	713	0.004201	54	0.2188673	767	0.004333	44.15
66	863	0.004101	71	0.103073	934	0.005060	38.45
67	1027	0.005287	74	0.175747	1101	0.005668	27.44
68	1099	0.005502	102	0.153383	1201	0.006013	27.88
69	1278	0.006208	118	0.142857	1396	0.006781	23.01
70	1363	0.006671	167	0.172165	1530	0.007489	25.81
71	1440	0.007290	179	0.154577	1619	0.008196	21.20
72	1496	0.007932	201	0.153552	1697	0.008998	19.36
73	1655	0.009283	225	0.146771	1880	0.010545	15.81
74	1626	0.009674	233	0.133985	1859	0.011060	13.85
75	1727	0.011098	274	0.139298	2001	0.012859	12.55
76	1666	0.011681	297	0.136929	1963	0.013763	11.72
77	1673	0.012902	334	0.142007	2007	0.015477	11.01
78	1699	0.014373	356	0.136242	2055	0.017385	9.48
79	1733	0.015839	382	0.131271	2115	0.019331	8.29
80	1578	0.016958	410	0.132600	1988	0.021365	7.82
81	1454	0.018963	406	0.131562	1860	0.024259	6.94
82	1270	0.020110	374	0.126995	1644	0.026032	6.32
83	1194	0.023042	360	0.132013	1554	0.029990	
84	1015	0.024161	277	0.112055	1292	0.030755	4.64
85 86	939	0.030587	285	0.138619	1224	0.039871	4.53
86 87	782 590	0.036397	221 159	0.135168 0.129690	1003 749	0.046684 0.051074	3.71 3.22
87 88	443	0.040232 0.045689	159 89	0.129690	749 532	0.051074	3.22 2.04
89	329	0.045689	47	0.093389	376	0.054868	2.04 1.26
90	214	0.053226	39	0.067143	253	0.060632	1.26
91	107	0.030300	21	0.054688	128	0.054818	1.19
92	51	0.036042	33	0.034000	84	0.059364	3.08
93	19	0.021493	20	0.093897	39	0.044118	4.37
94	11	0.019643	7	0.046980	18	0.032143	2.39
95	4	0.010152	6	0.072289	10	0.025381	-
96	2	0.008230	1	0.020833	3	0.012346	_
97	0	0.000000	2	0.066667	2	0.012422	-
98	0	0.000000	0	0.000000	0	0.000000	-
99	0	0.000000	1	0.111111	1	0.020833	-

Appendix H-5 (Page 2 of 2) Male LTC Mortality Rates

	Active Lives		Disable	ed Lives	Total L		
Attained	Number of Deaths	Mortality	Number of Deaths	Mortality	Number of Deaths	Mortality	Disabled/
Age 40	or Deaths	Rate 0.001559	0 Deaths	0.000000	29	Rate 0.001559	Active
41	29	0.001500	2	0.000000	31	0.001533	
42	33	0.001654	0	0.000000	33	0.001654	0.00
43	28	0.001351	3	0.142857	31	0.001495	105.77
44	34	0.001580	2	0.086957	36	0.001672	55.05
45	27	0.001232	3	0.150000	30	0.001369	121.72
46	32	0.001392	0	0.000000	32	0.001392	0.00
47	36	0.001520	4	0.129032	40	0.001689	84.88
48	50	0.002028	4	0.129032	54	0.002190	63.63
49	46	0.001785	3	0.103448	49	0.001901	57.96
50 51	60 82	0.002198	6 3	0.230769 0.103448	66 85	0.002418 0.003042	104.98 35.25
52	78	0.002934 0.002808	2	0.103446	80	0.003042	21.58
53	80	0.002000	6	0.166667	86	0.002000	59.73
54	94	0.002730	7	0.259259	101	0.003382	82.38
55	120	0.003855	2	0.054054	122	0.003920	14.02
56	121	0.003747	9	0.281250	130	0.004026	75.05
57	107	0.003158	8	0.242424	115	0.003395	76.75
58	138	0.003802	6	0.162162	144	0.003967	42.65
59	169	0.004146	6	0.171429	175	0.004293	41.35
60	229	0.004995	3	0.047619	232	0.005060	9.53
61	235	0.004568	23	0.294872	258	0.005015	64.56
62	346	0.005872	14	0.147368	360	0.006110	25.10
63 64	394 533	0.005879	15 26	0.116279 0.171053	409 559	0.006103 0.006317	19.78
64 65	687	0.006024 0.006223	33	0.171053	720	0.006517	28.40 29.96
66	799	0.006593	53	0.180441	852	0.000321	33.64
67	1001	0.000333	66	0.224490	1067	0.007030	28.87
68	1180	0.008900	62	0.167116	1242	0.009368	18.78
69	1330	0.009652	117	0.217069	1447	0.010501	22.49
70	1420	0.010419	141	0.221003	1561	0.011453	21.21
71	1608	0.012250	172	0.240896	1780	0.013560	19.67
72	1732	0.013991	164	0.207071	1896	0.015316	14.80
73	1728	0.015032	184	0.207675	1912	0.016633	13.82
74	1747	0.016368	199	0.202442	1946	0.018233	12.37
75	1776	0.018380	217	0.195495	1993	0.020626	10.64
76 77	1777 1840	0.020554 0.024188	285 294	0.228000 0.224771	2062 2134	0.023851 0.028052	11.09 9.29
78	1787	0.024188	304	0.234930	2091	0.028032	8.82
79	1707	0.028467	319	0.234731	2021	0.031173	8.25
80	1590	0.032010	325	0.235678	1915	0.038553	7.36
81	1364	0.034387	303	0.238395	1667	0.042026	6.93
82	1222	0.039004	301	0.245915	1523	0.048612	6.30
83	1069	0.043586	242	0.232469	1311	0.053453	5.33
84	829	0.043747	186	0.203057	1015	0.053562	4.64
85	720	0.055101	150	0.199734	870	0.066580	3.62
86	549	0.064158	116	0.201389	665	0.077714	3.14
87	389	0.070484	110	0.270936	499	0.090415	3.84
88	255	0.074978	63	0.221831	318 217	0.093502	2.96
89 90	192 90	0.092308 0.075885	25 15	0.138889 0.116279	105	0.104327 0.088533	1.50 1.53
90	54	0.073663	6	0.116279	60	0.066533	1.00
92	24	0.052317	6	0.036624	30	0.031403	
93	14	0.061674	8	0.142857	22	0.096916	2.32
94	5	0.035211	3	0.120000	8	0.056338	-
95	1	0.011494	0	0.000000	1	0.011494	-
96	0	0.000000	0	0.000000	0	0.000000	-
97	1	0.024390	0	0.000000	1	0.024390	-
98	1	0.041667	0	0.000000	1	0.041667	-
99	3	0.187500	0	0.000000	3	0.187500	-

Appendix H-6 (Page 1 of 2) Female Select and Ultimate LTC Mortality Rates by Attained Age Band

EXPOSURE		Attained Age							
Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	1,067,441	61,667	96,288	201,190	295,496	220,859	143,351	45,966	2,624
2	799,768	40,971	61,359	119,935	229,540	180,431	114,407	46,936	6,189
3	614,884	27,943	41,141	79,265	167,107	149,737	95,361	45,875	8,455
4	466,667	19,398	27,376	50,703	116,309	122,297	78,607	42,858	9,119
5	336,721	13,762	17,213	30,332	73,271	93,363	62,228	37,937	8,615
6	226,216	9,047	10,462	15,998	37,599	66,463	47,310	31,340	7,997
Dur 7-15	412,640	11,435	13,206	18,090	36,493	103,633	114,263	75,793	39,727
Total	3,924,337	184,223	267,045	515,513	955,815	936,783	655,527	326,705	82,726
Dur 5-15	975,577	34,244	40,881	64,420	147,363	263,459	223,801	145,070	56,339
Dur 6-15	638,856	20,482	23,668	34,088	74,092	170,096	161,573	107,133	47,724

NUMBER	OF	DEAL	HS
	_		

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	5,370	86	244	671	1,259	1,324	1,241	511	34
2	5,163	80	147	479	1,163	1,281	1,229	680	104
3	4,911	38	128	375	994	1,242	1,164	780	190
4	4,148	36	81	220	715	1,059	1,028	760	249
5	3,401	26	46	125	431	802	918	770	283
6	2,681	16	21	59	209	636	734	709	297
Dur 7-15	7,957	18	25	58	209	1,236	2,184	2,301	1,926
Total	33,631	300	692	1,987	4,980	7,580	8,498	6,511	3,083
Dur 5-15	14,039	60	92	242	849	2,674	3,836	3,780	2,506
Dur 6-15	10,638	34	46	117	418	1,872	2,918	3,010	2,223

MORTALITY RATES

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	0.5%	0.1%	0.3%	0.3%	0.4%	0.6%	0.9%	1.1%	1.3%
2	0.6%	0.2%	0.2%	0.4%	0.5%	0.7%	1.1%	1.4%	1.7%
3	0.8%	0.1%	0.3%	0.5%	0.6%	0.8%	1.2%	1.7%	2.2%
4	0.9%	0.2%	0.3%	0.4%	0.6%	0.9%	1.3%	1.8%	2.7%
5	1.0%	0.2%	0.3%	0.4%	0.6%	0.9%	1.5%	2.0%	3.3%
6	1.2%	0.2%	0.2%	0.4%	0.6%	1.0%	1.6%	2.3%	3.7%
Dur 7-15	1.9%	0.2%	0.2%	0.3%	0.6%	1.2%	1.9%	3.0%	4.8%
Total	0.9%	0.2%	0.3%	0.4%	0.5%	0.8%	1.3%	2.0%	3.7%
Dur 5-15	1.4%	0.2%	0.2%	0.4%	0.6%	1.0%	1.7%	2.6%	4.4%
Dur 6-15	1.7%	0.2%	0.2%	0.3%	0.6%	1.1%	1.8%	2.8%	4.7%

1.) RATIOS TO DUR 5-15 (SELECT FACTORS)

		•							
Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	35.0%	79.6%	112.6%	88.8%	74.0%	59.1%	50.5%	42.7%	29.1%
2	44.9%	111.4%	106.5%	106.3%	87.9%	70.0%	62.7%	55.6%	37.8%
3	55.5%	77.6%	138.3%	125.9%	103.2%	81.7%	71.2%	65.3%	50.5%
4	61.8%	105.9%	131.5%	115.5%	106.7%	85.3%	76.3%	68.1%	61.4%
Dur 5-15	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

2.) RATIOS TO DUR 6-15 (SELECT FACTORS)

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	30.2%	84.0%	130.4%	97.2%	75.5%	54.5%	47.9%	39.6%	27.8%
2	38.8%	117.6%	123.3%	116.4%	89.8%	64.5%	59.5%	51.6%	36.1%
3	48.0%	81.9%	160.1%	137.8%	105.4%	75.4%	67.6%	60.5%	48.2%
4	53.4%	111.8%	152.2%	126.4%	109.0%	78.7%	72.4%	63.1%	58.6%
5	60.7%	113.8%	137.5%	120.1%	104.3%	78.1%	81.7%	72.2%	70.5%
Dur 6-15	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

3.) RATIOS TO DUR 7-15 (SELECT FACTORS)

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	26.1%	88.6%	133.9%	104.0%	74.4%	50.3%	45.3%	36.6%	26.7%
2	33.5%	124.0%	126.6%	124.6%	88.5%	59.5%	56.2%	47.7%	34.7%
3	41.4%	86.4%	164.3%	147.6%	103.9%	69.5%	63.9%	56.0%	46.4%
4	46.1%	117.9%	156.3%	135.3%	107.3%	72.6%	68.4%	58.4%	56.3%
5	52.4%	120.0%	141.2%	128.5%	102.7%	72.0%	77.2%	66.9%	67.8%
6	61.5%	112.4%	106.0%	115.0%	97.1%	80.2%	81.2%	74.5%	76.6%
Dur 7-15	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Appendix H-6 (Page 2 of 2) Male Select and Ultimate LTC Mortality Rates by Attained Age Band

EXPOSURE		Attained Age	9						
Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	688,592	43,462	58,187	122,609	207,925	147,852	82,806	24,666	1,085
2	511,791	30,983	38,502	70,539	155,205	122,162	67,150	24,559	2,691
3	390,891	22,578	27,262	46,534	108,670	101,558	57,026	23,684	3,579
4	293,134	16,016	18,605	30,025	72,928	82,171	47,946	21,605	3,838
5	208,523	11,765	12,404	18,388	44,147	61,202	38,242	18,711	3,664
6	137,950	8,087	8,475	10,696	21,598	41,782	28,883	14,967	3,462
Dur 7-15	223,276	8,661	10,918	12,937	20,238	56,304	63,961	35,952	14,305
Total	2.454.157	141.552	174.353	311.728	630.711	613.031	386.014	164.144	32,624

85,983

41,836

159,288

98,086

131,086

92,844

42,021

23,633

21,431

17,767

69,630

50,919

569,749

361,226

28,513

16,748

31,797

19,393

Dur 5-15

Dur 6-15

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	5,366	112	204	556	1,287	1,436	1,251	497	23
2	5,409	93	155	406	1,177	1,507	1,324	641	106
3	5,001	61	97	294	993	1,413	1,234	752	157
4	4,378	42	77	208	726	1,201	1,165	784	175
5	3,557	32	50	121	453	949	954	780	218
6	2,598	23	16	87	202	683	732	640	215
Dur 7-15	6,770	31	56	65	159	1,046	2,222	1,980	1,211
Total	33,079	394	655	1,737	4,997	8,235	8,882	6,074	2,105
Dur 5-15	12,925	86	122	273	814	2,678	3,908	3,400	1,644
Dur 6-15	9,368	54	72	152	361	1,729	2,954	2,620	1,426

MORTALITY RATES

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	0.8%	0.3%	0.4%	0.5%	0.6%	1.0%	1.5%	2.0%	2.1%
2	1.1%	0.3%	0.4%	0.6%	0.8%	1.2%	2.0%	2.6%	3.9%
3	1.3%	0.3%	0.4%	0.6%	0.9%	1.4%	2.2%	3.2%	4.4%
4	1.5%	0.3%	0.4%	0.7%	1.0%	1.5%	2.4%	3.6%	4.6%
5	1.7%	0.3%	0.4%	0.7%	1.0%	1.6%	2.5%	4.2%	5.9%
6	1.9%	0.3%	0.2%	0.8%	0.9%	1.6%	2.5%	4.3%	6.2%
Dur 7-15	3.0%	0.4%	0.5%	0.5%	0.8%	1.9%	3.5%	5.5%	8.5%
Total	1.3%	0.3%	0.4%	0.6%	0.8%	1.3%	2.3%	3.7%	6.5%
Dur 5-15	2.3%	0.3%	0.4%	0.6%	0.9%	1.7%	3.0%	4.9%	7.7%
Dur 6-15	2.6%	0.3%	0.4%	0.6%	0.9%	1.8%	3.2%	5.1%	8.0%

1.) RATIOS TO DUR 5-15 (SELECT FACTORS)

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	34.4%	85.4%	91.4%	69.8%	65.4%	57.8%	50.7%	41.3%	27.6%
2	46.6%	99.5%	104.9%	88.6%	80.1%	73.4%	66.1%	53.5%	51.3%
3	56.4%	89.6%	92.7%	97.2%	96.5%	82.8%	72.6%	65.0%	57.2%
4	65.8%	86.9%	107.9%	106.6%	105.2%	86.9%	81.5%	74.3%	59.4%
Dur 5-15	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

2.) RATIOS TO DUR 6-15 (SELECT FACTORS)

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	30.0%	79.9%	94.4%	70.5%	71.7%	55.1%	47.5%	39.2%	26.4%
2	40.8%	93.1%	108.4%	89.5%	87.9%	70.0%	62.0%	50.7%	49.1%
3	49.3%	83.8%	95.8%	98.2%	105.9%	78.9%	68.0%	61.7%	54.7%
4	57.6%	81.3%	111.5%	107.7%	115.4%	82.9%	76.4%	70.5%	56.8%
5	65.8%	84.4%	108.6%	102.3%	118.9%	88.0%	78.4%	81.0%	74.1%
Dur 6-15	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

3.) RATIOS TO DUR 7-15 (SELECT FACTORS)

Dur	Total	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
1	25.7%	72.0%	68.4%	90.3%	78.8%	52.3%	43.5%	36.6%	25.0%
2	34.9%	83.9%	78.5%	114.6%	96.5%	66.4%	56.8%	47.4%	46.5%
3	42.2%	75.5%	69.4%	125.7%	116.3%	74.9%	62.3%	57.7%	51.8%
4	49.3%	73.3%	80.7%	137.9%	126.7%	78.7%	69.9%	65.9%	53.9%
5	56.3%	76.0%	78.6%	131.0%	130.6%	83.5%	71.8%	75.7%	70.3%
6	62.1%	79.5%	36.8%	161.9%	119.0%	88.0%	73.0%	77.6%	73.4%
Dur 7-15	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Appendix H-7
Mortality Rates by Issue Age Group, Type of Underwriting and Duration

Issue Age		Full UW		Simplifed U	JW	Guaranteed Issue		
Group	Duration	Deaths	Rate	Deaths	Rate	Deaths	Rate	
50-59	1	163	0.11%	172	0.66%	209	0.30%	
	2	176	0.17%	139	0.73%	173	0.33%	
	3	194	0.25%	104	0.65%	147	0.38%	
	4	165	0.29%	96	0.73%	138	0.49%	
	5	146	0.36%	54	0.84%	109	0.53%	
	6	109	0.41%	7	0.45%	71	0.48%	
	7	83	0.52%	5	0.56%	44	0.61%	
	8	49	0.49%	5	0.61%	40	0.69%	
	9	37	0.58%	10	1.34%	31	0.61%	
	10	12	0.41%	5	1.98%			
	Total	1,134	0.24%	597	0.71%	962	0.40%	
60-69	1	1,808	0.30%	1,292	0.92%	149	0.60%	
	2	2014	0.46%	1332	1.20%	127	0.68%	
	3	1989	0.60%	1274	1.37%	97	0.68%	
	4	1797	0.74%	1082	1.37%	108	1.06%	
	5	1508	0.89%	819	1.45%	74	0.93%	
	6	1302	1.17%	451	1.29%	59	1.39%	
	7	979	1.43%	460	1.84%	11	0.98%	
	8	732	1.70%	534	2.94%	6	0.73%	
	9	559	1.97%	457	3.54%	10	1.51%	
	10	391	2.37%	436	4.15%			
	Total	13,079	0.64%	8,137	1.49%	641	0.78%	
70-79	1	2,876	0.68%	2,234	1.78%	63	1.53%	
	2	3257	1.06%	2372	2.42%	51	1.57%	
	3	3075	1.35%	2307	2.84%	43	1.61%	
	4	2939	1.79%	1960	2.83%	45	2.34%	
	5	2609	2.31%	1687	3.04%	38	2.34%	
	6	2208	2.93%	1192	2.88%	16	2.96%	
	7	1677	3.52%	1196	3.82%	2	3.51%	
	8	1319	4.29%	1203	5.15%	0	0.00%	
	9	914	4.54%	1089	6.65%	0	0.00%	
	10	562	4.74%	922	7.35%			
	Total	21,436	1.52%	16,162	3.07%	258	1.81%	
80-89	1	1268	0.35%	903	0.95%	58	0.75%	
	2	1386	0.51%	981	1.28%	50	0.83%	
	3	1428	0.70%	950	1.48%	37	0.77%	
	4	1307	0.87%	830	1.51%	54	1.64%	
	5	1110	1.05%	641	1.54%	30	1.13%	
	6	985	1.41%	385	1.38%	22	1.86%	
	7	746	1.71%	398	1.96%	1	0.57%	
	8	575	2.07%	433	2.97%	3	2.81%	
	9	431	2.31%	384	3.75%	1	1.23%	
	10	300	2.71%	373	4.46%			
	Total	9688	0.76%	6892	1.62%	256	0.98%	

TABLE J-1
SOA 1984-99 Long Term Care Intercompany Study
Total Termination Rates by Issue Age Group, Issue Year Group and Duration

Age Group	Issue Year Group	Duration	Exposure	Terminations	Rate
Under 50	1984-87	1	210	59	28.09%
		2	151	22	
		3	129	20	
		4	108	10	
		5	75	11	
		6	60	12	
		7	43	6	
		8	23	2	
		9	18	2	
		10	14	2	
		11	12	1	
		12	11	0	0.00%
		13	2	0	0.00%
		14	2	0	0.00%
		15	1	0	0.00%
			859	147	17.11%
	1988-91	1	61,777	6,294	10.18%
		2	55,282		
		3	49,903	4,234	8.48%
		4	40,214	2,537	6.30%
		5	30,371	1,525	5.02%
		6	24,913	1,052	4.22%
		7	18,085	562	3.10%
		8	17,518		2.31%
		9	13,660	257	1.88%
		10	1,026	51	4.97%
		11	517		2.70%
			313,266		7.04%
	1992-95	1	82,406	8,589	10.42%
		2	66,850	5,235	7.83%
		3	49,275	2,968	6.02%
		4	45,637	2,253	4.93%
		5	37,291	1,955	5.24%
		6	23,197	1,592	6.86%
		7	5,725	205	3.58%
			310,381		7.34%
	1996-98	1	36,824	4,110	11.16%
		2	22,439		
		3	10,810	570	5.27%
			70,072	6,530	9.31%

	All Years	1 2 3 4 5 6 7 8 9 10 11 12 13 14	181,218 144,721 110,117 85,959 67,737 48,170 23,853 17,541 13,678 1,040 529 11 2 2 1	19,052 12,256 7,792 4,800 3,491 2,656 773 407 259 53 15 0 0	10.51% 8.46% 7.07% 5.58% 5.15% 5.51% 3.24% 2.32% 1.89% 5.09% 2.83% 0.00% 0.00% 0.00%
50-54	1984-87	1 2 3 4 5 6 7 8 9 10 11 12 13	1,722 1,493 1,352 1,219 1,074 182 115 96 40 35 29 27 1	222 146 113 87 64 14 6 2 1 1 0 2 0	12.89% 9.78% 8.35% 7.13% 5.96% 7.71% 5.21% 2.08% 2.50% 2.85% 0.00% 7.40% 0.00%
	1988-91	1 2 3 4 5 6 7 8 9 10		3,086 2,237 1,623 984 507 282 194 152 117 37 13	10.28% 8.79% 7.29% 5.27% 3.76% 2.74% 2.45% 2.00% 1.96% 2.91% 2.23%
	1992-95	1 2 3 4 5 6 7	32,560 25,435 18,723 16,182 11,645 7,529 2,456		5.71% 5.06% 4.22% 4.25% 4.72% 3.37%
	1996-98	1 2 3	22,434 12,673 6,714 	723	5.70% 5.33%
	All Years	1	86,729	7,923	

		2 3 4 5 6 7 8 9 10 11 12	65,038 49,031 36,056 26,180 17,979 10,488 7,669 5,993 1,305 610 27 1	4,559 3,042 1,755 1,067 652 283 154 118 38 13 2 0	7.00% 6.20% 4.86% 4.07% 3.62% 2.69% 2.00% 1.96% 2.91% 2.13% 7.40% 0.00%
55-59	1984-87	1 2 3 4 5 6 7 8 9 10 11 12 13	7,989 7,209 6,545 5,978 5,333 1,467 1,153 1,032 649 580 536 496 132	772 664 514 449 349 100 68 54 38 26 19 22 1	9.66% 9.21% 7.85% 7.51% 6.54% 6.81% 5.89% 5.23% 5.85% 4.48% 3.54% 4.43% 0.75% 0.00%
	1988-91	1 2 3 4 5 6 7 8 9 10	39,111 59,621 49,021 41,988 35,579 23,436 16,520 11,203 9,990 7,281 2,825 1,325	3,076 6,651 3,977 2,817 1,726 858 663 421 283 203 95 38	7.86% 11.15% 8.11% 6.70% 4.85% 3.66% 4.01% 3.75% 2.83% 2.78% 3.36% 2.86% 6.85%

	1992-95	1 2	47,874 35,590	4,066 2,018	8.49% 5.67%
		3	25,560	1,281	5.01%
		4	19,837	854	4.30%
		5	13,921	518	3.72%
		6	8,901	400	4.49%
		7	3,517	125 	3.55%
			155,200	9,262	5.96%
	1996-98	1	33,607	2,488	7.40%
		2	17,441	1,055	6.04%
		3	8,251	381	4.61%
			59,299	3,924	6.61%
	All Years	1	149,091	13,977	9.37%
		2	109,261	7,714	7.06%
		3	82,344	4,993	6.06%
		4	61,394	3,029	4.93%
		5	42,690	1,725	4.04%
		6	26,887	1,163	4.32%
		7	15,873	614	3.86%
		8	11,022	337	3.05%
		9	7,930	241	3.03%
		10	3,405	121	3.55%
		11	1,861	57	3.06%
		12	496	22	4.43%
		13	132	1	0.75%
		14	12	0	0.00%
			512,398	33,994	6.63%
60-64	1984-87	1	30,992	3,768	12.15%
		2	27,113	3,209	11.83%
		3	23,869	2,899	12.14%
		4	20,791	2,636	12.67%
		5	16,719	1,679	10.04%
		6	9,282	670	7.21%
		7	8,154	466	5.71%
		8	6,859	459	6.69%
		9	4,816	305	6.33%
		10	4,273	241	5.63%
		11	3,857	230	5.96%
		12	3,493	215	6.15%
		13	1,139	67	5.88%
		14	104	13	12.50%
			161,460	16,857	10.44%

1988-91	1	142,046	17,772	12.51%
	2	116,140	10,781	9.28%
	3	98,294	7,404	7.53%
	4	82,176	4,615	5.61%
	5	55,976	2,607	4.65%
	6	37,412	1,815	4.85%
	7	23,676	1,240	5.23%
	8	19,634	924	4.70%
	9	14,105	589	4.17%
	10	8,353	400	4.78%
	11	3,853	135	3.50%
				
		601,664	48,282	8.02%
1992-95	1	108,990	10,450	9.58%
	2	76,464	5,519	7.21%
	3	52,695	3,638	6.90%
	4	37,715	2,282	6.05%
	5	25,245	1,178	4.66%
	6	15,385	685	4.45%
	7	6,962	242	3.47%
		323,456	23,994	7.41%
1996-98	1	62,201	5,478	8.80%
	2	33,515	2,396	7.14%
	3	15,259	915	5.99%
		110,974	8,789	7.91%
All Years	1	344,229	37,468	10.88%
	2	253,232	21,905	8.65%
	3	190,117	14,856	7.81%
	4	140,682	9,533	6.77%
	5	97,939	5,464	5.57%
	6	62,079	3,170	5.10%
	7	38,791	1,948	5.02%
	8	26,493	1,383	5.22%
	9	18,921	894	4.72%
	10	12,626	641	5.07%
	11	7,709	365	4.73%
	12	3,493	215	6.15%
	13	1,139	67	5.88%
	14	104	13	12.50%
		1,197,554	97,922	 8.17%

65-69	1984-87	1	74,732	10,326	13.81%	
		2	64,047	7,791	12.16%	
		3	56,114	6,860	12.22%	
		4	49,023	6,603	13.46%	
		5	39,524	4,211	10.65%	
		6	27,994	1,951	6.96%	
		7	24,609	1,633	6.63%	
		8	18,775	1,553	8.27%	
		9	12,132	1,187	9.78%	
		10	10,068	900	8.93%	
		11	8,717	735	8.43%	
		12	7,594	677	8.91%	
		13	3,163	294	9.29%	
		14	443	41	9.24%	
		14			5.2470	
			396,934	44,762	11.27%	
	4000.04	4	000 040	04 400	40.700/	
	1988-91	1	228,243	31,422	13.76%	
		2	187,849	17,539	9.33%	
		3	160,519	12,111	7.54%	
		4	134,198	7,752	5.77%	
		5	95,230	5,302	5.56%	
		6	65,067	4,173	6.41%	
		7	41,016	2,935	7.15%	
		8	32,969	2,197	6.66%	
		9	24,454	1,527	6.24%	
		10	15,728	972	6.17%	
		11	6,949	487	7.00%	
			992,223	86,417	8.70%	
	1992-95	1	162,959	15,930	9.77%	
	1002 00	2	113,905	9,102	7.99%	
		3	77,084	6,101	7.91%	
		4				
			54,594	4,148	7.59%	
		5	35,351	2,173	6.14%	
		6	20,909	1,242	5.94%	
		7	9,678	528	5.45%	
			474,481	39,224	8.26%	
	1996-98	1	82,288	8,321	10.11%	
	.000 00	2	45,465	3,512	7.72%	
		3	20,563	1,336	6.49%	
		J		1,330	0.49%	
			148,317	13,169	8.87%	
	All Years	1	548,223	65,999	12.03%	
		2	411,267	37,944	9.22%	
		3	314,279	26,408	8.40%	
		4	237,814	18,503	7.78%	
		5	170,105	11,686	6.86%	
		6	113,970	7,366	6.46%	
		7	75,304	5,096	6.76%	
		8	51,744	3,750	7.24%	
		9			7.41%	
			36,587	2,714		
		10	25,796	1,872	7.25%	
		11	15,666	1,222	7.80%	
		12	7,594	677	8.91%	
		13	3,163	294	9.29%	
		14	443	41	9.24%	
			2,011,955	183,572	9.12%	

1984-87						
2 49,951 6,842 13,69% 3 42,991 5,838 13,57% 4 37,011 5,374 14,51% 5 29,091 3,414 11,73% 6 21,666 1,790 8,26% 7 18,831 1,479 7,85% 8 14,506 1,401 9,65% 9 9,095 1,035 11,37% 10 7,018 773 11,01% 11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%	70-74	1984-87	1	60.814	10.439	17.16%
3 42,991 5,838 13,57% 4 37,011 5,374 14,51% 5 29,091 3,414 11,73% 6 21,666 1,790 8,26% 7 18,831 1,479 7,85% 8 14,506 1,401 9,65% 9 9,095 1,035 11,37% 10 7,018 773 11,01% 11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%						
4 37,011 5,374 14,51% 5 29,091 3,414 11,73% 6 21,666 1,790 8,26% 7 18,831 1,479 7,85% 8 14,506 1,401 9,65% 9 9,095 1,035 11,35% 10 7,018 773 11,01% 11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%						
5						
6 21,666 1,790 8.26% 7 18.831 1,479 7.85% 8 14,506 1,401 9.65% 9 9,095 1,035 11,37% 10 7,018 773 11,01% 11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14.89% 303,325 39,893 13,15% 1988-91 1 171,558 28,805 16,79% 2 137,093 14,777 10,77% 3 115,475 9,378 8,12% 4 95,227 6,398 6,71% 5 68,397 4,713 6,89% 6 47,173 3,869 7,82% 7 29,773 2,715 9,11% 8 22,872 1,972 8,62% 9 16,810 1,495 8,89% 10 10,848 1,001 9,22% 11 4,761 482 10,12% 719,987 75,425 10,47% 1992-95 1 115,602 13,055 11,29% 2 78,136 6,949 8,89% 3 51,542 4,679 9,07% 4 34,225 2,802 8,18% 5 20,893 1,520 7,27% 6 11,991 803 6,69% 7 5,486 387 7,05° 3 317,876 30,195 9,49% All Years 1 409,733 59,371 14,49% 2 227,983 31,620 7,27% 6 11,991 803 6,69% 7 5,486 387 7,05° 3 14,581 1,063 7,29% 6 11,991 803 6,69% 7 5,486 387 7,05° 3 14,581 1,063 7,29% 6 11,991 803 6,69% 7 5,486 387 7,05° 3 14,581 1,063 7,29% 6 11,991 803 6,69% 7 5,486 387 7,05° 3 14,581 1,063 7,29% 6 11,991 803 6,68% 7 5,548 39,371 14,49% 2 227,983 31,620 7,27% 6 11,991 803 6,68% 7 5,486 387 7,05° 3 14,581 1,063 7,29% 6 8 337,376 30,195 9,49% All Years 1 409,733 59,371 14,49% 2 227,988 31,620 7,27% 6 80,831 6,282 7,77% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 11 10,390 1,121 10,78% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 11 10,390 1,121 10,78% 8 31,948 274 14,06% 14 296 44 14,89%						
7 18,831 1,479 7,85% 8 14,506 1,401 9,65% 9 9,095 1,035 11,37% 10 7,018 773 11,01% 11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89% 303,325 39,893 13,15% 1988-91 1 171,558 28,805 16,79% 2 137,093 14,777 10,77% 3 115,475 9,378 8,12% 4 95,227 6,398 6,71% 5 68,397 4,713 6,89% 6 47,173 3,689 7,82% 7 29,773 2,715 9,11% 8 22,872 1,972 8,62% 9 16,810 1,495 8,89% 10 10,848 1,001 9,22% 11 4,761 482 10,12% 11 4,761 482 10,12% 11 4,761 482 10,12% 11 4,761 482 10,12% 11 4,761 482 10,12% 6 11,991 803 6,69% 3 51,542 4,679 9,07% 4 34,225 2,802 8,18% 5 20,893 1,520 7,27% 6 11,9191 803 6,69% 7 5,486 387 7,05% 1996-98 1 61,758 7,072 11,45% 6 11,991 803 6,69% 7 5,486 387 7,05% 1996-98 1 61,758 7,072 11,45% 2 32,804 2,694 8,21% 3 14,581 1,063 7,29% 1996-98 1 61,758 7,072 11,45% 5 118,381 9,647 8,76% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 5 118,381 9,647 8,75% 6 80,831 6,282 7,77% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 11 10,948 274 14,06% 14 296 44 14,89%						
8						
9 9,095 1,035 11,37% 10 7,018 773 11,01% 11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%						
10 7,018 773 11.01% 11 5,629 639 11.35% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89% 303,325 39,893 13.15% 1988-91 1 171,558 28,805 16.79% 2 137,093 14,777 10.77% 3 115,475 9,378 8.12% 4 95,227 6,398 6.71% 5 68,397 4,713 6,89% 6 47,173 3,689 7.82% 7 29,773 2,715 9,11% 8 22,872 1,972 8,62% 9 16,810 1,495 8,89% 10 10,848 1,001 9,22% 11 4,761 482 10,12% 719,987 75,425 10,47% 1992-95 1 115,602 13,055 11,29% 2 78,136 6,949 8,89% 3 51,542 4,679 9,07% 4 34,225 2,802 8,18% 5 20,893 1,520 7,27% 6 11,991 803 6,69% 7 5,486 387 7,05% 317,876 30,195 9,49% All Years 1 409,733 59,371 14,49% 2 297,983 31,262 10,49% 3 14,581 1,063 7,29% All Years 1 409,733 59,371 14,59% 2 297,983 31,262 10,49% 3 224,588 20,958 9,33% 4 166,464 14,574 8,75% 5 118,381 9,647 8,14% 6 80,831 6,282 7,77% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 11 10,390 1,121 10,78% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%			8	14,506	1,401	9.65%
11 5,629 639 11,35% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89% 303,325 39,893 13,15% 1988-91 1 171,558 28,805 16,79% 2 137,093 14,777 10,77% 3 115,475 9,378 8,12% 4 95,227 6,398 6,71% 5 68,397 4,713 6,89% 6 47,173 3,689 7,82% 7 29,773 2,715 9,11% 8 22,872 1,972 8,62% 9 16,810 1,495 8,89% 10 10,848 1,001 9,22% 11 4,761 482 10,12% 719,987 75,425 10,47% 1992-95 1 115,602 13,055 11,29% 2 78,136 6,949 8,89% 3 51,542 4,679 9,07% 4 34,225 2,802 8,18% 5 20,893 1,520 7,27% 6 11,991 803 6,69% 7 5,486 387 7,05% 317,876 30,195 9,49% 1996-98 1 61,758 7,072 11,45% 2 32,804 2,694 8,21% 3 14,581 1,063 7,29% All Years 1 409,733 59,371 14,49% 2 297,983 31,262 10,49% 3 224,588 20,958 9,33% 4 166,464 14,574 8,75% 5 118,381 9,647 8,14% 6 80,831 6,282 7,77% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 9 25,905 2,530 9,76% 11 10,390 1,121 10,78% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%			9	9,095	1,035	11.37%
12			10	7,018	773	11.01%
12			11	5.629	639	11.35%
13						
14						
1988-91						
1988-91			14	290		14.0370
2 137,093 14,777 10.77% 3 115,475 9,378 8.12% 4 95,227 6,398 6.71% 5 68,397 4,713 3,689 7.82% 6 47,173 3,689 7.82% 7 29,773 2,715 9,11% 8 22,872 1,972 8.62% 9 16,810 1,495 8.89% 10 10,848 1,001 9.22% 11 4,761 482 10,12%				303,325	39,893	13.15%
2 137,093 14,777 10.77% 3 115,475 9,378 8.12% 4 95,227 6,398 6.71% 5 68,397 4,713 3,689 7.82% 6 47,173 3,689 7.82% 7 29,773 2,715 9,11% 8 22,872 1,972 8.62% 9 16,810 1,495 8.89% 10 10,848 1,001 9.22% 11 4,761 482 10,12%		1000 01	1	171 550	20 005	16 700/
3		1900-91				
4 95,227 6,398 6,71% 5 68,397 4,713 6.89% 6 47,173 3,689 7.82% 7 29,773 2,715 9.11% 8 22,872 1,972 8.62% 9 16,810 1,495 8.89% 10 10,848 1,001 9,22% 11 4,761 482 10,12% 719,987 75,425 10,47% 1992-95 1 115,602 13,055 11,29% 2 78,136 6,949 8.89% 3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7,27% 6 11,991 803 6.69% 7 5,486 387 7,05% 317,876 30,195 9.49% 1996-98 1 61,758 7,072 11,45% 2 32,804 2,694 8.21% 3 14,581 1,063 7,29% All Years 1 409,733 59,371 14,49% 2 297,983 31,262 10,49% 3 224,588 20,958 9.33% 4 166,464 14,574 8,75% 5 118,381 9,647 8,14% 6 80,831 6,282 7,77% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 11 10,390 1,121 10,78% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%						
5 68,397 4,713 6.89% 6 47,173 3,689 7.82% 7 29,773 2,715 9,11% 8 22,872 1,972 8.62% 9 16,810 1,495 8.89% 10 10,848 1,001 9,22% 11 4,761 482 10,12% 719,987 75,425 10,47% 719,987 75,425 10,47% 1992-95 1 115,602 13,055 11,29% 2 78,136 6,949 8.89% 3 51,542 4,679 9,07% 4 34,225 2,802 8,18% 5 20,893 1,520 7,27% 6 11,991 803 6,69% 7 5,486 387 7,05% 317,876 30,195 9,49% 1996-98 1 61,758 7,072 11,45% 2 32,804 2,694 8,21% 3 14,581 1,063 7,29% All Years 1 409,733 59,371 14,49% 109,143 10,829 9,92% All Years 1 409,733 59,371 14,49% 3 224,588 20,958 9,33% 4 166,464 14,574 8,75% 5 118,381 9,647 8,14% 6 80,831 6,282 7,77% 7 54,090 4,581 8,46% 8 37,378 3,373 9,02% 9 25,905 2,530 9,76% 10 17,866 1,774 9,92% 11 10,390 1,121 10,78% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%						
6 47,173 3,689 7.82% 7 29,773 2,715 9,11% 8 22,872 1,972 8,62% 9 16,810 1,495 8,89% 10 10,848 1,001 9,22% 11 4,761 482 10,12%			4	95,227	6,398	6.71%
6 47,173 3,689 7.82% 7 29,773 2,715 9,11% 8 22,872 1,972 8,62% 9 16,810 1,495 8,89% 10 10,848 1,001 9,22% 11 4,761 482 10,12%			5	68,397	4,713	6.89%
7 29,773 2,715 9.11% 8 22,872 1,972 8.62% 9 16,810 1,495 8.89% 10 10,848 1,001 9.22%			6	47,173		
8 22,872 1,972 8.62% 9 16,810 1,495 8.89% 10 10,848 1,001 9.22% 11 4,761 482 10.12% 719,987 75,425 10.47% 1992-95 1 115,602 13,055 11.29% 2 78,136 6,949 8.89% 3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05% 317,876 30,195 9.49% 1996-98 1 61,758 7,072 11.45% 2 32,804 2,694 8.21% 3 14,581 1,063 7.29% All Years 1 409,733 59,371 14.49% 109,143 10,829 9.92% All Years 1 409,733 59,371 14.49% 2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9,76% 10 17,866 1,774 9.92% 11 10,390 1,121 10,78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
9						
10						
11 4,761 482 10.12% 719,987 75,425 10.47% 1992-95 1 115,602 13,055 11.29% 2 78,136 6,949 8.89% 3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05% 317,876 30,195 9.49% 1996-98 1 61,758 7,072 11.45% 2 32,804 2,694 8.21% 3 14,581 1,063 7.29% All Years 1 409,733 59,371 14.49% 2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9,76% 10 17,866 1,774 9.92% 11 10,390 1,121 10,78% 12 4,478 551 12,30% 13 1,948 274 14,06% 14 296 44 14,89%						
719,987 75,425 10.47% 1992-95 1 115,602 13,055 11.29% 2 78,136 6,949 8.89% 3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05%						
1992-95			11	4,761	482	10.12%
2 78,136 6,949 8.89% 3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05%				719,987	75,425	10.47%
2 78,136 6,949 8.89% 3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05%		1002.05	1	115 602	12.055	11 200/
3 51,542 4,679 9.07% 4 34,225 2,802 8.18% 5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05%		1992-95				
All Years 1 409,733 59,371 14.49% All Years 1 409,733 59,371 14.574 3 296 44 14.89% All Years 1 10,390 1,121 10,78% 10,104 10,390 1,121 10,78% 10,104 10,906 1,706 11 10,78% 10,104 10,906 1,706 11 10,78% 10,104 10,390 1,121 10,78% 10,104 10,906 14,906 1,704 9,92%						
5 20,893 1,520 7.27% 6 11,991 803 6.69% 7 5,486 387 7.05% 317,876 30,195 9.49% 1996-98 1 61,758 7,072 11.45% 2 32,804 2,694 8.21% 3 14,581 1,063 7.29%				51,542		9.07%
6 11,991 803 6.69% 7 5,486 387 7.05% 317,876 30,195 9.49% 1996-98 1 61,758 7,072 11.45% 2 32,804 2,694 8.21% 3 14,581 1,063 7.29% 109,143 10,829 9.92% 109,143 10,829 9.92% 22,4588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89% 11 1.0590 14.89%			4		2,802	8.18%
7 5,486 387 7.05% 317,876 30,195 9.49% 1996-98 1 61,758 7,072 11.45% 2 32,804 2,694 8.21% 3 14,581 1,063 7.29%			5	20,893	1,520	7.27%
317,876 30,195 9.49% 1996-98 1 61,758 7,072 11.45% 2 32,804 2,694 8.21% 3 14,581 1,063 7.29% 109,143 10,829 9.92% All Years 1 409,733 59,371 14.49% 2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			6	11,991	803	6.69%
1996-98			7	5,486	387	7.05%
2 32,804 2,694 8.21% 3 14,581 1,063 7.29%				317,876	30,195	9.49%
2 32,804 2,694 8.21% 3 14,581 1,063 7.29%						
3 14,581 1,063 7.29%		1996-98				
All Years 1 409,733 59,371 14.49% 2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			2	32,804	2,694	8.21%
All Years 1 409,733 59,371 14.49% 2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			3	14,581	1,063	7.29%
2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%				109,143	10,829	9.92%
2 297,983 31,262 10.49% 3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%		All Years		409,733	59,371	14.49%
3 224,588 20,958 9.33% 4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			2	297,983	31,262	10.49%
4 166,464 14,574 8.75% 5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
5 118,381 9,647 8.14% 6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
6 80,831 6,282 7.77% 7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
7 54,090 4,581 8.46% 8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
8 37,378 3,373 9.02% 9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
9 25,905 2,530 9.76% 10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			8	37,378	3,373	9.02%
10 17,866 1,774 9.92% 11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			9	25,905	2,530	9.76%
11 10,390 1,121 10.78% 12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%			10		1,774	
12 4,478 551 12.30% 13 1,948 274 14.06% 14 296 44 14.89%						
13 1,948 274 14.06% 14 296 44 14.89% 						
14 296 44 14.89%						
1,450,330 156,342 10.77%			14	296	44	14.89%
.,,				1,450,330	156.342	10.77%
				., 100,000	.50,072	70

75-79	1984-87	1	43,652	8,875	20.33%
10 10	1304 07				
		2	34,414	4,932	14.33%
		3	29,379	3,783	12.87%
		4	25,477	3,314	13.00%
		5	20,540	2,247	10.93%
		6			
			16,231	1,381	8.50%
		7	14,174	1,195	8.43%
		8	10,694	1,186	11.09%
		9	6,737	899	13.34%
		10	4,964	759	15.28%
		11	3,767	588	15.61%
		12	2,868	523	18.23%
		13	1,265	244	19.29%
		14	227	47	20.70%
			214,390	29,973	13.98%
	1000 01	1	110 027	22.450	20.259/
	1988-91	1	110,837	22,450	20.25%
		2	84,925	10,219	12.03%
		3	70,421	6,633	9.41%
		4	57,170	4,576	8.00%
		5	40,848	3,493	8.55%
		6	28,411	2,805	9.87%
		7	18,263	2,107	11.53%
		8	14,056	1,715	12.20%
		9	10,228	1,225	11.97%
		10	6,546	876	13.38%
		11	2,810	452	16.08%
			2,0.0		
			444,516	56,551	12.72%
	1992-95	1	66,167	8,620	13.02%
		2	43,732	4,551	10.40%
		3	27,725	2,822	10.17%
		4	17,515	1,767	10.08%
		5	10,477	967	9.22%
		6	5,869	542	9.23%
		7	2,563	243	9.47%
			174,047	19,512	11.21%
			•	•	
	1006.00	1	25 467	4 626	12 100/
	1996-98	1	35,167	4,636	13.18%
		2	17,838	1,876	10.51%
		3	7,502	656	8.74%
			60.500	7 400	11 0 407
			60,508	7,168	11.84%
	All Years	1	255,824	44,581	17.42%
		2	180,909	21,578	11.92%
		3	135,028	13,894	10.28%
		4	100,163	9,657	9.64%
		5	71,865	6,707	9.33%
		6			
			50,510	4,728	9.36%
		7	35,001	3,545	10.12%
		8	24,750	2,901	11.72%
		9	16,964	2,124	12.52%
		10	11,511	1,635	14.20%
		11	6,576	1,040	15.81%
		12	2,868	523	18.23%
		13	1,265	244	19.29%
		14	227	47	20.70%
			893,461	113,204	12.67%
			,	,	,0
00 0 4	4004.07	4	0 440	0 == 1	07.000
80-84	1984-87	1	9,440	2,571	27.23%

	2 3 4 5 6 7 8 9 10 11 12 13	6,859 5,848 5,129 3,756 2,956 2,506 2,021 1,295 959 741 533 215 55	989 698 699 505 429 384 348 259 196 171 141 57 12	14.41% 11.93% 13.62% 13.44% 14.51% 15.32% 17.21% 20.00% 20.43% 23.08% 26.43% 26.57% 21.81%
1988-91	1 2 3 4 5 6 7 8 9 10	39,311 28,060 22,221 17,150 11,994 7,780 4,692 3,137 2,147 1,337 569	10,005 3,956 2,518 1,684 1,387 1,120 787 570 407 275 146	25.45% 14.09% 11.33% 9.81% 11.56% 14.39% 16.77% 18.16% 20.57% 25.66%
1992-95	1	25,670	3,730	14.53%
	2	16,626	1,987	11.95%
	3	10,475	1,273	12.15%
	4	6,349	818	12.88%
	5	3,790	516	13.61%
	6	2,035	269	13.21%
	7	801	130	16.23%
1996-98	1 2 3	11,705 5,641 2,321 19,668	1,816 656 240 	15.51% 11.62% 10.33% 13.78%
All Years	1	86,126	18,122	21.04%
	2	57,187	7,588	13.26%
	3	40,865	4,729	11.57%
	4	28,628	3,201	11.18%
	5	19,540	2,408	12.32%
	6	12,770	1,818	14.23%
	7	7,999	1,301	16.26%
	8	5,159	918	17.79%
	9	3,442	666	19.34%
	10	2,296	471	20.51%
	11	1,310	317	24.20%
	12	533	141	26.43%
	13	215	57	26.57%
	14	55	12	21.81%
1984-87	1	531	11	2.07%
	2	520	6	1.15%

85-89

	3	514	9	1.75%
	4	504	40	7.94%
	5	464	80	17.23%
	6	382	87	22.75%
	7	296	69	23.30%
	8	228	58	25.48%
	9	154	43	28.01%
	10	111	35	31.53%
	11	76	16	21.05%
	12	60	20	33.33%
	13	23	11	47.82%
	14	5	3	60.00%
		3,867	488	12.61%
1988-91	1	1,140	156	13.68%
	2	982	77	7.84%
	3	895	96	10.72%
	4	753	102	13.54%
	5	543	77	14.19%
	6	332	65	19.55%
	7	208	44	21.12%
	8	137	29	21.18%
	9	97	31	32.06%
	10	55	13	23.63%
	11	32	7	21.87%
		5,174	697	13.47%
1992-95	1	1,538	240	15.60%
	2	1,136	190	16.72%
	3	788	111	14.09%
	4	569	70	12.29%
	5	423	68	16.07%
	6	293	65	22.15%
	7	138	30	21.76%
		4,885	774	15.84%
1996-98	1	584	72	12.33%
	2	143	14	9.81%
	3	59	6	10.19%
		785	92	11.71%
All Years	1	3,792	479	12.63%
	2	2,780	287	10.32%
	3	2,256	222	9.84%
	4	1,826	212	11.61%
	5 6	1,430	225 217	15.73%
	7	1,008 642	143	21.52% 22.26%
	8	364	87	23.86%
	9	250	74	29.58%
	10	166	48	28.91%
	11	108	23	21.29%
	12	60	20	33.33%
	13	23	11	47.82%
	14	5	3	60.00%
		14,711	2,051	13.94%
1984-87	1	127	0	0.00%
1007-01	2	127	0	0.00%
	3	127	3	2.36%
			_	

90 and Over

	4	124	14	11.29%
	5	110	22	
				20.00%
	6	88	28	31.81%
	7	60	27	45.00%
	8	33	9	27.27%
	9	23	7	30.43%
	10	16	8	50.00%
	11	8	4	50.00%
	12	4	1	25.00%
	13	2	2	100.00%
	13	2	2	100.0076
		849	125	14.72%
1988-91	1	114	7	6.16%
	2	107	8	7.47%
	3			
		98	21	21.42%
	4	74	16	21.52%
	5	58	12	20.54%
	6	43	12	28.23%
	7	28	8	28.74%
	8	20	6	30.00%
	9	12	3	24.65%
	10	7	4	57.14%
	11	2	1	50.00%
		2	'	30.0070
		563	98	17.41%
1992-95	1	167	30	17.93%
1002 00				
	2	133	33	24.82%
	3	97	19	19.60%
	4	73	17	23.15%
	5	54	12	22.18%
	6	37	10	26.90%
	7	12	1	8.69%
		573	122	21.28%
1000 00		4-		00 000/
1996-98	1	15	3	20.00%
	2	3	0	0.00%
	3	3	0	0.00%
		21	3	14.28%
All Years	1	423	40	9.45%
All I cais				
	2	370	41	11.08%
	3	325	43	13.23%
	4	272	47	17.29%
	5	223	46	20.67%
	6	168	50	29.82%
	7	99	36	36.24%
	8	53	15	28.30%
	9	35	10	28.43%
	10	23	12	52.17%
	11	10	5	50.00%
	12	4	1	25.00%
	13	2	2	100.00%
		2,006	348	17.34%

All Ages	1984-87	1 2	230,208 191,884	37,043 24,601	16.09%
					12.82%
		3	166,868	20,737	12.42%
		4	145,364	19,226	13.22%
		5	116,684	12,582	10.78%
		6	80,307	6,462	8.04%
		7	69,941	5,333	7.62%
		8	54,267	5,072	9.34%
		9	34,958	3,776	10.80%
		10	28,039	2,941	10.48%
		11	23,372	2,403	10.28%
		12	19,566	2,152	10.99%
		13	7,889	950	12.04%
		14	1,144	160	13.98%
		15	1	0	0.00%
			1,170,492	143,438	12.25%
	1988-91	1	844,660	126,648	14.99%
	1300 31	2		68,720	
			684,895		10.03%
		3	582,055	46,835	8.04%
		4	481,197	30,390	6.31%
		5	340,315	20,481	6.01%
		6	237,918	15,676	6.58%
		7	154,861	11,013	7.11%
		8	127,906	8,253	6.45%
		9	94,748	5,854	6.17%
		10	47,996	3,724	7.75%
		11	21,398	1,775	8.29%
		11	21,390		0.2970
			3,617,950	339,369	9.38%
	1992-95	1	643,935	67,561	10.49%
		2	458,008	37,037	8.08%
		3	313,963	23,840	7.59%
		4	232,697	15,695	6.74%
		5	159,090	9,403	5.91%
		6	96,146		
				5,964	6.20%
		7	37,337	1,974	5.28%
			1,941,176	161,474	8.31%
	1996-98	1	346,583	35,760	10.31%
		2	187,962	14,776	7.86%
		3	86,062	5,525	6.41%
			620,608	56,061	9.03%
	All Years	1	2,065,387	267,012	12.92%
	, iii i cais	2	1,522,749	145,134	9.53%
		3	1,148,949	96,937	8.43%
		4	859,258	65,311	7.60%
		5	616,090	42,466	6.89%
		6	414,372	28,102	6.78%
		7	262,139	18,320	6.98%
		8	182,173	13,325	7.31%
		9	129,706	9,630	7.42%
		10	76,034	6,665	8.76%
		11	44,769	4,178	9.33%
		12	19,566	2,152	
					10.99%
		13	7,889	950	12.04%
		14	1,144	160	13.98%
		15	1	0	0.00%
			7,350,226	700,342	9.52%

TABLE J-2
SOA 1984-99 Long Term Care Intercompany Study
Total Termination Rates by Issue Age Group, Type of Underwriting and Duration

Age Group	Type of Underwriting	Duration	Exposure	Terminations	Rate
Under 50	Full	1	52,396	5,910	11.27%
Oridor oo	· uii	2	39,776	3,408	8.56%
		3	30,692	2,377	7.74%
		4	24,254	1,374	5.66%
		5	18,083	979	5.41%
		6	12,584	770	6.11%
		7	6,194	295	4.76%
		8	4,120	154	3.73%
		9	2,472	92	3.72%
		10	1,020	53	5.19%
		11	518	14	2.70%
		12	10	0	0.00%
		13	1	0	0.00%
		14	1	0	0.00%
		15	1	0	0.00%
			192,121	15,426	8.02%
	Simplified	1	6,453	684	10.59%
		2	5,238	349	6.66%
		3	4,595	261	5.68%
		4	3,216	187	5.81%
		5	2,038	90	4.41%
		6	1,936	70	3.61%
		7	1,757	29	1.65%
		8	1,667	22	1.31%
		9	1,561	23	1.47%
		10	19	0	0.00%
		11	10	1	10.00%
		12	1	0	0.00%
		13	1	0	0.00%
		14	1	0	0.00%
			28,493	1,716	6.02%
	Guaranteed	1	116,166	11,707	10.07%
		2	96,214	8,172	8.49%
		3	72,538		6.85%
		4	57,035	3,152	5.52%
		5	46,770		5.10%
		6	33,239	1,805	5.43%
		7	15,786	448	2.83%
		8	11,742	231	1.96%
		9	9,643	144	1.49%
			459,134	33,019	7.19%

	Other	1	457	43	9.41%
		2	253	21	8.29%
		3	116	3	2.58%
		4	41	1	2.43%
		5	25	2	8.08%
		6	7	0	0.00%
		7	3	0	0.00%
			902	70	7.76%
50-54	Full	1	46,601	4,259	9.13%
		2	33,944	2,436	7.17%
		3	25,079	1,632	6.50%
		4	18,143	929	5.12%
		5	13,158	563	4.27%
		6	8,824	339	3.84%
		7	5,143	170	3.30%
		8	3,317	87	2.62%
		9	2,128	67	3.14%
		10	949	28	2.95%
		11	398	9	2.26%
		12	13	0	0.00%
		13	1	0	0.00%
			157,697	10,519	6.67%
	Simplified	1	7,666	1,062	13.85%
		2	5,414	491	9.06%
		3	4,540	336	7.40%
		4	3,488	197	5.64%
		5	1,752	86	4.90%
		6	800	26	3.24%
		7	592	21	3.54%
		8	482	15	3.11%
		9	400	6	1.50%
		10	75	7	9.28%
		11	33	0	0.00%
		12	5	0	0.00%
			25,246	2,247	8.90%
	Guaranteed	1	24,674	1,815	7.35%
		2	21,144	1,254	5.93%
		3	16,505	869	5.26%
		4	12,608	509	4.03%
		5	10,117	379	3.74%
		6	7,627	261	3.42%
		7	4,295	78	1.81%
		8	3,542	41	1.15%
		9	3,157	38	1.20%
			103,668	5,244	5.05%

	Other	1 2 3 4 5 6 7 8	951 606 372 214 115 40 10 3	54 42 25 17 2 3 0 0	5.67% 6.93% 6.72% 7.96% 1.74% 7.53% 0.00% 0.00%
55-59	Full	1 2 3 4 5 6 7 8 9 10 11 12	93,322 68,358 51,117 37,248 26,834 17,734 10,662 6,703 4,192 1,969 850 34	8,029 4,602 2,964 1,766 1,012 747 451 218 137 68 27 2	8.60% 6.73% 5.79% 4.74% 3.77% 4.21% 4.23% 3.25% 3.26% 3.45% 3.17% 5.88%
	Simplified	1 2 3 4 5 6 7 8 9 10 11 12	20,364 15,363 12,826 10,965 5,955 1,924 1,240 980 745 422 178 22	2,619 1,387 910 623 317 113 53 42 40 20 5 3	12.86% 9.02% 7.09% 5.68% 5.32% 5.87% 4.27% 4.28% 5.36% 4.73% 2.81% 13.43%
	Guaranteed	1 2 3 4 5 6 7 8 9	16,913 14,291 11,339 8,756 6,970 5,267 2,576 2,189 1,923	1,461 800 533 347 209 202 52 23 24	8.63% 5.59% 4.70% 3.96% 2.99% 3.83% 2.01% 1.05% 1.24%

	Other	1 2	3,056 2,008	271 134	8.86% 6.67%
		3	1,351	100	7.40%
		4	881	45	5.10%
		5	541	23	4.24%
		6	249	11	4.24%
		7	60	3	5.03%
		8	16	0	0.00%
		o .			
			8,162	587	7.19%
60-64	Full	1	231,962	21,963	9.46%
		2	170,546	12,777	7.49%
		3	126,717	8,526	6.72%
		4	91,918	5,280	5.74%
		5	64,524	3,067	4.75%
		6	41,884	2,034	4.85%
		7	25,075	1,204	4.80%
		8	15,440	729	4.72%
		9	9,853	426	4.32%
		10	5,445	268	4.92%
		11	2,226	83	3.72%
		12	52	5	9.61%
		13	5	1	20.00%
		14	3	0	0.00%
			785,650	56,363	7.17%
	Simplified	1	51,001	7,945	15.57%
		2	39,550	5,289	13.37%
		3	32,672	3,694	11.30%
		4	27,660	2,652	9.58%
		5	18,421	1,518	8.24%
		6	10,134	602	5.94%
		7	7,426	469	6.31%
		8	5,624	402	7.14%
		9	4,130	263	6.36%
		10	3,053	213	6.97%
		11	1,755	125	7.12%
		12	670	68	10.14%
		13	284	23	8.09%
		14	25	8	32.00%
			202,407	23,271	11.49%
	Guaranteed	1	11,915	1,274	10.69%
		2	9,860	524	5.31%
		3	7,823	362	4.62%
		4	5,727	202	3.52%
		5	4,488	141	3.14%
		6	2,702	88	3.25%
		7	849	12	1.41%
		8	709	6	0.84%
		9	579	11	1.89%
			44,655	2,620	5.86%

	Other	1	10,496	1,026	9.77%
		2	7,411	585	7.89%
		3	5,450	420	7.70%
		4	3,839	229	5.96%
		5	2,666	89	3.33%
		6	1,368	54	3.94%
		7	327	14	4.28%
		8	106	6	5.67%
			31,664	2,423	7.65%
65-69	Full	1	362,139	34,474	9.51%
		2	271,060	20,049	7.39%
		3	203,639	13,727	6.74%
		4	149,990	9,476	6.31%
		5	105,191	6,219	5.91%
		6	69,596	4,606	6.61%
		7	43,422	2,879	6.63%
		8	27,677	1,855	6.70%
		9	18,576	1,171	6.30%
		10	11,057	741	6.70%
		11	4,604	354	7.68%
		12	540	45	8.33%
		13	319	45 29	9.09%
		14			
		14	147	19	12.92%
			1,267,957	95,644	7.54%
	Simplified	1	103,227	16,173	15.66%
	Simpilieu	2			
			83,468	10,865	13.01%
		3	70,469	8,244	11.69%
		4	60,689	6,258	10.31%
		5	46,806	4,030	8.61%
		6	32,758	1,924	5.87%
		7	24,572	1,735	7.06%
		8	18,003	1,519	8.43%
		9	12,718	1,206	9.48%
		10	9,894	835	8.43%
		11	6,722	576	8.56%
		12	3,821	413	10.80%
		13	1,661	171	10.29%
		14	185	12	6.47%
			474,994	53,961	 11.36%
			714,334	JJ,301	11.30/0
	Guaranteed	1	6,669	789	11.83%
		2	5,481	254	4.63%
		3	4,435	133	2.99%
		4	3,013	106	3.51%
		5	2,267	63	2.77%
		6	1,013	31	3.06%
		7	1,013	2	
					1.66%
		8	96	4	4.14%
		9	80	2	2.49%
			23,173	1,384	5.97%
			•		

	Other	1 2 3 4 5 6 7 8	19,946 14,260 10,643 7,756 5,491 3,168 908 385	2,691 1,407 897 509 292 168 43 24	13.49% 9.86% 8.42% 6.56% 5.31% 5.30% 4.73% 6.22%
70-74	Full	1 2 3 4 5 6 7 8 9 10 11 12 13	62,558 266,414 194,704 144,924 104,372 72,022 48,067 30,279 19,360 12,620 7,427 3,286 516 283 115	6,031 28,488 15,503 10,540 7,320 5,069 3,711 2,536 1,665 1,081 679 321 64 44 12	9.64% 10.69% 7.96% 7.27% 7.01% 7.03% 7.72% 8.37% 8.60% 8.56% 9.14% 9.76% 12.41% 15.54% 10.43%
	Simplified	1 2 3 4 5 6 7 8 9 10 11 12 13	904,389 77,857 61,190 50,923 43,422 34,729 25,750 19,486 14,688 10,480 7,922 4,902 2,339 1,073 118 354,879	77,033 14,733 9,048 6,636 5,062 3,483 1,937 1,618 1,398 1,182 862 582 298 165 19	8.51% 18.92% 14.78% 13.03% 11.65% 10.02% 7.52% 8.30% 9.51% 11.27% 10.88% 11.87% 12.74% 15.38% 16.17% 13.25%
	Guaranteed	1 2 3 4 5 6 7 8	3,015 2,493 2,067 1,453 1,082 363 15 14 12	357 98 79 50 40 12 1 0 0	11.84% 3.93% 3.82% 3.43% 3.69% 3.30% 6.59% 0.00% 6.05%

	Other	1	16,192	2,862	17.67%
		2	10,915	1,322	12.11%
		3	7,777	754	9.69%
		4	5,476	418	7.63%
		5	3,726	255	6.84%
		6	2,144	137	6.39%
		7	631	42	6.65%
		8	211	19	8.99%
			47,073	5,809	 12.34%
			47,070	0,000	12.0470
75-79	Full	1	157,790	19,293	12.22%
		2	113,347	10,179	8.98%
		3	83,359	6,823	8.18%
		4	59,566	4,861	8.16%
		5	40,747	3,547	8.70%
		6	27,242	2,751	10.09%
		7	17,273	1,875	10.85%
		8	11,401	1,348	11.82%
		9	7,516	898	11.94%
		10	4,427	602	13.59%
		11	2,048	298	14.55%
		12	467	86	18.41%
		13	244	42	17.21%
		14	107	19	17.75%
		14			
			525,535	52,622	10.01%
	Simplified	1	57,196	11,941	20.87%
		2	43,928	6,726	15.31%
		3	36,451	4,670	12.81%
		4	31,195	3,494	11.20%
		5	25,765	2,542	9.86%
		6	20,205	1,623	8.03%
		7			8.97%
		8	15,753 11,860	1,414 1,367	
			11,869 8 215	1,367 1,061	11.51%
		9	8,215	1,001	12.91%
		10	0.004		44.000/
		10	6,021	885	14.69%
		11	3,645	885 608	16.67%
		11 12	3,645 1,743	885 608 327	16.67% 18.75%
		11 12 13	3,645 1,743 799	885 608 327 155	16.67% 18.75% 19.40%
		11 12	3,645 1,743	885 608 327	16.67% 18.75%
		11 12 13	3,645 1,743 799	885 608 327 155	16.67% 18.75% 19.40%
	Guaranteed	11 12 13	3,645 1,743 799 101	885 608 327 155 21	16.67% 18.75% 19.40% 20.79%
	Guaranteed	11 12 13 14	3,645 1,743 799 101 	885 608 327 155 21 	16.67% 18.75% 19.40% 20.79% 14.01%
	Guaranteed	11 12 13 14	3,645 1,743 799 101 	885 608 327 155 21 	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55%
	Guaranteed	11 12 13 14 1 1 2 3	3,645 1,743 799 101 	885 608 327 155 21 	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22%
	Guaranteed	11 12 13 14 1 1 2 3 4	3,645 1,743 799 101 	885 608 327 155 21 36,834 130 41 26 19	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22% 4.20%
	Guaranteed	11 12 13 14 1 2 3 4 5	3,645 1,743 799 101 	885 608 327 155 21 	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22% 4.20% 4.68%
	Guaranteed	11 12 13 14 1 2 3 4 5 6	3,645 1,743 799 101 	885 608 327 155 21 36,834 130 41 26 19 17 6	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22% 4.20% 4.68% 6.26%
	Guaranteed	11 12 13 14 1 2 3 4 5 6 7	3,645 1,743 799 101 	885 608 327 155 21 36,834 130 41 26 19 17 6	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22% 4.20% 4.68% 6.26% 0.00%
	Guaranteed	11 12 13 14 1 2 3 4 5 6 7 8	3,645 1,743 799 101 	885 608 327 155 21 	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22% 4.20% 4.68% 6.26% 0.00% 0.00%
	Guaranteed	11 12 13 14 1 2 3 4 5 6 7	3,645 1,743 799 101 	885 608 327 155 21 	16.67% 18.75% 19.40% 20.79% 14.01% 14.12% 5.55% 4.22% 4.20% 4.68% 6.26% 0.00%

	Other	1 2 3 4 5 6 7 8	9,188 5,680 3,710 2,388 1,351 706 186 58	2,114 909 487 280 131 79 14 9	23.00% 16.00% 13.12% 11.72% 9.69% 11.18% 7.52% 15.51%
			23,268	4,023	17.29%
80-84	Full	1 2 3 4 5 6 7 8 9 10 11 12 13 14	56,133 39,221 28,303 19,696 13,051 8,412 5,293 3,167 1,940 1,177 627 192 99 44	7,687 3,863 2,690 1,981 1,511 1,213 847 564 395 249 149 47 25 10	13.69% 9.84% 9.50% 10.05% 11.57% 14.41% 16.00% 17.80% 20.35% 21.14% 23.77% 24.47% 25.25% 22.72%
	Simplified	1 2 3 4 5 6 7 8 9 10 11 12 13 14	177,356 9,253 6,572 5,220 4,364 3,659 2,548 1,499 1,160 839 578 271 64 23 1	21,231 2,578 1,340 846 513 489 316 242 207 151 114 61 21 6 0	11.97% 27.85% 20.38% 16.20% 11.75% 13.36% 12.40% 16.14% 17.84% 17.99% 22.50% 32.60% 26.66% 0.00%
	Guaranteed	1 2 3 4 5 6	36,050 310 230 195 135 123 30 1,022	6,884 61 12 17 10 9 0	19.09% 19.70% 5.22% 8.74% 7.39% 7.34% 0.00%

	Other	1	3,070	920	29.96%
	Othor	2	1,731	326	18.83%
		3	1,163	181	15.56%
		4	728	109	14.97%
		5	414	57	13.77%
		6	209	45	21.51%
		7	49	8	16.27%
		8	20	1	5.00%
			7,384	1,647	22.30%
85-89	Full	1	2,573	241	9.36%
		2	1,818	104	5.72%
		3	1,492	123	8.24%
		4	1,183	128	10.81%
		5	927	140	15.10%
		6	665	142	21.36%
		7	463	106	22.87%
		8	315	76	24.12%
		9	216	61	28.24%
		10	146	46	31.50%
		11	92	22	23.91%
		12	48	18	37.50%
		13	20	9	45.00%
		14	5	3	60.00%
			_		
			9,963	1,219	12.23%
	Simplified	1			12.23% 26.05%
	Simplified		9,963	1,219	
	Simplified	1	9,963 180	 1,219 47	26.05%
	Simplified	1 2	9,963 180 134	1,219 47 30	26.05% 22.36%
	Simplified	1 2 3	9,963 180 134 104	1,219 47 30 18	26.05% 22.36% 17.34% 20.50% 20.25%
	Simplified	1 2 3 4	9,963 180 134 104 83	1,219 47 30 18 17	26.05% 22.36% 17.34% 20.50% 20.25% 7.05%
	Simplified	1 2 3 4 5 6 7	9,963 180 134 104 83 64 43 25	1,219 47 30 18 17 13 3	26.05% 22.36% 17.34% 20.50% 20.25%
	Simplified	1 2 3 4 5 6 7 8	9,963 180 134 104 83 64 43 25	1,219 47 30 18 17 13 3 7 5	26.05% 22.36% 17.34% 20.50% 20.25% 7.05%
	Simplified	1 2 3 4 5 6 7 8	9,963 180 134 104 83 64 43 25 19	1,219 47 30 18 17 13 3 7 5	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31%
	Simplified	1 2 3 4 5 6 7 8 9	9,963 180 134 104 83 64 43 25 19 12	1,219 47 30 18 17 13 3 7 5 6	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00%
	Simplified	1 2 3 4 5 6 7 8	9,963 180 134 104 83 64 43 25 19	1,219 47 30 18 17 13 3 7 5	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31%
	Simplified	1 2 3 4 5 6 7 8 9	9,963 180 134 104 83 64 43 25 19 12	1,219 47 30 18 17 13 3 7 5 6	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00%
	Simplified	1 2 3 4 5 6 7 8 9 10 11	9,963 180 134 104 83 64 43 25 19 12 5	1,219 47 30 18 17 13 3 7 5 6 1	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00% 0.00%
		1 2 3 4 5 6 7 8 9 10 11	9,963 180 134 104 83 64 43 25 19 12 5 2 670 93 68	1,219 47 30 18 17 13 3 7 5 6 1 0	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00% 0.00%
		1 2 3 4 5 6 7 8 9 10 11	9,963 180 134 104 83 64 43 25 19 12 5 2	1,219 47 30 18 17 13 3 7 5 6 1 0	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00% 0.00% 21.92% 25.92% 7.38% 6.57%
		1 2 3 4 5 6 7 8 9 10 11	9,963 180 134 104 83 64 43 25 19 12 5 2 670 93 68 61 48	1,219 47 30 18 17 13 3 7 5 6 1 0 147 24 5 4 5	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00% 0.00%
		1 2 3 4 5 6 7 8 9 10 11	9,963 180 134 104 83 64 43 25 19 12 5 2 670 93 68 61 48 43	1,219 47 30 18 17 13 3 7 5 6 1 0 147 24 5 4	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00% 0.00% 21.92% 25.92% 7.38% 6.57%
		1 2 3 4 5 6 7 8 9 10 11	9,963 180 134 104 83 64 43 25 19 12 5 2 670 93 68 61 48	1,219 47 30 18 17 13 3 7 5 6 1 0 147 24 5 4 5	26.05% 22.36% 17.34% 20.50% 20.25% 7.05% 28.18% 27.02% 49.31% 20.00% 0.00% 21.92% 25.92% 7.38% 6.57% 10.36%

Other	1	66	19	28.67%
	2	36	8	22.01%
	3	25	3	12.20%
	4	16	3	19.25%
	5	8	1	12.24%
	6	5	2	44.44%
	7	2	0	0.00%
		157	36	22.86%
90 and Over Full	1	255	6	2.35%
	2	238	8	3.35%
	3	230	22	9.56%
	4	204	30	14.70%
	5	171	33	19.29%
	6	133	43	32.45%
	7	85	35	41.25%
	8	50	14	28.00%
	9	33	9	27.13%
	10	23	12	52.17%
	11	10	5	50.00%
	12	4	1	25.00%
	13	2	2	100.00%
		1,438	220	15.30%
Simplified	1	6	1	16.66%
	2	5	0	0.00%
	3	5	0	0.00%
	4	4	0	0.00%
	5	2	0	0.00%
	6	2	0	0.00%
	7	2	0	0.00%
	8	2	0	0.00%
	9	2	1	50.00%
		30	2	6.66%
Guaranteed	1	31	4	13.04%
	2	25	3	12.00%
	3	19	2	10.52%
	4	16	3	18.36%
	5	13	2	14.90%
	6	6	0	0.00%
	7	1	0	0.00%
	8	1	1	100.00%
		112	 15	13.34%

TABLE J-3
SOA 1984-99 Long Term Care Intercompany Study
Total Termination Rates by Issue Age Group, Gender and Duration

Age Group	Gender	Duration	Exposure	Terminations	Rate
Age Group Under 50	Male	Duration 1 2 3 4 5 6 7 8 9 10 11 12 13 14	78,107 63,286 48,554 37,227 29,094 21,083 10,061 7,546 5,992 404 212 6	8,086 5,441 3,432 2,071 1,582 1,254 356 181 137 18 8 0	10.35% 8.59% 7.06% 5.56% 5.43% 5.94% 3.53% 2.39% 2.28% 4.45% 3.77% 0.00% 0.00%
		15	1	0	0.00%
			301,575	22,566	7.48%
	Female	1	101,234	10,567	10.43%
		2	80,700	6,572	8.14%
		3	61,218	4,239	6.92%
		4	48,544	2,672	5.50%
		5	38,550	1,886	4.89%
		6	27,059	1,402	5.18%
		7	13,792	417	3.02%
		8	9,994	226	2.26%
		9	7,687	122	1.58%
		10	636	35	5.50%
		11 12	317	7 0	2.20%
		13	5 1	0	0.00% 0.00%
		14	1	0	0.00%
		14			
			389,738	28,145	7.22%
	All Genders	1	179,341	18,653	10.40%
		2	143,986	12,013	8.34%
		3	109,772	7,671	6.98%
		4	85,772	4,743	5.52%
		5	67,644	3,468	5.12%
		6	48,142	2,656	5.51%
		7	23,853	773	3.24%
		8	17,541	407	2.32%
		9	13,678	259	1.89%
		10	1,040	53	
		11	529	15	2.83%
		12	11	0	0.00%
		13 14	2	0	0.00% 0.00%
		15	1	0	0.00%
		.0			

			691,313	50,711	7.33%
50-54	Male	1 2 3 4 5 6 7 8 9 10 11	34,174 26,477 20,393 14,883 11,068 7,958 4,573 3,470 2,812 450 198 5	2,926 1,743 1,260 702 443 278 130 59 51 16 3	8.56% 6.58% 6.17% 4.71% 4.00% 3.49% 2.84% 1.70% 1.81% 3.55% 1.51% 20.00%
			126,460	7,612	6.01%
	Female	1 2 3 4 5 6 7 8 9 10 11 12 13	52,051 38,307 28,529 21,109 15,072 10,004 5,915 4,199 3,181 855 412 22 1	4,923 2,767 1,758 1,038 619 373 153 95 67 22 10 1 0	9.45% 7.22% 6.16% 4.91% 4.10% 3.72% 2.58% 2.26% 2.10% 2.57% 2.42% 4.54% 0.00%
	All Gende	ers 1 2 3 4 5 6 7 8 9 10 11 12 13	86,225 64,784 48,921 35,992 26,139 17,962 10,488 7,669 5,993 1,305 610 27 1	7,849 4,510 3,018 1,740 1,062 651 283 154 118 38 13 2	9.10% 6.96% 6.16% 4.83% 4.06% 3.62% 2.69% 2.00% 1.96% 2.91% 2.13% 7.40% 0.00%
			306,117	19,438	6.34%

55-59	Male	1	53,773	4,811	8.94%
		2	39,879	2,702	6.77%
		3	30,412	1,800	5.91%
		4	22,754	1,073	4.71%
		5	16,013	608	3.79%
		6	10,527	430	4.08%
		7	6,075	209	3.44%
		8	4,333	115	2.65%
		9	3,232	83	2.56%
		10	1,062	39	3.67%
		11	555	23	4.14%
		12	120	4	3.33%
		13	38	1	
					2.63%
		14	3	0	0.00%
			400 770	44.000	
			188,776	11,898	6.30%
	Female	1	94,529	9,052	9.57%
		2	68,979	4,973	7.20%
		3	51,763	3,164	6.11%
		4	38,536	1,932	5.01%
		5	26,618	1,110	4.17%
		6	16,337	733	4.48%
		7	9,797	405	4.13%
		8	6,688	222	3.31%
		9	4,698	158	3.36%
		10	2,343	82	3.50%
		11	1,306	34	2.60%
		12		18	
			376		4.78%
		13	94	0	0.00%
		14	9	0	0.00%
			322.072	21 002	6 70%
			322,072	21,883	6.79%
	All Gende	rs 1	148,302	13,863	9.34%
		2	108,858	7,675	7.05%
		3	82,175	4,964	6.04%
		4	61,290	3,005	4.90%
		5	42,630	1,718	4.03%
		6	26,864	1,163	4.32%
		7	15,872	614	3.86%
		8	11,021	337	3.05%
		9	7,930	241	3.03%
		10	3,405	121	3.55%
		11	1,861	57	3.06%
		12	496	22	4.43%
		13		1	
			132		0.75%
		14	12	0	0.00%
			510,849	33,781	6.61%

60-64	Male	1	127,981	13,711	10.71%
		2	93,432	7,727	8.27%
		3	69,893	5,232	7.48%
		4	51,569	3,354	6.50%
		5	35,587	1,859	5.22%
		6	22,306	1,126	5.04%
		7	13,286	616	4.63%
		8	9,011	460	5.10%
		9	6,399	282	4.40%
		10	4,018	219	5.45%
		11	2,433	108	4.43%
		12	1,047	76	7.26%
		13	292	18	6.17%
		14	19	5	26.31%
			437,271	 34,793	7.95%
			,	,	
	Female	1	215,064	23,579	10.96%
		2	159,217	14,129	8.87%
		3	119,970	9,596	7.99%
		4	88,950	6,160	6.92%
		5	62,250	3,594	5.77%
		6	39,728	2,042	5.13%
		7	25,503	1,332	5.22%
		8	17,481	923	5.27%
		9	12,522	612	4.88%
		10	8,608	422	4.90%
		11	5,276	257	4.87%
		12	2,447	139	5.68%
		13	848	49	5.78%
		14	85	8	9.41%
			757.040		0.000/
			757,949	62,842	8.29%
	All Gende	rs 1	343,045	37,290	10.87%
		2	252,649	21,856	8.65%
		3	189,862	14,828	7.80%
		4	140,518	9,514	6.77%
		5	97,837	5,453	5.57%
		6	62,034	3,168	5.10%
		7	38,789	1,948	5.02%
		8	26,492	1,383	5.22%
		9	18,921	894	4.72%
		10	12,626	641	5.07%
		11	7,709	365	4.73%
		12	3,493	215	6.15%
		13	1,139	67	5.88%
		14	104	13	12.50%
			1 105 220	07.625	0.460/
			1,195,220	97,635	8.16%

65-69	Male	1	224,303	26,870	11.97%
		2	166,807	15,331	9.19%
		3	126,429	10,525	8.32%
		4	94,854	7,427	7.82%
		5	66,984	4,692	7.00%
		6	43,649	2,930	6.71%
		7	27,768	1,994	7.18%
		8	18,498	1,391	7.51%
		9	12,915	1,066	8.25%
		10	8,876	759	8.55%
		11	5,318	508	9.55%
		12	2,511	264	10.51%
		13	922	105	11.38%
		14	113	16	14.20%
		14			14.20 /0
			799,949	73,878	9.23%
	Female	1	322,803	38,973	12.07%
		2	243,939	22,570	9.25%
		3	187,652	15,869	8.45%
		4	142,819	11,069	7.75%
		5	103,035	6,988	6.78%
		6	70,280	4,435	6.31%
		7	47,533	3,102	6.52%
		8	33,245	2,359	7.09%
		9			
			23,670	1,648	6.96%
		10	16,919	1,113	6.57%
		11	10,348	714	6.89%
		12	5,083	413	8.12%
		13	2,241	189	8.43%
		14	331	25	7.56%
			1,209,898	109,467	9.04%
	All Genders	1	547,107	65,843	12.03%
		2	410,746	37,901	9.22%
		3	314,081	26,394	8.40%
		4	237,674	18,496	7.78%
		5	170,019	11,680	6.86%
		6	113,929	7,365	6.46%
		7	75,301	5,096	6.76%
		8	51,743	3,750	7.24%
		9	36,586	2,714	7.24%
		10	25,795	1,872	7.25%
		11	15,666	1,222	7.80%
		12	7,594	677	8.91%
		13	3,163	294	9.29%
		14	443	41	9.24%
			2,009,846	183,345	9.12%

70.74	Mala	4	162 100	22.206	14.070/
70-74	Male	1 2	163,108	23,286 12,395	14.27%
		3	118,206	8,442	10.48% 9.50%
		4	88,810 65,423	5,782	
			-	•	8.83%
		5	45,965	3,821	8.31%
		6	30,366	2,425	7.98%
		7	19,560	1,845	9.43%
		8	13,019	1,358	10.43%
		9	8,854	1,014	11.45%
		10	5,965	679	11.38%
		11	3,374	423	12.53%
		12	1,387	189	13.62%
		13	552	83	15.03%
		14	72	5	6.91%
			564,661	61,747	10.93%
			·	- ,	
	Female	1	245,993	36,037	14.64%
		2	179,489	18,857	10.50%
		3	135,675	12,510	9.22%
		4	100,960	8,782	8.69%
		5	72,369	5,822	8.04%
		6	50,449	3,856	7.64%
		7	34,529	2,736	7.92%
		8	24,359	2,015	8.27%
		9	17,050	1,516	8.89%
		10	11,901	1,095	9.20%
		11	7,017	698	9.94%
		12	3,091	362	11.71%
		13	1,395	191	13.68%
		14	223	39	17.47%
			884,501	94,516	10.68%
	All Genders	1	409,101	59,323	14.50%
	All Ochacis	2	297,695	31,252	10.49%
		3	224,485	20,952	9.33%
		4	166,383	14,564	8.75%
		5	118,334	9,643	8.14%
			•	•	
		6 7	80,815	6,281	7.77% 8.46%
			54,089 27,279	4,581	
		8 9	37,378 35,005	3,373	9.02%
			25,905 17,966	2,530	9.76%
		10	17,866	1,774	9.92%
		11	10,390	1,121	10.78%
		12	4,478	551 274	12.30%
		13	1,948	274	14.06%
		14	296	44	14.89%
			1,449,163	156,263	10.78%

75-79	Male	1 2	92,559 64,734	16,105 8,071	17.39% 12.46%
		3	47,576	5,257	11.04%
		4	34,569	3,872	11.20%
		5	23,958	2,460	10.26%
		6	16,171	1,780	11.00%
		7	10,171	1,700	12.27%
		8	7,076	984	13.90%
		9	4,726	730	15.44%
		10	3,018	494	16.36%
		11	1,647	316	19.18%
		12	687	155	22.57%
		13	270	60	22.25%
		14	44	13	29.54%
		14			
			307,607	41,595	13.52%
	Female	1	162,973	28,456	17.46%
		2	116,040	13,496	11.63%
		3	87,404	8,636	9.88%
		4	65,557	5,782	8.81%
		5	47,891	4,245	8.86%
		6	34,336	2,948	8.58%
		7	24,428	2,247	9.19%
		8	17,673	1,917	10.84%
		9	12,238	1,394	11.39%
		10	8,493	1,141	13.43%
		11	4,929	724	14.68%
		12	2,182	368	16.86%
		13	995	184	18.48%
		14	183	34	18.57%
			585,323	71,572	12.22%
	All Genders	1	255,532	44,561	17.43%
		2	180,774	21,567	11.93%
		3	134,979	13,893	10.29%
		4	100,126	9,654	9.64%
		5	71,850	6,705	9.33%
		6	50,506	4,728	9.36%
		7	35,001	3,545	10.12%
		8	24,750	2,901	11.72%
		9	16,964	2,124	12.52%
		10	11,511	1,635	14.20%
		11	6,576	1,040	15.81%
		12	2,868	523	18.23%
		13	1,265	244	19.29%
		14	227	47	20.70%
			892,930	113,167	12.67%

80-84	Male	1	29,140	6,210	21.31%
		2	18,942	2,687	14.18%
		3	13,164	1,734	13.17%
		4	8,960	1,105	12.33%
		5	5,990	870	14.52%
		6	3,766	642	17.04%
		7	2,166	433	19.98%
		8	1,299	262	20.16%
		9	825	187	22.67%
		10	519	119	22.92%
		11	277	79	28.57%
		12	87	31	35.66%
		13	24	11	45.83%
		14	5	1	20.00%
			85,164	14,371	16.87%
	Female	1	56,963	11,911	20.91%
		2	38,222	4,897	12.81%
		3	27,685	2,993	10.81%
		4	19,658	2,095	10.65%
		5	13,546	1,538	11.35%
		6	9,002	1,176	13.06%
		7	5,832	868	14.88%
		8	3,859	656	16.99%
		9	2,618	479	18.29%
		10	1,777	352	19.81%
		11	1,033	238	23.03%
		12	447	110	24.63%
		13	191	46	24.14%
		14	50	11	22.00%
		1-7			
			180,880	27,370	15.13%
	All Genders	1	86,102	18,121	21.04%
		2	57,164	7,584	13.26%
		3	40,849	4,727	11.57%
		4	28,617	3,200	11.18%
		5	19,536	2,408	12.32%
		6	12,768	1,818	14.23%
		7	7,999	1,301	16.26%
		8	5,159	918	17.79%
		9	3,442	666	19.34%
		10	2,296	471	20.51%
		11	1,310	317	24.20%
		12	533	141	26.43%
		13	215	57	26.57%
		14	215 55	12	20.57%
		14			Z1.0170
			266,045	41,741	15.68%

85-89	Male	1	1,083	145	13.38%
		2	770	107	13.90%
		3	604	73	12.08%
		4	465	72	15.47%
		5	341	77	22.58%
		6	224	56	25.04%
		7	145	45	31.05%
		8	76	28	36.64%
		9	47	17	36.49%
		10	25	11	44.00%
		11	14	5	35.71%
		12	5	3	60.00%
		13	2	2	100.00%
			3,800	641	16.86%
	Female	1	2,701	332	12.29%
		2	2,004	179	8.93%
		3	1,647	147	8.92%
		4	1,357	139	10.24%
		5	1,087	148	13.61%
		6	784	160	20.39%
		7	497	98	19.70%
		8	288	59	20.48%
		9	204	57	27.99%
		10	141	37	26.24%
		11	94	18	19.14%
		12	55	17	30.90%
		13	21	9	42.85%
		14	5	3	60.00%
		14			
			10,884	1,403	12.88%
	All Gende	rs 1	3,784	477	12.60%
		2	2,773	286	10.31%
		3	2,251	220	9.77%
		4	1,822	211	11.58%
		5	1,428	225	15.75%
		6	1,008	216	21.42%
		7	642	143	22.26%
		8	364	87	23.86%
		9	250	74	29.58%
		10	166	48	28.91%
		11	108	23	21.29%
		12	60	20	33.33%
		13	23	11	47.82%
		14	5	3	60.00%
			14,685	2,044	13.91%

OO and Over Male	4	04	40	44.000/
90 and Over Male	1	91	13	14.23%
	2 3	78	8	10.30%
	3 4	69 57	9 13	13.04%
				22.84%
	5	47	8	17.08%
	6 7	39	12	30.76%
		25	8	32.00%
	8	17	3	17.64%
	9	13	6	45.56%
	10	8	4	50.00%
	11	4	2	50.00%
	12	1	0	0.00%
	13	1	1	100.00%
		450	87	19.33%
Female	1	331	27	0 160/
remale	1		27	8.16%
	2 3	291	33	11.33%
	3 4	256	33	12.89%
		215	34	15.82%
	5	176	38	21.63%
	6	129	38	29.53%
	7	74	28	37.66%
	8	36	12	33.33%
	9	22	4	18.18%
	10	15	8	53.33%
	11	6	3	50.00%
	12	3	1	33.33%
	13	1	1	100.00%
		1,554	260	16.73%
All Gend		422	40	9.48%
	2	369	41	11.11%
	3	325	42	12.92%
	4	272	47	17.29%
	5	223	46	20.67%
	6	168	50	29.82%
	7	99	36	36.24%
	8	53	15	28.30%
	9	35	10	28.43%
	10	23	12	52.17%
	11	10	5	50.00%
	12	4	1	25.00%
	13	2	2	100.00%
		2.004	247	 17 240/
		2,004	347	17.31%

All Ages	Male	1	804,321	102,163	12.70%
		2	592,610	56,212	9.48%
		3	445,903	37,764	8.46%
		4	330,761	25,471	7.70%
		5	235,046	16,420	6.98%
		6	156,088	10,933	7.00%
		7	94,233	6,934	7.35%
		8	64,346	4,841	7.52%
		9	45,815	3,573	7.79%
		10	24,346	2,358	9.68%
		11	14,031	1,475	10.51%
		12	5,855	723	12.34%
		13	2,101	281	13.37%
		14	257	40	15.56%
		15	1	0	0.00%
			2,815,716	269,188	9.56%
	Female	1	1,254,642	163,857	13.06%
		2	927,188	88,473	9.54%
		3	701,798	58,945	8.39%
		4	527,705	39,703	7.52%
		5	380,593	25,988	6.82%
		6	258,108	17,163	6.64%
		7	167,899	11,386	6.78%
		8	117,823	8,484	7.20%
		9	83,890	6,057	7.22%
		10	51,687	4,307	8.33%
		11	-	•	
			30,738	2,703	8.79%
		12	13,710	1,429	10.42%
		13	5,788	669	11.55%
		14	887	120	13.53%
			4,522,457	429,284	9.49%
	All Genders	1	2,058,963	266,020	12.92%
		2	1,519,799	144,685	9.52%
		3	1,147,701	96,709	8.42%
		4	858,466	65,174	7.59%
		5	615,639	42,408	6.88%
		6	414,196	28,096	6.78%
		7	262,132	18,320	6.98%
		8			
			182,170	13,325	7.31%
		9	129,705	9,630	7.42%
		10	76,033	6,665	8.76%
		11	44,769	4,178	9.33%
		12	19,566	2,152	10.99%
		13	7,889	950	12.04%
		14	1,144	160	13.98%
		15	1	0	0.00%
			7,338,173	698,472	9.51%
			1,000,113	030,412	3.51%

Appendix J-4
Total Termination Rates by Age Groupings

Attained	Female	Female	Female	Female	Female	Female
Age	Exposure	Terms - LTC	LTC	Qx - 83GAM	Qx - A2000	Qx - SOA
40-49	205,180	12,815	0.0625	0.0011	0.0010	0.0017
50-59	417,351	29,086	0.0697	0.0028	0.0026	0.0047
60-69	1,562,682	139,952	0.0896	0.0077	0.0067	0.0113
70-79	1,732,182	177,939	0.1027	0.0221	0.0165	0.0253
80-89	464,526	54,085	0.1164	0.0568	0.0451	0.0622
90-99	11,931	2,358	0.1976	0.1336	0.1196	0.1725
Total	4,393,852	416,235	0.0947	0.0181	0.0143	0.0216

Attained	Male	Male	Male	Male	Male	Male
Age	Exposure	Terms - LTC	LTC	Qx - 83GAM	Qx - A2000	Qx - SOA
40-49	153,786	9,819	0.0638	0.0023	0.0018	0.0026
50-59	277,596	17,599	0.0634	0.0063	0.0046	0.0071
60-69	984,528	86,982	0.0883	0.0175	0.0111	0.0192
70-79	1,076,157	112,790	0.1048	0.0413	0.0260	0.0421
80-89	218,792	30,273	0.1384	0.0924	0.0584	0.0912
90-99	3,298	833	0.2526	0.1851	0.1265	0.1804
Total	2,714,157	258,296	0.0952	0.0312	0.0197	0.0321

LTC: LTC Total Terminations (Mortality and Lapse)

Qx - 83GAM: 83 Group Annuity Table Qx - A2000: 2000 Annuity Table

Qx - SOA: 1985-90 Society of Actuaries Life Insurance Table, ultimate rates